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SUMMARY 
Infections are the most important cause of morbidity in patients with haematological 
malignancies and those undergoing haematopoietic stem cell transplantation.  Coagulase 
negative Staphylococcus (CoNS) species are among the most frequently encountered 
isolates in this hospitalised bacteraemic patient group. The common therapeutic agent for the 
treatment of these clinically significant isolates is vancomycin. However, the emergence of 
resistance to other commonly used antibiotics and a shift towards the predominance to multi-
resistance has resulted in new challenges to these opportunistic pathogens.  Therefore, new 
therapeutic agents are required to combat the emergence of resistance for optimal clinical 
outcomes. This thesis is a study designed to characterise CoNS using phenotypic and 
genotypic methods together with determining the presence of important virulence factors, 
antibiotic-resistance including the magnitude of susceptibility to vancomycin and some of the 
newer class of antimicrobials used for the treatment of bacteraemic patients hospitalised for 
haematological malignancies.  Characterisation and analysis was carried out on a total of 
100 CoNS strains consecutively isolated from blood cultures of patients hospitalised in the 
haematology and Bone Marrow Transplant (BMT) unit of the Queen Elizabeth Hospital from 
April 2010 to March 2012. Comparative identification and susceptibility testing was also 
performed on 100 CoNS skin colonising strains obtained from a pre-admission patient 
(control) group.  This study addresses the issue that skin colonisers could be regarded as the 
putative source of opportunistic bacteraemia in haematology patients. The key question 
being whether the CoNS strains as the aetiological agents of bacteraemia, originated from 
random carriage on the skin of the patients or were a result of distinct strains with enhanced 
virulence due to antibiotic pressure. Conventional and molecular techniques identified major 
phenotypic and genotypic differences with low-level similarities within and between in-patient 
blood culture isolates of CoNS and those skin-colonisers which could be regarded as 
inducers of bacteraemia.  Biotyping revealed a total of eleven CoNS species of which 
Staphylococcus epidermidis was the most prevalent followed by Staphylococcus hominis and 
Staphylococcus haemolyticus in both patient groups. Likewise, slime the main virulent factor, 
was prevalent amongst both patient group S. epidermidis isolates.  Interestingly, resistance 
to principal classes of commonly used anti-staphylococcal drugs was also species-specific 
with S. epidermidis demonstrating a propensity for both methicillin-resistance and multi-drug 
resistance. Significantly high levels of teicoplanin resistance among both S. epidermidis and 
S. haemolyticus in-patient isolates were also likely to express low-level or heteroresistance to 
vancomycin. Of the newer antibiotics evaluated, daptomycin demonstrated broad-spectrum 
in-vitro activity. The study focussing on clinically relevant combinations of vancomycin with 
rifampicin, gentamicin and daptomycin demonstrated either an additive or indifference effect 
with no antagonistic activity. Conversely vancomycin, daptomycin and rifampicin, individually 
and in combination demonstrated antagonistic interactions against S. epidermidis biofilm-
embedded cells. Hence, these combinations may not be considered as potential adjunctive 
agents for the treatment of BSIs caused by biofilm-producing strains.  Phenotypic and 
genotypic characterisation to ascertain the likelihood of skin-colonising strains as aetiological 
agents of bacteraemia revealed the presence of diverse heterogenic populations amongst all 
CoNS species-specific isolates of both patient groups.  The findings of this study therefore do 
not support the hypothesis that endogenous skin-colonisers could be the potential source of 
CoNS-associated bacteraemia in the haematology patient group. 
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Chapter 1 General Introduction 
 
1.1 Coagulase Negative Staphylococci 
Staphylococcus is a genus of aerobic or facultatively anaerobic Gram-positive bacteria which 
under the microscope appear as round (cocci) in a grape-like cluster formation (Ryan et al., 
2004).  These organisms can survive and persist in environments which include acidic 
conditions, high sodium concentrations and wide temperature variations.  The heterogenous 
group of coagulase-negative staphylococcus (CoNS) are defined by their lack of production 
of the secreted enzyme coagulase hence, their inability to clot plasma (Hubner and 
Goldmann, 1999).  This diagnostic feature fulfils the clinical need to differentiate between the 
pathogen Staphylococcus aureus (S. aureus) due to its prominent role in infection and other 
staphylococci that were historically classified as less or non-pathogenic (Becker et al., 2014).  
As a group, CoNS are the major component of the skin and mucous membranes, functioning 
mainly as commensals or saprophytic organisms, having a benign symbiotic relationship with 
the host (Otto, 2010).   The conversion of these innocuous members of the skin microbiota 
into potential pathogens is dependent on the skins capacity to resist infection and the hosts 
effective defence response (Otto, 2009; Piette and Verschraegen, 2009). However, in 
susceptible patient groups with impaired host response functions, these colonising CoNS 
strains act as a key source of endogenous infections (Cogen et al., 2008). 
Despite being commensals, the ability of CoNS to cause a variety of infections are 
dependent on strain-specific features at a subspecies level and their association and 
interaction with host-specific characteristics.  Thus, non-virulent skin colonising strains of 
CoNS may cause infection, if associated with co-factors such as immunosuppression or the 
presence of indwelling medical devices (Yuen et al., 1998; et al., von Eiff et al., 2002; Coello 
et al., 2003; Zitella, 2003).  
The prevalent bacterial communities on the skin are known to consist mainly of saprophytic 
CoNS strains.  These strains are significantly heterogenic in both pathogenicity and habitat 
preference and have emerged as significant nosocomial pathogens in hospitalised 
immunocompromised patients due to changes in patient demographics and advances in 
interventional medical procedures (Kloos and Bannerman, 1994; Piette and Verschraegen 
2009; Becker et al., 2014).  The increasing significance of CoNS infections associated with 
this high-risk patient group has highlighted the importance of accurate identification of CoNS 
isolates to the species level for diagnostic purposes, as this can have both clinical and 
epidemiological implication (Tacconelli et al., 2003). 
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CoNS are a diverse group of organisms, as such that in the smaller arena of opportunistic 
human infections where commensal CoNS colonising strains abound, minor difference 
between related isolates need to be identified.  This is in order to make a differential 
diagnosis of the infective organism, the species type, and the environmental distribution of an 
epidemic strain.  Previously, taxonomists like Kloos and Schleifer (1975) grouped these 
diverse organisms into classes or species with common properties on the basis of 
phenotypic characterisation and DNA homology.  This was based on the Baird-Parker 
scheme, whereby a small number of easily definable key characteristics were used to identify 
isolates at the species and subgroup levels.  Conversely, the most recent taxonomy and 
classification status, using advanced molecular techniques such as 16S rRNA (rDNA) gene 
sequence analysis, demonstrates that the genus Staphylococcus comprises of more than 41 
recognised taxa (Takahashi et al., 1999).  These include at least 47 species and 23 subspecies 
of which, nine have two subspecies and one has three subspecies designations.  Among the 
heterogenous group of CoNS subsets, 21 species of these have been identified as common 
to humans (Euzéby, 2007; Becker et al., 2014).  As native flora of the skin and mucus 
membranes, all these CoNS species types are known to be capable of causing opportunistic 
infections, particularly when natural host barriers are breached either by cutaneous-puncture 
or by plastic biomaterials device placements (Zitella, 2003; Falcone et al., 2004).  
1.2 Species-specific CoNS isolates  
The key source of endogenous infections by recognised strains of CoNS are those that are 
normal physiological colonisers of different areas of the skin and mucous membranes 
(Cogen et al., 2008; Otto, 2010).  Research on healthy adult human nasal microbiota is 
composed of more species rich and diverse microbe communities with fewer staphylococci 
being harboured in the nares in comparison to other areas of the body (Frank et al., 2010). 
Among the eighteen predominant CoNS known to colonise humans, Staphylococcus 
epidermidis and Staphylococcus hominis are the most abundant of the CoNS species, 
accounting for 60-70% and 22% respectively, of the total staphylococci species recovered 
from individuals (Kloos and Bannerman 1994; Widerström et al., 2012).  As an integral part 
of normal skin flora, different species of CoNS predominate in preferential host ecological 
niche areas.  S. epidermidis are particularly prevalent in areas such as the anterior nares, 
axillae inguinal and perineal areas, reaching population density of up to a million colony 
forming units per centimetre square (Kloos and Schleifer 1975; Becker et al., 2014).  
Likewise, S. hominis and Staphylococcus haemolyticus have a predilection to colonise areas 
of the skin high in apocrine glands such as axillae and pubic areas.  Other species such as 
S. capitis predominate in areas surrounding sebaceous glands whereas S. auricularis are 
exclusive to the external auditory meatus region (Kloos and Schleifer 1975; Widerström et 
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al., 2012).  S. haemolyticus an important nosocomial pathogen on the other hand, 
predominating in the perineum and inguinal areas is the second most clinically isolated 
CoNS after S. epidermidis (Karchmer, 2000; D’Mello et al., 2008; Kristóf et al., 2011).   
Other commonly found species of CoNS that are indigenous to humans include S. caprae, S. 
warneri, S. simulans, S. saccharolyticus, S. lugdunensis, S. cohnii, S. xylosus and the 
recently identified skin coloniser strain, S. pettenkoferi (Kloos et al., 1994; Becker et al., 
2014).  Among the colonising strains of CoNS, S. epidermidis, S. haemolyticus, S. hominis, 
S. caprae, S. warneri, S. capitis and S. lugdunensis are the only seven species commonly 
implicated in nosocomial spread (Widerström et al., 2012).  Cases of nosocomial infection 
caused by some of these indigenous CoNS species are commonly reported in patients with 
depressed immune systems, undergoing severe hospital chemotherapies.  In such specific 
clinical situations these CoNS isolates are therefore regarded as exceptional opportunistic 
pathogens (von Eiff et al., 2002; Tashiro et al., 2015).  
1.3 Emergence of CoNS as nosocomial pathogens 
CoNS are important and frequently encountered pathogens in the healthcare setting and 
account for the majority of nosocomial infections, presenting in indolent rather than in acute 
infections (von Eiff et al., 2002).   The increasing importance of recognising CoNS as a group 
of opportunistic pathogens may be partly due to radical changes in the hospitalised patient 
populations with multiple co-morbidities as well as the development and increased use of 
transient or permanent medical devices (Coello et al., 2003).  A variety of CoNS infections 
associated with the widespread use of intravascular catheters and prosthetic devices in the 
severely immunocompromised, for example, patients with cancer, transplants or those in 
intensive care have been confirmed by numerous clinical studies (Worthington et al., 2000; 
Zitella, 2003; Falcone et al., 2004).  Other factors, such as malignancies and aggressive 
anticancer treatments together with the use of broad-spectrum antimicrobial therapies 
dramatically shift the incidence of CoNS related infections (Pagano et al., 1997; Costa et al., 
2006; Chen et al., 2010).  
The enhanced risk of nosocomial CoNS infections acquisition is further increased by cross-
transmission of isolates which can occur between patients, healthcare personal or the 
hospital environment colonised or infected with resistant isolates.  Commensal CoNS 
isolates are defined by the immunological tolerance afforded to them by an 
immunocompetent host.  In clinical conditions such as immune suppression arising from the 
disease state and associated treatments such as in patients with haematology malignancies 
undergoing immuno-modulation therapies received during haematopoietic stem cell 
transplantation may shift the demarcation between innocuous skin commensal and disease-
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causing pathogen.  CoNS, as typical opportunists comprise one of the major nosocomial 
pathogens and the most common cause of blood stream infections (BSIs) in the intensive 
care setting.  BSIs is a term interchangeably used with bacteraemia when referring to 
bacterial growth from blood cultures of patients displaying signs of infection (Diekema et al., 
2001; Fluit et al., 2001).  The increasing incidence of Gram-positive bacteria causing BSIs 
and the extensive emergence of multi-drug resistant strains has been associated with 
increased risk of morbidity, mortality and cost (Wisplinghoff et al., 2003; Caggiano et al., 
2005; Cosgrove, 2006; Tumbarello et al., 2009).   
Bacteraemia remains a significant cause of life-threatening complication in patients with 
haematological malignancies and those undoing autologous or allogenic transplants (Raad et 
al., 2007; Klastersky et al., 2007). In this predisposed patient group, intensive immune-
modulating therapies, the immune-compromised state related to indolent malignancy or graft-
versus-host disease may give rise to prolonged at-risk periods for opportunistic infections 
(Yuen et al., 1998). Gram-positive bacteria have been microbiologically documented to 
account for between 60 to 70% infections in haematology patient group, commonly 
translocating from the skin or oral cavity into the bloodstream (Hughes et al., 2002; Ahlstrand 
et al., 2012).  Over the last two decades, some predominant species of CoNS have been 
recognised as one of the most important causes of opportunistic infections worldwide, 
principally related to BSIs (Emori et al., 1993; Pfaller et al., 1999; Marin et al., 2014).  Most 
previous clinical studies do not however, differentiate between CoNS species, primarily 
addressing CoNS as a group or collectively as S. epidermidis.  Therefore, infections caused 
by infrequently occurring CoNS species and their clinical significance may possibly have 
remained under-reported. Together with having an accurate diagnosis of the aetiological 
agent, the positive predictive value of CoNS species specific identification increases 
knowledge of their individual pathogenicity; in turn contributing to understanding their clinical 
significance and epidemiology.  Earlier and recent trends in epidemiology also reflect 
significant CoNS species to species differences demonstrating variances in antimicrobial 
susceptibilities, thus markedly enhancing their clinical significance (Christensen et al., 1983; 
Burnie et al., 1997; Chen et al., 2010).  Additionally, the recent observed increase in 
antibiotic resistance among CoNS isolates causing BSIs threatens the ability to manage such 
infectious complications common to the immunocompromised patient group (Worth et al., 
2009; Chen et al., 2010).  Hence the overall pathogenic potential of CoNS species in 
nosocomial infections reflects the escalating adverse clinical impact of these isolates in the 




1.3.1 Clinical manifestation of CoNS 
Staphylococci including CoNS are known to have an ability to form a slimy biofilm, which 
enables them to adhere to medical devices such as catheters.  These isolates also form a 
protective layer around themselves, making eradication difficult either by the patient’s 
immune response or by the administration of antimicrobial therapy (de Allori et al., 2006; 
Arslan et al., 2007; Smith et al., 2008). 
S. epidermidis the most intensively studied species, is the most frequent of the CoNS 
species to be associated with nosocomial BSIs predominantly as biofilm-associated 
infections on indwelling medical devices. The occurrence and frequency of S. epidermidis 
related infections however can vary considerably, dependent on geographical locations 
(Sader et al., 2001).  S. hominis strains colonise the skin for shorter periods of time 
compared to other Staphylococcus species, can nonetheless, sometimes cause infections in 
patients with abnormally weak immune systems.  Likewise, the species, S. haemolyticus 
implicated as a common causative agent of vascular catheter-associated infections are also 
associated with serious medical complications including septicaemia in neutropenic patient 
(Sloos et al., 2000; von Eiff et al., 2002).  S. epidermidis is a major inhabitant of the skin and 
mucosa and the most common clinical isolate of the cutaneous microbiota comprises greater 
than 90% of the aerobic resident flora of an immune-competent host (Cogen et al., 2008).  S. 
epidermidis over the past two decades has emerged as a frequent cause of nosocomial 
infections, facilitated by several extrinsic factors which contribute its conversion from an 
innocuous member of the resident microflora to pathogen (Otto, 2009).  Extrinsic factors that 
cause S. epidermidis to become a pathogenic agent include the immunocompromised state 
of the host and indwelling medical devices, which act as major access ports for systemic 
infections (Coello et al., 2003; Costa et al., 2006).  Infectious strains of CoNS in particular S. 
epidermidis selected from among the abundant diverse clones in the normal skin flora, have 
an advantage in terms of pathogenicity due to their greater ability to adhere to foreign body 
implants (Galdbart et al., 2000; Bjarnsholt, 2013).  This characteristic is an important clinical 
pathogenic mechanism which some species of CoNS are more adaptive than others in 
causing of persistent chronic infections particularly in the immunocompromised host (Otto, 
2009). 
1.3.2 CoNS virulence 
The capacity of a bacterium to cause disease reflects in its relative pathogenicity when host 
natural and immune defences are compromised.  Virulence is defined as a measure of the 
pathogenicity of the bacterium and the degree of virulence is therefore stated to be related 
directly to the ability of the organism to cause disease by disrupting host defence 
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mechanisms (von Eiff et al., 2002).  The expression of virulence determinants are stimulated 
and regulated by conditions encountered in the host which are unique to the metabolic 
requirements of the infective agents (Fey, 2010).  In accordance with the relatively benign 
relationship that CoNS isolates have with their host, most, if not all the virulence factors of 
the species appear to have association with original functions compatible with the 
commensal lifestyle of the bacterial species.  Of clinical importance, many of the virulence-
associated infections that affect immunocompromised patient populations involve CoNS 
species that are part of the normal human microbiota or are ubiquitous to the hospital 
environment (Ziebuhr, 2006). Pathogenicity of CoNS therefore appears to stem from 
molecular determinants that evolved from life as skin commensals to facilitate survival during 
course of infection (Otto, 2009)   
Enzymes and toxins produced by bacteria are usually a means by which pathogenicity is 
established (Cunha et al., 2006).  It has been recognised that various CoNS species produce 
a number of exoenzymes including haemolysins, several lipases and proteases which 
contribute to the pathogenesis of CoNS (Otto, 2004).  These findings are consistent with 
reports of a study investigating clinically significant CoNS infections in hospitalised new-born 
infants.  The presence of one or more virulence factors including haemolysin and lipase were 
reported to be prevalent in 77.8% of the CoNS isolates contributing to pathogenicity of 
infections in patients with underdeveloped immunity (Cunha et al., 2006).   Moreover, this 
study suggests that the presence of these CoNS virulence factors provides a selective 
advantage for skin colonisers in high-risk hospitalised patient groups which may also lead to 
an increase in the severity of infection.   This, therefore, puts patients with either an under-
developed immune system or are immunodeficient due to malignancy at a higher risk of 
subsequent CoNS related infections when submitted to invasive procedures (Klingenberg et 
al., 2007).  
Exoenzymes such as haemolysins that contribute to pathogenicity are produced by various 
CoNS species including S. epidermidis, S. haemolyticus and S. warneri amongst others.  
The haemolysins act by binding to susceptible host tissue cells causing damage and release 
of vital cellular content.  More importantly however, haemolysin binding to host red blood 
cells leads to lysis, releasing free iron molecules, an essential growth factor for bacterial cell 
multiplication (Cunha et al., 2004).  Lipases are exoenzymes and their production, an 
adaptive response aiding persistence in fatty secretions.  Lipase production has been 
demonstrated by S. epidermidis and various other CoNS species including S. hominis, S. 
capitis, S. caprae, S. cohnii, S. warneri and S. simulans (Otto, 2004; Longauerova, 2006).  
Likewise, proteases production by isolates of CoNS can also be an important virulence factor 
with the potential to damage functional proteins that are constituents of host tissues 
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associated with immune defences.  Studies have suggested that proteases production and 
interaction with the host defence proteinaceous barriers could be a contributory factor for 
enhancing bacterial disease pathogenesis (Otto, 2004).  Including the production of 
haemolysin, proteases and lipases involved with invasive diseases, CoNS species such as 
S. lugdunesis express other virulent determinants like thermostable DNAse and clumping 
factors phenotypically similar to those of S. aureus (Hellbacher et al., 2006). 
In contrast to the large arsenal of toxins produced by S. aureus causing infection in the host, 
relatively few toxin related virulence traits have been identified in CoNS isolates.  Through in-
vitro studies, authors demonstrate that in order for CoNS to exhibit pathogenicity, these 
strains predominately express virulence traits primarily associated with adhesion, 
translocation, or evasion of host immune responders (Cogen et al., 2009).  Therefore, in 
patients with an impaired immune system such as those with haematological malignancies, 
expression of such virulence traits leads to pathological changes that are clinically 
detrimental to the host. 
1.3.2.1 Biofilms 
Biofilm, also referred to as “slime” is the virulence factor associated with chronic infections in 
many diseases, principally characterised by extreme resistance to antimicrobial agents and 
excessive capacity to withstand host immune responses (Xu et al., 2000; Høiby et al., 2010). 
The production of biofilm composed of capsular polysaccharides is a universal attribute of 
many bacteria which allows them the adhere to and persist on almost any surface.  In 
general, bacterial growth and proliferation occurs phenotypically as either single cells 
(planktonic) or as sessile aggregates (biofilm) composed of multiple bacteria forming a 
consortium.  The primary stage in biofilm development is the binding of planktonic bacterial 
cells to a foreign body or host tissue.  The second stage in the development of biofilm which 
allows intracellular aggregation is the liberations of extracellular material consisting of 
polysaccharides, proteins and bacterial DNA.  This is followed by biofilm maturation and 
dispersal of the biofilm encased bacterial cells (Costerton, 1999; Otto 2008).  Capsular 
polysaccharide synthesised by many microorganisms are high-molecular weight polymers 
which are associated with pathogenicity and virulence promoting factors.  Of these polymers, 
exopolysaccharides constitute a source of carbon and energy reserves, providing cell 
adhesion and protection against adverse environmental conditions (Otto 2008, 2009, 2010).   
Biofilms are therefore, defined as multicellular aggregated architecturally complex 
communities held together by self-produced extracellular matrix (slime) tolerant of most 
antibiotics and host defences compared with planktonic cells (Bjarnsholt, 2013).  Of clinical 
importance, many of the biofilm-associated infections that affect immunocompromised 
25 
 
patient populations involve bacterial species that are part of the normal human microbiota or 
are ubiquitous to the hospital environment (Ziebuhr et al., 2006).  Factors such as nutrition 
availability, aspects of environmental stress including temperature and osmolarity and sub-
inhibitory antibiotic concentrations play a significant role in both the formation and/or 
repression of biofilm formation (Mertens and Ghebremedhin, 2013). 
The ability to develop biofilm is one of the major pathogenic determinants of CoNS isolates.  
Biofilms produced by CoNS species vary, dependent on environmental condition and specific 
strain attributes.  Formation of biofilm is highly beneficial to CoNS communities which exist 
within them, providing protection against host defence systems and conferring resistance to 
many antimicrobials.  Biofilm producing CoNS are mainly associated with medical devices 
such as catheters or implanted material often resulting in treatment failures in chronic 
infections (O'gara and Humphreys 2001).  
CoNS isolates like other bacterial population within biofilms exist within a wide range of 
adaptive physiological states.  Both genotypically and phenotypically diverse populations 
within the biofilm express distinct biological activities and antimicrobial stress responses (Xu 
et al., 2000).  A number of mechanisms contribute towards the physiological and genetically 
diverse heterogenic nature of this response (Singh et al., 2017).  These include factors such 
as local environmental adaptation affecting antibiotic diffusion, microscale chemical gradients 
within the biofilm environment, stochastic genotypic expression and variation through 
mutation and selection (Stewart and Franklin 2008).  Tolerance to antibiotic killing is 
therefore likely due to reduction in nutrient availability and oxygen from the periphery to the 
centre of the biofilm.  These conditions lead to a state of starvation-induced antibiotic tolerant 
isolates which may be responsible for recalcitrance of biofilm infections associated with 
treatment failures (Radlinski and Conlon 2018). 
Of all the CoNS species, the emergence of S. epidermidis as an opportunistic pathogen has 
been synonymous with the widespread use of intravascular medical devices colonised by 
these isolates (Otto, 2009; Bjarnsholt, 2013).  S. epidermidis, the most ubiquitous of skin -
colonisers have the inherent ability of forming mucoid biofilms on the inert surfaces of 
indwelling medical devices associated with persistent and chronic infections, resulting in 
serious clinical consequences (Galdbart et al., 2000; O'gara and Humphreys 2001; 





1.3.2.1.1 S. epidermidis biofilms 
The pathogenic mechanisms by which S. epidermidis are implicated in a range of 
nosocomial infections are not well established but are to a degree similar to the spectrum of 
infections caused by S. aureus (Costa et al., 2006).  It therefore appears plausible that these 
two staphylococcal species share one or more virulence determinants such as cell-wall 
associated adhesins and secreted proteins that are involved in pathogenesis (Fey, 2010). 
These include the extracellular matrix and plasma proteins which promote adherence playing 
a central role in colonisation of medical devices (Arciola et al., 2004).  As such these have 
been shown to be the foci of device-related infections, as large numbers of biofilm enchased 
bacteria have been observed to be present on these devices on removal (Costerton et al., 
1999; Galdbart et al., 2000).   Established device-related biofilm infections are difficult to 
treat, therefore necessitating device removal to eradicate both the organism and eliminate 
the source of persistent infection (Høiby et al., 2015).  
S. epidermidis despite their supposed low virulence, can cause devastating chronic 
infections in the compromised host.  Such virulent strains have been observed to produce a 
family of pro-inflammatory peptides which have multiple functions in immune evasion and 
biofilm development (Otto, 2009).  Diversity among S. epidermidis isolates distinguishes 74 
clonal types of which Sequence Type 2 (ST2) has been identified as the most prevalent and 
invasive.  Molecular analysis further shows that the ST2 contains the IS256 and ica genes 
which are correlated with S. epidermidis invasiveness and biofilm formation (Otto,2004, 
2009; Schoenfelder et al., 2010). 
Immune-incompetent patients including those with haematological malignancies have a high 
propensity for infection by S. epidermidis.  Together with intravascular device infections, 
cancer patients undergoing myelosuppressive chemotherapy with accompanying 
neutropenia also renders them at a greater risk of developing S. epidermidis associated BSIs 
(von Eiff et al., 2002; Wisplinghoff et al., 2003).  Patients with haematological malignancies 
where both the cellular and humoral immune response is severely compromised, 
antimicrobial therapy eradicates planktonic cells released from biofilm but is observed to be 
ineffective against biofilm encased sessile populations (Mah and O’Toole, 2001).  Similarly, 
in the immune-competent host, biofilms produced by virulent S. epidermidis afford the strains 
partial protection from both the hosts immune system and exogenous antimicrobial agents.  
Furthermore, virulent biofilm producing strains are also a major complicating factor in the 
management of S. epidermidis sepsis as these have a reduced affinity for common 
antimicrobial agents thereby resulting in treatment failures (Arslan and Özkardes, 2007).  Of 
all the ubiquitous human commensal, S. epidermidis is primarily an optimal carrier and 
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reservoir for antimicrobial resistance genes, thus enhancing its overall pathogenic potential 
(Otto, 2009).  
1.3.2.2 Biofilm mediated antimicrobial resistance 
Biofilm producing bacteria are significant contributors to human disease accounting for over 
80% of biofilm-related infections which fail eradication with standard antimicrobial treatments 
(Davis, 2003).  The basic mechanism of biofilm resistance to antimicrobial therapy is due to 
failure of the antimicrobial agent penetration to the full depth of the biofilm.  The diffusion of 
the antimicrobial agent is known to be retarded by the polymeric substances which are part 
of the biofilm matrix (Stewart and Costerton, 2001; Stewart, 2002).  Reduced biofilm 
susceptibility to particular antimicrobial agents is dependent of several factors.  These 
include diffusion limitation due to the molecule size of the agent, deactivation of the agent in 
the outer layers of the biofilm and antimicrobial tolerance (Mah and O'toole 2001; Otto, 2004, 
2008, 2009). The glycoprotein and polysaccharide components of the biofilm limits the 
transportation and activity of the antimicrobials resulting in sub-inhibitory activity.   Antibiotic 
resistance is further supported due to the bacterial cells transitioning from the exponential to 
either slower or no growth and an adaptative ‘persister cell’ phenomena (Singh et al., 2017).   
Nutrient-starved slower growing or stationary-phase cells in the deeper layers of biofilm are 
also less susceptible to antimicrobial agents.  This adaptive phenotypic response for survival 
is characteristic of biofilm encased bacterial cells (Stewart, 2002; Stewart and Franklin 2008).  
Furthermore, a review publication by Stewart, (2002) of antibiotic penetration limitation in 
biofilm indicated that biofilms formed by beta-lactamase producing bacteria prevent the 
penetration of penicillin through the biofilm due to antibiotic reaction-diffusion interactions.  
Similarly, the penetration of positively charged aminoglycoside agents such as gentamicin, 
are retarded by the active binding of these molecules to the negatively charged biofilm matrix 
polymers.  Reduced antimicrobial susceptibility in biofilm producing bacteria has also been 
proposed due, not only to phenotypic adaptive responses, but additional genotypic 
mutational events within the biofilm.  These genetic changes allow the emergence of high-
level persister cells present within the biofilm that remain refractory to antimicrobial 
challenges despite removal of antibiotic pressure (Costerton et al., 1999; Stewart and 
Franklin 2008).   
It has been postulated that pathogenic strains of CoNS are reliant on the presence or 
absence of specific genes that are involved in both the virulence and antimicrobial resistance 
process.  Studies have demonstrated that the two most important virulence characteristics of 
S. epidermidis both sharing the same genetic pathway are biofilm formation and expression 
of methicillin resistance (Mack et al., 2007).  The genes involved in the process of primary 
28 
 
attachment to medical devices are the ica gene and altE gene.  These genes encoding the 
vitronectin-binding cell surface protein and the mecA gene encoding the control of PBP2a 
synthesis in methicillin-resistant staphylococci are found on the same genetic loci (Mah and 
O'toole 2001; Blair et al., 2015).  Therefore, in mecA positive S. epidermidis strains insertion 
of transposons at these specific regulatory gene loci, influence both the formation of biofilm 
and expression of methicillin resistance, thus hampering treatment opportunities against 
infections caused by these strains (Mack et al., 2007).  Hence these genetic and regulatory 
level adaptations contribute to the evolutionary success of nosocomial strains of S. 
epidermidis as opportunistic pathogens in the immunocompromised host (Schoenfelder et 
al., 2010).  
1.4 Haematological malignancies and bone marrow transplantation 
Advances in medical interventions over the past few decades such as allogeneic and 
autologous bone marrow transplantation (BMT) part of haemopoietic stem-cell 
transplantation for the therapeutic management of patients with haematological malignancies 
have gained much importance.  Autologous or allogenic BMTs are classified according to the 
source of the haematopoietic stem cells.  Allogenic BMT are harvested and infused either 
from donor bone marrow or peripheral blood cells treated with granulocyte colony stimulating 
factor whereas autologous are cells sourced from the recipient (Yuen et al., 1998; Collin et 
al., 2001).  These therapies have been implemented in specialist hospital haematology units 
for patients primarily diagnosed with haematological malignancies such as; acute 
myelogenous leukaemia, chronic myelogenous leukaemia, acute lymphoid leukaemia, non-
Hodgkin’s lymphoma and myelodysplastic syndrome amongst other multiple myelomas.  The 
underlying disease state and therapeutic interventions related to specific humoral and 
cellular defects puts this patient population at a greater risk of BSIs an important cause of 
both mortality and morbidity (Klastersky et al., 2007; Cervera et al., 2009; Garcia-Vidal et al., 
2018).   
Severe infections are also a frequent and life-threatening complication of haematopoietic 
stem cell transplantation due to the abnormalities of the hosts defence system (Neuburger 
and Maschmeyer, 2006).  Haematological disease-related and treatment induced 
neutropenia together with immunosuppression puts these patients at a greater risk of 
acquired opportunist infection (Dettenkofer et al., 2003).  A major complication of cancer 
chemotherapy is development of febrile neutropenia which may probably be the only 
indication of severe underlying infectious state.  The extent and duration of the neutropenic 
state is, therefore, a key risk factor for extent of fever and hence also the development of 
serious infection complications (Feld, 2008; Marin et al., 2014).  BSIs rank first in terms of 
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serious infectious complication of febrile neutropenia and are associated with higher rates of 
morbidity and mortality (Caggiano et al., 2005; Kleinhendler et al., 2018).   
Similarly, patients undergoing bone marrow transplantation (BMT) have illnesses associated 
with immunological deficiency which are further compounded and compromised by pre-
treatment chemotherapeutic regimens (Bal and Gould 2007). The incidence of BSIs due to 
opportunistic infections appears to be higher in BMT patients in comparison to non-BMT 
haematology patients. This is mainly due to factors which significantly effect poor prognosis 
such as relapse, uncontrolled malignancy and the neutropenic state amongst others (Worth 
and Slavin, 2009).  Ablative chemotherapeutic regimens as part of BMT is known to 
invariably lead to patients developing severe neutropenia particularly after the post-
engraftment period.  The resulting loss of immune-reactivity for varying periods of time after 
BMT leaves the patients extremely susceptible to bacterial infections in the early stages of 
post transplantation due to severe impairment of cellular and humoral immunity (Dettenkofer 
et al., 2003).  BMT patients are also known to be infected with the same primary organisms 
as in the general haematology neutropenic or non-neutropenic patient.  Similarly, the most 
frequent cause of bacteraemia due mainly to the prolonged neutropenic state in BMT 
receipts are the Gram-positive isolates (Chen et al., 2010).  However, treatment-induced 
neutropenia, long central venous catheter (CVC) dwell times, and the use of 
immunosuppressive agents’ place BMT recipients at a higher risk of CVC related BSIs 
(Kratzer et al., 2007).   
The most common causative organisms of device related infection are usually the ubiquitous 
skin flora of hospitalised patients, primarily CoNS isolates (Casey et al., 2007). The 
association of CoNS bacteraemia with the use of indwelling intravascular devices is a well-
established observation.  This is due the capacity of CoNS to colonise by adhering to these 
devices via the production of extracellular glycocalyx (slime) and adhesins (Arciola et al., 
2004).  Other portals of organism entry include, skin catheter hubs, infusion solutions and 
colonised insertion sites which are a major risk factor for infection.  Additional potential 
sources of CoNS colonisation and infection include nasal area, oral mucosa and skin lesions 
which occur secondary to chemotherapy and/or graft versus host disease causing loss of 
natural skin integrity (Wolf et al., 2008).  Furthermore, the infective agents from both 
endogenous and exogenous sources colonising long-term indwelling catheters proliferate 
within biofilms and disseminate into the bloodstream resulting in severe systemic infections 
(Raad et al., 2007).  The incidence of such catheter-related BSIs (CR-BSIs) has been shown 
to correlate greatly with the degree of immunosuppression in the haematology and oncology 
patient groups.  CR-BSIs in cancer patients remain among the most common of observed 
complications, with a reported prevalence as high as 38% in this group, however a significant 
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increase in disease-related mortality associated with CRIs is not observed (Madani, 2000; 
Wolf et al., 2008).  Conversely, reports of increased morbidity, prolonged hospitals stays with 
increasing costs associated with CRIs in cancer patients make CR-BSIs the most frequent 
and costliest of healthcare-associated infections (Beekmann et al., 2003) 
Reducing poor clinical outcomes associated with bacteraemia in patients with haematological 
malignancies remains challenging due to the emergence of resistance to multi-drug classes 
used for effective therapy.  In most healthcare settings the prompt implementation of broad-
spectrum empiric antimicrobial therapy with the addition of vancomycin limits the progression 
of bacteraemia and increases the chances of a favourable outcome for the BMT receipts 
(Hughes et al., 2002; Raad et al., 2007; Zakhour et al., 2016).    Reports of mortality 
attributed to CoNS-related bacteraemia, therefore, remain low (<5% of 57% diagnosed with 
GP-bacteraemia) particularly in patients receiving autologous or allogenic transplants 
dependent on prompt infection prophylaxis, diagnosis and treatment (Collin et al., 2001; 
Freifeld et al., 2011). 
1.4.1 Blood stream associated infections 
Healthcare-associated infections (HAI) or nosocomial Blood stream infections (BSIs) are the 
most common complication in hospitalised patients especially those with terminal 
malignancies, resulting in increased morbidity and mortality rate of 18%-42% (Wisplinghoff et 
al., 2004; Kleinhendler et al., 2018).  The progress made in modern medical care and 
availability of greater chemotherapeutic options with an increase in transplantations has 
nonetheless substantially increased the risk of CoNS infection complications in cancer 
patients.  The overall individual incidence of BSI for haematology patients is three-fold higher 
in comparison to oncology patients equally related to CoNS as the predominant isolate in this 
patient group (Schelenz et al., 2013). 
BSIs have been reported to be among the most common infectious complications observed 
in haematology patients, the majority of which are associated with GP-organisms (57.1%) 
together with the significant predicator of mortality being prolonged neutropenia concomitant 
with nosocomial infection (Tumbarello et al., 2009). The altered immune status of these 
vulnerable patient groups due to interference of immunosuppressive factors facilitates the 
risk of BSIs resulting in significant disease and morbidity particularly among transplant 
recipient patients.  Moreover, the risk of developing nosocomial BSIs in neutropenic patients 
who have undergone BMT has been documented to be much greater than in non-
transplanted patients with other malignancies and neutropenia.  As such, investigators have 
reported incidence rates of 360 BSIs per 1000 neutropenic episodes in BMT patients in 
comparison to 11-38% reported cases of BSIs in neutropenic patients (Wisplinghoff et al., 
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2003; 2004).  This has been attributed to neutropenic patients with haematological 
malignancies unable to mount an adequate inflammatory response to infective agents with 
fever presenting as the only symptom of serious infection.   Neutropenia-associated  
hospitalisation was also reported to be more common in haematology patients with 
chemotherapy-treated leukaemia (1 in 6 patients) relating to  the highest incidence and cost 
per in-patient stay (Caggiano et al., 2005)  Overall, neutropenic-associated infection relating 
to  hospital costs in patients with haematologic cancers were projected to be a fifth higher in 
comparison to patients undergoing chemotherapy for other cancers (62% in comparison to 
22-53% respectively).  In another well-documented review study, Goto and Al-Hasan (2013), 
report that there were a total number of 200,000 nosocomial BSI episodes with a total of 
157,000 associated deaths in Europe which were a consequence of local primary or 
secondary immunodeficiency disorder of the immune system.  This population-based study 
also reports an estimated occurrence of 96,000 BSI episodes totalling 12000-19000 related 
deaths in England alone.  Furthermore, focusing on the preventative measures for reducing 
nosocomial BSIs in haematology and oncology patients, authors suggest including 
monitoring and identification of common causative organisms with timely implementation of 
appropriate empirical antimicrobial therapies thus reducing the overall burden of disease. 
The evolution of medical care and development of potent anti-staphylococcal agents has led 
to the change in the predominance and clinical significance of Gram-positive associated 
bacteraemia mainly in the immunocompromised hospitalised patient population (Karchmer, 
2000; Klastersky et al., 2007; Cervera et al., 2009).  This is evidenced in a multi-centre pan-
European observational study of sepsis occurrence in acutely ill patients reporting that the 
highest percentage of Gram-positive associated bacteraemia in the critical ill patient through 
normal and/or nosocomial acquisition, was predominantly due to methicillin sensitive and 
resistant strains of both S. aureus and CoNS (Vincent et al., 2006).  Infections occurring due 
to the progressive increment of virulent multi-drug resistant strains appears to have been 
fuelled by selective pressure resulting from the extensive use of broad-spectrum 
antimicrobials (Huges et al., 2002; Trecarichi et al., 2015).  Therefore, in line with the 
changing patterns of acquired nosocomial BSIs, a life-threatening complication of cancer 
therapy, hospitals implement agreed treatment protocols for a rational choice of single or 
combination therapy, dependent on local patterns of antimicrobial resistance.  These 
effective therapeutic protocols are for the treatment and management of febrile neutropenic 





1.4.2 Sources of BSIs 
BSI are usually representative of compromised immune system failing to contain infection at 
a focal site and the consequent dissemination of disease.  Bacteraemia is usually the most 
common manifestation of CoNS infection.  Several literature reviews report the global trend 
of increasing incidence and severity of CoNS bacteraemia, whereas previously these isolates 
were exclusively regarded as contaminants arising from the hosts cutaneous flora (Weinstain 
et al., 1997; García et al., 2004).  It is generally believed that the CoNS isolates colonising 
the skin of the individual patient are usually the source of CoNS-associated bacteraemia 
concomitant with indwelling prosthetic device-related infections (Christensen et al., 1983; 
Coello et al., 2003; Costa et al., 2004).  However, CoNS as benign residents on skin 
surfaces and as aetiological agents of BSIs usually arise only in conjunction with specific 
host predispositions.  
CoNS-associated bacteraemia is a well-recognised complication of intravascular medical 
device-related infections. These devices implanted during patient’s hospitalisation are an 
essential requirement for continuous intravascular access (Zietella, 2003).  CoNS are 
frequently implicated as the infective agent due to the prevalence on the skin and isolation 
from colonised foreign body devices and their insertion sites (Marin et al., 2014).  
Confirmation that these devices are the source of infection remains challenging as skin 
contaminants can be acquired from the various sources during surgical implantation (von Eiff 
et al., 2002; Ahlstrand et al., 2012).  However, a marked increase in CoNS CR-BSIs relating 
to endogenous sources in the critically ill has been observed over the past few decades.  
Studies conducted evaluating the source(s) of CoNS bacteraemia using specific defined 
criteria for CoNS bacteraemia, report that mucosal sites other than the skin as potential 
sources of infection, are likely to be an important source of CoNS bacteraemia (Costa et al., 
2004).  Further evidence is provided by another prospective study describing the relationship 
between colonising and invasive strain patterns of CoNS among patients undergoing 
treatment for haematological malignancy. The authors also document that CoNS-associated 
bacteraemia in patients with haematological malignancy and those undergoing BMT are 
commonly due to translocation from the skin or mucosa into the bloodstream (Ahlstrand et 
al., 2012).  Therefore, disruption of skin integrity and prolonged use of catheters which are 
highly likely to become infected during the course of disease, increase the risk of CoNS 





1.4.2.1 Device-related bloodstream infections  
The majority of intravascular devices are long-term insertions in patients with haematological 
malignancies undergoing chemotherapy with a high prevalence of neutropenia (Falcone et 
al., 2004; Martiínez-Morel et al., 2014). Continuous intravascular access is an essential 
requirement for these patients in particular recipients of stem-cell transplants to secure 
access for blood product transfusions, chemotherapeutics, parental nutrition, antibiotics and 
stem-cell infusions (Zakhour et al., 2016). The most commonly used devices include 
percutaneous non-cuffed non-tunnelled CVCs and cuffed tunnelled CVSs (Hickman, Broviac 
and Groshon). Long term use of CVCs together with disruption of skin integrity and 
treatment-induced neutropenia therefore places BMT recipients at a higher risk of CoNS 
device-related infection (Zietella, 2003; Martiínez-Morel et al., 2014; Yamada et al., 2017).   
Bacteraemia remains among the top four causes of HAI commonly associated with the use 
of peripherally inserted central catheters especially in the intensive care setting.  This is 
evidenced by a hospital-wide surveillance of hospital-acquired bacteraemia in English 
hospital between 1997 and 2001, conducted by the Nosocomial Infection National 
Surveillance Scheme (NINSS), reported that the incidence of device-related bacteraemia 
was highest among high-risk patient specialists where central lines were the commonest 
source of infection (Coello et al., 2001).  
Frequent use of long-term intravascular accesses and other implantable devices are 
implicated as the major source of infections caused by Gram-positive cocci. The high 
incidence of CoNS BSIs has been directly correlated with intensity and length of neutropenia 
and the higher CVC usage in cancer patients (Pagano et al., 1997; Marin et al., 2014).  
Infections in patients with haematological malignancies undergoing chemotherapy are 
promoted by treatment-induced disruption of both mucosal surfaces and damage to the skin. 
Invasive procedures such as insertions of CVCs or percutaneous biopsy procedures provide 
portals of entry and proliferation of opportunistic pathogens originating from the skin 
commensal flora (Neuburger and Maschmeyer, 2006; Ahlstrand et al., 2012).  The 
endogenous lining of the interior surface of intravascular catheters have been found to be 
colonised by biofilm forming microorganisms within 24 hours of insertion. The protective 
properties of biofilm appear to be an important pathogenic mechanism for the development 
of catheter-related infection (Wolf et al., 2008). This, therefore, increases the risk of CoNS 
bacteraemia in haematological malignancies due to the prolonged use of catheters which are 
likely to become infected during the course of disease (Wisplinghoff et al., 2003).   Raad and 
colleagues (2007), in their study demonstrated that CVCs, localised entrance and exit sites 
were the major source of BSIs in patients with underlying haematologic malignancy. 
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Likewise, the authors of another study have also documented a significantly higher figure of 
CR-BSIs in a large number of BMT recipients during neutropenic state (Dettenkofer et al., 
2003).  Poor clinical outcomes were also associated with CoNS bacteraemia in the presence 
of persistent neutropenia in this patient group.  
Marin and colleagues (2014) in their prospective observational study also reported that an 
endogenous source and catheter-related incidence of BSIs were most frequent in 
neutropenic patients with haematological malignancies.  In this study, out of the 579 
episodes of BSI in neutropenic patients, 493 (85%) occurred in patients with haematological 
malignancies with CoNS (41.8%) identified the predominant causative isolates (Marin et 
al.,2014). Similarly, in a review study looking at 110 episodes of CVC related BSIs, in 82 
patients with haematological malignancy, CoNS were the most commonly isolated organisms 
(Zakhour et al., 2016).  Several strategies to reduce catheter colonisation have been 
considered for efficacy such as antimicrobial lock therapies for prevention and eradication of 
CVC related BSIs.   Catheter removal on the other hand, is a component of definitive 
treatment for BSIs caused by colonising strains of CoNS and other Gram-positive organisms 
but is highly detrimental for the clinical management of critically ill patients (Zitella, 2003, 
Worth and Salvin 2009).  Implementation of appropriate intravenous antibiotic including 
catheter lock solutions and/or removal of the implanted lines remains the mainstay of 
treatment in most cases of CR-BSIs in patients with haematological malignancies (Zakhour 
et al., 2016). 
1.5 Diagnosis of bacteraemia 
Fatal bacteraemic infections in patients with acute leukaemia were commonly due to Gram- 
negative bacilli in the early 1970s.  However, in the past few decades, the major group of 
organisms contributing to a shift towards Gram-positive single-organism bacteraemia are 
predominantly the CoNS (Wisplinghoff et al., 2004; Wilson et al., 2011; Zakhour et al.,2016).    
A prospective study carried out by Denttenkofer and colleagues (2003), on patients with 
haematological malignancies and post BMTs, documented that the highest incidence of 
nosocomial infection especially during the neutropenic phase was mainly due to CoNS 
species.  Similarly, authors of another study demonstrated that in BMT recipients, risk factors 
for CoNS bacteraemia not only included aplasia and graft-versus-host-disease (GvHD) but 
the relatively high incidence of CoNS catheter-related infections resulted in exacerbation of 
chronic GvHD with aggravation of immunosuppressive therapy (Kratzer et al.,2007). Thus, 
the potential factors predisposing this patient group to CoNS-associated BSIs amongst other 
factors include immunosuppressive therapy, biofilm encased organisms in colonised invasive 
devices and procedures such as ventilator use, and selective pressure exerted by 
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antimicrobial therapy (Zakhour et al.,2016). Furthermore, bacteraemia associated with frank 
sepsis in the haematology patient group involving highly virulent strains of CoNS such as S. 
lugdunensis have been linked to fatal clinical outcomes (Pagano et al., 1997).  Accurate 
diagnosis of CoNS bacteraemia is therefore essential in this patient group, dependent on 
both the clinical presentation and in the majority of cases, isolation of the same strain or 
clonal population.  This is imperative when bacteraemia is associated with infections related 
to colonised indwelling medical devices usually implicated as the source of infection 
(Worthington et al., 2000; Zitella, 2003).  Poor clinical presentation associated with ineffective 
therapeutics therefore necessitates removal of the device to eradicate the possible source of 
infection at a potential risk to the patient (Worth et al., 2009). 
The clinical significance of BSIs due to CoNS in the critically ill patient is being increasingly 
recognised with the elucidation of their pathogenic nature (von Eiff et al., 2000).  Diagnosis of 
CoNS-associated BSIs is, however, difficult in hospitalised patients as the clinical signs and 
symptom in the critically ill patient may be masked and non-specific (Longauerova, 2006).  
However, CoNS as ubiquitous skin commensals of low virulence and common contaminates 
of blood cultures can also be the cause of true BSIs in patients undergoing various surgical 
procedures and the immunocompromised (Piette and Verschraegen, 2009; Becker et al., 
2018). These factors, therefore, makes differentiating true infection from colonisation, 
challenging.  Hence, accurate surrogate markers to differentiate between CoNS BSIs and 
contamination are used in conjunction with clinical, laboratory and microbiological 
parameters for an improved diagnostic approach (Pfaller and Herwaldt 1998).  In the high-
risk patient population clinical characteristics of the patients together with the microbiological 
evidence provides the clinicians with information to distinguish between true CoNS BSI or 
contamination.  Nonetheless, the general approach adopted by clinicians in most healthcare 
settings is to treat patients with broad-spectrum empirical antibiotics prior to microbiological 
diagnosis to improve patient outcomes and decrease mortality due to risk factor of febrile 
neutropenia (Huges et al., 2002; Kleinhendler; et al., 2018).  
Bacteraemic patients with febrile neutropenia due to their immunocompromised state and 
poor inflammatory response do not demonstrate localised signs or symptoms other than 
fever associate with infection. Temperature spiking in association with bacteraemia, has 
been shown to occur around an hour following the organism’s entry into the blood stream.  
Therefore, obtaining blood cultures at the time of onset of fever has shown to greatly 
increases the likelihood of detecting bacteraemia (Synder, 2015).  This conventional method 
of obtaining blood cultures for microbiologic diagnosis of BSIs in this patient group has some 
limitations due to lack of rapidity and sensitivity and associated factors such as previous 
antimicrobial therapy affecting isolation and identification of the causative organism in blood 
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cultures which significantly increases the morbidity and mortality risk in this patient group 
(Marin et al., 2014).   Other studies have shown that molecular techniques such as real-time 
polymerase chain reaction (RT-PCR) that are not affected by prior antibiotic prophylaxis have 
added clinical benefits for febrile patients due to their greater sensitivity, specificity and 
speed of diagnosis (Mancini et al., 2008).  Nonetheless despite the advantage of rapidity for 
detection of the infecting organism, antimicrobial susceptibility still remains the limiting factor 
as detection of resistance marker genes have yet to be fully evaluated with such molecular 
based techniques (Guido et al., 2012).  Detection of blood stream isolates in critically ill 
patients is therefore of both major diagnostic and prognostic importance.  The management 
of bacteraemia is consequently undertaken in accordance with published guidelines and 
current local hospital policies which include sampling of blood for culture if possible, prior to 
initiation of broad-spectrum empirical antimicrobial therapy (Weinstain et al., 1997 Chen et 
al., 2005; BMJ, Best Practice 2017).  Blood Culture specimens are a critical tool for the 
detection of organisms in the blood stream which may be potentially pathogenic, 
representing a clinically significant infection associated with a high risk of morbidity 
(Weinstein et al., 1997).  Hence, blood cultures remain the “gold-standard” for microbiological 
diagnosis of bacteraemia in hospitalised haematology-oncology patients enabling targeting of 
therapy against specific organisms.  The clinical microbiology laboratories plays an important 
predictive role in rapid diagnosis of bacteraemia by identifying the aetiological infectious 
agent and guidance relating to evaluated antimicrobials, consequently resulting in effective 
management of critically ill patients.   
Advances in microbiological diagnostic platforms and complementary assays have facilitated 
the identification of clinically important pathogens. In most clinical laboratories at present, 
blood cultures are currently performed using fully automated continuous-monitoring computer 
assisted systems.  These include systems such as BactT/Alert-3D (bioMérieux, France) 
using colorimetric sensors detecting microbial growth by analysing the production of carbon 
dioxide.  Positive signals indicating the growth of organisms are usually flagged-up by the 
automated system within 24 to 48 hours followed by a preliminary presumptive identification 
of the organism performed by Gram-stain test (Beekmann et al., 2003; Mancini et al., 2008).  
Following this, confirmation of infectious aetiology is carried out by use of rapid phenotypic 
tests for accurate pathogen identification and evaluation of antimicrobial susceptibilities.  The 
provision of microbiological diagnostic results allows clinicians to implement optimal effective 
antimicrobial therapeutics in a timely manner limiting the development and spread of drug-
resistance.  Furthermore, effective therapeutics also lower the risk of possible clinical failures 
in severely ill patients with life threatening diseases (Wisplinghoff et al., 2003; 2004).  
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Correct interpretation of positive blood culture may be difficult since the sources of CoNS 
BSIs may simply be due to skin colonising CoNS strain contaminants or derived from 
catheter colonisation.  Therefore, a combination of both clinical and microbiological criteria 
are usually applied to assess the significance of CoNS and other isolates deemed to be 
potential skin contaminants as significant causative agents of BSIs.  These criteria include 
continued isolation of the same isolate from multiple blood cultures and/or in conjunction with 
isolation of the same isolate from colonised intravenous catheters or sites (Casey et al., 
2007, 2007).  However, similar criteria applied to assess the clinical significance of CoNS 
isolated from blood cultures of haematology patients remain difficult in clinical practice.  In 
such cases clinical diagnosis together with isolation from either a single or at least two blood 
cultures are frequently thought to be representative of CoNS-associated infection (Marin et 
al., 2014).  Henceforth, S. epidermidis bacteraemia, a very frequent event in BMT recipients 
associated with either a single or multiple positive blood cultures are often considered as tthe 
significant causative agent (Ninin et al., 2006).  It has been noted that blood culture 
methodology is nevertheless limited by a lack of both rapidity and sensitivity for a targeted 
approach to antimicrobial therapy initiation; significantly increasing the risk of morbidity and 
mortality in this patient group (Marin et al., 2014). 
 
Studies utilising molecular techniques such as RT-PCR for the rapid diagnosis of BSIs in 
febrile neutropenic patients show superiority over conventional diagnostic systems by 
providing positive and negative predictive value algorithms for effective diagnosis (Mancini et 
al., 2008).  Such molecular techniques remaining unaffected by prior antibiotic prophylaxis 
for detection purposes, however, have their performance limited by the requirement of further 
testing to determine susceptibility, since rapid detection of resistance marker genes have yet 
to be fully evaluated with this methodology (Guido et al., 2012).  The application of rapid 
molecular techniques are however, emerging as the new standard for microbial identification 
and differentiation of clinically significant CoNS to the subspecies level.  Therefore, rapid 
diagnosis using molecular techniques can prove to be a valuable contributory factor towards 
the clinical management of patients with haematological malignancies. Currently blood 
cultures remain the reference method for the diagnosis of bacteraemia in the majority of 
clinical microbiology laboratories for guidance of targeted treatment strategies resulting in 





1.6 Identification of aetiological agents of bacteraemia 
The appropriate management of bacteraemic infection is dependent upon accurate and rapid 
identification of the infecting organism.  Despite the increased recognition of the significance 
of infections attributed to the heterogenous group of CoNS isolates, species level 
identification generally, still remains an undefined clinical requirement.  The identification of 
CoNS as a group, is basically restricted to clonal morphology, Gram-stain characteristics, 
catalase production and the absence of coagulase determined by latex and tube 
agglutination tests.  The application of these tests limit the classification of staphylococci into 
the two groups, the well-established pathogen S. aureus and the CoNS.  Generally, species 
level identification are not thought to be necessary for the clinical management of infections 
in some patient groups.  However, several investigators evaluating the importance of 
identifying CoNS to the species level from blood cultures as a predicator of clinical 
significance demonstrated that some species-specific strains were more commonly 
associated with bacteraemia than others in high-risk patient groups (Weinstein et al.,1998; 
Heikens et al., 2005).  Accurate identification of clinically significant CoNS isolates is 
therefore essential for the early prediction of potential pathogenicity.  
The fundamental principles of character analysis by conventional identification methods of 
CoNS species and sub-species are based on the original scheme proposed by Kloos and 
Schleifer (1975).  This widely used taxonomic system for the sub-classification of CoNS is 
based on 13 key characteristics which include coagulase activity, haemolysis, nitrate 
reduction and acid production from carbohydrate substrates.  Due to the improved taxonomic 
knowledge of staphylococci and the availability of new reliable identification methods and 
technologies; precise identification of strains of various Staphylococcus species involved in 
clinical infections are currently becoming the rule in routine diagnostic laboratories. These 
standard automated Identification methodologies, in high-throughput clinical microbiology 
laboratories have been shown to impact directly on improving the quality of patient care and 
management (Barenfanger et al., 1999 Funke et al., 2005; Patel et al., 2017).  Moreover, 
molecular based commercial assays in comparison to standard identification techniques, 
although not as cost effective have proved to be more accurate in identifying staphylococci to 
the species level (Mehta et al., 2009).  
Of the eleven different species of CoNS isolated from bacteraemic patients, S. epidermidis, 
S. hominis and S. haemolyticus are the three most commonly species detected, accounting 
for both the clinically significant isolates and contaminating skin flora (Diekema et al., 2001; 
Kristóf et al., 2011).  The other less commonly involved species in bacteraemia include S. 
capitis and S. lugdunensis.  S, cohnii, S. auricularis, S. simulans, S. caprae S. sciuri and S. 
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warneri, these species when isolated, are usually deemed as blood contaminant isolates but 
in the immunocompromised host may be significant.  Epidemiological studies ascertaining 
the species-species strain distribution of blood culture isolates of CoNS reported the 
dominance of S. epidermidis (68.7%) and S. haemolyticus (14.8%) among adult 
haematology patients (Burnie et al., 1997; Tacconelli et al., 2003).  The other species of 
CoNS detected included strains of S. hyicus, S. warneri, S. cohnii, and S. saprophyticus.  
The isolation of diverse CoNS species-specific isolates from bacteraemic patients therefore 
indicates the importance of species level identification, as isolation of certain species-specific 
strain are associated with a predilection to cause disease. 
A number of commercial automated systems are widely used by routine microbiology 
laboratories for the accurate identification of clinically important Staphylococcus species. 
Among these, the utilisation of the VITEK®2-Gram-Positive identification card (GP-ID; 
bioMérieux, Marcy L’Etoile, France) has been designed to increase identification of Gram-
Positive cocci (Layer et al., 2006).  The VITEK®2 and other commercial phenotypic based 
identification systems such as the BD Phoenix system (Becton Dickinson Diagnostic 
Systems, Sparks, MD) under normal laboratory conditions, reliably identify up to 90% of the 
staphylococcal species in comparison to reference molecular strain identification methods 
(Ligozzi et al., 2002).  However, mis-identification of S. hominis particularly with respect to S. 
epidermidis still remains to be improved as these strains demonstrate similar biochemical 
activity (Cunha et al., 2004; Layer et al., 2006).  Accurate identification of CoNS species may 
therefore require additional verification by either molecular testing or other suggested 
differential tests, notably when appropriate treatment is dependent on correct species 
identification. 
Advancing automated technology has led to the emergence of genotypic methods as a new 
standard for bacterial identification to both the species and subspecies level. These 
commercial systems utilise comparisons of both the variable and conserved regions of 16S- 
ribosomal RNA (rRNA) sequences for differentiation of organisms to species level (Layer et 
al., 2006; Kim et al., 2008).  The use of phenotypic based methodologies in routine 
diagnostic laboratories however predominate over genotypic methodologies due to cost 
pressures and the availability of sensitive, cost-effective mass-spectrometry based 






1.6.1 Biotyping using VITEK®2 
In the routine clinical laboratory setting, commercial automated systems such as the 
VITEK®2 (bioMérieux SA, Marcy-'Etoile, France) is used for the identification of CoNS by 
their biochemical reaction patterns (“biotyping”).  This rapid phenotypic micro-method is a 
cost effective system for accurate identification of medically relevant CoNS species (Funke et 
al., 2005).  The VITEK®2 system is based on an auto-modular format, consisting of a dilution 
mode, filler-sealer module, a fluorogenic technology based optical reader, incubator and a 
computer control module.  The system utilises uniquely coded small plastic cards consisting 
of individual wells, containing a variety of reagents, substrates or antibiotics for identification 
or antimicrobial susceptibility testing. 
Inoculated, sealed cards placed in the reader-incubator are scanned by light emitting diodes 
and phototransistor detectors every fifteen minutes, after baseline readings are taken. The 
changes in light transmission readings, detected by the photometer are transferred to the 
computer module which interprets the data determining the organism’s biotype and 
identification. (Product Literature, 2004). 
 
1.6.1.1 CoNS species identification utilising VITEK®2   
Commercial rapid automated systems now routinely used in the clinical laboratory setting 
have a high degree of sensitivity and specificity for speciation of Staphylococcus species. 
The identification of most human Staphylococcus species and sub-species is comparable to 
an accuracy of 70 to >90% as these systems undergo continuous improvements with the 
addition of more discriminatory tests included within the identification panel (Logozzi et al., 
2002) 
The Gram Positive (GP) reagent card has 64 wells, of which 43 wells are for fluorescent and 
inhibitory tests that include biochemical tests measuring carbon source utilisation, enzymatic 
activities and resistance, pH change tests and derivatives for the detection of enzymes, 
amiopeptidases and –osidases.  Substrates present in 21 wells, measure various metabolic 
activities such as acidification, alkalinisation, enzyme hydrolysis and growth in the presence 
of inhibitory substances.  The GP card, well contents listed in Table 1-1 is used for the 
identification of 115 taxa of the most significant non-spore-forming Gram-Positive bacteria. 




Table 1-1: GP card well contents for the identification of Staphylococcal species 
(Adapted from VITEK®2 GP product information).  Note: Non-designated well numbers 
are empty (control) wells. 
The VITEK®2 GPC-ID panel for the phenotypic identification of CoNS, results in recording of 
the tests as 0 for negative results and 1 for positive.  These values are compacted by the 
VITEK software computing system by combining triplets of positive/negative binary results 
into a 16 digit VITEK Bionumber.  Organism identifications are made based on test 
probabilities of each taxon in the data base of the VITEK systems. (Bannerman et al., 1993; 
Product Literature: 2004; Layer et al., 2006). 
Although this type of phenotypic identification system, based on the organism’s metabolic 
activity enables identification of the bacterial isolate to the species level with ease, there are 
several factors that limit the degree of accuracy achieved (Spanu et al., 2003, Funke and 
Funke-Kissling, 2005).  The factors that compromise accuracy of the system include, 
different stains of the same species exhibiting variation in phenotypic characteristics 
dependent on external factors such as culture media, length of culture incubation and 
Well  Test 
Amount/Well 
mg/L Well  Test 
Amount/Well 
mg/L 
2 D-AMYGDALIN  0.1875 31  UREASE 0.15 
4 
PHOSPHATIDYLINOSITOL 
PHOSPHOLIPASE  0.015 32 
 POLYMYXIN B 
RESISTANCE 0.00093 
5 D-XYLOSE 0.3 37 D-GALACTOSE 0.3 
8 ARGININE DIHYDROLASE 1 0.111 38 D-RIBOSE 0.3 
9  BETA-GALACTOSIDASE 0.036 39 D-RIBOSE 0.15 
11 ALPHA-GLUCOSIDASE  0.036 42  LACTOSE 0.96 
13 Ala-Phe-Pro ARYLAMIDASE  0.0384 44 
 N-ACETYL-D-
GLUCOSAMINE 0.3 
14 CYCLODEXTRIN 0.3 45 D-MALTOSE  0.3 
15  L-Aspartate ARYLAMIDASE 0.024 46 
BACITRACIN 
RESISTANCE 0.00006 
16  BETA GALACTOPYRANOSIDASE  0.00204 47 
 NOVOBIOCIN 
RESISTANCE  0.000075 
17 ALPHA-MANNOSIDASE 0.036 50 GROWTH IN 6.5% NaCl  1.68 
19  PHOSPHATASE PHOS 0.0504 52 D-MANNITOL 0.1875 
20  Leucine ARYLAMIDASE 0.0234 53 D-MANNOSE  0.3 
23 L-Proline ARYLAMIDASE 0.0234 54 
METHYL-B-D-
GLUCOPYRANOSIDE 0.3 
24 BETA GLUCURONIDASE 0.0018 56  PULLULAN  0.3 
25 ALPHA-GALACTOSIDASE 0.036 57 D-RAFFINOSE 0.3 
26 L-Pyrrolidonyl-ARYLAMIDASE 0.018 58 
O/129 RESISTANCE 
(comp.vibrio.) 0.00084 
27 BETA-GLUCURONIDASE 0.0378 59 SALICIN  0.3 
28 Alanine ARYLAMIDASE  0.0216 60 
 
SACCHAROSE/SUCROSE 0.3 
29 Tyrosine ARYLAMIDASE 0.0275 62 D-TREHALOSE  0.3 
30  D-SORBITOL 0.0875 63 
ARGININE DIHYDROLASE 
2 0.27 
31  UREASE 0.15 64  OPTOCHIN RESISTANCE 0.000399 
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temperature conditions.  Typically expressed biochemical characteristics of isolates may also 
be influenced by chemotherapeutic agents such as those recovered from critical ill patients 
on long-term antimicrobial therapies (Ligozzi et al., 2002; Kim et al., 2008). 
 
1.6.1.2 Identification with VITEK®-Mass Spectrometry   
Diagnostic microbiology in recent times has rapidly evolved towards the use of more 
streamlined automated organism identification systems such as, Matrix-Assisted Laser 
Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS).  Traditionally 
identification of bacteria from clinical samples has been done by examination of clinical 
morphology and by biochemical characterization classically using substrate and enzymatic 
tests (Bannerman et al., 1993; Kloos et al., 1975, 1994; Cunha et al., 2004). These tests 
routinely used in clinical laboratories remain the “gold standard” for identification but are 
subjective to interpretation if done manually.  Inoculum density and process error in some 
cases of micro-dilution based automation can also be a major limitation factor.  These 
drawbacks have however been alleviated by the development and implementation in the 
routine clinical laboratory of MALDI-TOF mass spectrometry, the intrinsic property of which is 
detection of mass-to-charge ratio (m/z) of the bioanalyte.  
Bacterial identification using mass spectrometry application is based on the acquisition of 
unique protein profiles when the isolate subjected to multiple laser shots vaporises and, in 
the process, gains an electric charge (ionisation) (Cabonnelle et al., 2011; Patel, 2015).  The 
procedure involves the conversation of biopolymer structural protein molecules present in the 
condensed phase into individual intact ionized bacterial macromolecules in the gaseous 
phase.  After migration in an electric field, these ions get separated according to their 
molecular weight followed by detection of representative masses, via the mass analyser 
component of the MS system.  Ion detection is characterised by the (m/z) ratio and relative 
intensity of the signal generated is displayed graphically as spectrum of peaks as illustrated 
in Figure 1-1.  The structure of the original bacterial molecules is deduced from analysing the 
spectral pattern of the ionised fragments (proteomic fingerprints) via the MS-software 
analysis component.  Interpretation of the generated sample spectra compared to a library of 
defined reference spectra of well characterised isolates provides high confidence level 
species identification (Theel, 2013).   
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Figure 1-1: Schematic of mass spectrometry sample ionization, capture of positively 
charged particles, mass analysis detection of ions (Da), mass spectrum production 
and Spectrum analysis, Data base comparisons and identification result. (Adapted 
from Theel, 2013) 
The application of mass spectrometry comprises accurate analysis of peptides and the 
determination of these peptide sequences identify and characterise the protein composition 
of the isolate.  The unique spectral fingerprints generated and interpreted are specific to 
bacterial genus, species and sometime subspecies providing high-level strain identification 
(Carbonnelle et al., 2012) 
MALDI-TOF MS, a fast, cost-effective and robust technique has transformed genus and 
species identification of clinically relevant etiological agent of infection (Carbonnelle et al., 
2011; Clark et al., 2013).  This versatile proteomics based technology is documented to 
provide highly reproducible data with good discriminatory power for identification of clinically 
relevant staphylococcal species (Patel, 2015).  The ease of use of this method makes it 
especially appealing in routine laboratories for identification of clinically important isolates to 
the subspecies level.  Undoubtedly, CoNS identification utilising the MALDI-TOF MS system 
is facilitated by the availability of simple and accurate procedures with sufficient database 
information for accurate species level classification.  Retrospective study carried out using 
MS-technology, by Argemi and colleagues (2015), assessing the clinical significance and 
species distribution of CoNS in various clinical specimens demonstrated that of all the CoNS 
identified, S. epidermidis was the most frequently isolated species from clinical samples.  
The other predominant species of CoNS identified were S. haemolyticus, S. hominis, and S. 
warneri amongst others including S. capre, S. cohnii, S. intermidius S. lugdunensis and S. 
simulans which are isolates rarely isolated from blood cultures (Kleeman et al., 1993; Kim et 
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al., 2008).  The extensive database of MALDI-TOF MS application also include newly 
identified CoNS species-specific strains such as S. pettenkoferi, S. condiment, and S. 
piscifermentan. The advancement, development and performance of these identification 
platforms showing a consistently higher degree (>99%) of correct species identification 
greatly improve laboratory diagnosis of infections a critical factor in ensuring maximum 
benefit to the patient (Widerström et al., 2012). 
Studies evaluating rapid diagnostic testing with use of MALDI-TOF MS as a diagnostic tool 
together with implementation of appropriate antimicrobial stewardship, a critical component 
for the management of bacteraemic patients, have demonstrated positive clinical outcomes 
(Loonen et al., 2012; Patel 2015; 2017).  Furthermore, the implementation of such diagnostic 
technologies are more importantly linked with a significant decrease in mortality rates and 
hence healthcare associated costs (Patel et al., 2017).  Therefore, the implementation and 
use of MALDI-TOF MS as a rapid diagnostic technology for the identification of pathogens 
associated with BSIs, in routine clinical laboratories in conjunction with subsequent 
improvements; impacting on the initiation of optimal antimicrobial therapy in future, will also 
most likely have a role in preventing the spread of nosocomial infection.  
 
1.6.2 Genotypic methods for speciation fingerprinting 
Identification established on basis of biotype and antibiotype are used for strain delineation in 
most clinical diagnostic microbiology laboratories.  More importantly, these phenotypic based 
typing methodologies have historically contributed to the understanding of epidemiology of 
infections caused by clinically relevant bacterial strains (Sloos et al., 2000).  Moreover, these 
phenotypic characteristics are known to be an expression of the organisms underlying 
genotype.  Therefore, analysis of the fundamental genetic make-up of the organism 
represents the ultimate metric for assessing strain relatedness.  Hence, comprehensive 
studies of the genotype provides a reliable epidemiological marker in differentiating clonal 
lineages; in turn, enabling elucidation of sources and transmission routes of infection 
(Goering, 2010). 
Several different epidemiological typing methods over the past few decades, have primarily 
been used to study specific nosocomial CoNS genotypes established as opportunistic 
pathogens associated with BSIs and foreign implanted devices in the healthcare setting 
(Björkqvist et al., 2002 Heikens et al., 2005; Hellbacher et al., 2006). The application of 
genotypic characterisation using molecular techniques, because of their greater sensitivity 
and specificity, demonstrate significantly higher accuracy of clonal delineation in comparison 
to phenotypic based typing methods.  Genotypic typing methods employed for 
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characterisation and evaluation of staphylococcal isolate clonality include, ribotyping 
targeting the 16S rRNA genes, pulsed-field gel electrophoresis (PFGE), multilocus sequence 
typing (MLST), random amplification of polymorphic DNA (RAPD), and various other PCR-
based techniques (Poyart et al., 2001; Miragaia et al., 2002; Wisplinghoff et al., 2003; 
Heikens et al., 2005; Casey et al., 2006;  Ibrahem et al., 2008).  Although the genotypic 
approach remains time-consuming and expensive compared to routinely employed 
phenotypic methods; they demonstrate greater discriminatory power in delineating clonal 
diversity among clinically relevant infective strains particularly those associated with 
nosocomial outbreaks (Heikens et al., 2005). 
Genotyping techniques utilising electrophoresis, PCR and amplicon sequencing parts of the 
genome and others including analysis of the whole bacterial genome serve as a tool for 
species delineation (Sloos et al., 2000; Deplano et al., 2011).  Despite recent advances in 
molecular typing techniques, PFGE has been by far the most frequently used typing method 
for DNA fingerprinting of clinical important strains.  Considered as the “gold standard” among 
molecular typing techniques, PFGE provides the most discriminatory and reliable method for 
CoNS strain characterisation.  Whole cell DNA from Staphylococcus isolates subjected to 
analysis by SmaI macrorestriction and PFGE is advantageous, allowing the study of large 
DNA fragments of up to one million base pairs in length (Miragaia et al., 2002). This 
genotyping methodology principally used to characterise CoNS species has greater 
discriminatory power and higher resolution in identifying clonally diverse strains of the same 
species with a high degree of reproducibility (Goering, 2010).  The limitations of the PFGE 
methodology, however, include substantial time measurement and resource requirements 
and a lack of resolution power translating to not distinguishing fragments of near similar sizes 
(Sabat et al., 2013).  To overcome these limitations a combination of PFGE and PCR-based 
techniques may be utilised to discriminate between unrelated strains or demonstrate genetic 
similarity.  Techniques employing PCR amplicon-sequencing have proven to be highly 
specific and sensitive for species level characterisation of CoNS strains (Poyart et al., 2001; 
Heikens et al., 2005). 
Genotyping techniques are increasingly becoming an integral part of clinical laboratories for 
rapid investigation of suspected healthcare-associated outbreak strains in real-time.  
Currently however, these detection techniques are still limited to reference laboratories, 
mainly due to the requirement of both specialised equipment and technical skills. Other, 
molecular typing systems such as repetitive-element based polymerase chain reaction (rep-
PCR) for strain categorisation requiring the use of specific performance characteristics based 
on objective criteria are a laboratory based typing tool used to differentiate between 
unrelated strains for species classification (Shutt et al., 2011).  Commercially available rep-
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PCR based technology, the DiversiLab system (bioMérieux®, Marcy l’Etoile, France) utilises 
the amplification of non-coding, repetitive sequences that are interspersed throughout the 
bacterial genome as a rapid method for strain typing.  This semi-automated rep-PCR system 
incorporates primers that target the non-coding repetitive sequence elements which are 
scattered in multiple regions throughout the bacterial genome. This typing system is based 
on PCR amplification and subsequent electrophoresis of the DNA between adjacent 
repetitive sequences.  Separation of the amplified genomic DNA carried out on chip-based 
microfluidic capillary electrophoresis result in data that is automatically collated and 
subsequently evaluated by the DivesiLab software Bioanalyser (Healy et al., 2005).  Virtual 
gel images, selectable demographic fields, dendrograms and scatter plots, generated 
automatically aid data interpretation and associated evaluation of clonal similarities and/or 
differences (Tenover et al., 2009; Shutt et al., 2011).   
Although highly standardised, the limitations identified with rep-PCR are specific to this 
technology which are substantially dependent on variations in assay conditions affecting 
correct data interpretation.  The resulting lack of reproducibility and reduction in resolution 
makes rep-PCR less discriminatory than PFGE particularly for typing of Gram-positive 
isolates such as MRSA and enterococci (Fluit et al., 2010).  However, other studies have 
demonstrated rep-PCR to be an effective and reliable methodology for typing of clinical 
isolates of S. epidermidis associated with nosocomial outbreaks and proved useful in 
determining the possible source of associated infection (Dutch et al., 2006; Trevino et al., 
2009).  Furthermore, studies demonstrate that the rep-PCR is of more use as a screening 
tool rather than a typing tool for potential hospital outbreaks as additional testing is required 
for confirmation of genetic relatedness of specific clonal types (Tenover et al., 2009; Fluit et 
al., 2010).  Overall, the use of molecular typing systems enable understanding of local trends 
in the aetiology of infection and aid in tracing the source of infection.  Additionally, these 
epidemiological tools are useful for monitoring disease progression and measure outcomes 
of interventional strategies that lead to the reduction and spread of nosocomial strains 
particularly amongst high-risk patient groups (Heikens et al., 2005; Piette and Verschraegen, 
2009) 
Revolutionary changes in diagnostic medical microbiology are currently taking place with the 
emergence of next generation sequencing techniques which enable bacterial whole genome 
sequencing (WGS) feasible.  These high-resolution sequencing technologies are gradually 
replacing the currently used molecular typing tools such as PFGE in research institutions for 
characterisation of bacterial isolates (Sabat et al., 2013).  More importantly, for enhanced 
surveillance and outbreak detection, these techniques can be used to establish absolute 
clonality, distinguishing strains derived from the common source of infection with superior 
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accuracy (Otto, 2013).  Furthermore, genotyping can also be used to identify clonally related 
species by tDNA intergenic spacer analysis from purified genomic DNA and more importantly 
for the detection of ccr and mec complexes which are antimicrobial resistance determinants 
(Argudín et al., 2015).  These genomic based methodologies will therefore translate into 
improving clinical outcomes by not only unlocking the epidemiology of the infecting pathogen 
but also the genes conferring resistance (McArthur and Wright, 2015).  
 
1.7 Antimicrobial therapy 
The discovery of antibiotics to combat infectious diseases caused by pathogenic bacteria 
marked a revolution in the 20th century.  Unfortunately, due to the inappropriate use of 
antibiotics, most bacterial isolates have developed the ability to oppose the action of 
antibiotics.  These antimicrobial activities include either the production of enzymes which 
block the antibiotic action, changes in the target site or develop mechanisms whereby the 
antibiotic is actively removed from the bacterial cells (Rossolini et al., 2010). Intrinsic 
bacterial resistance, defined as the organism’s natural resistance to specific antibiotics, 
forms the basis of determining the susceptibility spectrum of an antibiotic.  Acquired 
resistance by bacteria particularly in the case of opportunistic pathogens such as the CoNS 
isolates, on the other hand is dependent on their ability to adapt by acquisition of genetic 
material or via spontaneous mutations.  Antibiotic resistance dissemination in CoNS isolates 
can therefore occur by either clonal spread, plasmid epidemics via replicon transfer or 
genetically, via transposons.  All three modes of resistance have been reported to be 
exponential in nature associated with duplication and transfer of pathogenic associated DNA 
material leading to greater resistance between and within genera (Hawkey 2008; Hawkey 
and Jones, 2009).  More importantly, with staphylococcal-associated opportunistic infections 
although few changes in traditional aetiologies have been noted, there have, nonetheless 
been reports of rapid changes in the phenotype in relation to resistance development 
(Gordon and Lowy 2008). 
Antibiotic resistance is conventionally viewed as bacteria that exhibit significantly reduced 
susceptibility to the tested antimicrobials in the laboratory.  Mechanisms which include 
altered drug uptake, alteration in drug target sites and drug inactivation are known to be the 
major contributors of antimicrobial resistance (Hogan and Kolter, 2009). Table 1-2 (Adapted 
from Walsh,2000) summarises the target sites modes of action and resistance mechanisms 
of commonly used anti-staphylococcal therapeutics (Blair. et al., 2015)  
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Table 1-2: Principal antimicrobial-resistance strategies to the main classes of anti-
staphylococcal drugs by which staphylococci nullify the action of the antibiotics  
CoNS as part of the normal human microbiota are known for their low virulence compared to 
other bacterial species well recognised in Gram-positive infections.  An increasing incidence 
of antibiotic resistance has however, been reported in Gram-positive associated bacteraemia 
in cancer patients’ concomitant with an increased risk of morbidity (Neuburger and 
Maschmeyer, 2006).  Currently, in the era of antimicrobial resistance there is a diminishing 
arsenal of antibiotics available for the treatment of serious infections caused by multi-drug 
resistant staphylococci.  
The increasing antimicrobial-resistance rates in CoNS isolates that are frequently associated 
with bacteraemia and hospital-acquired infections therefore poses a serious problem for 
treatment of clinically significant infections (Koksal et al., 2009; Ma et al., 2011).  One of the 
most common comorbid diseases associated with the presence of infection in particular 
CoNS line-related bacteraemia is malignancy. These device-related infections associated 
with phenotypic growth of bacteria as adherent biofilms play a vital role in altering the 
antimicrobials mode of action.  This is a well-recognised phenomenon of clinical failure due 
to factors other than those related to the patient’s clinical state (Pozo and Patel 2007). 
Antibiotic Target Mode of Action Resistance Mechanism
Cell Wall




Vancomycin D-Ala-D-Ala terminal peptiodoglycan and of Replacement of D-Ala-D-Ala with
Teicoplanin Lipid II  D-Ala-D-Lac or  D-Ala-D-Ser 
Cyclic Lipopeptide: Membrane potential depolarisation Inhibition of protein, DNA and RNA synthesis
Daptomycin
Protein Synthesis










Tetracycline Protein synthesis blockage Proteins produced act as drug export or efflux
Tigecycline Binding to 30S ribsome effecting entry of
Peptidyl Transferase amino-acyl molecules
Oxazolidinones:




Ciprofloxacin DNA Gyrase Blockage of DNA replication Gyrase mutations to drug resistance 
Rifampicin DNA Transcripition Blocakage of RNA polymerase ß-RNA subunit mutational change 
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Due to the severity of the underlying disease state and other co-morbidities, the occurrence 
and frequency of CoNS related bacteraemia poses a serious challenge with respect to 
treatment options.  Therefore, adequate and rational use of antimicrobial agents is required 
for treatment to be both effective and efficient.  Inadequate antimicrobial therapy, defined as 
an infection that is sub-optimally treated has been postulated to be a determinant factor in 
the emergence of antimicrobial resistance influencing both patient outcomes and resource 
utilisation (Kollef, 2000; Cosgrove 2006; Galar et al., 2012; Goto and Al-Hasan 2013).  
Adverse clinical outcomes due to infection caused by antimicrobial resistant organisms’ 
impact more severely among patients experiencing haematological malignancies, as these 
are associated with increase in morbidity, increasing treatment costs and in some cases 
equally higher mortality rates (Wisplinghoff et al., 2003; Tumbarello et al., 2009; Islas-Muñoz 
et al., 2018).  Therefore, nosocomial infections caused by such multi-drug resistant (MDR) 
CoNS principally related to BSIs, represent a major therapeutic challenge associated with 
worse clinical outcomes (Pfallar et al., 1999; Sader et al., 2001). 
Inappropriate prescribing of broad-spectrum antibiotics in this high-risk patient group not only 
incurs unnecessary economic cost but more importantly, has epidemiological repercussion 
since it leads to selection and dissemination of resistant strains (Galar et al., 2012 Islas-
Muñoz et al., 2018).  Presentation of fever during chemotherapy-induced neutropenia may 
be the only diagnostic factor indicating severe underlying infection.  Recommendations 
across most healthcare centres at present, are that neutropenic patients who present with 
fever be treated swiftly with broad spectrum antibiotics to cover eradication of both Gram-
positive and Gram-negative pathogens (Hughes et al., 2002; Freifeld et al., 2011).  The most 
prevalent empirical antibiotics used in patients with haematological malignancies with BSIs 
are the carbapenems and glycopeptides (Garcia-Vidal et al., 2018).  This recommended 
practice followed by most UK based haematology units where combination therapy is 
initiated using aminoglycoside e.g. gentamicin and a β-lactam such as 
piperacillin/tazobactam with the addition of vancomycin (Cohen and Drage, 2011).  Others 
initiate therapy with vancomycin and a carbapenem such as meropenem (Freifeld et al., 
2011; BMJ, 2017).  However, antibiotic resistance has arisen due to excessive overuse or 
inappropriate prolonged use of broad-spectrum antimicrobials within most healthcare 
facilities (Sujatha and Praharaj, 2012).  Other factors such as changes in the treatment and 
management of patients with haematological malignancies during neutropenia using different 
anti-cancer therapies can also influence antimicrobial resistance characteristics and BSI 
outcomes (Vardakas et al., 2005).  Gudiol and colleagues (2013), in their study showed that 
neutropenic cancer patients treated with corticosteroids, antifungal and quinolone 
prophylaxis in the presence of CVCs were more likely to be associated with CoNS 
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bacteraemia originating from exogenous sources.  Additionally, in immunocompromised 
patients including recipients of haematopoietic stem cell transplants the use of quinolone 
prophylaxis is a known risk factor for selection and dissemination of MDR strains of 
organisms such as E. coli and MRSA.  Although Gram-Negative bacteria are frequently 
documented as aetiological agents of BSIs in the U.S, Gram-Positive associated 
bacteraemia however, remains prevalent across most of Europe (Marin et al., 2014).  Stefani 
and Varaldo (2003), in their study showed that despite marked geographic variation across 
areas of Europe, hospital acquired infections due to methicillin resistant CoNS isolates were 
proportionally higher (60-70%).  Additionally, these isolates displayed an ability to 
accumulate antibiotic resistance determinants leaving susceptibility limited to a few anti-
staphylococcal agents.  Inappropriate antimicrobial therapy has been observed to be an 
independent risk factor for morbidity in CoNS related bacteraemia in patients with 
haematological malignancies (Wisplinghoff et al., 2003; 2004).  Mucositis and soft-tissue 
infections as exogenous sources of BSIs are frequently due to CoNS and as such the β-
lactam antibiotics and glycopeptides constitute the backbone of therapy for CoNS related 
infections.  Both the glycopeptides, vancomycin and teicoplanin are at present known to 
exhibit and retain outstanding activity against Gram-positive pathogens.  Selective pressure 
exerted by use of beta-lactam antibiotics and the underlying condition however, influences 
outcome in neutropenic cancer patients with BSIs (Tumbarello et al., 2009; Montassier et al., 
2013).   
Most clinical strains of CoNS are known to be highly resistant to penicillin due to the 
production of penicillinase and resistance has also emerged to other alternative anti-
staphylococcal agents such as the aminoglycosides, macrolides and tetracycline (Johnson et 
al., 1990; Fluit et al., 2001; Martins et al., 2013).  Furthermore, the value of methicillin and 
other penicillinase-stable β-lactam anti-staphylococcal agents has also been compromised 
by the emergence and subsequent nosocomial spread of both methicillin resistant strains of 
S. aureus and CoNS, demonstrating a worldwide prevalence of 35% and 75-80% 
respectively (Yang and Kerdel 2006; Piette and Verschraegen, 2009; Wilson et al., 2011).   
 
1.7.1 Principal anti-staphylococcal agents 
1.7.1.1 Methicillin 
Methicillin, a semisynthetic penicillin was developed as an anti-staphylococcal agent to which 
resistance occurred soon after its use, however “methicillin resistance” is a generic 
terminology used to describe resistance to oxacillin and most β-lactam antibiotics (John and 
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Harvin, 2007).  Methicillin resistant strains of CoNS and S. aureus have been reported 
worldwide since the first strains of MRSA occurred in European hospitals in the early 1960s 
(Diekema et al., 2001).  The increasing problems associated with methicillin resistance soon 
after its introduction in S. aureus, have been well documented (Hiramatsu et al., 1997; 
Hanaki et al., 1998).  Similar trends have now also been noted in nosocomial CoNS isolates 
becoming increasingly resistant to the semisynthetic penicillins (Livermore, 2000).   
Methicillin non-susceptibility has been primarily identified as intrinsic in nature and not due to 
destruction of the antibiotic by β-lactamase produced by the staphylococcal strains as was 
previously postulated (Fluit et al., 2001).  Resistance to methicillin (oxacillin) in staphylococci 
is often expressed heterogeneously with only 1 of 10⁴-10⁸ cells, expressing the resistance 
trait.  This phenomenon is therefore known to complicate the accuracy of determining 
resistance with the use of standard phenotypic test methods (Hussain et al., 2000; Martins et 
al., 2007). This in turn limits the use of methicillin as a treatment option for the management 
of CoNS infections in the immunocompromised patient group with underlying risk factors. 
The emergence of methicillin resistance in staphylococci results from the acquisition of the 
mecA-encoded penicillin-binding protein 2a (PBP2a), a transpeptidase conferring broad 
spectrum beta lactams resistance (IWG-SCC. 2009).  Similarly, many of the CoNS species 
display resistance to the β-lactam antibiotics, including methicillin by virtue of either β-
lactamase activity or a low affinity for the penicillin-binding protein PBP2a production 
encoded by the mecA gene.  This is the defining determinant of broad-spectrum β-lactam 
resistance in CoNS as well as in other staphylococci (Rossolini et al., 2010).  PBP2a an 
inducible membrane bound DD-peptidase enzyme determines methicillin or oxacillin 
resistance by catalysing the transpeptidase reaction that disrupts cell wall peptidoglycan 
cross-linkage.  Published reports indicate that increased rates of methicillin resistance 
observed in clinical samples from patients in the intensive care setting are due to the 
horizontal transfer of the methicillin resistant gene, mecA located on the genetic element 
staphylococcal cassette chromosome (SCC) between staphylococcal species (Mombach et 
al., 2007; Blair et al., 2015).  The acquisition and insertion of the SCC-mec element into the 
chromosome of susceptible staphylococcal strain leads to the emergence of methicillin 
resistance clonal lineages (Zong et al., 2011).  Such evidence, moreover, implies that CoNS 
could be serving as reservoir for the nosocomial spread of resistant genes which adds to 
their own pathogenic potential (Otto, 2009; May et al., 2014).  This has also  been noted in 
studies evaluating the genomic structure of S. haemolyticus, showing unique chromosomal 
regions containing frequently rearranged insertion sequences thus defining species 
diversification and adaptation to antimicrobial resistance acquisition (Del’Alamo et al., 1999; 
Stefani and Varaldo, 2003; Koksal et al., 2009; Sader et al., 2012).  It has been further 
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postulated that MDR-CoNS, most notably MDR-S. epidermidis probably act as a reservoir of 
SCC-mec for isolates of S. aureus.  Evidence for transfer of SCC-mec elements associated 
with methicillin resistance from CoNS in particular from S. epidermidis to isolates of S. 
aureus is quite strong due to the homology of DNA sequences between the SCC-mec Type 
IV elements (98-99%) present in both isolates.  Methicillin resistance (MR) rates are much 
higher among S. epidermidis and S. haemolyticus in comparison to S. aureus; an 
observation that indicates that the transfer of SCC-mec elements may also originate from 
other CoNS prior to their transfer to S. epidermidis (Otto, 2013). 
In addition to nosocomial CoNS strains acquiring resistance to other anti-staphylococcal 
agents, resistance frequency of 80% to methicillin among CoNS isolates causing BSIs has 
been reported (Sader et al., 2001; Wroblewska et al., 2002).  A high proportion of these BSI 
MR-strains are also frequently reported to demonstrate resistance to other classes of 
antibiotics including the macrolides, aminoglycosides, fluoroquinolones and trimethoprim 
(Moreira and Daum 1995; Fluit et al., 2001; Martins et al., 2013). The emergence and 
dissemination of these highly resistant strains are considered to be due to accelerated 
evolution propelled by selective pressure due to the unwarranted excessive use of broad-
spectrum antibiotics. (Davies and Davies 2010; Galar et al., 2012 Islas-Muñoz et al., 2018).  
Therefore, the current interventional strategy universally accepted for the treatment of such 
infections in almost all healthcare settings is the use of vancomycin (Safdar and Rolston 
2006, Sader et al., 2012; BMJ: Best Practice 2017).  Furthermore, the excessive use and at 
times, the unnecessary use of vancomycin has also led to the emergence of vancomycin 
resistant strains of both enterococci and staphylococci in the healthcare setting (Srinvasan et 
al., 2002; Howden et al., 2004, 2010; Tenover and McDonald, 2005; Deresinski, 2009; 
Edwards et al., 2011). 
Interestingly, it had been noted in an early study by Dopeling and colleagues, (1996) that it 
was unnecessary to incorporate vancomycin instead of methicillin or other β-lactams 
empirically for febrile neutropenia with haematological malignancies associated with Gram-
positive bacteraemia.  Further studies have now shown that the addition of glycopeptides 
appears to have had little impact on clinical outcomes but have conversely been associated 
with adverse events including potential toxicity (Levine, 2006; Fullmer et al., 2014).  Despite 
these finding, vancomycin remains the therapeutic drug of choice in most healthcare settings 
as the initial empiric regimen for Gram-positive infection and/or associated with persistent 
febrile state.  Although hospital-acquired infections due to multidrug-resistant pathogens are 
currently the major resistance challenges among Gram-positives due to their global 
dissemination and clinical impact, glycopeptide resistance in staphylococci still remains 
uncommon. This phenomenon could likely be due to fitness issues based on the 
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mechanisms of evolution of the resistant phenotype (Rossolini et al., 2010).  Conversely, 
some antibiotic resistance traits for widely used anti-staphylococcal drugs could compete as 
important drivers for the emergence of hypervalent strains of staphylococci associated with 
reduced susceptibility to the glycopeptides (Ahlstrand et al., 2012; Sujatha and Praharaj, 
2012).  Inadequate empiric therapy is an added risk factor associated with poor clinical 
outcomes in the immune-incompetent patients with MDR-CoNS associated BSIs.  Hence, for 
severe infections, time to appropriate therapy implementation with adequate empiric 
antimicrobial treatment is therefore a decisive factor for survival.  
 
1.7.1.2 Glycopeptides 
In most healthcare institutions, patients with haematological malignancies are usually 
prescribed broad-spectrum antibiotics in the course of a neutropenic episode with 
presentation of fever.  Empirical cover and definitive therapy of the increasing incidence of 
Gram-positive bacteraemia in neutropenic patients with cancer is commonly provided by 
administration of a glycopeptide antibiotic (Ahlstrand et al., 2011, 2012).  Of the 
glycopeptides, teicoplanin has similar activity to vancomycin against both methicillin resistant 
and susceptible strains of staphylococci however, monotherapy for persistent bacteraemia 
has been noted to result in therapeutic failures, leading to superinfections (D’Antonio et al., 
2004).  Additionally, suboptimal clinical outcomes in these patients have also been reported 
due to emergence of resistance during therapy (Johnson et al., 1990; Falcone et al., 2006; 
Kristóf et al., 2011).  Nonetheless, teicoplanin use in adjunctive therapy has proved to be 
efficacious in the treatment of bacteraemia in febrile neutropenic haematology patients 
(D’Antonio et al., 2004).  Vancomycin monotherapy use in this patient group on the other 
hand has proved to have superior efficacy as it appears to demonstrate greater bactericidal 
activity against most CoNS species (Menichetti, 1992, Menichetti et al., 1994; Ma et al., 
2011). 
Both the glycopeptides exert their antimicrobial effect by inhibition of staphylococcal cell-wall 
synthesis.  Acquired resistance to vancomycin and teicoplanin although a rare event, is 
however, postulated to be associated with multi-step genetic acquisition of thickened 
peptidoglycan constituents of the staphylococcal cell-wall.  This stronger extracellular 
peptidoglycan structure results in trapping and preventing the high molecular weight 
glycopeptide compound from reaching the target site (Hiramatsu, 2001; Srinvasan et al., 
2002).  Cell-wall thickening, a major contributor to glycopeptide resistance has been 
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extensively studied in clinical VISA, however, the exact mechanism of glycopeptide 
resistance in CoNS remains to be fully elucidated (Hanaki et al., 1998; Nunes et al., 2006). 
Structurally, both vancomycin and teicoplanin although similar, display differing antimicrobial 
and pharmacokinetic properties.  The biochemical mode of resistance is based on the 
glycopeptides having a high affinity for the terminal D-alanyl-D-alanine residues.  These 
residues are a ubiquitous component of the bacterial cell-wall precursor, Lipid II present in 
the cytoplasmic membrane which carries the building blocks of the cell-wall peptidoglycan 
terminating with the D-alanyl-D-alanine dipeptide (Rossolini et al., 2010).  On the basis of 
their chemical composition similarity, both vancomycin and teicoplanin demonstrate a 
comparable mode of activity against Gram-positive microorganisms by targeting the D-
alanyl-D-alanine terminus.  The glycopeptides inhibit polymerisation of peptidoglycan by 
interacting and enclosing the terminal D-alanyl-D-alanine region of the pentapeptide side 
chains further inhibiting enzyme mediated peptidoglycan precursors.  Vancomycin forms 
dimers when binding to the D-alanyl-D-alanine terminal chain of developing peptidoglycan 
layer whereas teicoplanin forms monomers due to lipophilic activity.  Hence, blocking of the 
transglycosylase function subsequently prevents cross-linkage and assembly of 
peptidoglycan constituents hindering the second stage of cell wall biosynthesis.  Inhibition of 
cross-bridge formation set of the peptidoglycan layer causes cell rupture (Hiramatsu, 2001) 
On the other hand, plasmid-mediated resistance activity involves modification of the cell wall 
synthesis precursors. This comprises incorporation of D-lactate instead of D-alanine in the 
normally occurring peptidoglycan precursor to which the antibiotic has a greatly reduced 
affinity seen commonly amongst enterococci than in staphylococci species (Hanaki et al., 
1999; Sujatha and Praharaj, 2012).  Resistance is typically associated with the dissemination 
of gene clusters including vanA and vanB prevalent amongst clinical isolates mediated by 
conjugative or non-conjugative transposons carried by transferable plasmids (Rossolini et al., 
2010). 
This phenomenon of reduced glycopeptide resistance has been observed both in multi-
resistant MRSA strains and increasingly in nosocomial MDR-CoNS strains, commonly 
associated with foreign body implants (Van Der Zwet et al., 2002; Zong et al., 2011). 
Investigators who first reported in-vivo resistance to vancomycin in S. haemolyticus, also 
demonstrated that in-vitro selection of resistant strains was associated with changes in cell 
wall, suggestive of decreased vancomycin penetration (Schwalbe et al., 1987).  However, 
MDR-CoNS strains demonstrating increasing resistance to teicoplanin with progressively 
high MICs have nonetheless been shown to remain correspondingly susceptible to 
vancomycin in-vitro (Tabe et al., 2001; Ma et al., 2011).  This has been noted predominantly 
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amongst MDR-S. haemolyticus strains which appear to sequester teicoplanin better than 
vancomycin.  The phenomenon may be dependent on parameters such as cell wall 
composition and synthesis or alteration of sites not associated with the D-alanyl-D-alanine 
target (Sujatha and Praharaj, 2012).  The thickening of the cell-wall in CoNS isolates in 
response to glycopeptide exposure that favours resistance development may also be due 
other mechanisms such as cell-wall metabolic alterations which affect antimicrobial activity 
(Palazzo et al., 2005).  Such alternation in the peptidoglycan outer layers results in a mesh-
like structure which trap vancomycin molecules, further preventing penetration of the 
antibiotic into the inner part of the cell-wall layers; where synthesis and assembly of new 
layers are formed thus reducing therapeutic efficacy (Hiramatsu, 2001; LaPlante et al., 
2009). 
In comparison to vancomycin, teicoplanin activity in CoNS isolates has also been noted to 
decrease with an increase in cell-wall thickness, similar to, but at much lower levels than 
resistance noted in MRSA isolates (Sieradzki et al., 1998; Cremniter et al., 2010).  
Mechanisms other than cell wall thickening such as increased transpeptidation inhibition by 
teicoplanin also contribute to acquisition of greater resistance in these strains.  However, 
significant increase of teicoplanin MICs from 2 to 8mg/L are usually seen to be accompanied 
by only small changes in vancomycin MICs with increasing antimicrobial pressure.  Despite 
removal of glycopeptide pressure, teicoplanin is observed to maintain its low-level or 
intermediate resistance activity (Hiramatsu, 2001).  Hence, increase in teicoplanin resistance 
could be used as a potential marker for prevention of developing vancomycin resistance in 
clinically significant staphylococcal infections. 
 
1.7.1.2.1 Teicoplanin therapy 
Teicoplanin as an alternative drug is more frequently used in European countries and is 
generally considered to be a safer drug with fewer rates of documented adverse events such 
as nephrotoxicity in comparison to vancomycin.  Teicoplanin has been shown to be effective 
in the treatment of febrile neutropenia and catheter-related staphylococcal infections 
amongst others caused by MDR-Gram-positive pathogens.  It has been demonstrated that 
teicoplanin binds more avidly to the specified target sites in comparison to vancomycin 
(Kristóf et al., 2011).  However, teicoplanin efficacy may be reduced due to its affinity for high 
protein binding because protein fixation impairs antibacterial activity (Bal and Gould, 2007).  
Additionally, teicoplanin has an advantage over vancomycin in that is has a longer 
elimination half-life, therefore allowing for longer dosing intervals thus reducing the potential 
for both ototoxicity and nephrotoxicity (Menichetti et al.,1994).  However, serum 
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concentrations of teicoplanin require frequent monitoring in order to achieve appropriate 
therapeutic concentration rather than risk developing nephrotoxicity.  The rate of therapeutic 
success is, nonetheless, limited with teicoplanin use for documented bacteraemia in 
neutropenic patients with haematological malignancies due to other factors.  These include 
persistence of fever over a longer period of time, higher relapse incidences after treatment 
and although not significantly so, a greater number of superinfections post-teicoplanin 
treatment than noted with vancomycin use (D’Antonio et al., 2004).  Utility of teicoplanin is 
therefore limited, as doubts also remain regarding daily dosage levels associated with 
required clinical response rates in neutropenic patients which may be variable for optimal 
management of staphylococcal infections. 
 
1.7.1.2.2 Vancomycin therapy 
Vancomycin, a first-generation bactericidal antibiotic is the most widely used empiric 
therapeutic agent.  After its approval by the FDA for clinical use in 1958 for its excellent 
activity against Gram-positive pathogens its use continues for the treatment of serious 
infections especially in immunocompromised hosts (Butler et al., 2014).  Its use became vital 
for the treatment of MRSA infections prevalent in many healthcare institutions worldwide 
more than four decades ago (Griffith,1984; Srinvasan et al., 2002; Steinkraus et al., 2007; 
Deresinski, 2009).  Vancomycin also remains one of the critically effective drugs currently 
available for the treatment of life-threatening infections such as MDR-CoNS associated 
bacteraemia.  The accelerated use of vancomycin since the 1980s has however, led to an 
increase in the emergence of vancomycin resistance amongst Gram-positive isolates 
(Levine, 2006; 2008).  Resistance noted particularly amongst isolates of S. aureus has led to 
serious limitations in therapeutic options available for the treatment of severe infections due 
to these isolates (Lodise et al., 2008; Sujatha and Praharaj, 2012).  Similarly, with the 
emergence of CoNS isolates with high rates of methicillin-resistance causing primary or 
secondary bacteraemia among immunocompromised patients has also accelerated the use 
of vancomycin as the therapeutic drug of choice (Schwalbe et al., 1987; Safdar and Rolston, 
2006; D’mello et al., 2009).  This in turn has also led to the rise in vancomycin resistance 
among clinically significant isolates of CoNS in many healthcare settings world-wide 
(Biavasco et al., 2000; Natoli et al., 2009; Sujatha and Praharaj, 2012).  Clinical failures with 
vancomycin therapy now raise concerns regarding its decreased bactericidal activity and 
clinical efficacy.   
Vancomycin resistance first described in S. haemolyticus species by Schwalbe and 
colleagues in1987, as an emerging nosocomial has been documented to develop resistance 
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to multiple antibiotic classes and is unique in its predisposition in also acquiring resistance to 
the glycopeptides (Sieradzki et al., 1998; Biavasco et al., 2000).  Reports of widespread 
resistance to vancomycin in CoNS, however, remain relatively limited following the first 
reported case in Japan by Hiramatsu (2001) of extensive resistance in isolates of S. aureus.  
Prior to this, Hiramatsu and colleagues (1997; 1998) were also the first to report case of 
clinical strain of MRSA with reduced vancomycin susceptibility displaying heterogenous 
resistance.  Despite, susceptibility test results showing retention of vancomycin activity 
against almost all Gram-positive pathogens, its increased use in the hospital environment 
has led to the emergence of resistance to vancomycin among strains of enterococci and 
heteroresistant, intermediate resistance or total resistance among strains of S. aureus 
(Jones, 2006; Howden et al., 2010).  Heterogeneous or intermediate-glycopeptide resistance 
particularly to teicoplanin, among species-specific CoNS strains, has been reported to be 
more prevalent among isolates of S. haemolyticus (Sieradzki et al., 1998; Biavasco et al., 
2000; Nunes et al., 2006).  These S. haemolyticus strains are characterised by thicker cell-
walls and increased amounts of unprocessed D-alanyl-D-alanine causing trapping of the 
teicoplanin molecules resulting in higher observed MIC values (Hiramatsu, 2001; LaPlante et 
al., 2009).  Such isolates representing heterogenous susceptibility are poorly detected by 
routinely used manual or automated susceptibility test systems.  Therefore, alternative 
diagnostic test methods are required in cases of persistent vancomycin therapy failure 
associated with infections caused by CoNS strains displaying heterogenous glycopeptide 
resistance profiles (Biavasco et al., 2000; D’mello et al., 2008).  Furthermore, based on 
clinical data analysis it has been established that patient’s exposure to vancomycin therapy 
relative to the isolates susceptibility to vancomycin is an effective predicator of clinical 
outcomes (Rybak et al., 2013).  Hence, the use of appropriate bactericidal assays to detect 
isolates with reduced susceptibility to vancomycin and teicoplanin could lead to better 
prediction of clinical outcomes (Levine, 2008; Satola et al., 2011). 
Vancomycin with its narrow therapeutic index and association with venous toxicity resulting 
in some limitations of use, therefore, necessitates close monitoring of serum concentrations 
(Levine, 2006; Rybak et al., 2009).  Due to the potential of ototoxicity and nephrotoxicity 
associated with vancomycin use, serum trough level assays are routinely performed to allow 
for dose adjustments concomitant with antimicrobial efficacy for optimal clinical outcomes 
(Levine, 2006; Rybak et al., 2009).  Determination of vancomycin serum trough level 
concentrations is the most widely used pharmacokinetic parameter for monitoring the clinical 
efficacy of the antibiotic.  The optimal focus on both toxicity and clinical efficacy also takes 
into account factors such as bacterial load and decrease of in-vivo bactericidal activity 
commonly associated with the presence of biofilm on intravascular devices (Kitzis and 
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Goldstein 2006).  Therapeutic monitoring therefore performed within a relatively narrow 
range minimises toxicity thus ensuring optimal therapeutic success.  Additionally, 
vancomycin-induced nephrotoxicity in patients with haematological malignancies receiving 
other combination nephrotoxic chemotherapies remain at a greater risk of adverse outcomes 
(Vardakas et al., 2005; Fullmer et al., 2014).  Trough serum concentration assays, 
recommended as the most practical and accurate method for monitoring drug efficacy are 
performed after continuous steady-state infusion therapy for 36 to 48 hours before 
administration of the next dose which is adapted in line with clinical correlation after further 
monitoring (Rybak et al., 2009).  Recommended target trough concentration levels are set at 
a therapeutic range of 15-20mg/L and dose adjustment are undertaken in conformity with 
national antibiotic policies (Penack et al., 2010). 
Achieving adequate serum concentration levels are therefore fundamental to eradication of 
serious infections in high-risk patient groups for improved clinical outcomes.  However, 
higher trough serum concentrations may become necessary for the treatment of 
staphylococcal strains displaying reduced susceptibility to the glycopeptides to avoid risk of 
clinical failure (Kitzis and Goldstein 2006).  Conversely, continuous administration of sub-
therapeutic dose levels of vancomycin increases the likelihood of MDR bacterial emergence. 
This is based on evidence which suggests that trough vancomycin serum concentrations of 
<10mg/L which is below the optimal target levels of 15-20mg/L can produce strains with 
vancomycin intermediate resistance-like characteristics (Rybak et al., 2009).  Compromising 
infection outcomes, therefore, further increases the burden of morbidity and in some cases a 
potential increase in mortality rates among cancer patients with BSIs (Marin et al., 2014; 
Kleinhendler et al., 2018). 
 
1.7.1.2.2.1 Heterogenous glycopeptide resistance 
The excessive use of vancomycin in the 1980s for the treatment of infections such as 
antibiotic-associated colitis and MRSA, has led to increasing cases of complete resistance or 
reduced susceptibility to vancomycin. (Levine, 2008).  The phenomenon of reduced 
resistance or heteroresistance has been widely observed in range of Gram-positive 
organisms particularly in infections caused by S. aureus (Geisel et al., 1999; Fridkin et al., 
2003; Hanaki et al., 1998; 2007).  In general, heteroresistance is defined as resistance to 
specific antimicrobial agents by a subset of isolates within a homogenous microbial 
population that are normally considered to be otherwise susceptible. The pathogenic 
potential and clinical significance of heteroresistance however, has yet to be clearly defined.  
Hetero-vancomycin resistance is postulated to constitute a precursor stage to the emergence 
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of vancomycin resistance in isolate populations consisting of a prevalence of heteroresistant 
strains within a homogenous population (Hiramatsu, 2001).   
The emergence of heterogeneously glycopeptide-intermediate staphylococci (hGIS) strains 
have been associated with increasing therapeutic adversities in infections caused by 
methicillin-resistant staphylococcal strains (Tenover and Moellering, 2007).  Intermediate and 
heterogeneous resistance to the glycopeptides (GIS and hGIS respectively) still remains best 
described for S. aureus isolates resistant to treatment (Hanaki et al., 2007).  These hGIS 
phenotypes are a small subset of the population with decreased susceptibility to vancomycin, 
not detected with standard susceptibility test methodologies.  These subsets within a 
susceptible strain population have, nonetheless, been purposed to be precursors to 
development of intermediate vancomycin resistance due to prolonged therapeutic pressure 
(Hiramatsu et al., 1997; Hiramatsu 2001). Prolonged duration of bacteraemia despite 
increased dose adjusted vancomycin therapy resulting in clinical evidence of vancomycin 
treatment failure has been observed to be due to episodes associated with higher bacterial 
loads of isolates expressing vancomycin heteroresistance (Charles et al., 2004).  
Additionally, low vancomycin trough serum levels observed in patients with hVISA 
bacteraemic infection indicate either induction of pre-existing vancomycin resistance or 
selection of resistant strains due to antibiotic pressure.  The use of linezolid as an alternative 
therapeutic agent in this case achieved an appropriate response among patients with hVISA 
infection where appropriate vancomycin serum levels failed to ensure improved outcomes.   
The association between emergence of heteroresistance and clinical failure has been further 
linked to the higher mortality rates observed in the immunocompromised host on prolonged 
ineffective vancomycin therapy (Tenover et al., 2001; Steinkraus et al., 2007; Howden et al., 
2004, 2005,2010).  
Unlike studies showing increasing glycopeptide resistance in S. aureus isolates associated 
with therapeutic failure, similar reports amongst CoNS isolates currently remain infrequent 
(Tenover et al., 2001; Walsh et al., 2001; Tenover and Moellering, 2007). Reduced 
susceptibility to the glycopeptides in particular, to vancomycin has however been reported in 
several species of CoNS with the frequency of expression differing among species 
dependent on factors such as the rate of clonal mutation occurrence under antibiotic 
pressure.  Of the clinically relevant CoNS species, both S. epidermidis and S. haemolyticus 
have been found to exhibit reduced susceptibility to the glycopeptides more frequently 
(Biavasco et al., 2000; D’mello et al., 2008).  Reports of homogenous resistance to 
vancomycin exhibiting MIC >8 mg/L based on BSAC classification, among strains of CoNS, 
continue to be rare, nonetheless, some strains demonstrating heteroresistance have been 
reported (Tevell et al., 2014).  Routine screening methods for staphylococcal strains 
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exhibiting heteroresistance, often with vancomycin MICs ranging between 1-4mg/L and 
subpopulations demonstrating MICs of up to 8mg/L, remain in flux (Hiramatsu, 1997; 
Hiramatsu et al., 2001).  Conversely, staphylococci isolates exhibiting such characteristics 
have been considered to be concomitant with either treatment failure or are likely to present 
as precursors of glycopeptide resistant strains (Sieradzki et al., 1998; Wong et al., 1999).  
Although the clinical significance of glycopeptide resistance in CoNS has yet to be clearly 
ascertained, a study by Nunes and colleagues, (2006) evaluating the prevalence of 
glycopeptide resistance amongst CoNS BSI isolates suggests that the presence of 
heterogeneous resistance these isolates could also be clinically relevant.  In their study, 
authors report that out of the 106 patients with bacteraemia, a prevalence of 9(8.5%) 
glycopeptide resistance was found among CoNS isolates of which, S. haemolyticus and S. 
epidermidis were the predominant species.  The observed incidence of reduced susceptibility 
to the glycopeptides amongst BSI strains in high risk patient populations, therefore, limits 
appropriate antimicrobial treatment leading to greater risk of poor clinical outcomes.  
Optimal laboratory screening methods for the detection of such heteroresistant vancomycin-
intermediate strains of staphylococci at present remain unclear.  However, monitoring the 
prevalence of isolates with reduced vancomycin susceptibility is of epidemiologic importance 
as these strains can become endemic within the hospital environment. Therefore, 
transmission of these resistant staphylococcal strains among immunocompromised hospital 
patients would places them at a greater risk of acquiring infections that can become 
increasingly difficult to treat (Srinvasan et al., 2002).  Whilst vancomycin has retained its 
considerable activity against MDR-staphylococci, the emergence of the heterogenous and 
vancomycin intermediate resistance has necessitated the exploration and use of either 
newer anti-staphylococcal drugs or alternative combination therapies. 
 
1.7.2 Newer therapeutics 
Patients with haematological malignancies who are subjected to both increasingly potent and 
intensive chemotherapeutic therapies require optimally defined antimicrobial agents and the 
prompt implementation of targeted therapy to reduce the risk of CoNS associated infection.  
The high frequency of oxacillin-resistant CoNS has rendered the empirical use of methicillin, 
obsolete for the treatment of such nosocomial infections.  Vancomycin as part of initial 
empirical treatment of febrile neutropenic patients with bacteraemia and severe neutropenia 
with microbiologically documented infections has been recognised to lead to better clinical 
outcomes (Safdar and Rolston, 2006; D’mello et al., 2009).  With increasing reports of 
emerging high levels of resistance to vancomycin, primarily considered the therapeutic drug 
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of choice for the treatment of proven or suspected Gram-positive bacteraemia in most 
healthcare settings the need for alternative therapeutics has therefore become of primary 
importance (Diekema et al., 2001).  Although adverse effects including nephrotoxicity are 
known to be more common in patients receiving a glycopeptide as part of their normal 
regimen, meta-analysis studies by Varsdakas (2005), report that mortality rates were no 
different in patients treated with or without addition of glycopeptides.  Despite these findings, 
the standard protocol in most healthcare setting and in haematology units is to administer 
antibiotic therapy with either cephalosporin or a β-lactam/ β-lactam plus inhibitor with the 
addition of an aminoglycoside and inclusion of vancomycin prior to microbiological sampling.  
The prompt administration of effective broad-spectrum antimicrobial therapy in haematology 
patients with fever and signs of bacteraemia is known to correlate well with patient outcomes 
(Cohen and Drage, 2011).  This in turn presents another important challenge for treatment of 
difficult to treat staphylococcal infections in these high-risk patient groups, requiring second 
or third-line agents for refractory cases. The advancing shift towards more resistant 
pathogens with fewer options for therapy underscores the continued need for prevention and 
need for newer therapeutic options.  Therefore, the use of alternative antimicrobial agents for 
clinical use with few minimal adverse effects could prove to be useful with the added 
advantage of reducing the threat of infection in high-risk patient groups and potential for 
improved clinical outcome (Raad et al., 2007; Chaftari et al., 2010; Moore et al., 2011). 
In light of emerging antibiotic resistance, a number of new anti-staphylococcal agents have 
recently been introduced and approved by the United States, Food and Drug Administration 
(FDA) and by the European Medicines Agency (EMA) for the treatment of severe 
staphylococcal infections.  Daptomycin, tigecycline linezolid and the fourth generation 
cephalosporins, have recently been introduced as back-up drugs mainly for the treatment of 
MRSA infections particularly in cases of clinical failures with standard therapies (Raad et al., 
2007; Moore et al., 2011).  These antibiotics, appear to have greater activity against 
methicillin and vancomycin resistant staphylococci and may prove to be clinically efficacious 
due to escalating resistance to vancomycin (Yang and Kerdel 2006; Raad et al., 2007; 
Rolston et al., 2014) 
 
1.7.2.1 Linezolid 
Linezolid a broad-spectrum synthetic class of antimicrobials, an oxazolidinone was approved 
by the FDA for use in units and patients where multi-resistant enterococci or staphylococci 
are documented (Lomaestro, 2003).  Linezolid, a weak reversible monoamine oxidase 
inhibitor, mode of action involves the binding of tRNA to the ribosome with the 50S subunit (V 
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domain of 23S rRNA) thus blocking bacterial cell protein synthesis.  Resistance to linezolid is 
conferred due mechanisms including mutation at the 23S rRNA but this remains rare as 23S 
rRNA is also encoded by several other genes (Walsh, 2000; Blair et al., 2015).  This is 
essentially a bacteriostatic mode of action allowing mRNA translation but inhibiting peptide 
elongation which appears to be effective in prevention of staphylococcal virulence factors 
such as coagulase and haemolysins (Livermore, 2003).  Due to its structure and unique 
mode of action, there is at present no observation of cross-resistance with other classes of 
antimicrobial agents. 
Although linezolid demonstrates potent activity against methicillin-resistant CoNS little is 
known regarding its efficacy in the treatment of patients with CR-BSIs where CoNS are 
commonly implicated as the source of infection (Gu et al., 2012).  Haematology units where 
there is a high incidence of multi-resistant Gram-positive organisms, have however 
introduced the use of linezolid as a second-line agent administered either orally or 
intravenously against clinically important Gram-positive cocci for better clinical outcomes. 
Linezolid is generally associated with high levels of bioavailability and its use does not 
require pharmacological monitoring (Cohen and Drage, 2011).  Currently there is limited data 
to show that linezolid is as effective as vancomycin in uncomplicated bacteraemia, as its 
bactericidal activity is thought to be limited in patients with immunosuppression.  Nonetheless 
it has been suggested that linezolid showing 100% bioavailability in-vivo with minimal 
adverse effects can be used in the event of severe VISA/VRSA infections for which there are 
few antimicrobial alternatives (Livermoore, 2000; Fridkin et al., 2003; Raad et al., 2007). 
Linezolid resistance among staphylococci remains uncommon however the development of 
resistance, although slow in the clinical setting for CoNS infections has been linked to 
previous therapeutic use (Kelly et al., 2006; John and Harvin 2007).  Furthermore, clones of 
linezolid-resistant CoNS due to selective pressure may be involved in colonisation of 
neutropenic patients thus becoming a source for transmission in the hospital environment 
(Mulanovich et al., 2014).  Prolonged treatment with linezolid (>2 weeks) has also been 
associated with other factors such as haematopoietic toxicity and a delay in white blood cell 
count recovery in febrile neutropenic patients with malignancies (Kuter, 2001).  Cases of 
reversable bone marrow suppression with anaemia, immune-mediated destruction or platelet 
aggregation have been reported with the prolonged linezolid administration (French, 2003).  
Therefore, its routine use particularly as a monotherapy remains limited in patients with 






Tigecycline belonging to the glycylcycline class of antibiotics, is an expanded spectrum 
tetracycline derivative, with excellent activity against a range of resistant Gram-negatives as 
well as Gram-positive cocci and bacilli (Livermoore, 2005).  Tigecycline exerts its 
bacteriostatic effectiveness by binding to a single high-affinity intracellular site on the 30S-
ribosome, thus preventing protein synthesis by blocking entry of amino-acyl molecules 
(Walsh, 2000).  The commonly occurring resistance phenotypes which include MRSA, VRSA 
and MR-CoNS appear to remain largely unaffected by its potent antibacterial activity where 
resistance is due to β-lactamase and penicillin-binding proteins modifications (Rubinstein and 
Vaughan.2005).  
Due to its potent activity against both susceptible and resistant BSI CoNS isolates, 
tigecycline has recently been introduced into clinical practice for the treatment of severe 
infections recalcitrant to commonly used antibiotics. (Raad et al., 2007).  In-vitro susceptibility 
data for tigecycline against clinically important methicillin susceptible and resistant strains of 
CoNS show MIC range of 0.25 to 1mg/L and range from 0.5-2mg/L, respectively, suggests it 
its greater potential role in eliciting the desired therapeutic response in-vivo (Garrison et al., 
2005).  Additionally, this data suggests that tigecycline has comparable or better activity in 
comparison to other agents with a lower potential for resistant development due to its 
pharmacokinetic profile (Garrison et al., 2005).  Although not a bactericidal drug, tigecycline 
has also demonstrated superior activity against high-biofilm producing MRSA clinical isolates 
in comparison to other anti-staphylococcal agents such as vancomycin, rifampicin and 
linezolid (Raad et al., 2007; Rose and Poppens 2009). 
Tigecycline demonstrates excellent in-vitro activity against BSI S. epidermidis and S. 
haemolyticus isolates from BMT recipients that are resistant to methicillin (Kratzer et al., 
2007).  Its role is, nevertheless, currently directed more towards empiric treatment of 
infections where either both MRSA and Enterobacteriaceae or MDR-Gram-positive isolates 
are likely (Livermore, 2005; Kratzer et al., 2007) 
 
1.7.2.3 Daptomycin 
Daptomycin is a lipopeptide (cyclic glycopeptide) antimicrobial agent, used mainly for the 
treatment of Gram-positive infections approved for clinical use in 2003.  This antimicrobial 
agent has a distinctive mechanism of action, exerting its bactericidal activity by disrupting the 
plasma membrane function and targeting anionic phospholipids without penetrating the 
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cytoplasm (Blair et al., 2015).  This mode of action also involves altering the bacterial cell 
membrane potential by impeding calcium-dependent channels which causes disruption of the 
cytoplasmic membrane.  The resulting loss of membrane potential, inhibition of DNA, RNA 
and protein synthesis, together with depolarisation leads to intracellular cell content loss and 
cell death (Walsh, 2000; Steenbergen et al., 2009; Blair et al., 2015). 
Daptomycin demonstrates concentration-dependent killing and has been predominantly used 
for the treatment of BSIs, and soft tissue infections.  Daptomycin retains potency against 
infections caused by methicillin-resistant and glycopeptide intermediate or resistant strain of 
S. aureus (Moor et al., 2011).  Moreover, daptomycin use in clinical trials of staphylococcal 
related bacteraemia has proved to be just as clinically effective as vancomycin (Fowler et al., 
2006).  Definitive efficacious empirical therapy for these serious BSIs is, however, at present 
still provided by the administration of the glycopeptide, vancomycin in most healthcare 
institutions (Deresinski, 2009).  Nonetheless, daptomycin in comparison, has also been 
shown to be just as efficacious as vancomycin in the treatment of CR-BSI and methicillin 
resistant CoNS in patients with cancer.  Additionally, nephrotoxicity has been shown to be 
reduced by three-fold with the use of daptomycin instead of vancomycin for the treatment of 
Gram-positive CR-BSI in cancer patients with faster symptom resolution, microbiological 
eradication and a significantly better clinical response (Chaftari et al., 2010).  Rolston and 
colleagues (2014), in their observational study, also documented improved clinical outcomes 
with the use of daptomycin to eradicate Gram-positive BSIs in haematology neutropenic 
patients.  Their study results showed the superior activity of daptomycin therapy, as of the 
156 patients investigated 31% failed vancomycin therapy but demonstrated better clinical 
outcomes post daptomycin therapy.  The decline in bactericidal activity of vancomycin 
particularly in neutropenic patients is of concern as the administration of bactericidal agents 
are the preferred for treatment of this patients.  The study results further demonstrate the 
superior efficacy of daptomycin in comparison to vancomycin as it is reported to be better 
tolerated with no effect on the degree of neutropenia in haematology patients during 
chemotherapy. 
Daptomycin remains clinically effective in a variety of infections for which it is indicated 
including bacteraemia as well as in non-indicated infections in neutropenic patients (Rolston 
et al., 2014).  Reports of daptomycin antimicrobial lock therapy with installation into the 
intravenous line of 2ml of antibiotic at 100-1000 times the systemic concentration further 
demonstrate its superior efficacy for microorganism eradication in comparison to vancomycin 
(LaPlante and Mermel, 2007).  The efficacy of daptomycin for the treatment of severely ill 
patient populations with multiple co-morbidities commonly infected with MDR CoNS 
demonstrate highly favourable earlier clinical and microbiological responses despite its use 
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as a frequent second-line or salvage therapy (Kelesidis, 2011).  Notwithstanding its 
increased use non-susceptible isolates have rarely been reported worldwide including non-
susceptibility among CoNS (Sader et al., 2014).  Furthermore, daptomycin alone, and in 
combination with other antibiotics such as rifampicin and gentamicin has also proved to have 
greater activity against staphylococci embedded in biofilm on catheter surfaces (LaPlante 
and Woodmansee 2009; Rolston et al., 2014).  Increased use of daptomycin for the 
treatment of complex infections caused by methicillin resistant strains of staphylococcus 
such as VISA has resulted in a notable decrease in susceptibility.  However, combination 
therapy with other β-lactams such as oxacillin or with cephalosporins such as ceftaroline has 
resulted in enhancing daptomycin activity.  Restoration of daptomycin susceptibility in 
combination therapy has been demonstrated in effective eradication of BSI MRSA isolates 




Recently resistance to the β-lactams has been combated by the introduction of ceftaroline, a 
fifth generation cephalosporin demonstrating broad spectrum activity against a range of 
multi-resistant organisms including MRSA, CoNS and VRE (Biek et al., 2010).  Ceftaroline 
has been approved by the FDA in the United States and in Europe by EMA for skin and soft 
tissue infections only.  The clinical efficacy of this agent has been demonstrated in the 
treatment of both complicated soft tissue infections and community-acquired pneumonia 
(Biek et al., 2010). 
Ceftaroline has also demonstrated activity superior to vancomycin which is attributed to its 
higher affinity for the modified PBP2a which confers resistance to most β-lactam 
antimicrobials.  This novel broad-spectrum cephalosporin exerts its bactericidal drug activity 
by binding to the PBPs inhibiting the transpeptidation reaction required for cell-wall 
biosynthesis resulting in lysis and cell death (Walsh, 2000; Laudano, 2011).  Ceftaroline, the 
new anti-MRSA cephalosporin may also be appropriate for use against methicillin resistant 
CoNS BSI isolates (Polenakovik and Pleiman 2013).  Several studies have demonstrated in-
vitro activity of ceftaroline against MRSA, MR-CoNS and non-susceptible vancomycin and 
daptomycin isolates with MIC values ranging from less than 0.12 to 0.5mg/L (Ge et al., 2008; 
Biek et al., 2010; Guay, 2011; Sader et al., 2013).  The positive attributes of ceftaroline with 
respect to treatment of CoNS associated bacteraemia in patients with haematological 
malignancy has yet to be evaluated in dedicated clinical studies.  Its approval for use in the 
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clinical setting may provide a potential empirical alternative to the commonly used anti-
staphylococcal therapeutic for CoNS associated bacteraemia. 
 
1.7.3 Antimicrobial Combination Therapy 
Broad-spectrum combination empiric therapeutics are commonly used to treat seriously ill 
patients to increase the likelihood of clinical success.  Combination therapeutics targeting 
metabolically active bacteria or specific bacterial metabolic sites have also been utilised to 
combat severe staphylococcal infections.  Additionally, the advantage of potential synergistic 
effect against the isolates, lowers the risk of resistance development which is likely to occur 
due to prolonged antibiotic use during the course of disease progression (Hughes et al., 
2002; Dall et al., 2018).  In-vitro studies demonstrating synergy with agents such as 
ciprofloxacin, gentamicin, tobramycin or rifampicin against clinical isolates of CoNS, used in 
combination have proved to be effective in the treatment of serious infections due to these 
organisms (Raad et al., 2007; LaPlante and Woodmansee 2009; Rose and Poppens 2009).  
Similarly, vancomycin has demonstrated greater clinical efficacy when used in combination 
with other anti-staphylococcal agents, in particular against biofilm producing methicillin-
resistant staphylococcal infections (Dall et al., 2018).  Likewise, rifampicin frequently used for 
the management of biomaterial related infections demonstrates superior bactericidal efficacy 
in eradicating biofilm enchased staphylococcal strains in combination with either tigecycline, 
daptomycin or linezolid (Walsh 2000; Fey, 2010).  This exceptional efficacy is attributed to 
the antibiotic action targeting RNA polymerase of metabolically diverse biofilm encased cells 
leading to eradication (Mah and O'toole 2001).  Conversely, although in-vitro activity of 
rifampicin may be similar to the other agents it is rarely used clinically as a mono-therapeutic; 
due to occurrence of single-step point-mutations in the beta-RNA subunit of the drug leading 
to rapid resistance development in-vivo (Fey, 2010). 
In clinical practice, antimicrobial combinations are increasingly used for therapeutic efficacy 
against recalcitrant infection and controlling resistance evolution (Steenbergen et al., 2009).  
As such, for treatment of bacteraemia particularly amongst cancer patients, most healthcare 
facilities follow the recommended empirical treatment guidelines comprising combination 
therapy to include an aminoglycoside.  Typically, in cases of severe bacteraemia, 
combination therapy includes the addition of gentamicin with a β-lactam as frontline therapy 
or with a cephalosporin as second-line therapy for patients non-respondent to first line 
therapeutics (BMJ-Best Practice, 2017).  In high-risk patient groups, the application of 
synergistic interaction between two antimicrobials or other compounds has also 
demonstrated a reduction in adverse drug reactions and increased drug potency of the 
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antimicrobial agent that may be less effective when used as a mono-therapeutic (Bollenbach, 
2015).  Combinations alternatives in cases of treatment failures due to toxicity include agents 
such as the trimethoprim-sulfamethoxazole, quinupristin-dalfopristin, rifampicin or the next 
generation of cephalosporins, including ceftobiprole and ceftaroline (Cervera et al., 2009).   
Sakoulas and colleagues (2014), in their study demonstrated excellent synergist activity of 
ceftaroline-daptomycin combination for the treatment of documented refractory 
staphylococcal bacteraemia.  Successful clinical outcomes were also demonstrated with the 
use of ceftaroline-daptomycin combination therapy in cases of refractory S. aureus, MRSA, 
VISA, and S. epidermidis in bacteraemic patients with underlying co-morbidities.  
Daptomycin activity appears to be enhanced by the superior binding affinity of ceftaroline to 
the PBPs, hence resulting in its synergistic effectiveness in reducing the infection burden in 
bacteraemic patients (Barber et al., 2014).  Combination therapy with ceftaroline has not only 
demonstrated rapid and sustained bactericidal susceptibility of daptomycin but also 
prevented emergence of resistance (Rose et al., 2012). 
Dose-response characteristic of antimicrobial combination determines both dynamics of 
effectiveness and resistance development.  Therefore, due to the reduction in mutational 
changes responsible for resistance emergence in response to combined antimicrobial 
challenges, a decrease in overall resistance evolution is observed (Bollenbach, 2015).  
Optimised treatment with appropriate antimicrobial combinations therefore appear to have 
greater potential for improving clinical outcomes in highly vulnerable patient groups with 
underlying disease (Climo et al., 1999; Dall et al., 2018).  
 
1.8 Antimicrobial Susceptibility Test methods 
Surveillance data shows that antimicrobial resistance is fast becoming a significant threat to 
both the prevention and treatment of hospital acquired bacteraemic infections particularly in 
the immunocompromised host.  Accurate predication of antimicrobial efficacy are therefore 
an essential requirement for successful treatment of BSIs.  Typically, genetic encoded 
mechanisms of antibiotic resistance determine antibiotic susceptibility during infection.  
Laboratory based phenotypic criteria dominates the field of antibiotic epidemiology and 
effectiveness.  In-vitro antibiotic testing techniques, however, are poor predictors of 
susceptibility as these do not take into account the presence of extrinsic determinants of 
antimicrobial susceptibility prevalent during the course of infection.  These factors include 
host-pathogen interaction, hosts immune response and environmental factors such as 
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bacterial heterogeneity due to the presence of biofilms and antagonising antibiotic efficacy 
which all contribute to therapeutic failure (Radlinski and Conlon, 2018). 
In most routine clinical laboratories traditional in-vitro antimicrobial susceptibility test (AST) 
methods utilise automation based on broth microdilution principles, ultimately generating 
results with a relatively high level of accuracy within 18-24 hours (Ligozzi et al., 2000; 
Nonhoff et al., 2005). These AST quantitative dilution techniques are based on two fold 
dilutions of the test antibiotic in broth media, which in turn generates the MIC value of the 
given antibiotic in mg/L at which bacterial growth is inhibited.  On the other hand, qualitative 
agar antibiotic disc-diffusion susceptibility categorisation may show reasonable but 
incomplete correlation with therapeutic outcomes due to factors affecting defined 
experimental conditions (Balouiri et al., 2016).  The disadvantage of routine implemented 
AST techniques at present also comes at the risk of reduced sensitivity for the detection of 
slow-growing, low frequency heteroresistance subpopulations.  This further increases the risk 
of underestimating the prevalence of antimicrobial resistance which in turn has a detrimental 
impact on clinical outcomes.  In the healthcare environment, high-risk patients are generally 
placed on broad-spectrum therapy without waiting for microbiology AST results.  This 
practice plays an important role in contributing to the emergence and spread of antimicrobial 
resistance (Montassier et al., 2013).   
In general, antibiotic susceptibility is examined in simple homogenous conditions in-vitro. 
Antibiotic efficacy is however, known to be affected by the dynamic and complex nature of 
host-pathogen interaction influenced by extrinsic factors during the course of infection.  In the 
immunocompromised host, these highly influential extrinsic factors together with the 
administration of inappropriate antimicrobial therapy, potentiates resistance selection 
resulting in treatment failure and exacerbation of disease progression (Radlinski and Conlon, 
2018).  In line with the changing patterns of nosocomial BSIs, a move towards optimal 
targeted patient therapy for the treatment of cancer patients with febrile neutropenia have 
been made recently by hospitals in accordance with national recommended guidelines 
(Penack et al., 2010; BMJ-Best Practice 2017).  Implementation of these procedures could 
lead not only to the avoidance of antibiotic-associated illness but also a decrease in selection 
and dissemination of resistance to commonly used broad-spectrum antimicrobial agents for 
better therapeutic response. 
Several test assay strategies performed routinely by clinical microbiology laboratories are 
utilised for the provision of accurate susceptibility results for treatment options, in the clinical 
context for a given patient population group.  Conventional, manual based qualitative and 
quantitative AST test methodologies take up to 24 hours or more for results reporting to the 
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clinicians for implementation of targeted empiric therapy.  Advances in technology in 
comparison to previously described AST methodologies have nonetheless demonstrated the 
clinical and financial benefits of rapid AST result reporting for the treatment and hence 
eradication of significant infections (Barenfanger et al., 1999).  Therefore, AST result 
provision for therapeutic guidance for implementation of optimum antimicrobial therapies for 
effective clinical outcomes. 
AST is important, not only to confirm susceptibility to the chosen empirical antimicrobial 
agent but also detection of acquired resistance mechanisms especially amongst species-
specific Staphylococcus isolates (Rossolini et al., 2010).  The MIC of antimicrobials tested, 
are primarily determined by the routine implemented test methodologies, which include the 
automated VITEK®2 and standard E-tests for confirmation.  The AST result breakpoint 
categorisation criteria of susceptible, intermediate and resistant are based on 
pharmacokinetics and pharmacodynamic interactions.  Pharmacokinetics refers to the dosing 
distribution and half-life of the antimicrobial agent that impact achievable concentrations in-
vivo and pharmacodynamic the interaction with the organism.  Therefore, the optimal 
interpretation of MICs are based on the pharmacokinetic/pharmacodynamics of the 
antimicrobial agent in terms of microbiological eradication and clinical efficacy.  These are 
referenced in expert sources such as CLSI, BSAC and EUCAST, which are web-based 
expert sources providing published guidelines for interpretative criteria for MICs that relate to 
proven clinical efficacy of specified antibiotics for a given bacterial species (Reller et al., 
2009).  
At present in-vitro AST testing in routine clinical laboratories is carried out based on three 
basic principles, including disc diffusion, gradient diffusion and broth microdilution.  Broth 
microdilution methods are presently incorporated in automated formats which include 
systems such as the VITEK®2 (bioMérieux, France).  These AST microdilution-based 
automated techniques are performed on planktonically growing isolates generally providing 
reliable test results for a range of antimicrobial agents.  The automated MIC systems utilise 
abbreviated dilutions across a narrow range generally covering the breakpoint concentration 
of the test drug (Ribeiro et al., 1999; Ligozzi et al., 2002; Nonhoff et al., 2005).  Routinely 
used AST methodologies, therefore, effectively provide results for prediction of therapeutic 
success or failure in most cases of systemically spreading infections. 
1.8.1 Automated AST systems 
The VITEK®2 automated commercial system microdilution procedure includes the generation 
of MICs with the convenience of computerised generated reports. This highly automated 
system uses compact plastic GP-reagent cards each containing microliter quantities of the 
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relevant test antibiotics and test media in a 64-well format inclusive of positive and negative 
control wells.  As previously described, the VITEK®2 system employs, 15 minutes, repetitive 
turbidimetric monitoring determined by fluorometric measurement of bacterial growth over an 
abbreviated incubation period of up to 18 hours. The quantitative antimicrobial susceptibility 
results are categorised according to the current installed version of the Global EUCAST/CLSI 
defined guidelines by the manufacturer (bioMérieux, UK).  The associated VITEK®2 
Advanced Expert System™ software programme analysis enables the biological validation 
and interpretation of antimicrobial susceptibilities and detection of resistant phenotypes.  
Modifications and upgrade of the VITEK®2 computer software and advanced expert system 
has further provided assurance of result interpretation and accuracy of reported susceptibility 
results to the clinician for better treatment options (Ligozzi et al., 2002; Product literature, 
2004; Funke and Funke-Kissling 2005).   
1.8.1.1 VITEK®2 GPC AST card 
The VITEK 2™ Gram-Positive susceptibility AST card used with the automated VITEK®2 
System (Software version 05.03–2011) is used as an in-vitro test to determine the 
susceptibility of Staphylococcus species to specified antimicrobial agents (Product 
Information Manual: www.biomerieux.com).  The AST-P578 card consists of eighteen test 
anti-staphylococcal antimicrobials inclusive of section well for detection of inducible 
clindamycin resistance as listed in Table-3.  Each test antibiotic is tested across a set range 
of pre-defined doubling dilution concentrations. The VITEK®2 automation is equipped with a 
second-generation Advanced Expert Software (AES).  The AES interprets AST results at 








   ≤ ≥    ≤ ≥ 
Benzylpenicillin PEN 0.03 0.5 Teicoplanin TEI 0.5 32 
Oxacillin FLU 0.25 4 Vancomycin VAN 0.5 16 
Gentamicin GEN 0.5 16 Tetracycline TET 1 16 
Kanamycin KEN 4 64 Tigecycline TIG 0.12 2 
Tobramycin TOB 1 16 Fusidic Acid FUS 0.5 32 
Ciprofloxacin CIP 0.5 4 Mupirocin MUP 2 512 
Erythromycin ERY 0.25 8 Chloramphenicol CHL 2 16 
Clindamycin CLI 0.25 4 Rifampicin RIF 0.5 4 
Linezolid LIZ 0.5 8 Trimethoprim TRI 0.5 16 
Table 1-3: Gram-Positive AST-P578 card well contents for the susceptibility testing of 
Staphylococcal species (Adapted from VITEK®2 GP-AST product package 
information). Susceptibility is defined as MIC (mg/L) of ≤ falling within the 
concentration calling-range of MIC ≥ defined as nonsusceptibility.   
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Analysis and susceptibility and non-susceptibility categorisation of each antibiotic are 
determined in accordance with the MIC interpretative guidelines based on the Global 
European interpretative guidelines (CLSI, 2005/2006; EUCAST 2010/2011).  The use of 
quantitative MIC tests, therefore, enables a targeted approach to implementation of 
therapeutic regimens regarding dose and dosing frequency thus improving clinical efficacy. 
Studies assessing the performance of VITEK®2 system for staphylococci AST demonstrate 
that the system provides accurate susceptibility test results with a sensitivity/specificity of 
90/96%, in agreement with reference test methods (Ligozzi et al., 2002; Nonhoff et al., 2005).  
The VITEK®2 test assays have however, proved to be unreliable for the detection of resistant 
subpopulations of cells present in an otherwise fully susceptible strain population at 
frequencies ranging from 10-6 to 10-7 CFU/mL.  These resistant subpopulations can miss 
detection due to sampling errors, as such resistance detection requires use of the inoculum 
above the standard threshold density of 5 x 105 CFU/mL (Wootton et al., 2001).  
1.8.2 Standard E-test antimicrobial test method 
Due to the pitfalls of conventional automated AST test methodologies for the determination of 
reduced susceptibilities to vancomycin in particular, non-automated MIC determination by 
agar or broth dilution and E-test (Epsilometer-test) are an alternative test methodology for 
resistance detection.  E-test methodology has proved have similar sensitivity but higher 
specificity in comparison to automated microdilution based methodologies (Tenover et al., 
2001). 
The principle of gradient test method utilising E-test antimicrobial MIC test strips is based on 
combining both dilution and diffusion procedures.  The E-tests are a quantitative assay for 
the determination of both MICs and detection of antimicrobial resistance.  These test strips 
are patented porous plastic or paper strips impregnated with a predefined 15 two-fold 
dilutions concentration gradient of antibiotic.  Application of E-tests on pre-inoculated 
susceptibility agar surface results in diffusion of antibiotic agents in a continuous and 
exponential concentration gradient range from one end of the strip to the other.  The MIC 
value for a specified antimicrobial-microorganism combination are therefore, determined at 
the point of interaction of the strip and the growth inhibition ellipse after incubation (ETEST® 
bioMérieux, 2012).  The predefined antibiotic gradient represents an accurate and 
acceptable strategy for routine susceptibility testing over an extended concentration gradient 
such that extreme ranges of both resistance and susceptibility are covered. These gradient 
based applications have been shown to correlate well with those determined by qualitative 
broth dilution methods (Balouiri et al., 2016).  The standardised approach of in-vitro 
susceptibility E-test susceptibility testing allows for quantification of antimicrobial efficacy and 
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hence, evaluation of clinically relevant results, an essential requirement for guidance of 
effective therapeutic selection. 
The E-test technique can also be used to determine the antagonist or synergistic effect of 
antimicrobial agents used in combination (White et al., 1996).  This methodology utilises E-
test strips impregnated with the two test antibiotics placed in a cross formation at angle of 
90° at the interaction between the scales at the respective MICs of the test microorganism. 
Using this combined E-test assay, synergy is detected by a decrease of the MIC of the 
combined antimicrobial agents by a factor of two dilutions in comparison to the antimicrobial 
agents tested alone.  Synergy or antagonism for the two antimicrobial compound 
combinations are defined by calculating the fractional inhibitory concentration index (FICI) 
and results categorised according dependent on calculated values (Doern, 2014; Balouiri et 
al., 2016). Therefore, synergy test techniques demonstrating antimicrobial interactions allow 
for the use of pharmacodynamic indices to select effective agents and dosing regimens for 
targeted therapy of serious infections (Bollenbach, 2015). 
The recent trends in epidemiology and antibiotic resistance observed in CoNS-associated 
bacteraemia in patients with life-threatening malignancies therefore necessitates appropriate 
antimicrobial interactions for accurate predication of efficacy. Hence targeted combination 
therapeutics for the management of the critically ill has not only been shown to significantly 
increase the likelihood of clinical success but also a decrease in emergence of resistance to 
the agents used for therapy (Bollenbach, 2015; Yan et al., 2018). 
 
1.8.2.1 Detection of heteroresistant Vancomycin-Intermediate resistance  
Screening for CoNS isolates with reduced susceptibility to the glycopeptides is becoming 
increasingly important in patients who do not respond to appropriate glycopeptide therapy. 
Vancomycin resistance amongst staphylococci appears not to be homogeneous 
characteristic, hence making the detection of heterogenous populations within susceptible 
and resistant cells difficult, using standard quantitative techniques.  Low-level glycopeptide 
resistance detection requires longer incubation times as well as enhanced growth media to 
allow expression of the resistance determinants and visible growth (Wong et al., 1999; van 
Hal et al., 2011).   
Subsequent to the first description of heteroresistance in clinical isolates of MRSA by 
Hiramatsu and colleagues (1997) in Japan, testing methodologies for the detection of 
heteroresistant vancomycin-intermediate strains have primarily focused on S. aureus. The 
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best accurate and cost-effective screening methods for the detection of heteroresistance in 
S. aureus isolates however, still remain unclear.  Similarly, there are at present no clearly 
defined phenotypic screening and confirmatory test methodologies for the detection of 
reduced or heteroresistant susceptibility to the glycopeptides in CoNS isolates.  Nonetheless, 
using a combination of previously described test methodologies, has shown an increase in 
overall accuracy of resistance detection (van Hal et al., 2011).   
Methodologies in different parts of the world to detect intermediate or heteroresistance differ 
in defining breakpoints and interpretative criteria.  Most of the work has been carried out on 
emerging isolates of S. aureus with reduced susceptibility to vancomycin (Walsh et al., 
2001).  The recommended simple screening method for detection of heteroresistance 
staphylococcal is the macro-method with E-tests which allows detection of specific resistant 
subpopulation phenotypes after 48hour incubation (van Hal et al., 2011).  These 
subpopulations within susceptible staphylococcal isolate groups achieve optimum growth in 
the presence of vancomycin concentrations ≥4mg/L after prolonged incubation.  Currently 
however, there are few systemic data available that provide evidence regarding clinical 
outcome in patients with such heteroresistance staphylococcal infections.  There may be 
other factors that lead to therapeutic failures which may not be linked to bacterial response to 
the glycopeptides.  These may include factors such as the inability to achieve sufficient 
serum levels of the antimicrobial to have an effective response in-vivo.  As the definitive type 
of testing algorithm for use of accurate detection of hVIS has yet to be clearly established, 
similar test strategies used for resistance detection in S. aureus have been used to 
determine the prevalence of reduced susceptibility to vancomycin in CoNS isolates 
(Ahlstrand et al., 2011). 
Simple and accurate phenotypic methods have yet to be established for the detection of 
glycopeptide heteroresistance as a standard in clinical laboratories.  The modified population 
analysis profile method using the area under the concentration-time curve (PAP-AUC) is 
considered the most reliable methodology for detection of heteroresistance.  The greater 
resolution of this method allows for detection of highly resistant subpopulations that are 
present in low frequencies.  The PAP-AUC remains the gold-standard method, however it is 
expensive, time consuming and labour-intensive hence limiting its use to specialised referral 
test laboratories (Wootton et al., 2001).  In comparison to the PAP-AUC method, the use of a 
combination of easy to perform test assays set up in parallel with routine susceptibility test 
methodologies have been shown to increase accuracy of detecting heteroresistance.  These 
test assays include the Glycopeptide Resistance Detection (GRD) E-test, the macro-method 
E-test together with the use of standard methodology for comparison purposes, have been 
shown to increase specificity and sensitivity for detection of heteroresistant strains (Yusof et 
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al., 2008; van Hal et al., 2011).  The GRD E-test, consisting of a double-sided predefined 
gradient of vancomycin and teicoplanin has been developed specifically to simplify detection 
of GIS and hGIS resistance phenotypes.  However, these prototype GRD E-tests are at 
present used for research purposes only and not validated for clinical use.  Therefore, 
optimal routine laboratory-directed approach to screen for heteroresistance still remain to be 
determined in cases where elevated vancomycin MICs are observed.  Such observations are 
clinically important in patients who remain non-responsive to standard glycopeptide therapy 
or those at risk of developing resistance due prolonged antimicrobial therapy. 
The recent trends in epidemiology and antibiotic resistance observed in CoNS-associated 
bacteraemia in patients with life-threatening malignancies therefore necessitates appropriate 
antimicrobial interactions for accurate predication of efficacy.  Targeted combination 
therapeutics for the management of the critically ill has also been shown to significantly 
increase the likelihood of clinical success and decrease emergence of resistance to the 
agents used for therapy (Bollenbach, 2015; Yan et al., 2018). 
 
1.9 Haematology and Bone Marrow Transplant unit  
At the time of this study the Queen Elizabeth Hospital (QEH) part of the University Hospitals 
Birmingham NHS Foundation Trust, was a 1200-bed tertiary care hospital located in the 
West Midland region of the UK.  All hospital services are now allocated in new larger block of 
buildings next to the former hospital building.  This adult specialist referral and teaching 
hospital provides a wide range of general and other specialist services including trauma, 
neurosurgery, cardiac, liver, renal, burns and plastics.  The hospital is the regional centre for 
cancer including haematological malignancies, bone marrow transplants and has the largest 
solid organ transplantation programme in England.  This specialist healthcare facility was 
documented to have the highest concentration of immunocompromised patients and the 
highest ratio of intensive care unit to general beds in England (CDR, 2006).  The in-patient 
population demographic and factors such as the high frequency use of invasive techniques, 
have contributed to greater levels of Gram-positive associated bacteraemia seen in this and 
other hospitals (Coello et al., 2001).  A prerequisite for infection in these high-risk patient 
populations is CoNS colonisation acquired either from environmental sources including 
healthcare staff or from endogenous translocation.  
Noting the rising levels of bacteraemia frequently reported in high-risk patient groups with 
underlying co-morbidities, a clinical surveillance laboratory audit of all positive blood cultures 
was undertaken by the microbiology clinician (Dr S Larkin, Specialist Microbiology Registrar); 
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to determine the infective agents most frequently isolated from these patients.  Audit results 
revealed high rates of CoNS-associated bacteraemia in all specialist units of the hospital.  
Overall results indicated that there was an incidence rate of 252 isolates from 206 blood 
cultures analysed from 173 bacteraemic patient episodes in the hospital.  Of these, the 
highest rate was attributed to the isolation of 106 non-speciated, CoNS in comparison to 36 
strains of other staphylococcal species.  Similar to other healthcare facilities, therapeutic 
options remain limited for the treatment of CoNS-associated infections.  This is 
predominantly attributed to factors such as the inherent ability of these CoNS isolates to 
express resistance to multiple antimicrobials, further complicating the management of the 
immunocompromised patient group.  Hence, in compliance with the hospital antimicrobial 
policies, vancomycin currently remains the drug of choice for the treatment of 
staphylococcal-associated bacteraemia.  The audit report also evidenced that the greatest 
rates of CoNS-associated bacteraemia linked with the extensive use of vancomycin therapy 
were in patients in the haematology and BMT unit followed by those in the renal unit.  The 
clinical significance of episodes of CoNS-associated bacteraemia in hospitalised patients has 
yet to be ascertained.  In the haematology patient group however, CoNS-associated 
bacteraemia is documented to be a risk factor linked with significant life-threatening 
consequences (Chen et al., 2010; Marin et al., 2014).   
1.9.1 Characteristics of QEH haematology patients  
The haematology patient population is comprised of patients receiving chemotherapy for a 
range of haematological malignancies and those receiving autologous stem cell therapy or 
primarily allogenic bone marrow transplantation.  Detailed description of patient care on the 
haematology unit and all information regarding diagnosis and treatment were kindly provided 
by Dr Sandeep Nagra (Clinical Haematology- Senior BMT Fellow). 
At the time of the study the haematology and BMT wards were located in the former QEH 
building.  The haematology and BMT unit comprised of two separate ward units linked by a 
common corridor divided by push plated double doors.  The ward area maps kindly provided 
by the microbiology infection control team, illustrate the areas accessed by all medical 
professionals, nursing staff and affiliated healthcare staff common to both ward areas 
(Figures 1-2 and 1-3). 
The general haematology (Ward West 5), comprises of 16 bed unit consisting of a series of 
four bed cubicles linked to the BMT ward area via a single corridor separated by a set of 
double doors (Figure1-2).  Nursing care in this specialist unit was administrated within the 
constraints of local infection control policies governing high-risk patient groups.  Likewise, the 
BMT ward area (Figure1-3) comprising special environmentally controlled single bed 
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isolation rooms were reserved for patients undergoing stem cell transplantation.  The six 
single isolation specialist rooms provide a protective environment reducing the risk of 
infection at the stage when patients are at their most vulnerable after transplantation.  The in-
built high efficiency particulate filtration system and positive air pressure application ensures 
removal of endogenous and exogenous contaminates.  Compliance with the control of 
infection cleaning procedures in this area further minimises risk of infection in the critically ill, 








Figure 1-2: Haematology ward area map (West 5: Queen Elizabeth Hospital).  This area 
comprises of four bed unit rooms.  Arrow marks the access corridor to the BMT ward 
area.  The 10 zones of high contact/touch points used by staff investigated for 
bacterial presence and load were along the area marked in red.  Investigation points 
include the nurses workstation, portable computer system, treatment room, waste 
disposal room, door handles, scanner unit, drugs trolley, bed-side tables and double-
door handles and push-plates. 
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Figure 1-3: The BMT ward area map (West 5: Queen Elizabeth Hospital).  This area 
comprises of single isolation rooms under positive pressure providing a protective 
environment for BMT patients.  Arrow marks the access corridor to the main general 
haematology ward area.  The 10 zones of high contact/touch points used by staff 
investigated for bacterial presence and load were along the area marked in red.  The 
10 surface areas of high-use include the clinical workstation front and rear surfaces, 
portable computer system located in the main corridor, treatment room work surface, 
macerator room door handles and door plate, side-room door handle, bed-side table 
and double-door handles and exit door push-plates. 
 
The adult haematology patient population treated at the hospital, ranges from age 55 to a 
maximum of 60 years.  Advanced technique utilisation, better supportive care and improved 
matching of donors for allogenic transplants resulting in lowering of transplant-associated 
toxicity has allowed inclusion of patients up to age 75 years. The autologous transplant 
population has increased from 30 to more than 100 patients over time: comprising of patients 
with various malignancies including those presenting with acute myeloid leukaemia, acute 
lymphatic leukaemia, lymphomas, myelomas, haemophiliacs and pathological conditions 
involving other bone marrow or immunodeficiency syndromes.  Previous transplant related 
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mortality was about 30%, that is 1 in 3 patients died because of infections or graft-versus-
host diseases. The mortality rate has currently improved, dropping to around 10% due to 
better clinical management regimens. 
For pre-planned admission of allogenic stem cell transplantation, all patients have tunnelled 
central lines implanted including Hickman catheters for long term vascular access 
chemotherapeutic administration and stem cell infusion. Chemo and radiotherapy 
conditioning therapy in the first seven days of admission followed by transplantation, leaves 
neutropenic patients extremely vulnerable to BSIs.  Early predication of bacteraemia and its 
associated source in neutropenic febrile patients is of importance for administration of 
appropriate empirical therapy to reduce risk of morbidity.  Diagnosis of bacteraemia includes, 
fever, defined as a single oral or tympanic temperature reading of ≥38°C with neutropenia as 
an absolute neutrophil count of <0.5 x 109/L expected to fall further during the course of 
disease.  Immunocompromised patients are therefore, classified as those receiving either 
chemotherapy six weeks post-admission, receiving high dose steroids, post-allograft or those 
having received extensive field radiotherapy over the final six weeks of post-admission.  
Therefore, following these parameters, haematology patients at the QEH undergo 
microbiological investigations with prompt administration of empirical broad-spectrum 
antimicrobial therapy in line with the national recommended clinical guidelines for the 
treatment of suspected infection in febrile neutropenic patients 
Initial microbiological investigations in onco-haematology patients suspected of bacteraemia, 
include two sets of blood cultures, one taken via peripheral venepuncture and another via 
Hickman line together with other appropriate specimens such as central line exit swabs.  In 
the high-risk neutropenic patient, empirical therapeutics are initiated immediately after the 
first episode of fever of unknown origin.  Algorithms for empirical treatment for haematology 
patients, with consideration given to the presence of localised signs and symptoms include 
meropenem given as intravenous injection three times a day with the addition of vancomycin 
to provide Gram-positive and Gram-negative cover.  Vancomycin is administered 
intravenously by intermittent infusion with the aim of achieving pre-dose serum levels of 
between 15-20mg/L.  In agreement and conforming to national recommended guidelines for 
clinical practice, patients with staphylococcal BSIs treated with vancomycin, have serum 
levels monitored for efficacy and prevention of toxicity.  Although CoNS isolates commonly 
recovered in cultures are thought to be representative of contaminants (pseudo-bacteraemia) 
or true BSI; broad-spectrum antimicrobial empiric therapy is always initiated prior to 
microbiological diagnosis due to the haematology patients underlying clinical co-morbidities, 
Patients are re-evaluated on receiving microbiological diagnosis and vancomycin therapy 
continued if signs of fever associated with staphylococcal bacteraemia persist after 72 hours.    
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Although patients with aggressive malignancies and those undergoing transplantation show 
a higher response rate with pre-emptive addition of glycopeptide agents, cyclosporin 
treatment is also initiated for those displaying signs of drug induced nephrotoxicity.  Line 
removal is also indicated in cases of persistent or proven bacteraemia with CoNS, S. aureus 
or other Gram-negative/positive organisms.  However, with positive cell engraftment in place, 
haematology and BMT patients are discharged on recovery from the complexities of 
associated infections with Hickman lines in-situ for follow-on therapeutics.  
 
1.10 Pilot study  
As described previously, the general practice guidelines includes prescribing vancomycin to 
treat bacteraemia in combination, with a carbapenem, usually meropenem as initial 
antimicrobial therapy in patients displaying signs of fever in the haematology and BMT unit.  
It was therefore postulated that antibiotic pressure resulting in resistance selection may be 
due to prolonged use of broad-spectrum antibiotics, particularly of vancomycin on the unit 
leading to therapeutic failures.  Although, in-vitro susceptibility tests do not predict clinical 
outcomes, several studies, primarily focusing on invasive S. aureus infections have observed 
higher vancomycin MICs within the susceptible range associated with treatment failures 
(Steinkraus et al., 2007; Rybak et al., 2009; Edwards et al., 2011).  With prolonged use of 
vancomycin in this high-risk patient group there was growing concern that vancomycin may 
also have diminished activity predominantly against MDR-CoNS isolates.  Therefore, 
detection of small changes in vancomycin MICs over time could be of clinical importance as 
these could signify development of resistance and hence explain clinical failures. 
A retrospective microbiological and clinical pilot study was therefore conducted to review the 
incidence of CoNS-associated bacteraemia in patients in the haematology and BMT unit.  A 
laboratory review of all CoNS-associated positive blood cultures obtained from these 
hospitalised patients with haematological malignancies was carried out over a nine month 
period.  The correlating microbiology laboratory antimicrobial susceptibility data was 
accessed via the laboratory electronic information system.  The reported susceptibility 
ranges of CoNS blood isolates were recorded to establish baseline characteristics of 
antimicrobial resistance to the glycopeptides, vancomycin and teicoplanin.  For comparative 
purposes, over the same time period, a blind clinical review of vancomycin serum levels of all 
in-patients in the haematology unit, diagnosed with CoNS bacteraemia treated with 
vancomycin was undertaken by the clinical microbiologist (Consultant Microbiologist, Dr 
Deborah Mortiboy).  The purpose of the pilot study was to explore the link between 
vancomycin reported susceptibility results and the therapeutic dose level achieved, as 
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assessed through vancomycin serum concentration levels in relation to CoNS bacteraemia.  
The predictive efficacy of vancomycin could therefore be extrapolated from correlating the 
laboratory susceptibility data with the results of the clinical review in association with 
expected clinical outcomes. 
During the study period, AST results of all CoNS isolates from blood cultures obtained from 
the haematology and BMT patients, judged to be the causative agents of infection were 
reviewed using the laboratory electronic information system.  Results revealed 71 blood 
cultures positive for CoNS in bacteraemic patients in the haematology unit (Ward 5) over a 
nine month period from July 2009 to April 2010.  Similar retrospective analysis of reported 
vancomycin and teicoplanin MICs was carried out on non-speciated CoNS isolates, 
according to standard routine microbiology protocol over the same period.  The susceptibility 
results were classified in accordance with the rule base of the VITEK®2 integrated software 
application system based on the rationale breakpoint of 2mg/L, the upper limit for reporting 
vancomycin susceptibility was applied.  This application was in accordance with protocol 
based on VITEK breakpoints defined for susceptibility interpretation for all staphylococcal 
species (EUCAST 2010; version 2.1), as exact breakpoints for result interpretation for non-
speciated CoNS isolates are yet to be defined.  These VITEK®2 breakpoint rationale are for 
all staphylococcal isolates and remain the current defined category for inclusion of S. 
lugdunensis, the most virulent of the CoNS species for treatment purposes and reporting to 
the clinicians (EUCAST 2010; BSAC May 2010 and 2014).  This application of a susceptible 
breakpoint of 2mg/L for vancomycin is consistent with a previous study detailing the in-vitro 
activity of antimicrobials against CoNS blood isolates from BMT recipients’ (Kratzer et al., 
2007). 
The initial pilot study laboratory data analysis results of vancomycin MICs of bacteraemic 
patient CoNS isolates (n = 71) isolates revealed resistance rate of 1%.  However, borderline 
vancomycin susceptibility of 2mg/L, defined to be at the upper end of susceptibility range 
was observed in almost half (47%) of the CoNS isolates.  On the other hand, resistance to 
teicoplanin was observed in 13 (18%) of the isolates with borderline teicoplanin susceptibility 
(MIC = 4 mg/L) observed in 11 (16%) of the CoNS isolates. The following observations were 
therefore drawn from the laboratory data analysis of reported glycopeptide susceptibilities: 
1. Almost half of the reported CoNS isolates in this bacteraemic patient group displayed 
vancomycin MIC of 2mg/L which are clinically, considered to be at the upper end of 
the susceptibility range. 
2. A significantly higher level of resistance was observed to the glycopeptide, teicoplanin 
in comparison to vancomycin. 
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Overall, although resistance to vancomycin was not observed in the BSI CoNS isolates 
analysed, the detection of significant levels of teicoplanin resistance were considered to be of 
clinical importance.  Due to the prolonged use of vancomycin in the haematology unit, the 
postulated emergence of resistance is highly likely, as observed by the prevalence of 
elevated MIC levels in almost half of the CoNS isolates analysed.  The likelihood of 
resistance development is further substantiated by the observed frequency of teicoplanin 
resistance, an agent known to be a good marker for emerging resistance to the 
glycopeptides (Biavasco et al., 2000; Levine, 2008).  
In accordance with the standard hospital policies, patients receiving vancomycin therapy 
have drug serum trough level assays routinely performed to monitor clinical efficacy and 
minimise toxicity of the antibiotic over the prescribed period.  In this high-risk patient group, 
monitoring vancomycin drug levels also ensures avoidance of other drug related toxic 
effects. These may include drug induced antagonistic or synergistic effects in combination 
with other commonly administered chemotherapies such as antifungal and corticosteroid 
therapies. 
In the absence of clinical correlations of serum levels with outcome or drug toxicity, a clinical 
data audit of vancomycin use and reported serum vancomycin levels for the patients on the 
haematology and BMT unit was also performed.  Electronic medical records and clinical 
pathology laboratory database were used to access patient demographic, clinical and 
laboratory analytical information. This clinical audit undertaken by Dr Mortiboy, included a 
retrospective medical record review of 252 vancomycin serum level reports for patients 
receiving vancomycin therapy for staphylococcal-associated BSIs, over an equivalent nine 
month period from January 2010 to September 2010.  The results of this clinical data 
analysis revealed 179(71%) of the reported vancomycin serum levels were below the target 
value of ≤10mg/L.  On the other hand, only 54(21%) of the reported vancomycin serum 
levels were within the expected target value of between 10-15mg/L. 
Comparative analysis of results of the clinical and laboratory audit was then undertaken to 
ascertain the link between higher vancomycin MICs and the therapeutic dose levels achieved 
in relation to the CoNS bacteraemia prevalence in the haematology/BMT patient group 
(Consultant Microbiologist, Dr Ira Das).  Correlating the findings from clinical data analysis 
with the laboratory data of reported vancomycin MICs, the following points were made in 
conclusion and presented to the clinical microbiology team. 
1. Majority of isolates exhibited high MICs to vancomycin. 
2. Majority of patients were not achieving therapeutic target levels of the drug. 
3. CoNS-associated bacteraemia in the unit are not treated adequately 
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4. Inadequate vancomycin therapy resulting in prolonged antibiotic use, also led to 
further unnecessary investigations and in many cases unwarranted removal of lines. 
5. Prolonged sub-therapeutic levels of vancomycin also favored emergence of 
vancomycin resistant organisms such as enterococci that are prevalent on this unit. 
 
On the basis of these conclusions drawn from the pilot study, it was suggested that further 
investigations were warranted to reliably evaluate the prevalence of antimicrobial resistance 
amongst CoNS isolates in this high-risk bacteraemic patient group.  Currently in accordance 
with the present antibiotic policies governing the treatment of Gram-positive bacteraemia, 
vancomycin still remains the drug of choice for the treatment of febrile neutropenic patients in 
the haematology and BMT wards.  Vancomycin serum levels routinely monitored in this 
patient group in order to avoid toxicity and maintain therapeutic levels indicated sub-optimal 
achievement.  Such factor favour the selection and emergence of resistance which is an 
important healthcare problem in high-risk patient groups.  Therefore, further exploration of 
the relationship between BSI CoNS species-specific isolates and prevalence of antimicrobial 
resistance with particular reference to the glycopeptides was also merited.  Additionally, 
further study would necessitate assessment of other factors that could potentially influence 
selection of multi-resistant isolates in haematology patients with suspected CoNS BSIs 
associated with elevated vancomycin MICs.  Informed decisions could therefore result in 
selection of appropriate antimicrobial therapeutics for the management of CoNS BSIs thus 
limiting potential clinical failures for optimum patient outcomes. 
 
1.10.1 Study design  
1.10.1.1 Source population characteristics 
The study was restricted to patients hospitalised in the haematology and BMT unit with 
CoNS-associated BSIs.  Episodes of CoNS bacteraemia over a two year period, from April 
2010 to March 2012 in this patient group were retrospectively identified from archived clinical 
microbiology laboratory computerised database records.  Over this two year period, a total of 
100 CoNS isolates recovered from blood cultures of patients in the unit were identified for 
further investigation. 
In principle, this was a laboratory-based retrospective study and was therefore carried out 
without requirement for and access to any patient clinical data.  Hence the results of CoNS-
positive blood cultures were interpreted to be probable or possible CoNS-associated 
bacteraemia based on the patients setting and the criteria applied for the sending blood 
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cultures for microbiological investigations.  In accordance with ethical standards, approval by 
the ethics committee was therefore not required for this study as all the non-clinical patient 
microbiological data obtained was anonymised and analysed retrospectively 
Assessment of the microbiological data obtained, consisted of analysis of the incidence of 
CoNS bacteraemia and antimicrobial susceptibilities, focussing particularly on reported 
susceptibility results of the glycopeptides, vancomycin and teicoplanin.  In accordance with 
standard laboratory protocol, the conserved CoNS isolates were identified via laboratory 
freezer storage records and a small amount retrieved from each stored sample for further 
analysis.  The study was designed to characterise these CoNS isolates using both 
phenotypic and genotypic techniques.  The primary goal of the study was to examine the 
relationship between antimicrobial resistances expressed to the commonly used anti-
staphylococcal agents, including vancomycin and other virulence factors which may have 
correlations with CoNS species-specific features.  Furthermore, the aim was to explore the 
prevalence of reduced glycopeptide resistance (heteroresistance) amongst these CoNS 
isolates, which could be associated with an impaired response to glycopeptide therapy 
resulting in clinical failure. 
  
1.10.1.2 Control patient population source 
CoNS are atypical virulent species forming part of the normal skin microbiota but are 
increasingly becoming the leading cause of nosocomial infection particularly amongst high-
risk patient groups.  it is postulated that the source of nosocomial infection, in particular 
CoNS-associated bacteraemia originates potentially from cutaneous sites of CVCs or from 
colonised mucosa of hospitalised patients undergoing immunosuppressive therapies (Costa 
et al., 2004). 
Due to the retrospective nature of this study, skin-colonising strains could not be obtained 
from the relevant in-patient population prior to hospitalisation for direct comparisons with 
bacteraemia strains.  As translocation of strains from colonised sites can only be further 
evidenced or supported by clinical, experimental and molecular relatedness studies; skin-
colonising strains deemed valid for this study were therefore obtained from cultures of swabs 
taken from three areas of patients skin, prior to hospital admission.  Therefore, for the 
purpose of this study, the yield of colonising flora from the nose, groin and throat regions of 
100 pre-admission patient swabs was examined prior to routine investigations for MRSA 
colonisation. The study was therefore directed towards evaluating the potential of 
predominant skin-colonising strains as the clinically significant putative source of CoNS- 
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associated bacteraemia in the hospitalised haematology patient group.  More importantly 
these disseminated skin-colonising staphylococcal isolates may have the potential not only to 
recolonise other body sites but also act as a source of cross-infection among other patients 
in the hospital environment. 
The increase in CoNS-associated bacteraemia in haematology and BMT patients undergoing 
sub-optimal antimicrobial treatment also carries significant clinical and epidemiologic 
implications.  At present, the widespread use of vancomycin as the therapeutic drug of 
choice could result in emergence of resistance due to selective pressure which is a matter of 
great concern as this leads to poor clinical outcome for the patient.  Effective screening 
methods utilised in this study would allow for the detection of CoNS species-specific 
resistance in this high-risk patient group.  Additionally, subtyping of CoNS to the species 
level is important for verification of clonally related colonising strains that are a potential 
source involved in translocation, dissemination, and/or cross-transmission events 
subsequent to acquisition of bacteraemia. 
With reports of emerging resistance to the glycopeptides, the results of the study has the 
potential for provision of information and clinical guidance for a more targeted approach for 
treating CoNS-associated bacteraemia.  The use of alternative newer antibiotics and 
effective combination regimens together with continuous therapeutic drug monitoring would 
represent key options for the treatment of these life-threatening opportunistic infections in 
haematological patients. 
 
1.11 Aims and objectives 
The primary aim of the study was to determine the phenotypic characteristics of CoNS 
isolates recovered from blood cultures of patients in the haematology and BMT unit.  The 
prevalence of species-specific characteristics were explored using both standard and 
advanced laboratory techniques. 
The main objectives of this study were: 
• To explore the phenotypic characteristics of the prevalent skin colonising strains 
of CoNS isolates recovered from the groin area of a group pre-admission patients 
for comparative purposes.  
• To investigate and determine the environmental prevalence of CoNS species in 
areas most frequently accessed by staff and patients in the haematology and 
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BMT wards. The aim of this investigation was to establish phenotypic correlation 
of environmental CoNS isolates with those of the in-patient population through 
cross-infection. 
• To determine genotypic differences or similarities between blood culture isolates 
of CoNS with those skin colonisers which could be regarded as inducers of 
bacteraemia in the haematology and BMT in-patient population.   
• To compare and investigate the phenotypic antibiotic resistance profiles of both 
the bacteraemic in-patient CoNS and those skin-colonising isolates obtained from 
the pre-admission patient using standard laboratory protocols.  The aim was to 
determine the prevalence of reported resistance amongst CoNS isolates to 
commonly used antimicrobials.  
• To investigate and determine the incidence of vancomycin and teicoplanin 
susceptibility among the well-characterised in-patient CoNS isolates using 
standard MIC susceptibility test methods.  
• To further evaluate the incidence of reduced activity of the glycopeptides, using 
susceptibility screening methods other than those in routine use.  These were 
utilised for the detection of glycopeptide resistance expressed heterogeneously. 
• To determine the activity of several new antimicrobial agents including 
daptomycin, tigecycline and ceftaroline against the BSI CoNS isolates. 
• To investigate the incidence of four commonly expressed virulence factors in 
correlation with the antibiotic resistant phenotype among both the in-patient and 
pre-admission group CoNS isolates. 
• To assess the activity of vancomycin, gentamicin, daptomycin and rifampicin 
applied in-vitro individually and in combination against three well characterised S. 
epidermidis BSI isolates representative of a range of susceptibility patterns.  A 
specified E-test technique was utilised to assess the synergistic or antagonistic 
effect of these antimicrobial agents.  
• To assess the biofilm-associated in-vitro activity of vancomycin daptomycin and 
rifampicin individually and in combinations against a well characterised S. 





Chapter 2 Comparative analysis of the prevalence of coagulase negative 
staphylococcus species-specific strains recovered from blood cultures of patients in 
the haematology and bone marrow transplant unit with those comprising skin 
microflora. 
2.1 Introduction  
CoNS have emerged as significant nosocomial pathogens, most commonly isolated from 
clinical blood culture specimens, but as part of the normal skin flora are also common blood 
culture contaminants.  Studies have shown that in patient with haematological malignancies 
and post-BMT, the highest incidence of nosocomial infection especially during the 
neutropenic phase was mainly due to CoNS species (Denttenkofer et al., 2003).  In the 
majority of cases isolation of CoNS is said to represent contamination and not true infection 
(García et al., 2004) and hence is commonly reported generically as CoNS species without 
further species-specific identification.  However, specific-species CoNS, in particular S. 
epidermidis have been implicated in clinically important infections representing the major 
cause of bacteraemia in the immunocompromised host with implanted or indwelling devices 
(Pagano et al., 1997; Pfaller et al., 1999; Sloos et al., 2000; Tashiro et al., 2015).   
CoNS bacteraemia if treated promptly and adequately is rarely life threatening (Pfaller et al., 
1988; García et al., 2004).  However, in patients with haematological malignancies there is 
potentially an increased risk of fatal outcome especially if more virulent strains of CoNS 
species such as S. lugdunensis are involved (Pagano et al., 1997: von Eiff et al., 2002).  Due 
to the pathogenic potential of these organisms, accurate identification and characterisation of 
CoNS species has becomes more important clinically.  Recognition of their clinical 
significance in nosocomial infections allows for predication of pathogenesis, determination of 
clinical significance and therefore intervention with appropriate antimicrobial therapy for 
optimal outcome. 
Hence, diagnosis of CoNS bacteraemia is dependent on accurately identifying species-
specific CoNS isolates from blood cultures as a predicator of their clinical significance (Zitella 
2003; Worth et al., 2009).  In the majority of cases, the same strain or clonal population 
repeatedly isolated from patient blood cultures is indicative of infection (Zitella 2003; Worth et 
al., 2009).  An early study carried out by Weinstein and colleagues (1998) showed that of the 
eleven different species of CoNS blood culture isolates, S. epidermidis, S. hominis and S. 
haemolyticus were the three most common species detected, accounting for both 98% of the 
clinically significant isolates as well as 89% of the contaminants.  The other less commonly 
isolated species included S. capitis and S. lugdunensis.  Other CoNS, including S. cohnii, S. 
auricularis, S. simulans, S. caprae S. sciuri and S. warneri when isolated are usually 
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considered as blood culture contaminants but in the immunocompromised host maybe 
clinically significant (Widerström et al., 2012; Becker et al., 2014).   
An epidemiological study of blood culture isolates of CoNS demonstrating hospital-acquired 
infection showed species distribution dominated by isolates of S. epidermidis (68.7%) and S. 
haemolyticus (14.8%) among adult haematology patients.  The other species of CoNS 
detected were S. hyicus, S. warneri, S. cohnii, and S. saprophyticus (Burnie et al., 1997).  
The diversity of CoNS species isolated from bacteraemic patients indicates that species level 
identification may aid clinicians and researchers to associate certain species-specific isolates 
with a predilection to cause disease. 
Traditionally, identification of bacteria from clinical samples has been carried out by 
examination of clinical morphology and by biochemical characterisation, using substrate and 
enzymatic tests. (Bannerman et al., 1993; Kloos et al., 1975,1994; Cunha et al., 2004).  
Commercial rapid automated systems such as VITEK®2 (bioMérieux SA, Marcy-'Etoile, 
France) are increasingly used in routine clinical laboratories because of their high degree of 
sensitivity and specificity for bacterial speciation  This micro-method is a cost effective 
system for accurate identification of medically relevant CoNS species (Funke et al., 2005).  
The VITEK®2 systems have an auto-modular format, consisting of a dilution mode, filler-
sealer module, a fluorogenic technology based optical reader, incubator and a computer 
control module.  The system utilises uniquely coded small plastic cards consisting of 
individual wells, containing a variety of reagents and substrates for species identification.  
Inoculated, sealed cards placed in the reader-incubator are scanned by light emitting diodes 
and phototransistor detectors, every fifteen minutes readings. The changes in light 
transmission from after initial baseline readings, detected by the photometer are transferred 
to the computer module analytical system where organism biotype is determined through 
data interpretation of the biochemical reaction patterns (Bannerman et al.,1993; Product 
Literature, 2004). The identification of most human Staphylococcus species and sub-species 
with these systems has been shown to be comparable to an accuracy of 70% to 90% with 
the addition of more discriminatory tests included within their test panels (Logozzi et al., 
2004). 
Diagnostic microbiology in recent times has rapidly evolved towards the use of more 
streamlined automated identification systems such as, Matrix-Assisted Laser Desorption 
Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS). The intrinsic property of the 
MALDI-TOF MS technology for isolate identification is based on the acquisition of the 
bioanalyte, generating a unique protein profile of the entire bacterial isolate (Cabonnelle et 
al., 2011; Patel, 2015).  Data analysis and comparisons with a library of reference spectra of 
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these unique generated spectral fingerprints specific to genus, allows species identification to 
subspecies level (Theel, 2013; Argemi et al., 2015).  This system effectively replaces 
conventional biochemical based bacterial identification to species level from 73 to >94% 
(Cabonnelle et al., 2011).  Rapid Identification methodologies have been shown to impact 
directly on improving the quality of patient care and management (Barenfanger et al., 1999 
Funke et al., 2005). 
 
2.2 Aim of this current study 
(a) To phenotypically characterise clinical isolates of CoNS recovered from 
bacteraemic patients on the haematology and BMT unit. 
(b) To investigate and characterise the predominant CoNS skin-colonisers recovered 
from pre-admission patients (control group). 
(c) To determine the distribution and prevalence of CoNS species, in the ward 
environment. 
 
2.3 Materials and Methods 
2.3.1 Risk Assessment 
The use of all equipment, procedures, handling and disposal of bacterial cultures and other 
waste was undertaken according to the standard operating procedures documentation 
inclusive of managing risks registers both at the department of Microbiology at the Queen 
Elizabeth Hospital Birmingham and at Aston University laboratories. 
 
2.3.2 Media 
All pre-poured media used in this study was obtained from bioMérieux (SA, Marcy-'Etoile, 
France) except where otherwise stated.  This includes Columbia Blood Agar (CBA) base with 
the addition of 5% w/v nicotinamide adenine dinucleotide (NAD) supplemented with 5% 





2.3.3 Microbial cultures 
A total of 100 blood culture positive CoNS isolates from in-patient haematology/BMT group 
and a 100 predominant CoNS skin-colonising isolates from pre-admission patients (control 
group) were investigated together with the geographical distribution of CoNS isolates from 
hospital unit comprising, both the haematology and BMT ward area.  
All in-patient and pre-admission (control) patient group isolates were made anonymous and 
serially coded with a designated differential letter and number. 
2.3.3.1 In-patient BSI CoNS isolates 
One hundred CoNS isolates were obtained from consecutive bacteraemic episodes from 
patients in the haematology and BMT unit from 11th April 2010 to 15th March 2012.  
(Designated isolate identifier code A1-A100). 
Isolates were obtained from blood cultures processed by the BacT/ALERT® (bioMérieux, 
France) automated blood culture system.  These CoNS isolates were identified in 
accordance with the recommended Public Health England (PHE), formally the Health 
Protection Agency (HPA) UK standards for microbiology investigations. 
CoNS isolated from positive blood culture bottles were cultured on Columbia Blood Agar 
(CBA).  Cultures were incubated in atmospheres of both 5% carbon dioxide and 
anaerobically at 37°C for 18 hours for further investigation.  
Primary identification of CoNS was based on colony morphology, Gram staining (ProLab- 
Diagnostics. UK) and the absence of coagulase activity screen (PASTOREX™ Staph-Plus 
BioRad. UK) and confirmed with DNase Agar and tube-coagulase test (Plasma source – 
QEH Blood Bank; plus, double strength tryptone water (Oxoid, UK).   The following control 
strains (LENTICULE® - PHE/ bioMérieux-UK.) were included in each test. 
Positive latex and coagulase test - Oxford Staphylococcus aureus NCTC 6571 
Negative latex and coagulase test – Staphylococcus epidermidis ATCC 12228 
2.3.3.2 Storage of isolates 
All CoNS Isolates for further investigation were saved and stored at -20°C using Microbank™ 





2.3.3.3 CoNS Isolate cultures for testing 
A single bead removed from Microbank™ vial stored at -20°C was sub-cultured onto a blood 
agar plate and incubated at 37°C for 18 hours in ambient atmosphere.  After recovery two 
subsequent subcultures of the isolates were carried out to stabilise the phenotype prior to 
further testing. 
 
2.3.3.4 Establishing the purity of CoNS blood culture isolates 
Different isolates of CoNS can appear morphologically similar on culture. Therefore, a 
preliminary evaluation was carried out to establish whether the BSI culture isolates were 
homogeneously pure and not representative of multiple CoNS species types. 
From the time of first positivity 10 consecutive sets (aerobic and anaerobic), of blood cultures 
from 10 different patients were tested. These were randomly selected, sequentially from the 
one hundred bacteraemia episodes investigated during the first part of the study period.  
CoNS isolates investigated were selected from primary CBA plates inoculated with samples 
from positive blood culture bottles incubated in an atmosphere of 5% CO2 at 37˚C for 18 
hours. 
Five colonies were randomly chosen from an inoculated CBA plates and each colony was 
then sub-cultured separately onto fresh blood agar. Of the 100 colonies analysed, all five 
selected from each bacteraemic episode were subjected to analyses for purity and 
phenotypic similarity by biochemical profiling and antimicrobial susceptibility testing. 
 
2.3.3.5 Selection of control group CoNS isolates from pre-admission patients  
Three screening swabs (Charcoal amies, Bibby Sterlin, Stone, UK) samples are routinely 
taken from the nose, throat and groin areas and analysed for MRSA carriage prior to hospital 
admission; in accordance with hospital and government implemented policy (HPA, 2010).  
Prior to analysis for MRSA,100 of these pre-admission patient screen samples were 
randomly selected for analysis of predominant skin-colonising isolates.  The nose, throat and 
groin swabs from each patient were then cultured to evaluate the sample area yielding the 
highest growth and distribution of normal skin-colonising CoNS.  Each sample site swab was 
cultured separately on CBA and incubated at 37˚C for 18 hours in ambient atmosphere.  The 
test procedure for the detection and identification of predominant CoNS isolates was 
determined as previously described. 
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The groin area of the 100 pre-admission patients sampled was identified as the area with the 
highest density of diverse CoNS species.  This area was therefore selected as representative 
of predominant patient skin-colonising isolates prior to hospital ward admission (Designated 
isolate identifier code G1-G100). 
 
2.3.3.6 Environmental sampling of haematology patient wards to determine CoNS species 
distribution. 
Geographically as shown previously in Figure1-2 the haematology ward unit consisting of 
four bed cubicles has access to the BMT ward area (Figure 1-3) via a common corridor 
through a set of restricted-use double doors (Chapter 1.9.1). Infection control procedures in 
place, including the use and disposal of personal protective equipment present at all key 
points of the ward areas ensure minimum transmission of potential pathogens.  Ten areas 
within each ward unit most frequently accessed by staff members common to both ward 
areas were identified and sampled for investigation along the red line marking the area of 
investigation (Figures 1-2 and 1-3).  These ‘high-touch/contact’ points near patients, included 
the nurses’ stations, portable patient information computer system (PICS), treatment room 
where drug preparation was carried out, macerator room for waste disposable, door handles, 
staff hand scanner clocking-in system (SMART), drugs trolley, patient bed side tables, 
double-door handles and push plates access link to the other ward area. 
Standard environmental HPA standard operating procedures (HPA: Environmental sampling 
2010; Lemmen et al., 2001) were followed when undertaking the sampling of the ward 
equipment and specified areas.  Sampling was carried out using a sterile swab (Charcoal 
Amies, Bibby Sterlin, Stone; U.K.) moistened with 0.5% w/v sterile saline solution.  The 
sample swabs were cultured on CBA, streaking out well across the whole of the plate to 
enable colony counts of bacterial population.  Culture plates were incubated at 37˚C for 18 
hours in an atmosphere of 5% CO2. Total colony counts were carried with preliminary 
identification of isolates based on colony morphology.  Identification of CoNS isolates were 







2.4 CoNS isolate preparation for VITEK®2 automated Identification  
Automated biochemical profiling of the CoNS isolates was undertaken using the GP-ID 
(Gram Positive-Identification) test card in accordance with the manufacture’s recommended 
procedure.  The inoculum using the VITEK®2 DensiCHEKTM meter (bioMérieux, Basingstoke, 
UK) was prepared from a fresh 18 hour culture.  Using a sterile swab, a few well isolated 
colonies were selected to prepare a homogenous suspension in 3ml sterile saline (aqueous 
0.45% NaCl, pH 7 bioMérieux, France) to a density equivalent to McFarland 0.5 standard. 
GP-ID card inoculated with the suspension was loaded onto the VITEK®2 automated 
systems for incubation and analysis, following the manufacturer’s instructions (User Manual- 
VITEK®2 systems product information 410791). Results interpretation was carried out in 
accordance with the manufacturers installed VITEK®2 software version 25; 5.04 
The recommended control strain S. aureus ATCC 29213 was included in each test batch for 
quality control and assurance.  
 
2.4.1 Identification of CoNS isolates using VITEK-MS MALDI-TOF system 
MALDI-TOF MS target slides were inoculated by picking up a freshly grown overnight colony 
of CoNS on CBA.  Deposits of each colony were made in two replicates on the 48 spot target 
slide and 1µL of the matrix-MALDI-CHCA (α-cyano-4-hydroxycinnamic acid dissolved in 50% 
v/v acetonitrile and 2.5% v/v trifluroacetic acid) was used to overlay the spots. Test spots 
were then allowed to air dry prior to acquisition, whereby desorption and ionisation of 
microbial analytes through the energy of the laser occurs resulting in mass spectra 
production.   
E. coli ATCC 8739 calibration control strain was used on each control spot section of the 
MALDI-TOF MS target slides as recommended by the manufacturer. 
The acquisition and detection of protein mass spectra detection based on mass-to-charge 
ratio was performed on the VITEK®-MS instrument version 2.0 with a mass-to-charge ratio 
(m/z) of 2 to 15 KDa.  For results the automated data analysis of raw spectra were matched 
with the spectra library in the VITEK®-MS software application version 1.1.0 which computes 
identification of staphylococci isolates, in accordance with applications system knowledge 





2.5 Statistical methods  
Data were analysed using the SPSS statistical software for Windows.  Descriptive statistics 
were computed for all variables in this study. Difference testing between the CoNS isolates 
obtained from the two patient groups, was performed using the Chi-squared test.  
Differences were considered statistically significant at p <0.05.  
The individual biochemical results extracted for VITEK®2 were compacted in Microsoft Excel 
and statistical analysis; Pearsons-Principle component analysis (PCA) with Unweighted Pair 
Group Method with Arithmetic Mean (UPGMA) was performed using the STATISTICA 
version 10 (USA) Software package. 
Asymptomatic Marginal-Homogeneity Test (Stuart-Maxwell Test) was used with R version 
3.2.3 (2015-12-10) – “Wooden Christmas-Tree Copyright (C) 2015. The R foundation for 
Statistical Computing for data analysis of CoNS species identification using the two test 
platforms.  (Data analysis assistance courtesy of Dr Martyn Wilkinson, Biomedical Scientist 
Statistician: Hospital Infection and Research Department QEHB. UK) 
2.6 Results 
2.6.1 VITEK®2 automated phenotypic Identification based on biochemical profiling of 
CoNS isolates 
2.6.1.1 Evaluation of culture purity 
The preliminary evaluation carried out to establish whether the bacteraemic culture isolates 
were mono-microbial and not representative of multiple strain types, showed that 99.6% of 
the strains were similar. A low-discriminatory power categorisation by the automated system 
requiring further manual tests for species differentiation was observed in <1% of the isolates 
tested.  Overall result analysis of isolates tested from selected bacteraemic episodes showed 
an absence of multiple species-specific isolates, indicating that the probability of 
polymicrobial bacteraemic episodes was highly unlikely. 
 
2.6.1.2 Speciation and distribution of CoNS isolates 
A total of 100 haematology patient blood culture isolates of CoNS, collected from 11th April 
2010 to 15th March 2012 were investigated together with a 100 CoNS skin isolates from pre-
admission (control) patient group. 
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Automated biochemical analysis and distribution of the CoNS species isolates from the two 
patient groups are summarised in Table 2-1.  One out of the 100 isolates of CoNS recovered 
from the in-patient group included in this study, was non-identifiable by VITEK®2 system.  
This in-patient CoNS isolate A23, was sent to the reference laboratory for identification and 
was confirmed to genus level as Staphylococcus species by PCR 16S RNA analysis, proven 
to be biochemically non-reactive.   
 
 
 CoNS Species 




Number of Species 
isolated from Control 
Patient Group 
S. epidermidis 57% 32% 
S. hominis 18% 24% 
S. haemolyticus 16% 17% 
S. capitis 3% 11% 
S. warneri 1% 7% 
S. lugdunesis 0% 5% 
S. auricularis 1% 1% 
S. simulans 0% 3% 
Kocuria/ Dermococcus Species 3% 0% 
Non-Reactive CoNS 1% 0% 
Table 2-1: Comparative distribution of CoNS species-specific isolates from the two 
patient groups, bio-analysed for identification using VITEK®2 system GP-ID card. 
In total there were eleven different CoNS species-specific isolates identified from both patient 
groups.  S. epidermidis (57%) was the most frequently recovered species from the in-patient 
group followed by S. hominis (18%) and S. haemolyticus (16%).  Similarly, in the control 
patient group the predominant CoNS species isolated was S. epidermidis (32%) followed by 
S. hominis and S. haemolyticus, 24% and 17% respectively.  
Among the 26% of the other minor group of CoNS species-specific isolates from the control 
patient group, the predominantly species was S. capitis (11%) followed by S. warneri (7%), 
S. lugdunesis (5%) S. simulans (3%) and S. auricularis (1%).  The range of the other CoNS 
species isolated from the in-patient group was however much smaller, differing considerably 
in comparison to the control group isolates.  S. capitis (3%) was still the predominant species 
isolated followed by Kocuria species (2%) and 1% each of S. warneri, S. auricularis and 
Dermococcus and the non-reactive Staphylococcus isolate. The comparative species 
distribution of the CoNS is illustrated graphically in Figure 2-1. 
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Figure 2-1: Comparison of phenotypically characterised CoNS species distribution, 
from bacteraemic patients in the Haematology and BMT with the pre-admission 
(control) patient group isolates. The other CoNS isolates from both patient groups 
included the following species: S. capitis, S. warneri, S. lugdunensis, S. simulans, S. 
auricularis, Kocuria, Dermococcus and non-reactive Staphylococcus species. 
Figure 2-1 and the corresponding tabulated results for each CoNS species reveals that the 
in-patient group had a higher frequency (91%) of the three predominant CoNS species 
isolates in comparison to 73% isolated from the control patient group.   
2.6.1.3 Chi-square statistical analysis: Difference in distribution of CoNS isolates 
categorised as the other CoNS species from the two patient groups 
The Chi-square 2 by 2 tests was used to determine the significance of observed difference 
between the distribution and range of the CoNS isolates categorised as the other CoNS 
species from the two patient groups.  Test analysis showed that there was a significant 
difference (p <0.0001 with 3df) between the distribution of the other CoNS species isolates 
from the in-patient group in comparison to those of the control group.  Analysis, therefore, 
reveals that there is significant association between the frequency and distribution of the 
minor CoNS species population and the patient group from which the isolates are derived.  
Data analysis further revealed that there was no significant difference (p >0.05) between the 
distribution frequency of S. epidermidis S. hominis and S. haemolyticus isolates from the in-
patient and the control patient groups.  Therefore, the distribution of the three predominant 























2.6.2 Data Analysis using Pearsons-Principle Component Analysis (PCA) with 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) 
The 100 CoNS isolates from each of the patient groups were further subjected to PCA with 
UPGMA analysis using the STATISTICA v.10 software.  Analysis was performed based on 
similarity or differences of CoNS strain biotype profiles and dendrograms created by means 
of UPGMA clustering of a similarity matrix band on band matching (Caddick et al., 2006).   
Figures 2-2 and 2-3 detail dendrograms constructed of the 100 CoNS isolates from in-patient 
and control patient groups. The scale bar at the top of the dendrogram represents the 
percentage similarity, where the cut-off value was set at 95%.  The UPGMA dendrogram 
analyses of biotype profiles of these CoNS species demonstrate a relatively high degree of 
strain un-relatedness between the isolates from each of the patient groups.  In both groups 
the numbers of clusters identified also demonstrate the high degree of un-relatedness within 
species-specific CoNS isolates as well. 
Isolates of S. haemolyticus in the in-patient group demonstrated the greatest degree of 
similarity as detailed in Figure 2-2, followed by isolates of S. epidermidis cluster number 3 
and 1 respectively.  Conversely in the control patient group, this degree of similarity was only 
apparent in isolates of S. epidermidis Figure 2-3 cluster number 3.  The other clusters in the 
control patient group in comparison to the in-patient group included a higher number of 




Figure 2-2:  Phenotypic relatedness of 100 in-patient group CoNS: Dendrogram based 









Figure 2-3:  Phenotypic relatedness of 100 control patient group CoNS: Dendrogram 
based on Vitek®2 biochemical analysis using Dice coefficient UPGMA method. 
 





















































































































































































































2.6.2.1 Interpretation of PCA data analysis 
PCA with UPGMA identified CoNS strain relatedness and clustering within the groups of 
CoNS based on biochemical profiling representing the degree of variance within the CoNS 
strains. 
Although a high degree of relatedness was observed between CoNS species-specific 
isolates from the in-patient group, significant differences in the biochemical profiles were 
observed among individual species isolates.  The dissimilarity between species-specific 
CoNS isolates was however even more evident in the control patient group whereby fewer 
and smaller clusters were identified compared to the in-patient CoNS.  
The biochemical profiling dendrograms for both patient groups show a high degree of diverse 
clonal types within each species-specific CoNS group as summarised in Table 2-2.  
Dendrogram Analysis In-patient Group Control Group 
       
Number of different biochemical profiles 
within all CoNS species isolates 67 (n=100) 92 (n=100) 
Number of different biochemical 
profiles within the predominant CoNS 
species.       
S. epidermidis (n=number of isolates) 51 (n=57) 27 (n=32) 
S. haemolyticus (n=number of isolates) 7 (n= 16) 12 (n=17) 
S. hominis (n=number of isolates) 18 (n=18) 15 (n=24) 
Table 2-2: Summary of PCA dendrogram analysis comparison within the two patient 
groups together with differences within CoNS species groups and isolate relatedness. 
CoNS species relatedness based on biochemical profiles determined by means of UPGMA 
dendrogram analysis (Figures 2-2 and 2-3) demonstrate a high degree of diversity amongst 
CoNS species in both patient groups.  This was more evident in the control group of patients, 
as there were 92 different biotype profiles out of the 100 CoNS isolates analysed, whereas of 
the 100 CoNS isolates, of the in-patient group overall, 33% of the isolates showed similarity 
out of the 67 different biotype profiles identified. 
For the in-patient group 100% phenotypic similarity was observed in 32% of the 100 CoNS 
profiles analysed.  In the in-patient group, small clusters of S. epidermidis isolates were 
observed, of which the largest consisted of 6 and 8 isolates (Figure 2-2 cluster 1) and 
smallest consisted of a minimum of two isolates demonstrate 100% phenotypic similarity.  
Conversely, only a few isolates of S. haemolyticus showed 100% similarity.  The diversity 
within CoNS species-specific relatedness was observed to be even higher in the control 
patient group with only 14% of the isolates showing 100% phenotypic similarity within the 
different CoNS species isolates.  Of the 27 isolates comprising the other minor group of 
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CoNS species in the control patient group, only two isolates each of S. capitis, and S. 
lugdunensis, demonstrated 100% relatedness.  Conversely in the in-patient group, all of the 
nine other CoNS species isolates demonstrated a poor degree of similarity, grouping 
together at <30% species-specific relatedness as illustrated (Figure 2-2, cluster 5). 
2.7 VITEK-MS MALDI-TOF identification of CoNS isolates based on proteomic analysis 
CoNS species identification analysis was performed by applying the recommended criteria of 
the VITEK® MS software calculated identification scores based on quantitative confidence 
values of between 60 to 99.9%, which are then displayed for significant organism group 
identification.  As designated in the MS database, scores of ≥ 95 and 99.9% were considered 
as high-confidence, genus level identification. In this study all the Staphylococcus species 
tested, scored between ≥ 98.9% and 99.9%, indicating a high probability of staphylococcal 
isolate identity to the species level.  The one isolate that was not identified by VITEK-MS 
MALDI-TOF, as was the case with biochemical profiling was in-patient CoNS isolate A23.  As 
previously confirmed by the reference laboratory this isolate identified as a non-reactive 
Staphylococcus isolate was included with the minor group of CoNS for overall analysis. 
All except 6% of the one hundred in-patients CoNS isolates analysed by MS MALDI-TOF 
presented the same CoNS species-specific identification when compared to those results 
obtained by biochemical profiling.  The differences in species identification using the two 
systems are detailed in table 2-3. 
 
  In-patient Group:  Difference in CoNS Identification 
Isolate VITEK®2 VITEK-MS  MALDI-TOF 
A30 S. hominis S. epidermidis 
A94 S. hominis S. epidermidis 
A98 S. hominis S. epidermidis 
A44 Kocuria varians S. auricularis 
A64 Kocuria rosea S. capitis 
A40 S. auricularis S. epidermidis 
Table 2-3: Difference in CoNS species identification with the use of VITEK®2 and the 
VITEK-MS  MALDI-TOF systems. 
 
Biochemically inert isolates such as Koucria species were identified to the CoNS sub-species 
level with MS MALDI-TOF system.  The two isolates Kocuria varians and Kocuria rosea with 
proteomic analysis identified as S. auricularis and S. capitis respectively.  Therefore, these 
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isolates were included in the other group of staphylococci for all further analysis, with the 
retention of their biochemically based species identification .  On the other hand, using the 
MS MALDI-TOF system, three isolates of the S. hominis and one of S. auricularis all 
identified as S. epidermidis with confidence value scores of between 95 and 98%.  These 
results for the in-patients group indicate that the probability of CoNS species-specific 
identification obtained to the sub-species level is comparatively higher with the MS 
methodology.  Conversely, for the pre-admission patient group isolates difference in species 
identification was observed in 22% of isolates with concordant identification observed in 88% 
of the 100 CoNS analysed as detailed in Table 2-4. 
 
 Control Patient Group:  Difference in CoNS Identification 
Isolate VITEK®2 VITEK-MS MALDI-TOF 
G2 S. hominis S. epidermidis 
G22 S. hominis S. epidermidis 
G24 S. hominis S. epidermidis 
G42 S. hominis S. epidermidis 
G60 S. hominis S. epidermidis 
G80 S. hominis S. epidermidis 
G92 S. hominis S. epidermidis 
G35 S. warneri S. haemolyticus 
G12 S. warneri S. hominis 
G18 S. warneri S. haemolyticus 
G20 S. warneri S. haemolyticus 
G21 S. warneri S. epidermidis 
G56 S. warneri S. capitis 
G57 S. epidermidis S. capitis 
G58 S. epidermidis S. capitis 
G59 S. epidermidis S. capitis 
G27 S. epidermidis S. capitis 
G70 S. epidermidis S. hominis 
G46 S. haemolyticus S. capitis 
G41 S. lugdunensis S. epidermidis 
G55 S. lugdunensis S. epidermidis 
G93 S. lugdunensis S. haemolyticus 
Table 2-4: Control patient group identification differences of CoNS species distribution 




In the control patient group, the largest difference in species identification using the VITEK-
MSMS MALDI-TOF system was observed with isolates of S. hominis (29%) identifying as S. 
epidermidis.  However, five isolates of S. epidermidis identified differently with MS MALDI-
TOF of which four were identified as S. capitis and one as S. hominis.  This resulted in  an 
overall, 5% increased difference in S. epidermidis species distribution.  Nonetheless, the 
error difference was minimal as these isolates remain the predominant species isolated in 
this patient group.  Of the other CoNS species, six and four isolates of S. warneri and S. 
lugdunensis respectively were identified as one of the three predominant CoNS species-
specific isolates. 
 
2.7.1 Comparison of CoNS species distribution using two different identification 
methodologies 
The difference in CoNS speciation using the biochemical profiling methodology VITEK®2 and 
proteomics based VITEK-MS MALDI-TOF in the two patient groups is illustrated in Figure 2-4 
below. 
Figure 2-4: Comparison of CoNS species identification and distribution in both in-
patient and control patient groups using the two automated systems for CoNS 
speciation. The minority group of other CoNS species group include isolates of S. 
capatis, S. warneri, S. lugdunensis, Kocuria species, S. auricularis, Dermacoccus 
species and the non-reactive Staphylococcus species. 
 
Phenotypic characterisation of CoNS isolates using the conventional biochemical profiling 
methodology comparison with MS MALDI-TOF for both in-patient and control group showed 


























observed with speciation of S. haemolyticus in-patient isolates, showing 100% identification 
result concordance.  It would appear from the initial result comparisons that morphologically 
similar but biochemically inert isolates such as the Kocuria species had a more definitive 
staphylococcal group speciation using MS MALDI-TOF system where, analysis is based 
specifically on structural/ribosomal proteins of the intact bacterial colony.  These differences 
were more apparent in the control patient group isolates, where 22% of the CoNS isolates 
differed in species identification with MS MALDI-TOF analysis.  In both patient groups, 
results show that isolates of S. hominis largely identified as S. epidermidis with MS MALDI-
TOF.  The speciation difference observed was greater in analysis of the other minor CoNS 
group isolates of the control patient group.  S. warneri and S. lugdunensis CoNS control 
group isolates mainly identified as the predominant CoNS species types, hence showing a 
5% and 3% difference in identification as S. epidermidis and S. haemolyticus respectively.   
Overall initial identification result analysis for the in-patient group show no difference in the 
predominant species isolated using the two different identification methodologies.  
Conversely for the control patient group isolates, using the two different identification 
methodologies the predominance of the second most isolated CoNS species differed 
significantly.  Although S. epidermidis remained the predominant species isolated, some 
isolates of S. hominis in the control patient group were speciated as S. haemolyticus by MS 
MALDI-TOF.  Further statistical analysis on both patient group isolates was carried out to 
verify the significance of CoNS species-specific result differences obtained using the two 
different identification systems. 
 
2.7.2 Statistical Analysis: CoNS species Identification using the VITEK®2 and VITEK-
MS MALDI-TOF 
The main objective of this analysis was to determine the presence of significant difference in 
CoNS species identification with the use of the two different automated technologies.  The 
null hypothesis proposed was that there is no significant difference in speciation dependent 
on the identification system used and the alternative hypothesis would be that there would be 
a significant difference.  A significant difference would be determined according to the critical 
p value of <0.05. 
The first analysis performed on the species identification data about using the two 
identification platforms based on different principles for species identification was the Stuart-
Maxwell test.  This was carried out using, The R Foundation for Statistical Computing version 
3.2.3 (10-12-2015). The Asymptotic Marginal-Homogeneity Test was applied to the data 
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where the outcome variable was CoNS species identification having more than two 
categories.  The two categories for the explanatory variable were the two automated 
identification systems, VITEK®2 and VITEK-MS MALDI-TOF.   
Results of the first analysis carried out on both in-patient and control group of patients 
together and data obtained by both identification systems stratified by block where, Chi-
squared value obtained was = 23.614, degrees of freedom = 8 and the p-value = 0.00266.  
Since the p-value obtained is less than the significance value of <0.05 suggesting that, 
statistically there was a significant difference in the performance of the two automated 
systems used for the identification of CoNS isolates. 
Further analysis carried out using the Asymptotic Marginal-Homogeneity Test: 
For the in-patient group:  
Data analysis, identification by two systems stratified by block where Chi-squared value = 6, 
degrees of freedom = 4 and the p= 0.1991.  This p-value exceeds the accepted significance 
value of ≤0.05 indicating that there was statistically no difference in identification of CoNS 
species with the use of either the VITEK®2 or VITEK-MS MALDI-TOF system, therefore the 
null hypothesis was accepted.   
For the control patient group: 
Data analysis, identification by two systems stratified by block where Chi-squared value = 
18.174, p = 0.005813 with 6 degrees of freedom, this suggests that there was statistically 
significant difference in the performance of the VITEK®2 and the VITEK-MS MALDI-TOF 
system used for the identification of the CoNS species isolated from the control patient 
group.  The null hypothesis would therefore be rejected in this case and the alternative 
hypothesis accepted.  
CoNS species identification data was subjected to further statistical analysis, to double check 
whether there was a difference in response with the use of two different identification 
systems.  In this case a probability of mismatch between the two identification systems for 
the two patient groups.  Using the computing software, a binomial (logistic) regression model 
was constructed, where the outcome variable (probability of mismatch) was related to the 
explanatory variable namely the patient group.  The final odds ratio: exp(ß) ~4.44 indicates a 
high likelihood of a significant difference in species identification dependent on which patient 
group the CoNS were isolated from.  This compares well with the species identification data, 
where for in-patient group 6 out of 98 CoNS isolates mismatched whereas for the control 
patient group 22 out of 98 isolates were mismatched. The salient p-value of 0.00216 
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resulting from the statistical tests based upon the linear logistic regression model, suggests 
that there is a significant difference in species identification performance with the use of the 
VITEK®2 and the VITEK-MS MALDI-TOF systems which is also significantly dependent on 
the patient group from which the CoNS isolates are derived. 
 
2.8 CoNS species distribution in the haematology and BMT wards 
Result analysis of the bacteria load from each in-patient ward area sampled using previously 
described identification protocols are shown in Table 2-6.  The overall bacterial load including 
the number of CoNS species isolated in the individual bed space area of the BMT ward were 
much lower than those isolated from the haematology ward area.  Consistency in type and 
numbers of CoNS species or other identifiable bacterial species was not observed over the 
two test periods. 
Most areas of the BMT ward demonstrated absence of bacterial growth or occurrence of low 
bacterial counts.  Relatively higher bacterial loads were observed on the BMT macerator 
handle where healthcare staff disposed of patient waste in comparison to the low bacterial 
load on the macerator handle in the haematology ward area.  Conversely the four bed 
shared ward units of the haematology ward areas had higher bacterial loads, including 
differences in types of CoNS species isolates.  Some patient areas had a higher bacterial 
load per cm2 of normal skin organisms including total number of CoNS species.  The 
bacterial load appeared to be transient as the numbers and types of CoNS species and other 
isolates showed little consistency over the two time periods of testing.  This was observed in 
areas of high access use by all healthcare workers such as the computer key board area of 
the PICs system in both ward areas.  Healthcare workers did not wear gloves as this was not 
a requirement when accessing this equipment as was the case when “clocking-in/out” using 
the SMART hand reader equipment located outside the entrance to the haematology ward 
area.  Common bacterial isolates associated with disease such as S. aureus were not 
identified in this environmental study, during the sampling period carried out, both in March 
and May 2011.  
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Table 2-5: Distribution and number of CoNS species-specific isolates and other bacterial species isolated from the same ward area- 
10 points of contact, screened over two times periods, March and May 2011.  The other bacterial isolates included: Non-Haemolytic 
Streptococci (NHS), Alpha Haemolytic Streptococci (AHS), Micrococcus (Mcoc), Bacillus (Baci), Corynebacterium (Coryne) and 
Coliforms (Cols).  
 
Environmental Screening of Haematology and BMT Ward Areas
Contact Site Area
Test Staphylococcus   Species Other Isolates Staphylococcus   Species Other Isolates
Points Haematology Ward
1 Bed 16 - Side table 10cm/10cm No growth 3-S. haemolyticus, 1-S. cohnii,  1-S. epidermidis 8-Cols, Mcoc, NHS
2 Drug Trolley - Blue 10cm/10cm 1-S. haemolyticus , 1-S. hominis 4 -Mcoc, Baci 2-S. haemolyticus ,1-S. cohnii,  1-S. hominis
3 Macerator handle 10cm/10cm No growth 16-Coryne, Mcoc, Cols
4 Nurse Station - Left side 10cm/10cm 1-Baci, 1-Dermococcus 2-S. epidermidis,  1-S.auricularis,  1-S. cohnii 8-Mcoc, Coryne
5 Nurse Station - Right side 10cm/10cm 1-Mcoc 1-S. epidermidis 1-NHS
6 Patient information computer system Keyboard area 10-S .haemolyticus, 11-S. epidermidis 29-Baci, Mcoc, Cols 16-S.epidermidis , 12-S. haemolyticus 48-Mcoc, AHS
7 Drug Trolley - Red (near Bed 3/8) 10cm/10cm 9-S. haemolyticus 31-Mcoc, Cols 1-S. warneri, 1-S. hominis
8 Treatment Room - Work surface 10cm/10cm No growth 1-S. warneri 2-Mcoc
9 SMART Clock-In  Unit 10cm/10cm 9-S. epidermidis, 9-S. auricularis 36-Cols, NHS 17-S. haemolyticus , 9-S. cohnii 22-Mcoc, Coryne
10 Rt. Side double door to BMT Push-plate 20cm/10cm 1-S. capitis, 2-S. epidermidis 1-S. hominis
BMT
1 Corridor - Computer Keyboard area 22-S. epidermidis 24-Mcoc, Cols, Baci 11-S. caprae , 4-S. capitis,   11-S. haemolyticus >100-Mcoc, Coryne
2 Work station surface - Front 10cm/10cm 8-AHS, Baci No growth
3 Work station surface - Indoor area rear end 10cm/10cm No growth No growth
4 Treatment Room - Work surface 10cm/10cm 3-S. hominis 1-S.hominis
5 Macerator handle 10cm/10cm 2-S. hominis 24-Mcoc, Cols 7-S. haemolyticus >100-AHS, Coryne, Mcoc, NHS
6 Bed 5 - Side table 10cm/10cm 2-Coryne No growth
7 Door plate - Macerator room 20cm/10cm 1-Mcoc No growth
8 Double door plate (next to Bed 4) 20cm/10cm 1-S. warneri 1-Mcoc 2-Mcoc
9 Door handle room - Bed 4 Whole area No growth No growth
10 Push plate- Exit door to North 20cm/10cm No growth 1-Mcoc
Number of Colony Forming Units /Standard Area Number of Colony Forming units/Standard Area
 March 2011  May 2011
108 
 
Overall data analysis of bacterial distribution in March 2011, areas of frequent use or 
equipment handling by staff such as PICS – Computer system keyboard areas had the 
highest percentage of CoNS species isolates compared to other areas on both the 
haematology and the BMT ward areas.  From the colony counts, it was observed that the 
overall number of other skin organisms such as Micrococcus species, Corynebacterium 
species, streptococci and other bacterial isolates such as Bacillus species and coliform 
organisms was also high. 
Although all health workers commonly accessed both ward areas, the haematology ward 
area had the highest distribution of different CoNS species-specific isolates including a 
number of other bacterial organisms.  The prevalence of these isolates was noted to be 
proportionally higher around the computer system keyboard area.   The PICS keyboard area 
in the haematology ward had almost similar distribution of CoNS species, 42% and 58% in 
March and May 2011, respectively.  S. epidermidis 22% in March and 21% in May 2011 was 
the predominant CoNS species in this area followed by S. haemolyticus 20 and 15% 
respectively. 
The distribution of CoNS species isolated from the computer keyboard area differed over the 
two time periods screened in the BMT ward area.  In March 2011 S. epidermidis (48%) was 
the only CoNS species isolated of the total bacterial load.  In May 2011 however, <20% of 
the total bacterial load were CoNS species of which S. caprae and S. haemolyticus (<9%) 
the predominate species isolated followed by S. capitis (<3%).  
Figure 2-5 illustrates the overall distribution frequency of the eight main CoNS species 
isolated from the two ward areas sampled over the two different time periods 
Figure 2-5: Environmental screening distribution of the CoNS species and bacterial 
load in specified ward areas over the two time period slots of March and May 2011.   
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The screening of the two geographically linked ward environmental areas showed that the 
distribution frequency of the different CoNS species-specific isolates varied considerably 
both between the March and May 2011.  
There were 25% more CoNS species types identified in the same areas in May compared to 
test sampling in March 2011.  Considerable variation was also noted in the numbers of 
colony forming units, per cm2 of the CoNS species isolated in the different areas sampled 
over the two time periods.  Of the CoNS species, S. caprae and S. cohnii were the two CoNS 
species present in May but not in March and S. caprae and S. warneri were the two species 
found only in the BMT area.  During March, greater than 40/CFU of S. epidermidis per 
10x10cm2 area sampled were isolated in comparison to around 20/CFU sampled in May 
making this the predominant of the CoNS species isolated.  Conversely S. haemolyticus was 
the predominant CoNS species isolated in May compared to March 2011 whereby this 
species was the preceded by S. epidermidis as the predominant CoNS species.  All CoNS 
species isolates identified in this environmental study were species that form part of the 
normal microbiota of human skin. 
 
2.8.1 Comparison of environmental CoNS species relatedness isolated from the two 
ward areas in March and May 2011 
Biochemical profile analytic results using the VITEK®2 displayed as Bionumbers of the eight 
CoNS species isolated from environmental sampling are detailed in Table 2-6.  As the 
species identification is based on the specificity of the Bionumbers, the results show how well 
matched these profile results are and hence how close the species clonal relatedness.  
Concordance was observed in two isolates of S. cohnii recovered from haematology area 1 
and 2, from bed 16 side table and the drugs trolley tested in May 2011.  The other colonies of 
S. cohnii isolated were not closely related.  A relatively high degree of phenotypic 
relatedness was observed among some isolates of S. epidermidis, S. haemolyticus and S. 
hominis based on the closely matching Bionumbers derived from biochemical profile analysis 
(Table 2-6).  Results show a high degree of phenotypic clonal relatedness between some S. 
epidermidis isolated from haematology ward area 6 in March with those isolated in 





Ward Area Period CoNS species Bionumber 
Haematology 1 May-11 S. epidermidis 000000074620211 
Haematology 6 Mar-11 S. epidermidis 000000074220211 
Haematology 9 Mar-11 S. epidermidis 000000074020211 
Haematology 10 Mar-11 S. epidermidis 020000076221211 
BMT 11 Mar-11 S. epidermidis 020000074221211 
Haematology 4 May-11 S. epidermidis 010400010621211 
Haematology 5 May-11 S. epidermidis 010000032421211 
Haematology 6 May-11 S. epidermidis 000000074621011 
Haematology 2 Mar-11 S. hominis 040000010220021 
Haematology 2 May-11 S. hominis 040000012222021 
Haematology 7 May-11 S. hominis 040000014260021 
Haematology 10 May-11 S. hominis 000000016330011 
BMT 14 Mar-11 S. hominis 010000014220021 
BMT 14 May-11 S. hominis 040000054320111 
BMT 15 Mar-11 S. hominis 010002006360231 
Haematology 1 May-11 S. haemolyticus 010002042620231 
Haematology 2 Mar-11 S. haemolyticus 010002142660231 
Haematology 2 May-11 S. haemolyticus 010002442660231 
Haematology 6 Mar-11 S. haemolyticus 030002044660231 
Haematology 6 May-11 S. haemolyticus 050002107362271 
Haematology 6 May-11 S. haemolyticus 070002147362231 
Haematology 9 May-11 S. haemolyticus 010002002760211 
BMT 11 May-11 S. haemolyticus 010002002320231 
BMT 15 May-11 S. haemolyticus 010002040660231 
Haematology 9 Mar-11 S. auricularis 010000000000201 
Haematology 4 May-11 S. auricularis 000002000020201 
Haematology 10 Mar-11 S. capitis 010000000061201 
BMT 11 May-11 S. capitis 010000002461201 
BMT 18 Mar-11 S. warneri 050002003262231 
Haematology 7 May-11 S. warneri 010002002220231 
Haematology 8 May-11 S. warneri 010000012060231 
Haematology 1 May-11 S. cohnii 010000002060221 
Haematology 2 May-11 S. cohnii 010000002060221 
Haematology 4 May-11 S. cohnii 000000000070221 
Haematology 9 May-11 S. cohnii 010400002070221 
BMT 11 May-11 S. caprae 010002012461221 
Table 2-6: Environmental Screening in March and May 2011.  Distribution of the 





Although 75% of the total environmental CoNS species isolates were from the haematology 
ward area, phenotypic relatedness appeared limited.  Isolates of S. hominis and S. 
haemolyticus recovered from different areas of the haematology ward over the two time 
period slots show that they were closely related similar clonal isolates.  The difference in the 
Bionumber obtained through biochemical reaction for identification of each species isolates 
indicates that these although closely related clonally are different phenotypes.  This degree 
of similarity was not observed in the BMT ward area CoNS species-specific isolates. 
Further comparison of biochemical profile Bionumbers with the 100 CoNS isolates each, 
from the in-patient and control group was carried out to determine phenotypic relatedness.  
Results of this comparison showed that none of the environmental CoNS species isolates 
Bionumbers had a 100% match with those of the similar CoNS species-specific isolates from 
the two patient groups.  Overall result comparison indicated a relatively high degree of 
phenotypic un-relatedness within patient groups and the CoNS species-specific isolates from 
the patient ward areas. 
 
2.9 Discussion  
The Queen Elizabeth Hospitals, NHS Trust as a major referral centre, provides a range of 
highly specialist services including haematology and allogenic BMT.  Such specialist service 
units have the highest concentration of immunocompromised patients and the highest ratio of 
ITU to general beds (CDR 2006).  These and other factors, such as the high frequency of 
invasive techniques in routine use, contribute to the high levels of staphylococcal associated 
bacteraemia episodes within the unit.  CoNS are now increasingly recognised as aetiological 
agents of a range of infections in particular, blood sepsis in this critically ill major patient 
population group in the Trust. 
CoNS as causative agents of nosocomial bloodstream infection are now frequently reported 
but their role as the major cause of morbidity and mortality has yet to be ascertained.  
Clinical surveillance laboratory report audit (Permission of Microbiology Specialist Registrar, 
Dr S. Larkin; June 2012) showed that there was an incidence rate of 252 isolates in 206 
blood cultures from 173 patient episodes over a 12 month period.  Of these, the highest rate 
was attributed to the isolation of 106 isolates of CoNS compared to 36 attributed to other 
staphylococci including both S. aureus and MRSA. 
Currently, speciation of blood culture isolates of CoNS, contributes little to the management 
of patients on the Haematology and BMT units, except to occasionally distinguish multiple 
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episodes of bacteraemia caused by CoNS.  These episodes may be considered as culture 
contaminants attributed to different species of CoNS or from sustained bacteraemia with the 
same CoNS species-specific isolate is when identification is requested for epidemiological 
surveillance.  However, it is now becoming increasingly important to accurately identify the 
isolates to the species level in order to determine their clinical significance as repeated 
isolation of the same species-specific isolate strongly supports its role as an aetiologic agent 
(von Eiff et al., 2002; Otto, 2010). 
The emergence of CoNS as human pathogens requires rapid reliable identification of species 
type in order to predict potential pathogenicity and clarify the clinical significance of each 
species.  An overview of recent medical literature (Piette et al., 2009) focusing on the role of 
CoNS as the etiological agents of bacteraemia especially in the immunocompromised host 
indicates the necessity of accurate sub-species identification enabling better understanding 
of the pathogenic potential of various species-specific CoNS. 
The development and use of simple specie-specific methodologies for staphylococcal 
identification are therefore of great importance, as this has the potential for directly impacting 
on patient management and clinical outcome.  Several studies have shown that in the in 
immunocompromised patient group in particular, that characteristics of distinctive CoNS 
species-specific isolates manifest in a difference in pathology and hence clinical outcome 
(Emori et al.,1993; Barenfanger et al., 1999; Dickema et al., 2001; Bjorkqvist et al., 2002).   
CoNS are not at present speciated routinely and are reported generically based on 
morphology and simple tests such as the inability to produce coagulase which delineates 
them from the pathogenic species S. aureus.  However, one of the objectives of this part of 
the study was to carry out speciation of CoNS to determine the prevalence of species-
specific isolates from bacteraemic haematology and BMT patients and those skin-colonising 
isolates obtained from the pre-admission patient control group.  Additionally, comparative 
distribution of CoNS isolates indigenous to the ward environment was carried out to 
demonstrate the prevalence of CoNS species-specific isolates in each group.  Speciation 
and prevalence of CoNS isolated from the two patient groups and the environment further 
allowed comparisons between identification methodologies and evaluation of phenotypic 
relatedness within and between each of these groups.  
With the use of the automated VITEK®2 identification system, characterisation of CoNS was 
carried out by exploring the utility of biochemical phenotypes which are usually reflective of 
stable, established chromosomal isolate characteristics (Spanu et al., 2009).  This 
methodology is reliant on testing for expressed gene products that are in turn limited by the 
propensity of the organisms to alter the expression of their genes depending on external 
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factors such as incubation period and temperature.  These phenotypes based on 
biochemical/enzymatic test reactions are considered to be relatively consistent across all 
isolates of a given bacterial species, usually reflective of stable established chromosomal 
strain characteristics.  Therefore, the use of this test methodology in this study comes close 
to biotype “fingerprinting” for CoNS species-specific isolate identification. 
VITEK®2 automation criteria results are based on >95% positive or >95% negative 
discriminatory power application for species identification and are displayed as Bionumbers 
based on the numerical probability calculations of the biopattern.  Published evaluations 
indicate the GPI-card correctly identifies between 70 and >90% of CoNS species (Pfaller and 
Herwaldt, 1988; Spanu et al., 2003).  Greater accuracy is further achieved by combining 
automated results with off-line coagulase test results as recommended by manufacturer 
(bioMérieux SA, Marcy-'Etoile, France).  The VITEK®2 database contains a large number of 
Bionumbers inclusive of new species variants, which makes it possible to resolve species 
into subspecies sufficient for CoNS species characterisation.  
Identification of the one hundred blood culture isolates of CoNS, collected over two years in 
comparison to the 100 predominant CoNS isolated from pre-admission patient skin-
colonisers using the VITEK®2 system revealed S. epidermidis as the most frequently 
recovered species (57% and 32% respectively).  The second most isolated species in both 
these patient groups was S. hominis (18 and 24%) followed by S. haemolyticus (16 and 
17%).  With respect to the total colony counts per environmental area sampled in the 
haematology and BMT wards, S. epidermidis (53%) was again the predominant species 
isolated.  These findings correlate well with previous studies which have shown that S. 
epidermidis is the most frequent of the CoNS species to be associated with nosocomial BSIs, 
predominantly as biofilm-associated infections of indwelling medical devices (Worthington et 
al., 2000; Wolf et al., 2008; Piette et al., 2009).  However, the frequency of occurrence can 
be variable, dependent on the geographical region of isolation (Sader et al., 2001).  As such 
environment sampling showed that although the frequency of occurrence varied, S. 
epidermidis was still the predominant species found both in patient ward area and skin- 
colonisers in the control patient group.  The predominance of S. epidermidis in the in-patient 
group could therefore be associated with the propensity of the species to be an opportunistic 
pathogen sourced from the environment or skin microbiota. 
S. hominis was the second most common of the species isolated from both patient groups 
and is known to be the second most abundant of the skin colonisers.  However, clinically it is 
S. haemolyticus that has been cited as the second most common cause of BSIs related to 
implantation and subsequent manipulation of intravascular medical devices (Kristóf et al., 
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2011).  The pathogenic potential of S. haemolyticus second only to S. epidermidis especially 
in the immunocompromised host has been reported by other authors (Sader et al., 2001; von 
Eiff et al., 2002).  Interestingly, although S. haemolyticus was the third most common of the 
species found in both the blood cultures of bacteraemic haematology patients and skin-
colonising isolates of the control group; this species was the least common of the CoNS 
found in the patient ward area environment.  The observation made from this study analysis 
suggests that S. haemolyticus has an apparent niche preference, such as regions 
endogenous to the patient but not to the patient’s environment.   
The other minor group of CoNS species isolated from the haematology and BMT ward areas 
included S. capitis, S warneri, S. auricularis and S. cohnii.  These CoNS species are known 
to be predominantly native to human skin.  However, S. caprae a rare isolate of human 
microbiota was recovered from the computer located in BMT ward area 11 corridor sampled 
in May 2011(Pfaller and Herwaldt, 1988; Kloos et al., 1994).  This suggests that the presence 
of this contaminant CoNS species may have been from a source other than from patients or 
healthcare staff.  Result analysis of the bacterial load from each in-patient ward area 
sampled (Table 2-6) show that the overall load, including the distribution of CoNS species 
isolated in the individual bed space areas of the BMT ward was much lower than those 
isolated from the haematology ward area.  A low isolation rate of all CoNS species as well as 
the complete absence of bacterial isolates was noted in most areas of the BMT ward area in 
comparison to the haematology ward area.  This is reflective of the infection prevention 
policies and procedures in place protecting the vulnerable state of the neutropenic and 
immunocompromised patients.  The BMT ward area comprising of single isolation rooms are 
disinfected between each use with accelerated hydrogen peroxide vapour, providing a sterile 
environment, hence the low bacterial load observed.  The air filters and positive air flow in 
this ward unit further ensures a protective environment by reducing contamination, exposure 
to and risk of infection with opportunistic pathogens thus the control of infection measures set 
in place support reduced organism transmission (Syndor et al., 2001).  
Hence the low numbers of bacteria from environmental sampling observed in this study 
evidences that infection control procedures were well adhered to by staff common to both 
ward areas.  This was further evident from results showing that most areas sampled in the 
BMT unit had either had no bacteria isolated or were present in relatively low numbers.  
Comparison of the isolation rate of common CoNS species from both ward areas revealed 
that in the BMT ward area CoNS isolates were present in only 9(11%) out of the total 40 area 
points sampled.  Higher numbers of CoNS species, indigenous to skin were isolated in areas 
of greater access, such as PIC system.  This may have been possibly due to healthcare staff 
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not having to wear essential personal protective equipment such as gloves in areas of no 
direct patient contact. 
Relatively higher bacterial loads were however observed on the BMT macerator handle 
where health workers dispose patient waste in comparison with the macerator handle of 
haematology ward which had comparatively few bacterial isolates.  These comparatively 
higher contaminant bacterial loads was observed in both the March and May sampling 
periods.  The difference in contamination may possibly have been due perhaps to a different 
approach for waste disposable in the BMT area in comparison to the haematology ward 
area.  On the other hand, this could be due to inadequate following of infection control 
procedures in place for this specified ward area. 
Conversely the four bed shared ward units of the haematology ward areas had a higher 
bacterial load, including the number of CoNS species-specific isolates.  Some patient areas 
had a higher bacterial load per cm2 of normal skin flora including CoNS species similar to the 
BMT ward.  Likewise, high access sampled areas also revealed greater bacterial loads.  The 
higher bacterial loads observed in the haematology ward area are probably due to the 
absence in this area of positive air flow system and no air filters, hence contamination is 
more likely even though control of infection protocols are still applicable in this area.  
Nonetheless no common pathogenic bacteria isolates such as S. aureus were identified in 
this environmental study. 
Although bacterial loads were variable dependent on sample area, the distribution of 
species-specific isolates was also inconsistent with time of sampling.  The numbers and 
prevalence of species-specific CoNS isolated in May were greater than those isolated in 
March 2011.  S. epidermidis was the predominant CoNS species isolated in March compared 
to dominance of S. haemolyticus isolation in May 2011.  Comparatively, S. epidermidis and 
S. hominis were the most prevalent of the CoNS species isolated in this environmental study.  
This correlates well with the predominance of S. epidermidis in both the in-patient and control 
patient group isolates investigated.  Although the level of predominance of all CoNS species 
varied dependent on the method of identification used, the level of variation was statistically 
insignificant (p >0.05).  However, when comparing species identification analysis individually 
for the control patient group, there was a significant difference dependent on the 
identification system used (p <0.05).  This strongly suggests that speciation was dependent 
on the type of identification system used for control patient group isolates.   
In both patient groups, it was apparent that speciation was more robust with MS MALDI-TOF 
than with VITEK®2.  The VITEK®2 system based on miniaturised biochemical reactions may 
have some limitations as identification is dependent on the variable expression of phenotypic 
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characteristics that are used as diagnostic parameters.  Studies have shown that such 
definitive identification is dependent on growth of the organism in-vitro to ascertain reactivity 
of the organism with specific biochemical tests (Spanu et al., 2003; Layer et al., 2006).  This 
methodology is therefore limited by the propensity of the organisms to alter gene expression 
which is dependent on factors affecting growth such as environmental temperature and 
incubation period of 18-24 hours or more.  These factors affect the biochemical colorimetric 
or fluorometric changes analysis by VITEK®2, consequently resulting in subjective 
interpretation hence leading to ambiguity in species identification.  Several drawbacks with 
this methodology also include technical factors which are primarily time dependent such as 
include time-dependent test set up and correct inoculum size, which can lead to subjective 
interpretation, rendering the result susceptible to misinterpretation. 
Studies by various investigators comparing the performance of VITEK GP-ID card for 
clinically relevant bacteria in comparison with established molecular reference methods, 
demonstrate a high degree of agreement with the results obtained in this study (Spanu et al., 
2003; Ligozzi et al., 2002; Layer et al., 2006; Funke et al., 2005).  These studies show an 
accuracy of between 90 and 93% of CoNS to the species level with the VITEK®2 system. 
This correlates well with the results obtained in this study particularly for the in-patient CoNS 
isolates where only 6% of the 100 isolates tested gave a differing identification when 
compared to results obtained by the proteomic test methodology.  Three out of the 18 
isolates of S. hominis together with one isolate of S. auricularis identified as S. epidermidis, 
whereas species of Kocuria known to be biochemically inert but morphologically similar to 
CoNS species were reliably characterised as S. capitis and S. auricularis based on 
proteomic analysis.  These finding concur with comparative study describing the erroneous 
reporting by the VITEK®2 system of some CoNS as Kocuria species, a group likely to be 
representative of misidentification (Layer et al., 2006).  Of the other minor CoNS group of 
isolates, S. capitis was found to be the predominate species in both patient groups and ward 
environment.  S. capitis, as a part of the normal skin flora usually resides on the upper half of 
the human body and has been implicated as the cause of opportunistic infection in the 
immunocompromised host (Kloos et al., 1994).  Hence, S. capitis nosocomial acquisition and 
infection in vulnerable hospitalised patients could be associated with its predominance 
observed in both patient groups and ward areas. 
Bannerman and colleagues, (1993) in their study evaluating the VITEK-GPI card showed that 
92% of S. epidermidis isolates were identified accurately by VITEK®2 however, of these 3% 
were unidentified and 5% misidentified.  Accuracy for identification of S. haemolyticus and S. 
capitis was 95% and 88% respectively, whereas S. hominis was identified with the least 
accuracy 63%, of which 43% were misidentified as S. epidermidis.  These results concur with 
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the findings of this study, where 17% of the in-patient S. hominis isolates identified as S. 
epidermidis, with the use of the VITEK-GPI card.  True reproducible differences between 
distinct strains and inconsistency in test findings are due to a number of factors which affect 
biochemical reactions of a given species (Bannerman et al., 1993).  Therefore, 
environmental or technical factors include inoculum, culture conditions and incubation 
temperatures may have affected the biological expression of the phenotype.  It is therefore 
possible that misidentification of S. hominis isolates as S. epidermidis may have been due to 
test performance variability affecting the phenotypic markers used for strain biotypic 
differentiation,  
This is further evidenced by Spanu and co-workers (2003) in their study using the VITEK®2 
system for the rapid identification of staphylococci isolates from BSIs.  The authors suggest 
that there is a need for further improvement in the identification of some CoNS species in 
particular, S. hominis as the degree of misidentification of this species is higher in 
comparison to other species types.  Similarly, for the control patient group CoNS isolates, 7 
out of the 24 S. hominis identified as S. epidermidis.  However, the difference in species 
identification was greater in this group where 22% of the isolates gave differing species-
specific identification, compared to identification using VITEK MS MALDI-TOF system. 
Additionally, higher rates of species identification differences were noted with the speciation 
of the other minor CoNS group of isolates, where 6 out of the 7 isolates of S. warneri 
identified as either S. hominis, S. haemolyticus or S. epidermidis.  Similarly, 3 out of the total 
of 5 (60%) isolates of S. lugdunensis identified by VITEK®2 were classified as S. epidermidis 
by MS MALDI-TOF.  Accurate identification of clinical isolates of S. lugdunensis is important 
as this isolate with closely resembling characteristics S. aureus is often reported to be 
associated with serious infection when found in normally sterile sites (Huebener et al., 1999; 
Hellbacher et al., 2005).  Conversely four out of five isolates of S. epidermidis in the control 
patient group were identified as the predominant minor group of skin commensals, S. capitis 
by MS MALDI-TOF.  It is, therefore, highly possible that these isolates of S. epidermidis may 
have been misidentified due to factors affecting their biochemical profiling.  Previous 
published studies looking at different comparative identification methodologies together with 
their stated limitations, confirm similar differences in misidentification of some CoNS species 
(Cuna et al., 2004; Layer et al., 2006).  Therefore, accuracy in identification of clinically 
relevant CoNS species associated with serious infections becomes increasingly important, 
for optimal patient management (Dettenkofer et al., 2003; Goto et al., 2013).  
S. epidermidis and S. haemolyticus are commonly encountered species associated with 
nosocomial BSIs particularly among immunocompromised patients.  As these isolates are 
increasingly categorised as emerging pathogens the value of differentiating CoNS isolates to 
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the species level is therefore also becoming clinically relevant.  Commonly used biotyping 
methods although easy to perform in routine laboratories, have a lower discriminatory power 
showing an over accuracy of 50-70% in comparison to genotypic based (Tan et al., 2012). 
Conventional biotyping systems for CoNS identification appear to be limited, mainly due to 
the relatively small numbers of recognised phenotypes and homogeneity of human strains 
and species distribution in clinical setting (Christensen et al., 1983; Kleeman et al., 1993).  
Although VITEK®2 automation provides a highly acceptable level of identification accuracy, 
species-specific isolate delineation is however dependent on both morphological and 
metabolic activity (Layer et al 2006).  Conversely, the MALDI-MS methodology criteria are, 
however, not dependent on phenotypically expressed characteristics therefore, species 
differentiation is maximised, and technical limitations are minimised to a large extent.  
Evaluating the species identification results using two different methodologies in this study 
shows that proteomic based identification has a higher degree of accuracy in comparison to 
the bio-analytical method used for isolate sub-species identification. 
The mass spectra generated for each test isolate by application of MALDI-TOF MS 
proteomics are representative of the organism’s peptide sequences characteristic of the state 
of proteins in the biological sample are therefore used to determine organism identity.  
Subsequent comparisons of these spectra to those in the database identifies microorganisms 
from different genera and species to the sub-species level (Carbonnelle et al., 2010).  This 
relatively new proteomic approach, independent of subjective interpretation, allows for 
accurate identification of bacteria as spectral “fingerprints” are specific to genus, species and 
subspecies.  The MALDI-TOF MS has a more superior knowledge base to VITEK®2 
database as each species and species group is represented in the database by an average 
of 10 isolates per species with a range of 2 to 475 depending on the organism (Rychert., et al 
2013).  There are comparatively fewer limitations and greater specificity with this technology 
in comparison to VITEK®2, such as inoculum dependency and requirement for additional off-
line tests, thus providing a more specific, highly accurate identification system for CoNS 
speciation (Loonen et al., 2011). 
The few limiting factors of the MS MALDI-TOF system affecting identification accuracy are in 
some instances, include bacterial culture growth conditions.  These factors can affect the 
bacterial RNA sequences and differences in chemical extraction processes in turn affecting 
spectral peak intensities.  The resulting spectra may also differ dependent on the nature and 
application of the matrix used with the MS for the ionisation process hence impacting on the 
degree of accuracy for isolate identification (Dubois et al., 2012; Patel, 2015).  Such limiting 
factor dependency, in this study was overcome by ensuring that the CoNS test isolates were 
fresh 24 hour double-passaged cultures before use, thus ensuring stabilisation of CoNS 
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phenotype.  The matrix application standard methodology was adhered to, in accordance 
with the manufacturers instruction and all CoNS isolates from both patient groups were 
double tested for enhanced accuracy.  From the reproducible speciation results obtained in 
this study with MS MALDI-TOF it is evident that the identification test sensitivity and 
specificity was ≥ 99%. 
Of the 100 CoNS in-patient isolates tested with MS system, all but one of the CoNS isolates 
not identified to the species level.  However, this isolate was grouped with the other minor 
group of CoNS in the study as it was identified as Staphylococcus species by the reference 
laboratory by molecular analysis.  On the other hand, biochemically inert Kocuria species 
isolates identified as S. auricularis and S. capitis giving a species level identification value of 
99%.  This high degree of species-specific identification was also noted with S. hominis 
isolates identifying as S. epidermidis.  These isolates may have been affected by factors 
impacting on phenotypic expression, manifested in biochemical reaction variations, thus 
resulting in misidentification by VITEK®2 methodology.  Difference may also be attributable to 
either metabolic activity and expression that both S. epidermidis and S. hominis have in 
common and/or influences of external technical and environmental factors including inoculum 
preparation and incubation.  
As MS MALDI-TOF is based on whole bacterial colony protein structure analysis and 
independent of external factor effects, specificity and accuracy is greater therefore, resulting 
in the less likelihood of CoNS species misidentification. Overall result comparisons revealed 
a minimal error difference (6%) in species identification for the in-patient group isolates, this 
however made no difference to the overall species-specific CoNS distribution.  Conversely, 
identification difference and species distribution was noted to be greater in the control patient 
group isolates.  Comparatively, in-patient isolates of S. hominis and S. lugdunensis also 
identified as S. epidermidis by MS MALDI-TOF methodology.  Noticeably 6 out of a total of 
7(86%) isolates of S. warneri in this group were identified differently among control patient 
group isolates.  In comparison to the in-patient isolates, a higher degree of differences (22%) 
was observed overall in distinguishing species-specific isolates.  These differences could be 
due to VITEK®2 systems low discriminatory power based on biochemical analysis which 
could be the limiting factor hence affecting result interpretation.  The MS database 
comparatively, showed scores of ≥95-99.9% considered as high-confidence genus level 
identification with all the CoNS isolates tested, thus indicating a high probability of correct 
species level identification.  Such species-specific isolate identification result accuracy has 
been corroborated by other authors, comparing staphylococci identification by replacing the 
conventional biochemical method with the MS MALDI-TOF system providing better 
identification to genus and species level for the majority of Gram-positive isolates 
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(Carbonenelle et al., 2012).  Likewise, this study also attests to the fact that some CoNS 
isolates gave inconsistent or low discriminatory power identification by biochemical analysis, 
whereas correct species level identification was achieved with the MS MALDI-TOF systems.  
The greater accuracy of MS system comparable to “gold standard” molecular approaches is 
attributed to the identification of specific protein markers in GP-isolates such as aconitate 
hydratase; thus, providing clearer differential results for staphylococcal speciation (Patel, 
2015). 
The overall results obtained comparing the identification of CoNS isolates using the two 
different methodologies also correlate well with other studies that demonstrate MS MALDI-
TOF performs better than biochemical identification systems.  Studies demonstrated that 
98% of clinical isolates of staphylococci, streptococci and enterococci were correctly 
identified to the genus level in comparison to the reference methodology (Carbonenelle et al., 
2010; Patel, 2015).  Furthermore, comparisons made with an entire repertoire of 
biochemical, immunological and genotype tests, the MS MALDI-TOF, proteomic based 
system displayed a high degree of accuracy in species level identification of CoNS (Rychert 
et al., 2013).  S. epidermidis in the present study remained the predominate CoNS isolate 
identified in both patient groups, with the use of the two different identification methodologies.  
However, difference in CoNS species distribution were more apparent in the control patient 
group whereby S. haemolyticus was the second commonly isolated of the species instead of 
S. hominis when identification was carried out using MS MALDI-TOF.   
Further analysis carried out to verify the significance of CoNS speciation result differences 
obtained using the two different identification systems revealed some dissimilarities.  For the 
in-patient group there was statistically no difference (p >0.05) in CoNS species identification 
with the use of either the VITEK®2 or MSMALDI-TOF system.  However, for the control 
patient group there was a statistically significant difference (p <0.05) observed in species 
identification and thus distribution dependent on the identification system used.  Further 
statistical analysis based upon the linear logistic regression model resulting in a salient p 
value of <0.05, suggests a high significant difference in species identification performance 
with the use of either the VITEK®2 or the MS MALDI-TOF systems.  Moreover, this was also 
significantly dependent on site of isolation that derived from either in-patient or the control 
patient group. 
This study therefore demonstrated that MS MALDI-TOF was a more reliable platform for 
identification of clinically important isolates such as those from BSIs.  This is especially 
beneficial for patient management as surveillance programmes have become increasingly 
important in defining species distribution of potentially pathogenic isolates associated with 
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BSIs.  Accurate CoNS species determination can therefore also aid clinicians in 
implementing targeted empirical therapeutics.  Furthermore, these measures have been 
shown to influence reduction of morbidity and mortality rates particularly among the critically 
ill (Wisplinghoff et al., 2004; Ortega et al., 2005; Worth et al., 2009; Ge et al., 2016). 
This study further investigated clonal relatedness of CoNS species in each of the patient 
groups, based on phenotypic characterisation.  The relationship between CoNS species-
specific isolates based on biochemical profiling was explored using Pearsons-Principle 
component dice coefficient analysis with UPGMA (Figures 2-2 and 2-3).  This analysis 
allowed the determination of relationships between and within each of the CoNS species 
isolates.  The results revealed a high degree of phenotypic relatedness amongst the 
predominant CoNS species showing five distinctive cluster groups (Figure 2-2).  However, 
significant differences in the biochemical profiles amongst individual isolates of each of the 
predominant CoNS species was observed amongst the in-patient group.  These differences 
were not observed amongst the control patient group CoNS isolates, where a high degree of 
diverse clonal types were observed within the predominant CoNS species clusters.  These 
observations were based on significant differences noted in biochemical profiles of individual 
species-specific CoNS isolates, with very few clusters (<2) of 100% showing matching 
profiles.  Similarly of the 51 profiles of S. epidermidis in-patient group isolates only six 
showed 100% similarity.  Conversely, S. haemolyticus isolates showed a greater level of 
similarity with four of the seven different profile cluster groups showing 100% similarity.  
Furthermore, both patient groups S. hominis and the other minor CoNS group of isolates 
showed no profile matches, suggesting the presence of extremely diverse range of clonal 
unrelatedness.  Overall, no similarity in biochemical profiles was detected amongst majority 
of species-specific CoNS isolates, suggesting that there were diverse phenotypes within 
each species what were associated with bacteraemia in the haematology patient group.  
Comparatively, differences in profiles within and between all species-specific CoNS isolates 
was much higher in the control patient group.  The greater degree of diversity observed 
within and between each of the CoNS species-specific isolates suggests that these are 
unlikely to be related to those recovered from the in-patient group.  However, these isolates 
could potentially be variants of the predominant clonal groups present on the skin or the 
environment.  Clonal changes which may have been triggered by adaptive responses for 
survival thus resulting in aetiological agents associated with nosocomial infections. 
The overall species distribution of CoNS isolates identified from both the in-patient and 
control groups confirm results reported by other researchers of similar studies (Kleeman et 
al., 1993; Piette et al., 2009; Argemi et al., 2015).  A high degree of hyper-variability was 
noted among and between all species-specific CoNS isolates of both patient groups.  As 
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such, it was possible to distinguish 51 different phenotypes among the 57 in-patient S. 
epidermidis isolates, hence clonal dissimilarity.  This phenomenon has been explored in a 
previous study showing that a single isolate was considered to be “composed of cell 
populations of common or clonal origin” with the possibility that phenotypic variants could be 
considered as separate strains or clonal variants from the same parental cell (Kleeman et al., 
1993).  The variability observed in the biochemical patterns within and between isolates of 
the same CoNS species and the rare presence of phenotypically identical isolates of CoNS 
in both patient groups could therefore be reflective of this phenomenon. 
A further objective of this study was to explore the possibility of environmental CoNS isolates 
and those representative of skin colonisers from the control patient group as the possible 
source of in-patient CoNS-associated bacteraemia.  The distribution of CoNS species among 
the environmental isolates identified S. epidermidis as the most prevalent species similar to 
both patient group isolates.  Analysis comparisons based on Bionumbers (biochemical based 
biotypic-analysis) of CoNS species-specific isolates showed extremely limited similarity with 
no exact matches within and between species-specific CoNS of both patient groups and the 
ward area sample isolates.  One isolate of S. cohnii exceptionally, recovered from 
haematology ward area 1 however demonstrated 100% match with the same species 
isolates found in haematology ward area 2 during May 2011 sampling.  Additionally, further 
data analysis indicated the presence of unique phenotypes within the ward environment.  
This relatively high degree of heterogeneity observed within and between CoNS species-
specific isolates from the ward environment suggests that these isolates are least likely to be 
exposed to micro-niches similar to the conditions found in the human host.  Therefore, it is 
possible that these biochemically distinct environmental CoNS species-specific isolates may 
have been derived from the same clonal linage but possess characteristics that allows them 
to adapt for survival in the hospital environment.  The incredible plasticity of these isolates to 
survive and adapt in all environments may be evolutionary; such that transient exposure to 
the human host either as colonisers or potential pathogens is indicated by the number of 
different phenotypes observed in this study. 
Therefore, the difference in unrelatedness observed in CoNS species derived from both 
patient groups and ward areas is highly suggestive of the fact that both environmental and 
CoNS skin-colonisers are highly unlikely to be the source of bacteraemia in the patients on 
the ward.  However, it is possible that in-patient CoNS isolates due to their hyper-variable 
nature may have originated from the same clonal strains in the environment or skin but 
consequently to their adaptive survival characteristics become the aetiological agents of such 
nosocomial BSIs.  Reported results obtained from other studies evaluating potential sources 
of CoNS-associated bacteraemia using molecular techniques, suggested that although skin 
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isolates could not be excluded as a potentially important source of bacteraemia particularly 
related to CVC infections, there was a significant lack of evidence suggesting it was the 
primary source of CoNS bacteraemia (Costa et al., 2004).  Nonetheless, the study reports 
that among cancer patients, there is a strong correlation between BSI CoNS isolates and 
those recovered from CVC hub areas and mucosal colonisers.  Furthermore, the molecular–
relatedness studies demonstrated a molecular match between BSI and skin CoNS isolates in 
24 of the 91(26%) of patients with CVC CoNS-related bacteraemia.  However, it has been 
suggested that additional studies are required to access the exact role of skin as primary 
source of bacteraemia in relation to its clinical significance (Costa et al., 2004; Widerström et 
al., 2012).  As CoNS isolation from bacteraemic patients remains both subjective and 
dependent on clinical-specific factors, isolate speciation requiring specialised technologies 
have yet to be implemented routinely in most laboratories  
The clinical microbiology laboratory, nonetheless, plays a critical role in the care of patients 
by providing rapid identification of the infective organism using definitive diagnostic methods.  
Species-specific identification for optimal clinical outcomes can therefore be valuable in 
providing therapeutic guidance for targeted and effective antimicrobial administration.  This 
has been shown to correlate directly with decreased mortality in patients with BSIs (Ge et al., 
2016).  In the present study it could not be conclusively proven that the potential source of 
CoNS-associated bacteraemia in the haematology patients was derived from either the skin- 
colonising isolates or the ward environment.  However, technologies such as MS MALDI-
TOF providing faster, more accurate identification of most clinically important CoNS isolates 
when compared to the more conventional methodologies, can directly influence patient 
diagnosis and management.  Studies have demonstrated the potential benefit of rapid 
species-specific level identification correlating with better clinical outcomes in bacteraemic 











S. epidermidis followed by S. hominis and S. haemolyticus accounted for the dominant CoNS 
species isolated from both the blood cultures of patients with haematological malignancies 
and those isolated from among the skin-colonising strains of the control patient group.  
Despite the lack of discriminatory power demonstrated by biotyping in comparison to the 
superiority of MS technology phenotypic characterisation of CoNS isolates at this level 
revealed no significant difference in the overall distribution of CoNS species-specific isolates 
in both patient groups.  Low levels of phenotypic similarity and a high degree of 
heterogeneity within and between CoNS species-specific isolates of both patient groups was 
evident in this study, thus reflecting the diverse and adaptable nature of these ubiquitous 
species.  The findings of this part of the study therefore do not conclusively support the 
hypothesis that endogenous skin-colonising isolates could be the potential source of CoNS-





















Chapter 3   Genotypic Characterisation of CoNS isolates from bacteraemic in-patients 
in the haematology and BMT unit and those skin-colonisers isolated from the pre-
admission patient group to determine CoNS species-specific relatedness. 
3.1 Introduction  
CoNS species are increasingly recognised as the leading cause of bacteraemia in 
neutropenic patients with indwelling prosthetic devices and as such results of specific 
diagnostic assays can be a key factor for medical decision making for antimicrobial choice for 
patient therapy and epidemiological studies (Galar et al., 2012). 
 
Establishing the primary source of clinically significant CoNS associated BSIs in cancer 
patients in particular, originating from either mucosa, skin or device colonisation is critical in 
prevention and management of infection (Costa, 2004; Worth et al., 2009).  Routinely used 
conventional methodologies for identification of such CoNS species have limited application, 
as diagnostic parameters are based on the variable expression of phenotypic characteristics 
which can result in anomalous result interpretation.  Although phenotypically expressed traits 
in species-specific isolates of CoNS may be predictive of therapeutic outcomes, these 
aspects however, may not be able to distinguish different strains of the same species 
expressing identical characteristics (Cunha et al., 2004).  Clonally related strains of CoNS 
can therefore be distinguished further by their genetic fingerprint thus providing a distinct link 
between potential sources of clinically defined infections. 
 
Microbial genotyping techniques incorporating molecular biology to reliably distinguish 
bacterial strains and clones have been shown to be superior to the conventional 
methodologies (Sloos et al., 2005).  Studies on the molecular epidemiology of CoNS 
incorporate genotypic techniques such as DNA banding patterns and DNA sequencing.   
Other methodologies for the determination of microbial genetic relatedness and diversity 
include multilocus sequence typing (MLST), ribotyping, PCR ribotyping, DNA sequencing - 
randomly amplified polymorphic DNA (RAPD), PFGE, repetitive sequence-based polymerase 
chain reaction (rep-PCR) and whole genome sequencing  (Miragaia et al., 2002; van Belkum,  
2003; Healy et al., 2005). These methodologies greatly improve discrimination and 
characterisation of CoNS species.  Of these the rep-PCR technique commercially adapted to 
a semi-automated format provides a PCR-based genotyping system based on amplification 
of flanking regions between repetitive DNA sequences found naturally interspersed within the 
bacterial genome. Therefore, for strain delineation the system utilises automation to include 
changes in rep-PCR chemistry, thermal cycling parameters, incorporation of microfluidics-
based amplicon fractionation followed by detection and result analysis assisted by an 
integrated internet-based computer application module (Shutt et al., 2005). This 
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epidemiological tool is commercially available as the DiversiLab® System (bioMérieux, Marcy 
l’Etoile, France) consisting of hardware, software and consumables for genotyping of 
bacteria.  For purpose of CoNS strain delineation, the process includes, amplification of DNA 
extracted from the CoNS isolates using rep-PCR, separation of amplified fragments leading 
to the generation of unique fingerprint patterns. These fragments are then compared to each 
other and to a database of characterised microbial isolates for strain relatedness evaluation 
(Healy et al., 2005).   
 
Although this PCR-based genotyping methodology is less labour intensive in comparison to 
other methods, it has however been reported to be less discriminatory than PFGE, regarded 
as the gold standard technique for establishing the true relatedness of bacterial strains 
(Tenover et al., 2009; Widerström et al., 2012).  As such, despite being relatively costly and 
time consuming PFGE is a highly discriminatory and reproducible technique often used to 
fingerprint CoNS species to distinguish characteristics that determine clonal relatedness 
(Dobbins et al., 2002).  In this part of the study, rep-PCR and PFGE methodologies were 
therefore assessed for their discriminatory power to determine strain delineation and clonal 
relatedness of skin-colonising CoNS species-specific isolates with those from bacteraemic 
patients in the haematology and BMT unit.  Comparisons of isolate and species-specific 
genotypic characteristics could then be used to elucidate skin colonisers as the potential 
source of bacteraemia in the haematology patient group. 
 
3.2. Aim of this current study 
(a) To compare genotypic characteristics of CoNS isolates recovered from bacteraemic 
patients in the haematology and BMT unit with those that are predominant skin 
colonisers recovered from the pre-admission patient group 
(b) Molecular characterisation and genotypic relatedness of the CoNS isolates from 
both patient groups was determined by using two different techniques: microbial DNA 
typing by automated Repetitive sequence-based PCR (rep-PCR) and PFGE. 
(c) To investigate and determine the prevalence of clones and the degree of genetic 
relatedness of CoNS species within each patient group by PCA analysis. 
(d) To determine the possible acquisition of bacteraemic CoNS species associated with 
those isolates that are skin colonisers. 
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3.3 Materials and Methods 
3.3.1 Bacterial isolates 
Previously phenotypically characterised strains of CoNS from both patient groups were 
investigated in this study as described in section 2.3.3.1 and 2.3.3.5.  The isolates stored on 
Microbank™ beads were recovered by subculture onto blood agar plates incubated at 37°C 
for 18 hours in ambient atmosphere.  Two further subcultures of the CoNS isolates were 
undertaken prior to further investigation for genotyping. 
3.3.2. Selection of isolates for rep-PCR analysis  
A total of all the 200 previously phenotypically characterised CoNS isolates from both patient 
groups were investigated for genotypic characterisation using rep-PCR methodology.   
3.3.2.1 Repetitive sequence-based PCR using the DiversiLab® System  
All CoNS strain typing kits were supplied by DiversilabTM (bioMérieux SA, France).  Bacterial 
DNA extraction was carried out using the MoBio Ultra Clean microbial DNA isolation kit 
following the manufacturers protocol (MO BIO Laboratories Inc.).   
For each sample isolate tested, a density >5 McFarland standard suspension was prepared.  
This was achieved by adding two, 10µl loops full of fresh 24 hour CoNS culture to a 
MicroBead tube consisting of a silicon column, into which 300µl MicroBead solution had been 
added.  Following addition of 50µl of MD1 solution the tubes were vortexed (Vortex-Genie 2 
Sigma-Aldrich) for 15 minutes at maximum speed.  The vortexed MicroBead tubes were then 
centrifuged (Sigma1-14) at 10,000g for 30 seconds.   
The supernatant from each of the MicroBead tubes was then carefully removed avoiding the 
sandy particles and transferred to a clean 2ml clean collection tubes into each of which 100 
µl of MD2 solution had been previously added.  The sample tubes were vortexed briefly and 
incubated at -20°C for 15 minutes, followed by centrifugation for one minute at 10,000g.  200 
µl of MD2 supernatant was then transferred into pre-prepared clean tubes containing 450 µl 
of MD3 solution.  Following a brief vortex-mix the tubes were centrifuged in short pulses for a 
few seconds at 10,000g, after which 650µl of the MD3 mixture was then transferred into 
clean spin filter tubes.  The spin filter tubes were centrifugation at 10,000g for 30 seconds 
and the flow through solution left in the bottom was discarded.  This was followed by addition 
of 300 µl of MD4 solution to the spin filter, centrifuged for 30 seconds at 10, 000g and the 
flow through solution discarded again.  The tubes were then dry spun for 1 minute at 
10,000g.   
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Discarding the collection tube, the spin filter was removed and placed in a clean collection 
tube to which 35µl of MD5 solution was added ensuring that the addition was made at the 
centre of the spin filter.  The tubes were centrifuged at 10,000g for 30 seconds and incubated 
at room temperature for 2 minutes.  Each spin filter was then discarded, and the extracted 
bacterial DNA retained in the collection tubes was quantified using a NanoDropTM Lite 
Spectrophotometer (Thermo Scientific, USA) following the manufacturers protocol.  
Absorbance readings were performed at 260nm and the number generated equates to the 
estimated yield and purity of DNA.  Therefore, the calculated absorbance ratio of 260/280nm 
equivalent to requisite ratio of 1.7-1.8 equated to good quantitative extracted DNA free from 
protein contamination hence acceptable for further analysis.   
 
3.3.2.2 rep-PCR DNA amplification using DiversiLab species-specific fingerprinting kit 
The extracted CoNS DNA was amplified in accordance with manufacturer’s protocol using 
the DiversiLab Staphylococcus DNA fingerprinting kit. This procedure was carried out in a 
“Clean room” and all equipment was cleaned with 70% ethanol and left under ultra-violet light 
for 15 minutes before use.  The kit containing the reagents for the Master Mix were kept 
frozen and thawed for 20 minutes prior to use with the exception of AmpliTaq® DNA 
Polymerase (Thermo Fisher Scientific).  Genomic DNA of each sample extracted was diluted 
using the MD5 solution supplied in the kit to give a final concentration of 35ng/µl for testing.   
Preparations for rep-PCR in the clean cabinet were carried out by first preparing the Master 
Mix in a 1.5 ml tube according to the number of samples tested in each test batch.  A 
positive- and negative-control supplied in the kit was included in each test batch.  For a final 
volume per reaction tube of Master Mix was made up of 18µl rep-PCR MM1, 2.5µl GeneAmp 
of 10 x PCR buffer, 2µl Primer mix and 0.5µl of AmpliTaq® DNA polymerase.  Using reverse 
pipetting, 23µl of the mixed and briefly spun Master Mix was added to the bottom of each 
labelled reaction tube placed in a cold block.  Addition of 2µl of DNA test sample and controls 
was then added to the bottom of each of the test tubes and mixed gently by pipetting up and 
down. 
The preheated thermal cycler (PCR cycler 5 Eppendorf Mastercycler Personal) was set at 
the following thermal cycling parameters: initial denaturation at 94°C for 2 minutes followed 
by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 45°C for 30 seconds and 




3.3.2.3 Semi-automated rep-PCR DNA fingerprinting 
Detection of DNA amplicons and analysis was performed with the DiversiLab system and 
accompanying software linked to a customer-specific secured web-based application 
accessible via the internet.  The generated PCR products were separated via electrophoresis 
performed in a microfluids DNA LabChip device.  
The protocol for loading the DNA LabChip device in accordance with the manufacturer’s 
instructions, illustrated in Figure 3-1 are as follows; all reagents supplied were brought to 
room temperature prior to use.  An aliquot of 9µl pre-prepared Gel-dye mix was reverse 
pipetted into the chip priming well.  The chip was then pressurised for 30 seconds with the 
syringe initially set at 1ml.  Similarly, 9µl aliquots of Gel-dye mix were added to the remaining 
two G wells with 5µl of marker added to the rest of the assigned sample wells marked 1 to 
13.  This was followed by the addition of 1µl of the test sample and molecular ladder agent 
provided in the kit.  The chip was then placed onto the vortex (Sigma-Aldrich) and the 
contents mixed for one minute.  The DNA LapChip was then run on the Agilent 2100 
BioAnalyser® which provided Rep-PCR fingerprints through microfluidic capillary 
electrophoresis (Figure 3-1).    
 
Figure 3-1: DiversiLab system utilising the microfluidics DNA LabChip for the 
separation of amplified fragments via electrophoresis run on Agilent 2100 
BioAnalyser®. 
 
Using the DiversiLab software (version 3.4 bioMérieux, Inc. USA) analytical tools, the raw 
signals generated for each test sample with the high and low markers showing the beginning 
and end of a fingerprint curve were processed to normalise the graphs generated as 
illustrated in figure 3-2.  Sample amplifications that yielded low intensity fluorescence or very 
few non-comparable peaks were repeated for analysis using freshly extracted DNA. 
Microfluidic chip
Agilent 2100 BioAnalyser®
Vortex and Microchip loading syringe
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Figure 3-2: rep-PCR technology for CoNS fingerprinting: Multiple fragments of many 
specific repetitive sequences throughout the genome, amplified and separated, 
generating unique fingerprint pattern made from the fragments. (Schematic diagram 
adapted from the DiversiLab® Training Guide 2014). 
 
3.3.2.4 rep-PCR data analysis using the DiversiLab web based Analysis-Tool. 
General guidelines for interpretation of DNA patterns for genetic relatedness were followed 
for rep-PCR in accordance with the manufacturers guidelines using the specified 
Staphylococcus kit and DiversiLab Software Guide v: 3.4.  Interpretation of bands to 
distinguish between strains of CoNS at the species level included the following criteria: 
0 band difference = indistinguishable strains (>95% similarity) 
1 to 2 band difference = similar strains  
More than 2 band difference = different strains (<95% similarity) 
The DNA band patterns generated were converted to virtual gel images and further analysis 
was carried out using the interactive DiversiLab Bacterial Barcodes software program which 
uses curve-based Pearson correlation coefficient to determine distance matrices for pairwise 
similarity scores.  For data interpretation, the resultant banding patterns were analysed to 
create dendrograms with a percentage similarity index set at ≥ 95% for cluster analysis in 
accordance with the manufacturer’s instructions.  This was carried out using the customer-
specific web-based computer application via the internet. 
 
3.3.3 Pulse-field gel electrophoresis analysis of CoNS 
This part of the study was kindly carried out courtesy of Professor Angela Kearns at the 
Staphylococcus reference unit laboratory, PHE Colindale London (UK) assisted by Mr. Mark 
Ganner. 
The protocol followed was that of the national Staphylococcus reference laboratory which 
has extensive experience with the technique for genotyping CoNS isolates.  The reference 
laboratory has developed and uses PFGE protocols with standardised parameters 
rep-PCR primers





demonstrating a high degree of reproducibility and an established national database for 
comparison (Kaufmann, 1998; Murchan et al., 2003). 
 
3.3.3.1 Selection of isolates for PFGE  
Fifty out of 200 (25%) of the predominant species of CoNS isolates were randomly selected 
from both the in-patient and pre-admission patient control groups for investigation.  This 
included 15 isolates of S. epidermidis and 5 isolates each of S. haemolyticus and S. hominis 
from each patient group. 
 
3.3.3.2 Preparation of chromosomal DNA 
Chromosomal DNA of the 50 CoNS isolates was prepared according to the PHE standard 
genotyping methodology used for comparing isolates of Staphylococcus species (Kaufmann, 
1998). 
The CoNS test isolates cultured on blood agar incubated at 37°C for 18 hours were prepared 
by suspending each isolate in 1ml of SE buffer (75mM NACL, 25 mM EDTA pH7.5) to a 
turbidity of 4 to 4.8 McFarland standard using a densitometer. (DensiCHEK bioMérieux) 
resulting in a concentration of 1X109 cells/ml.  An equal volume (400µl) of bacterial 
suspension was then mixed with 2% low-melting temperature agarose (MacroSieve LM 
agarose, Flowgen Bioscience) and dispensed into the assembled well moulds.  After cooling 
and solidification of the molten mixture, each test block was placed in a bijoux and treated 
with 5mg/L of high concentration lysis buffer (6mM Tris, 0.5M EDTA, NaCl 0.5% w/v Brig 58, 
0.25%w/v Sodium deoxyclate, 0.5% N-Lauroyl sarcosine, 1mM MgCl2), 1.5mg/ml, Lysozyme 
and 3µL Lysostaphin (Sigma-Aldrich, UK).  This was followed by incubation at 37°C with 
gentle shaking at 150rpm (New Brunswick Scientific innOva 2100 Platform shaker) for four 
hours. 
After incubation the first lysis buffer was removed and discarded from each test bijoux.  This 
was followed by the addition of 3ml of Alkaline Lysis Buffer (1% w/v N-Lauroyl sarcosine, 0.5 
M EDTA pH 9.5) and 1mg/L Proteinase K (Sigma-Aldrich).  The bijoux were incubated 
overnight at 50°C water bath (Grant SBBS Waterbath) with gentle shaking. 
A modified DNA chromosomal preparation was used for CoNS isolates that gave weak or 
unreadable bands which included treatment and washing of agarose blocks using a higher 
concentration of Lysostaphin (5mg/ml) and a prolonged incubation period of 20-24 hours.  
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The blocks were subsequently washed three times with TE buffer (10mM Tris, 10mM EDTA 
pH 7.5) after removal of the Alkaline Lysis Buffer and Proteinase K solution.  Each wash step 
included addition of fresh TE buffer and incubation at 4°C for 30 minutes.  After the final 
wash step the agarose blocks containing extracted whole CoNS chromosomal DNA were 
suspended in TE buffer ready for the restriction enzyme digestion step. 
The prepared agarose blocks prepared were digested with endonuclease FastDigest Smal 
(Roche, UK) in buffer incubated at 30°C for 30 minutes prior to loading into the wells of a 1% 
agarose gel for electrophoresis. 
 
3.3.3.3 Pulse-field gel electrophoresis. 
Agarose gel was prepared by dissolving 2.04g agarose (CertifiedTM Molecular Biology 
Agarose, Bio-Rad Laboratories Inc.) in 153ml distilled water and 17ml of 5 x TBE buffer 
commercially prepared solution (Invitrogen Ultrapure 10x TBE Buffer).  Agrose plug sections 
containing the digested DNA were loaded into the wells in the gel together with two 
molecular weight markers (Lambda Ladder PFG Marker, New England BioLabs.) in the first 
and last well of each gel.  All the wells were sealed with the previously prepared molten 
agarose kept at 56°C. 
Sufficient electrophoresis buffer (2 litres 0.5x TBE per gel) prepared and maintained at 12°C 
was poured into the tank of the electrophoresis apparatus (Biorad CHEF DRII) to cover the 
gel.  The following electrophoresis parameters on the control module were set for 
Staphylococcus species: Total run time 30 hour; Initial switch time 1 second; Final switch 
time 80 Seconds; Voltage/cm of 6 volts. 
 
3.3.3.4 Staining, Gel visualisation and interpretation 
On completion of electrophoresis the gel was stained with 60µl of 10,000 x Gel Red (Biotium) 
diluted in 200mL 0.1M NaCl for one hour protected from light at all times. Visualisation of the 
gel was carried out under ultraviolet transillumination and photographed using the 
laboratories gel documentation system.  Digital images of the gel were saved and stored as 
electronically as TIFF files and were analysed visually with the GelCompar system (Applied 
Maths, Belgium).  The PFGE generated banding patterns were categorised according to the 
proposed guidelines described by Tenover and co-workers (1995) as follows: (a) banding 
patterns from the majority of the related CoNS isolates appearing identical in size and 
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number of bands were considered to be representative of the same strain type and was 
designated as pulsotype A; (b) CoNS isolates differing from the main banding pattern by 
three or less band differences were designated as those of the subtype within the main group 
(e.g. pulsotype A-1); and (c) banding pattern that differed from the main pulsotype by more 
than four or more bands were designated as different strain types ( e.g. designated as 
pulsotypes B, C, D and E etc.).  
Further data analysis of SmaI PFGE patterns was carried out using the UPGMA clustering 
algorithm method to produce a hierarchical dendrogram.  Genetic similarity between CoNS 
species isolates was calculated using Dice coefficient with a cut-off values set at >90%. This 
data analysis was performed using the Bionumeric software Statistica version 10 package.  
 
3.4 Results  
3.4.1 rep-PCR fingerprint profiles  
The requisite quantitative genomic DNA, linear range absorbance target performed at 260nm 
equivalent to value of >1.7 was achieved for all the one hundred CoNS isolates from each of 
the two patient groups. Amplification of the rep-PCR or the separation of the amplified 
fragments for analysis was not achievable for all the isolates in both patient groups.  
Samples that failed analysis were repeat tested twice.  However, 14% and 12% of the CoNS 
isolates from in-patient and the control group respectively resulted in abnormal rep-PCR 
DNA fingerprints.  The isolates (26%) that presented discrepant results were removed from 
final analysis due to large difference in either overall intensity resolution or migration 
differences leading to poor unresolved fingerprints. 
In total 234 rep-PCR fingerprint profiles were generated including one ladder standard and 
analysed for the 174 (87%) out of the 200 CoNS isolates tested for genotyping using the 
DiversiLab system.  Analysis included repeated testing of some CoNS isolates for better 
resolution or to run a full thirteen slot, LabChip for electrophoresis. CoNS species 
classification was based on previous phenotypic characterisation of strains (Chapter 2) for 
rep-PCR analysis.  The identities of all CoNS isolates were entered as ‘Alternative ID’ for 
complete data generation analysis and report presentation.  
Figure 3-3 illustrates a typical rep-PCR DNA graphical fingerprint profile with multiple bands 
of varying intensity representative of most of the S. epidermidis isolates in both patient 
groups.  The other CoNS species produced fewer peaks of lower intensity or more peaks of 
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variable intensities dependent on electrophoretic resolution as observed with S. haemolyticus 
isolates. 
 
Figure 3-3: rep-PCR fingerprint profile for S. epidermidis in-patient isolate A3. 
Using the analytic tool application, the relevant graphical data within the specified criteria for 
all the CoNS isolates was converted to virtual gel profiles for visual assessment of strain 
relatedness. The gel profiles were visualised as representative of 150-5000 base pairs of the 
rep-PCR elements.  
3.4.1.2 rep-PCR generated fingerprint data analysis results  
To ascertain strain relatedness between CoNS isolates and species, the interactive 
interpretation DiversiLab tool was used to create a dendrogram of rep-PCR fingerprint 
profiles of all CoNS isolates tested from both patient groups. Automated analysis was based 
on Pearson’s correlation methodology to calculate percentage similarities between CoNS 
isolates, based on emphasis on rep-PCR electrophoretic peak intensities rather than peak 
presence or absences.  Overall data analysis results using the specified criteria for strain 
relatedness of all the 233 CoNS rep-PCR fingerprints generated as a complete dendrogram 
are displayed in Appendix 1 revealing a total of nine clusters. 
The observed clusters included CoNS isolates from both patient groups, that showed a high 
level of similarity but demonstrated a variable degree of relatedness within each of the 
species-specific isolates.  The majority of clusters consisted of groups of closely related 
isolates of the same CoNS species with a genetic similarity index of >95% as well as a 
number of isolates demonstrating clonal similarity.  This level of isolate similarity was 
identified in clusters 2, 3, 4, 6, 7 and 9.  Conversely cluster 1, 5 and 8 consisted of different 
CoNS species-specific isolates from both patient groups exhibiting poor genetic similarity 
(<90%).  The dendrogram results of CoNS species-specific isolates from both patient groups 





CoNS Species Indistinguishable Strains (100% Similarity) 
  In-patient Isolates Control Patient Isolates 
S. epidermidis A25 G11, G36 
S. epidermidis A89, A7, A3   
S. epidermidis A63, A47, A45 G75 
S. epidermidis A26, A48   
S. epidermidis   G100, G96 
S. epidermidis A88, A14, A38   
S. epidermidis A5, A50, A24   
S. epidermidis A29, A42, A5   
S. epidermidis A72, A95, A92, A43 G93, G91 
S. epidermidis   G51, G40, G83 - S. hominis 
S. epidermidis A77, A60, A36, A98 - S. hominis   
S. epidermidis A9 G23 
S. epidermidis A45, A51, A46 G13 
S. haemolyticus A58, A39, A67   
S. haemolyticus A99, A86   
S. haemolyticus A87, A80   
S. haemolyticus A8 G79 
S. haemolyticus A10 G6 
S. haemolyticus A81 G71 
S. capitis   G34, G39, G37 
S. capitis A34, A11   
Table 3-1: Dendrogram (Appendix 1); result summary of in-patient and control patient 
group CoNS species-specific isolates demonstrating clonal relatedness. 
Of a total of 174 CoNS isolates tested from both patient groups, clonal relatedness was 
observed in 24% and 10% of isolates from the in-patient and control patient groups 
respectively.  Isolate similarity was observed most commonly amongst the S. epidermidis 
species in both patient groups.  Conversely, there was low degree of clonal relatedness 
between species-specific CoNS isolates recovered from the two patient groups.  Out of a 
total of 60 isolates demonstrating 100% strain similarity 12 (20%) control patient group CoNS 
exhibited clonal relatedness with 18 (30%) of the in-patient isolates.  Of the other minor 
group of CoNS species-specific isolates, clonal relatedness was demonstrated only by 
isolates of S. capitis in both patient groups.  Conversely, clonal relatedness was not 
observed in and between any CoNS species-specific isolates of S. hominis in both patient 
groups.  
Of the CoNS isolates 23 (13%) were re-run at least twice to obtain well resolved rep-PCR 
fingerprint profiles for analysis.  Fingerprint profiles for 15 (9%) of these CoNS isolates 
exhibited 100% similarity proving reproducibility of the rep-PCR assay.  Conversely, 4(1%) 
strains of S. epidermidis isolate A88, S. lugdunensis isolate G45, S. hominis isolate A71 and 
Kocuria species isolate A44 exhibited 95% similarity on repeat re-analysed fingerprint 
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profiles.  The differences of <95% strain similarity was observed in one S. haemolyticus, 
strain A81, tested three times and in two S. hominis isolates A71 and A69 tested twice.  The 
disparity in isolate similarity was even more evident in one, S. capitis, isolate A34 analysed 
twice on the same DNA Lab-Chip.  The difference in similarity observed with this isolate was 
at <75% indicating a lack of reproducibility may possibly have been affected by technical 
and/or environmental factors in this case. 
Overall characterisation by rep-PCR revealed similarity at 90 and 95% between most CoNS 
species-specific isolates from the two patient groups.  However, the same degree of 
similarity was not apparent within and between isolates of the same CoNS species in each of 
the two patient groups. 
Results of further analysis conducted to highlight any potential similarities between each of 
the CoNS species-specific isolates from both patient groups are summarised in scatterplot 
Figure 3-4.  The 2D PCA rep-PCR fingerprint analysis of all the 233 CoNS isolates tested 
from both patient groups enabled visualisation of overall pair-wise similarity thus 
demonstrating relatedness within and between similar CoNS species-specific isolates. 
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Figure 3-4: Scatterplot summary of 2D PCA rep-PCR fingerprint analysis of the 233 
CoNS isolates from both patient groups.  Colour-coded data clustering indicates 
degree of similarity between each of the CoNS species-specific isolates. 
The results of the scatterplot demonstrate the direct relationship each CoNS isolate has with 
each of the other isolates from both patient groups.  The 5% similarity spacing points set on 
the grid of the scatterplot illustrate that the majority of the CoNS isolates are spaced at 
distances of >5% which is indicative of a relatively low degree of isolate and species-specific 
similarity. 
One hundred and eight (46%) of the 233 CoNS isolates tested were observed to be 
dissimilar as determined by their distance from each other on the plot.  The colour-coding in 
the scatterplot exhibiting a high level view of clustering also highlights a degree of species-
specific similarity within CoNS isolates from both patient groups.  The results of 2D PCA 
analysis of rep-PCR fingerprint of CoNS species-specific isolates from both patient groups 
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that have a higher direct percentage similarity to each other are represented by the close 
grouping within three clusters in the plot.  This plot also highlights the close relatedness 
observed in the clusters between and within different CoNS species from both patient 
groups. The same species-specific isolates in comparison when represented on the 
dendrogram (Appendix 1) displayed a level of strain similarity of between >70% and >90% 
within the nine defined clusters.  
 
3.4.1.2.1 Definitive analysis of rep-PCR fingerprint profiles using a randomly selected 
smaller data set of in-patient CoNS isolates 
Further data analysis to explore strain similarity on a more defined scale from the large 
amount of rep-PCR fingerprint data generated, was carried out on a randomly selected 
number of CoNS isolates.  Analysis was limited to up to 50 isolates at any one time due to 
data handling constraints of the DiversiLab analytical tool as specified by the manufacturer. 
Analysis of the rep-PCR fingerprint data, refined by selecting a random sample of 44 CoNS 
isolates from the in-patient group, reveal a high degree of species heterogeneity between 
some isolates of the same species.  However, with a few exceptions, rep-PCR profiles also 
reveal closely relatedness of the same CoNS species-specific isolates grouping well within 












Figure 3-5: Dendrogram illustrates the rep-PCR electrophoresis profiles of a collection 
of 44 CoNS species-specific isolates from the in-patient group.  The scale bar below 











Isolates of S. hominis represented in cluster 1 all at a similarity index of <80% included two 
other Staphylococcus species strain displaying the same level of similarity.  However, one 
strain of S. hominis isolate A62 appeared to be closely related (similarity index <90%) to all 
the other strains of S. epidermidis represented in cluster 2 displaying similarity of >95%.  This 
may have been due to the misclassification of phenotypic identity of the S. hominis strain as 
biochemically expressed traits are remarkably similar to those of S. epidermidis. 
Indistinguishable strains of S. epidermidis isolates A7 and A3 were closely related to isolate 
A5 (>95% similarity) as were the two other indistinguishable isolates A26 and A24 present in 
cluster 2.  However there was a relatively higher degree of strain diversity displayed between 
the other strains of S. epidermidis isolates in clusters 2, 4 and 6.  Conversely, although 
strains of S. haemolyticus grouped (cluster 5) well together, the difference in strain similarity 
was higher at less than 90% similarity with the exception of the indistinguishable strain 
isolates A67 and A58.  These results were reflective of the overall rep-PCR dendrogram 
based data analysis.  
 
3.4.1.2.2 rep-PCR analysis using the Similarity Matrix 
Further comparisons of rep-PCR fingerprint profiles of the 44 in-patient isolates to assess the 
percentage similarities between two individual isolates of the same CoNS species instead of 





Figure 3-6:  Similarity matrix analysis of the 44 in-patient CoNS isolates to determine 
pair-wise similarities.  Level of similarity is reflected by the coloured percentage 
similarity scale at the top.  The triage of red boxes (95-100% similarity) indicates 
isolate clusters. 
 
For individual CoNS strain comparisons, the similarity matrix of the 44 CoNS isolates 
represented in the same order as the dendrogram Figure 3-5 show four clusters consisting of 
isolates demonstrating >95% pair-wise similarity.  The lack of significant clusters (red boxes) 
further demonstrated CoNS species heterogeneity of the 44 isolates analysed indicated by 





3.4.1.2.3. Analysis using a randomly selected smaller data set for comparison of CoNS 
species-specific isolate similarities from both patient groups 
Forty eight CoNS isolates from both patient groups, representing well resolved rep-PCR 
fingerprints were randomly selected for further comparative analysis of similarity.  Analysis 
data included ten isolates each of S. epidermidis, S. hominis, S. haemolyticus and four 
isolates each of the other CoNS species from each of the two patient groups.  
Dendrogram analysis of rep-PCR profiles comparing the distribution of CoNS isolates from 
the in-patient and control patient group demonstrate clustering of the same species within 







Figure 3-7: Dendrogram illustrates the comparative analysis of rep-PCR profiles of 48 








With reference to Figure 3-7, comparing isolates from both patient groups, species-specific 
diversity was most notable between isolates of S. hominis at a similarity index of <90% 
(cluster 1).  S. epidermidis isolates, A7 and A3 (cluster 2) demonstrated 100% similarity and 
isolate A42 demonstrated close relatedness to these two isolates at a similarity of > 95%.  
Similarly, S. epidermidis isolates G100 and G96 from the control patient group demonstrated 
clonal relatedness.  Similarity of 100% was also observed between two in-patient isolates of 
S. capitis A34 and A11.  These two clonally related isolates however, also demonstrated 
similarity at >95% with a control patient group isolate G5.  Conversely, clonal relatedness 
between species-specific isolates from the two patient groups was only observed among S. 
haemolyticus isolates G86 and A10 as well as G71 and A81 (cluster 4). 
Overall comparative profile analysis of isolates recovered from the two patient groups 
indicates that clonal relatedness is more common within species-specific CoNS isolates.  
Conversely, there was poor correlation of clonal relatedness observed between similar CoNS 
species-specific isolates from the two different patient groups.  Clonal similarity at 100% 
between species-specific isolates was observed in 8% of the total CoNS recovered from the 
two patient groups.  The differences in pair-wise similarity were further demonstrated in the 




Figure 3-8: Scatterplot summary of 2D PCA rep-PCR fingerprint comparative analysis 
of the 48 CoNS species-specific isolates from both the patient groups.  Colour-coded 
data clustering indicates degree of similarity between each CoNS species. 
The comparative result analysis of the 2D PCA rep-PCR fingerprint plot of isolates from the 
two patient groups demonstrates a high degree of dissimilarity with no evidence of clustering.  
The colour-coded data clustering that indicates the degree of isolate similarity between each 
patient group, species-specific CoNS show very few isolates exhibiting >5% similarity.  Less 
than half of the 48 CoNS isolates (43%) from the two patient groups exhibited similarity 
between each of the same species-specific isolates.  
Overall rep-PCR data analysis results indicate that the degree of strain relatedness was 
relatively high within the same species-specific CoNS isolates from the two patient groups as 
observed in the dendrogram analysis (Figure 3-7).  Conversely, the degree of similarity 
exhibited between the same species-specific isolates was comparatively much lower 
indicating a high level of diversity within and between the same CoNS species-specific 
isolates (Figure 3-8).   
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3.4.2 PFGE Data analysis 
3.4.2.1 SmaI restriction generated DNA-band profile data analysis 
The number and sizes of electrophoretically separated DNA profiles generated by SmaI 
restriction endonuclease digestion of the 50 isolates of the three predominantly isolated 
CoNS species varied dependent on species-specific type.  Isolates of S. hominis from both 
patient groups yielded DNA-band profiles varying from between five to fifteen bands ranging 
from 50 to 1018 Kb (Figure 3-9).  The DNA-band profiles of S. haemolyticus isolates from 
both patient groups varied from between six to ten bands ranging from 50 to 533Kb.  S. 
haemolyticus in-patient isolates A53 and A81 together with control patient isolates G4 and 
G81 that were poorly resolved in the first PFGE gel were re-run giving a better band 
resolution in the second gel (Figure 3-9 Lanes 2a – 5a).  The in-patient S. hominis isolate 
A55 remained unresolved yielding no band profiles due to the indigestible nature of its DNA  
(Figure 3-9 Lanes 3 and 1a)
 
 
Figure 3-9: PFGE after SmaI digestion of S. hominis and S. haemolyticus isolates from 
the in-patient and the control patient groups.  Lane marked λ= molecular weight 
ladder. Numbers to the middle indicate molecular size standard (kilobases).  Lanes 1-5 
represents in-patient S. hominis isolates A2, A19, A55, A70 and A82.  Lanes 6-10 
represent S. hominis control patient group isolates G62, G65, G83, G85 and G87. 
Lanes 11-15 represent in-patient S. haemolyticus isolates A10, A35, A53, A65, A81 and 
Lanes 16-20 represent control patient group S. haemolyticus isolates G4, G26, G48, 
G61, G86.  Repeat PFGE gel run: Lane 1a = in-patient S. hominis isolates A55 
(undigested).  In-patient S. haemolyticus isolates Lane 2a = A53, Lane 3a = A81, and 




Figure 3-10: PFGE generated banding pattern based DNA fingerprints of S. 
epidermidis isolates from the in-patient and the control patient groups.  Lane marked 
λ= molecular weight ladder. Numbers to the right indicate molecular sizes (kilobases).  
Lanes 1-10 represent, in-patient isolates A91, A73, A95, A26, A13, A57, A17, A61, and 
A9.  Lanes 11-15 represent control patient isolates G69, G70, G75, G96 and G100. 
 
Similarly, the SmaI restriction DNA-profiles generated for the S. epidermidis isolates from 
patient groups yielded banding patterns varying in number and size. The number of bands 
yielded varied from eight to a maximum of fifteen bands ranging from 50 to 1000kb (Figure 3-
10 and 3-11). 
The majority of S. epidermidis isolates yielded up to fifteen closely positioned DNA-band 
profiles in the range of 50kb to 485kb.  The exceptions to this were the two in-patient and two 
control patient group isolates A32, A37 and G9, G70 respectively (Figure 3-10, Lane 4,11 12 
and Figure 3-11, lane 12).  These four isolates of S. epidermidis displayed banding patterns 




Figure 3-11: PFGE generated banding pattern based DNA fingerprints of S. 
epidermidis isolates from the in-patient and the control patient groups.  Lane marked 
λ= molecular weight ladder.  Numbers to the right indicate molecular sizes (kilobases).   
Lanes 1-10 represent control patient isolates G3, G13, G17, G29, G30, G33, G38 G40, 
G51 and G68.  Lanes 11-15 represent in-patient isolates A37, A32, A59 A74 and A72. 
 
3.4.2.2 Interpretation of DNA restriction patterns produced by PFGE  
The banding patterns of the 50 isolates of the predominant CoNS species subjected to PFGE 
were analysed and categorised in accordance with the criteria established by Tenover and 
colleagues, (1995) to identify clones and strain similarity.   
Each unique electrophoretic DNA- banding pattern fingerprint subjected to visual inspection 
was defined as a pulsotype for interpretation and comparison.  For each of the CoNS species 
analysed, the resulting band pattern pulsotypes were designated alphabetically with letters A 
onwards and each closely related band pattern or subtype was given a number in relation to 






In-patient Group  Control Patient Group 
S. epidermidis Pulsotype  S. epidermidis Pulsotype 
A91 A  G3 K 
A73 B  G13 L 
A95 A-1  G17 M 
A26 B  G29 N 
A13 B  G30 O 
A57 C  G33 P  
A17 B-1  G38 Q 
A61 D  G40 R 
A84 E  G51 S 
A9 F  G68 T 
A37 G  G69 U 
A32 H  G70 V 
A59 I  G75 W 
A74 J  G96 X 
A72 A-1  G100 R-1 
 
In-patient Group  Control Patient Group 
S. hominis Pulsotype  S. hominis Pulsotype 
A2 A  G62 E 
A19 B  G65 F 
A55 Undigested  G83 A 
A70 C  G85 G 
A82 D  G87 H 
 
In-patient Group  Control Patient Group 
S. haemolyticus Pulsotype  S. haemolyticus Pulsotype 
A10 A  G4 F 
A35 B  G26 G 
A53 C  G48 H 
A65 D  G61 I 
A81 E  G86 B-1 
Table 3-2: The number and sizes of electrophoretically separated DNA SmaI digested 
fragments of 50 CoNS species-specific isolates from both patient groups assessed by 
visual inspection were assigned Pulsotypes in accordance with the Tenover criteria 
for strain characterisation. 
Application of the designated comprehensive criteria for standardised interpretation of PFGE 
profiles used for clonal similarity of the 50 CoNS isolates recovered from both patient groups 
revealed multiple species-specific isolate profiles.  Out of the 50 isolates tested only four 
(8%) similar isolate sub-types were identified.  The large number of different pulsotypes 
identified in both patient groups indicates a wide genotypic heterogeneity among all the 
isolates of the three predominant CoNS species. 
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Considering S. epidermidis isolates from both patient groups 27 different PFGE pulsotypes 
were assigned among the 30 isolates studied (Table 3-2).  Prevalent PFGE clonal pulsotypes 
(A to W) common to the two patient groups were not identified.  However, the numbers of 
similar and closely related strains were predominantly observed only in the in-patient S. 
epidermidis isolates in comparison to the control patient group isolates.  In accordance with 
the Tenover criteria for strain similarity, the three (10%) S. epidermidis in-patient Isolates 
A73, A26 and A13 assigned as pulsotype B strains were considered indistinguishable as 
these isolates displayed identical banding patterns.  Only one (3%) of the in-patient isolate 
A17 pulsotype sub-type B-1 was observed to be closely related with less than three band 
difference to the pulsotype B isolate.  Similarly, two (7%) S. epidermidis sub-type A95 and 
A72, in-patient isolates assigned pulsotype A-1 were observed to be closely related to 
isolates A91 pulsotype A. 
Among the control patient group all 15 (100%) S. epidermidis isolates tested from this group 
were assigned different PFGE pulsotypes representative of multiple genetic variants.  
However, sub-type isolate G40 was closely related to G100 with a three band difference 
observed.  Overall analysis of restriction DNA-band pulsotypes indicates that there was no 
genetic similarity between in-patient and control group S. epidermidis isolates.  Conversely 
one in-patient S. hominis isolate A2 (Pulsotype A) exhibited 100% clonal similarity to control 
patient group isolate G83.  Close clonal relatedness was likewise observed in one in-patient 
S. haemolyticus isolate A35 (Pulsotype B) with control patient isolate G86 (Pulsotype B-1).  
3.4.2.3 UPGMA dendrogram analysis of PFGE profiles 
The level of genetic similarity between each of the three predominant CoNS species isolates 
from both patient groups was determined by means of UPGMA dendrogram analysis of 
PFGE profiles.  Multiple genotypes were identified within each of the 30 isolates of S. 






Figure 3-12: Dendrogram (UPGMA cluster analysis based on Dice correlation 
coefficient) comparison of PFGE DNA-band profiles of the 30 S. epidermidis isolates 
of the predominant CoNS species from both the in-patient and control patient groups. 
The scale bar at the top represents percentage similarity with the cut-off value set at 
>90%. Both isolates A26 and A13 show 100% similarity. 
 
Comparative genotypic characterisation based on PCA analysis of PFGE DNA-band profiles 
of S. epidermidis isolates from the two patient groups revealed a significant lack of 
association between and within isolates (Figure 3-12).  The majority of S. epidermidis 
isolates from both patient groups demonstrated similarity of between 60 and 80% with the 
exception of three in-patient isolates exhibiting >90% similarity.  The in-patient, S. 
epidermidis isolates A26 and A13 displayed indistinguishable DNA fingerprints thus 
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considered to be clonally related (same isolate).  The genetic fingerprint of isolate A73 
differing by less than a three band difference (>95% similarity) was considered to be closely 
related to the clonal isolates A26 and A13.  Comparing the PFGE profile results by means of 
UPGMA analysis with those obtained with the visual interpretation of banding patterns (Table 
3-2) indicated clonal similarity between all three isolates A26, A13 and A73 (Pulsotype B).  
Sub-type A17 (Pulsotype B-1) was closely related however UPGMA dendrogram analysis 
revealed that this isolate was not closely related (<90% similarity) to any of the three 
Pulsotype B-S. epidermidis isolates.  Likewise, isolate A91 (Pulsotype A) revealed close 
relatedness to isolate sub-types A95 and A72 (Pulsotype A-1) however the dendrogram 
based analysis revealed a genetic similarity of <90% between these three isolates. 
Higher variations in genetic similarities and differences were also observed within and 
between in-patient and control patient group isolates of S. haemolyticus (Figure 3-13). 
 
Figure 3-13: UPGMA dendrogram and band-based Dice analysis and comparison of 
PFGE profiles among S. haemolyticus isolates from both in-patient and control patient 
groups.  The scale bar at the top representing percentage similarity with the cut of 
value set at >90%. 
 
The dendrogram analysis of S. haemolyticus isolates from the two patient groups identified 
two in-patient isolates, A53 and A81 at a genetic similarity of 80% with the rest of the isolates 
(70%) displaying genotypes at <60% similarity.  In comparison, the visual band-pattern 
analysis results showed control patient groups S. haemolyticus G86 (Pulsotype B-1) was 
closely related to in-patient isolate A35 (Pulsotype B).  However, genetic similarity between 




Multiple genotype strains were also identified amongst strains of S. hominis from the two 
patient groups (Figure 3-14). 
 
Figure 3-14: UPGMA dendrogram and band-based Dice analysis and comparison of 
PFGE profiles among S. hominis isolates from both in-patient and control patient 
groups. The scale bar at the top representing percentage similarity with the cut of 
value set at >90%. 
The in-patient S. hominis isolate A2 was closely related to control patient isolate G83 at 
>90% similarity however, visual band analysis results indicated that these two strains were 
clonally related (Pulsotype A).  In comparison distinct genotypes were identified in S. hominis 
isolates from both patient groups at a genetic similarity of <70%. 
Overall analysis of PFGE generated fingerprint profiles demonstrated the presence of 
genotypically divergent isolates within the same CoNS specie-specific isolates recovered 
from the two patient groups. 
3.5 Discussion 
Bloodstream infections due to CoNS are the most common cause of bacterial nosocomial 
infections associated with high rates of morbidity in patients with haematological disorders 
(Worth et al., 2009).  Epidemiological studies of infection caused by CoNS species are 
complicated by the fact that these organisms are also ubiquitous commensals of the healthy 
human skin and mucosa (Costa et al., 2004).  However, the predominant skin colonising 
CoNS species, particularly S. epidermidis, S. hominis and S. haemolyticus have emerged as 
opportunist pathogens associated with clinically significant bacteraemia in those patients with 
intravascular devices and underlying immunocompromised states.  These opportunistic 
infections are usually associated with species-specific strains possessing determinants which 
facilitate their survival on skin and device surfaces (Sloos et al., 2000; Coello et al., 2003). 
Establishing the source of CoNS related bacteraemia in the immunocompromised host is 
therefore critical in the prevention and management of infection (Coello et al., 2003).   
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Continuing progress in genomic and molecular epidemiology has provided an interesting 
insight into the flexibility of skin colonising species of CoNS generating novel genotypic 
variants associated with opportunistic infections in the immunocompromised host 
(Schoenfelder et al., 2010).  To establish the link between potential sources and clinical 
infection, molecular techniques are now routinely employed for definitive genotypic 
differentiation of species-specific strains of CoNS isolates.  The detection of these pathogens 
usually focuses on single isolate types present in both epidemic and endemic settings as 
species-specific knowledge is required to assess the impact on transmission and infection 
from the implicated sources (Carretto et al., 2005).  Molecular based techniques are highly 
sensitive and specific and have been shown to perform better than conventional phenotypic 
methodologies for isolate delineation.  The results of these molecular based diagnostic 
assays can be a key factor in making medical decisions not only for epidemiological studies 
but more importantly for targeted patient therapy (Galar et al., 2012). 
The primary objective of this part of the study was to determine the genotypic differences or 
similarities between bacteraemic in-patient CoNS isolates and those skin colonising strains 
that could potentially be regarded as inducers of sepsis in the immunocompromised host.  In 
this study rep-PCR and PFGE were the two genotypic methods used to compare the 
possible genetic relationship between the CoNS isolates from bacteraemic patients with 
those that are normal skin-colonising strains.  The requirement of the molecular methodology 
employed for isolate typing in this study was based on the ability of the techniques to group 
genetically related isolates and to differentiate those that were unrelated.  Both the genotypic 
methods provided high discriminatory power, using cut-off values for acceptable levels of 
similarity whereby indistinguishable isolates could be differentiated by their genetic 
fingerprints.  These two genotypic methods used for typing permitted the delineation of CoNS 
isolates for characteristic comparison whilst assessing the measure of similarity. 
The rep-PCR DiversiLab® system used in this study is an alternative molecular typing 
technique not routinely used in clinical diagnostic laboratories.  The system has however 
been evaluated for various Gram-negative and Gram-positive associated hospital outbreaks 
(Tenover et al., 2009; Hurmic et al., 2014).  The system was evaluated for vancomycin 
resistant Enterococcus species, Pseudomonas aeruginosa and Acinetobacter species 
outbreaks and transmission between patients at the Queen Elizabeth Hospital and was 
kindly loaned out for characterisation of CoNS isolates for this part of the study. 
The application of the rep-PCR for CoNS strain typing relies on amplification of the non-
coding intergenic (highly conserved) repetitive sequences interspersed throughout the 
genome using specific primers targeting these regions (Healy et al., 2005).  The amplification 
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process therefore created multiple DNA fragments varying in size, generating fingerprints 
reflecting the potential genetic differences or similarity to be studied for each of the CoNS 
isolates from the two patient groups.   
The DiversiLab software also permitted efficient analysis of the large amount of rep-PCR 
fingerprint data generated for the 174 CoNS species-specific isolates from both patient 
groups.  Of the 233 isolates, 59 were re-evaluated to obtain well resolved rep-PCR 
fingerprints.  These were analysed for similarity comparisons, shown as a dendrogram 
(Appendix 1) which demonstrated that isolates from both patient groups generally clustered 
well by species at >95% similarity.  The results of this complex data analysis further revealed 
the genetic diversity among and between isolates of the same CoNS species from the two 
patient groups.  It is evident from the results of this study that the rep-PCR molecular typing 
method has a relatively high discriminatory power in determining isolate delineation and 
clonal relatedness.  Of these, most species-specific CoNS isolates grouped together in 
defined clusters.  However, results also showed that some CoNS species displayed 
genotypic fingerprint profiles that were similar to those of a different CoNS species in some 
cluster groups.   
CoNS identification to the species-specific level was based on their biochemical profiles 
using the VITEK®2 system and the phenotypic identities were additionally used for further 
genotypic characterisation.  Therefore, it is highly likely that the genotypically similar isolates 
observed in this analysis may have been inaccurately identified as different CoNS species-
specific biotypes.  These results are concomitant with previous studies highlighting the 
limitations of routinely used phenotypic methodologies in comparison to molecular methods 
for species identification and differentiation (Cunha et al., 2004; Metha et al., 2009).  Such 
differences were mainly observed among isolates of S. hominis clustering predominantly 
within the S. epidermidis isolate clusters.  Previous studies have also demonstrated the high 
probability of misclassification of S. hominis isolates as S. epidermidis because the 
phenotypic differential between this species is based on a single biochemical reaction 
difference (Logozzi et al., 2004).  Such discrepancies with regards to false negative results 
for acid production from lactose with the absence of phosphatase activity in S. hominis have 
been demonstrated in previous studies evaluating the VITEK®2 GP-card for CoNS species 
identification (Bannerman et al., 1993; Spanu et al., 2003).  The rep-PCR typing technique, 
although not used for species identification appears to be more discriminatory based on 
genotypic profiles among the isolates that are misclassified by their phenotypic profile.  
These isolates characteristically clustered together at a similarity cut-off value of >95%.  In 
this study, some isolates of S. hominis based on VITEK®2 biochemical analysis were 
identified as S. epidermidis using the MALDI-TOF MS system (Chapter 2).  Interestingly, it 
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was noted that if the MALDI-TOF MS species identification results were uploaded for rep-
PCR data analysis instead of the biochemical based identification, these strains would 
cluster together within species-specific group similarity of >95%.  These results confirm a 
comparative study by Loonen and colleagues (2012) using proteomic methodology for 
identification of CoNS verifying the accuracy of MALDI-TOF MS for CoNS species 
identification.  As such, in the dendrogram analysis (Appendix 1 cluster 4) genotypic rep-
PCR profile of S. hominis control isolate G42 was closely related to the in-patient S. 
epidermidis isolate A17.  Likewise, S. hominis control isolates G88 and G22 identified as S. 
epidermidis species by MALDI-TOF MS system would therefore demonstrate clonal 
relatedness to S. epidermidis isolate A46 and A9.  It is therefore evident from the genotypic 
rep-PCR fingerprint profiles comparison with that of MALDI-TOF MS analysis that these 
isolates are highly likely to be closely related to the same CoNS species-specific isolates.  
The DiversiLab system could therefore be used not only for CoNS typing but also facilitate 
species-specific identification.  Studies based on molecular assays for Staphylococcus 
species identification have demonstrated greater accuracy in comparison to routinely used 
standard phenotypic based methodologies (Mehta et al., 2009).  This correlates well with the 
degree of reproducibility observed with this genotyping technique as demonstrated with in-
patient strains A97, A52, A84, A59, A39, A67, A8 and A83. These strains when re-run more 
than once displayed 100% similarity as did control patient isolates G35, G44, G45, G48, G83 
and G79 (Healy et al., 2005).   
Importantly, some limitations of this rep-PCR technique for species-specific isolate 
differentiation were also noted in this study.  The rep-PCR fingerprint analysis results for 
some CoNS isolates that were re-run either due to poor resolution or to complete the 13 
wells of the same DNA LabChip did not exhibit 100% similarity.  S. capitis control patient 
isolate G37 and the in-patient S. epidermidis isolate A85 amongst a few others displayed 
less than 95% similarity on repeat analysis, indicating that these species-specific isolates 
were not indistinguishable.  More importantly, G45, the same S. lugdunensis control patient 
isolate re-run twice displayed <90% similarity, suggesting that this isolate would have been 
classified as different species-specific genotype.  In the hospital setting this observation 
would provide a diagnostic dilemma as the isolate typing result would potentially lead to the 
mistaken assumption that these dissimilar isolates were not part of an outbreak investigation.  
Such apparent aberrant results impact directly on early management of suspected outbreaks 
and patient treatment, particularly in situations involving infections with more virulent isolates 
of CoNS such as S. lugdunensis (Hellbacher et al., 2006).  Elements of caution were also 
applied when analysing and interpreting the comprehensively large amount of rep-PCR data 
generated.  The DiversiLab system application is a genotypic tool effectively used for 
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resolving sources of outbreaks where only a small number of isolates are involved for 
comparisons of genotypic similarity.  Nonetheless, the large data set results obtained in this 
study correlated well with that displayed in the smaller defined analysis of up to 50 CoNS 
isolates.  Overall results reveal that the degree of similarity exhibited between each isolate of 
the same species was less than the set defined cut-off value of 95% for isolate similarity.  
These results, therefore, provide confirmation of the high level of diversity existing within and 
between CoNS species-specific isolates from both patient groups as illustrated in the 
scatterplot analysis (Figures 3-4 and 3-8).  Moreover, comparisons of CoNS species-specific 
isolates from the two patient groups, revealed a relatively low degree of clonal relatedness 
between and within the same CoNS species.  It is therefore evident from the results of the 
rep-PCR data analysis that there were no significant correlations between the skin colonising 
strains and those CoNS isolates obtained from the bacteraemic in-patient group. 
The rep-PCR based DiversiLab system in comparison to other molecular typing tools has 
had a limited application as a standard differential method for genotyping; restricted mainly to  
identification of small number of specified bacterial species commonly associated with 
hospital related outbreaks such as MRSA (Fluit et al., 2010; Sabat et al., 2013).  Currently 
few studies have been published demonstrating the clinical utility of rep-PCR specifically for 
genotypic characterisation of CoNS isolates.  Although molecular techniques are fast 
progressing toward DNA sequencing of highly variable genes, PFGE however remains the 
most widespread used tool for molecular typing.  Hence, the PFGE technique was utilised to 
further verify the clonal relatedness of CoNS isolates recovered from the two patient groups 
in this study. 
DNA fingerprinting by PFGE known to provide better strain discrimination compared to other 
molecular techniques, is however a both time consuming and costly technique requiring 
specialised technical skill (Widerström et al., 2012).  Therefore, due to the cost and time 
constraints, 50 of the 100 isolates of the predominant CoNS species were subjected to 
PFGE analysis.  Overall result analysis identified a limited degree of similarity between in-
patient and the skin-colonising isolates regarded as potential inducers of sepsis in the 
haematology patient group.  
Primary visual analysis of genomic DNA fingerprints based on specific band differences 
facilitated the comparisons between CoNS species-specific isolates from both patient 
groups.  The visual analysis criteria followed was based on detecting differences in the 
intensities of specific bands.  In addition, the Bionumeric software employed for analysis 
determined the relatedness of isolates by observing the absence or presence of comparative 
bands.  Based on these criteria, visual analysis carried out with the aim of determining the 
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degree of clonal relatedness between isolates of the two patient groups revealed a high level 
of genotypic diversity within the three predominant CoNS species. 
Based on the Tenover, (1995) criteria for classification of the PFGE fingerprint assessing 
band patterns revealed that clonal relatedness within the S. epidermidis isolates from the in-
patient group was greater in comparison to those from the control patient group.  Three of 
the in-patient S. epidermidis isolates classified as Pulsotype B (Table 3-2) were observed to 
be clonally related.  The Pulsotype B isolates were observed to be genotypically similar 
therefore possibly derived from a common parent.  However, researchers suggest that such 
isolate clonality can only be considered to be relative rather than absolute as PFGE 
fingerprinting does not have the potential for detecting cryptic genetic changes (Tenover et 
al., 2009).  The observed results could be representative of either the possibility of cross-
infection between patients on the haematology unit or isolation of the same isolate from a 
single patient’s repeated blood cultures.  Conversely, such PFGE band pattern similarities 
were not observed between the S. epidermidis isolates from the control patient group.  These 
S. epidermidis isolates were seen to be genotypically distinct in comparison to in-patient 
isolates.  The level of clonal diversity observed between and among S. epidermidis isolates 
from the two patient groups suggests that these skin-colonising isolates may not be inducers 
of bacteraemia in the in-patient group. 
Conversely, visual band analysis revealed one identical S. hominis in-patient isolate to be 
another skin-colonising isolate from the control patient group.  These two S. hominis isolates 
possibly sharing clonal ancestry, provide potential indication of sharing a common source.  
Distinct genotypic band patterns were displayed by S. haemolyticus isolates from both 
patient groups with the exception of one sub-type isolate from each patient group, 
demonstrating close genotypic relatedness.  
Further comparison of PFGE band analysis data calculated by Dice coefficient (1% tolerance 
level) and represented by UPGMA clustering revealed a significant lack of association 
between isolates of S. epidermidis, S. hominis and S. haemolyticus from the two patient 
groups.  Overall results, therefore, indicated a high degree of genotypic diversity within and 
between all CoNS species-specific isolates with the exception of two in-patient S. 
epidermidis strains A26 and A13 demonstrating 100% clonal relatedness (Figure 3-12). 
Interestingly however application of guidelines set by Tenover and colleagues (1995) for 
visual interpretation of PFGE generated chromosomal DNA restriction profiles, genetic 
similarity, classified as closely related, was also observed among four of the in-patient S. 
epidermidis isolates, A26, A13 and A73 and isolate A17.  The greater discriminatory power of 
UPGMA in assessing strain relatedness in comparison to visual band profile assessment 
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could account for disparity in result interpretation and classification.  The statistical protocol, 
widely used for performing cluster analysis for assessing strain relatedness readily identifies 
bands within complex genotypic profiles in comparison to assessing band profile visually 
(Caddick et al., 2005).  Therefore, isolates A2 and G83 of S. hominis, each from the two 
different patient groups classified previously as clonally related, with UPGMA analysis were 
classified as similar and not indistinguishable.  The closely-related classification between 
these two isolates is more likely due to the three band differences observed with UPGMA 
cluster analysis.  Likewise, both in-patient and control patient group S. haemolyticus isolates 
were therefore categorised as distinct genotypes displaying as values at <60%, well below 
the acceptable cut-off value for isolate relatedness.  Hence, molecular typing by PFGE in this 
study identified distinct genotypic isolates prevalent within and between all predominant 
species-specific CoNS from both patient groups.  These results reflect observations made in 
previous studies demonstrating the presence of heterogeneous PFGE profiles between and 
within the same CoNS species-specific isolates (Lang et al., 1999; Casey et al., 2005). 
Following data analysis, both the rep-PCR and PFGE molecular typing techniques proved to 
have the required discriminatory power needed to distinguish unrelated CoNS species-
specific isolates.  The main point of consideration when comparing the two typing methods 
was the difference in isolate clonal relatedness assessment.  Such that, clonal relatedness 
through rep-PCR is defined as visualisation of 150-5000 base pairs, whereas PFGE 
thorough the digestion of the entire genome visualises 50,000 to 500,000 base pairs.  These 
typing techniques subjective to different selective pressures therefore effect the defined cut-
off values used for interpretative criteria for isolate relatedness (Fluit et al., 2010).  The rep-
PCR web-based DiversiLab software, however, facilitates comparative genotypic analysis of 
the large data set generated to assess clonal relatedness between all the CoNS isolates. 
Such generated rep-PCR fingerprints allowed comparative assessment of detailed genetic 
variability based on the difference in DNA sequences between and within groups of similar 
species-specific isolates (Healy et al., 2005; Shutt et al., 2005).  Hence, result analysis 
comparing rep-PCR CoNS fingerprints highlighted the heterogenic nature of the CoNS 
isolates, as multiple genotypes were observed within CoNS species-specific isolates from 
both patient groups.  These results were concordant with PFGE DNA band analysis but on a 
larger scale, whereby several different clusters of the CoNS species-species isolates 
comprised of similar diverse genotypes.  Moreover, some clonal relatedness with rep-PCR 
fingerprint profiling was also observed between some species-specific isolates from each of 
the patient groups.  More importantly, similar levels of clonal relatedness were however not 
apparent between in-patient and control patient group CoNS isolates with both typing 
techniques which demonstrated the presence of diverse genotypes. 
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It is evident from this study that the genotypically dissimilar CoNS isolates from bacteraemic 
patients and the skin colonisers are unlikely to be derived from common ancestral clones.  
Nonetheless, it can perhaps also be envisaged that these clones may have undergone 
random genetic alterations including point mutations and insertion and deletions of DNA 
during the course of infection hence resulting in distinct clonal types.  Hence, investigation 
facilitated by the two molecular typing tools in this study exploring the clonal relatedness of 
CoNS isolates present on the skin as the potential source of bacteraemic infection, 
demonstrated the presence of clonally diverse isolates.  
3.6 Conclusion 
CoNS normally identified as skin commensals and their potential role as pathogens 
associated with nosocomial bacteraemia in patients with haematological malignancies are 
increasingly being recognised.  Although endemic transmission of nosocomial pathogens in 
the hospital environment are often poorly defined, some epidemiological, clinical and 
molecular relatedness studies have supported the assumption that translocation of isolates 
from the skin may be associated with BSIs in the immunocompromised host.  Moreover, 
recent literature indicates that genotypic methods providing highly accurate level of clonal 
delineation can be used to evidence the pathogenic potential of various CoNS species. 
The two molecular typing techniques used in this study to distinguish and characterise both 
in-patient BSI isolates and skin-colonising isolates demonstrated a high degree of genotypic 
diversity.  Prevalent genotypic diversity within and between the same CoNS species-specific 
isolates was more evident in isolates of S. epidermidis, S. hominis and S. haemolyticus 
recovered from both patient groups.  However, a degree of clonal relatedness was evident 
within some of the same CoNS specie-specific isolates from the in-patient group.  
Conversely, there was little evidence of clonal relatedness between in-patient and control 
patient CoNS species-specific isolates which further underscores the heterogenic nature of 
these diverse variants.  The apparent clonal diversity within and between species-specific 
isolates of CoNS provides some evidence that dissemination of skin colonisers in association 
with bacteraemia is limited and therefore, skin as the source of infection may be unlikely.  
In summary, the lack of association between CoNS skin-colonising strains and those 
recovered from in-patient group supports the hypothesis, that skin-colonising strains are 
unlikely to be the primary source of CoNS-associated bacteraemia in the haematology and 




Chapter 4 Comparison of antibiotic resistance profiles of coagulase negative isolates 
(CoNS) recovered from blood cultures of patients with bacteraemia with skin-
colonising strains isolated from the pre-admission patient group. 
4.1 Introduction  
Patients with haematological malignancies and those, undergoing allogeneic stem cell 
transplantation are at an increased risk of acquiring infections due to the profound 
impairment of their immune system.  Due to the wide use of prophylactic antibiotics and 
indwelling venous catheters, CoNS have emerged as the most frequently blood-isolated 
pathogen associated with primary bacteraemia in many cancer centres (Collin et al., 2001; 
Wisplinghoff et al., 2003). 
CoNS infections may be attributable to endogenous strains from patient’s normal flora, the 
hospital environment or transmitted among hospitalised patient populations.  Reports relating 
to the incidence of antimicrobial resistance associated with nosocomial CoNS in-patient 
infections in immunocompromised patients have increased dramatically (Becker et al., 
2014).  These have mainly been linked with CoNS strains possessing multiple antimicrobial 
resistance mechanisms in particular, resistance to methicillin (Huebner and Goldmann 1999; 
Henwood et al., 2000; Syndor and Perl, 2011).  Methicillin, as an antibiotic of first choice 
against staphylococcal infections, poses a major problem, particularly in nosocomial strains 
of S. epidermidis demonstrating resistance rates of up to 75-90% (Otto, 2009).  Therefore, 
for better prognosis, the recommended empirical therapeutic agents for such serious 
staphylococcal infections in most healthcare settings are the cyclic glycopeptides (Menchetti, 
1992; Yamada et al., 2017).   
Currently, of the glycopeptides, vancomycin remains the drug of choice for the treatment of 
BSIs caused by multidrug resistant CoNS (Diekema et al., 2001 Natoli et al., 2009).  Until 
recently, there were few reported cases of vancomycin resistance in clinically important 
isolates of CoNS, however events associated with hospitalisation and increased vancomycin 
use are thought to be associated with emergence of resistance.  Of the CoNS, glycopeptide 
resistance is the most commonly observed in isolates of S. haemolyticus (Veach et al., 1990; 
Biavasco et al., 2000; Tabe et al., 2001).  Other species associated with emerging 
glycopeptide resistance include S. epidermidis, S. warneri and S. hominis (Ma et al., 2011).  
Additionally, heterogeneous forms of glycopeptide resistance may also be present in some 
CoNS isolates; however, due to the presence of specific resistance mechanisms, their 
detection, clinical and therapeutic relevance still remains challenging (Wong et al., 1999; 
Biavasco et al., 2000: D’mello et al., 2008). 
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Although the prevalence of glycopeptide resistance amongst clinical isolates of CoNS has 
shown an upward trend, their association with clinical outcome has nonetheless been 
infrequently reported, due mainly to the poor pharmacokinetic properties and dose 
optimisation of the drug (Tacconelli et al., 2001; Natoli et al., 2009; Ahlstrad et al., 2011).  
Increasing multidrug resistance among CoNS and the possible emergence of vancomycin 
resistant strains has led to the need for newer antimicrobials as alternatives agents to 
improve clinical outcomes and avoid the development and spread of antibiotic resistance 
(Harbarth et al., 2003; Falcone et al., 2015).  Of the newer antimicrobial agents, daptomycin 
has been shown to have excellent activity against all species of CoNS, with few cases of 
reported resistance (Sakoulas et al., 2014).  The proven clinical efficacy and safety of 
daptomycin with few adverse effects may therefore prove to be a favourable alternative for 
the treatment of serious CoNS infections in the immunocompromised host (Steenbergen et 
al., 2009; Chaftari et al., 2010; Sader and Jones, 2012).   
As acquired bacteraemia in the haematology patient carries a poor prognosis, information 
regarding the susceptibility patterns of infective agents can therefore be invaluable in aiding 
selection of appropriate empirical regimens for therapeutic success.  The introduction and 
use of new antibiotic classes also represents an important contribution to limiting resistance 
development and spread. 
 
4.2 Aims of this study 
 
(a) To assess the in-vitro antimicrobial susceptibility patterns of well-characterised 
CoNS isolates recovered from blood cultures of patients on the haematology and BMT 
unit in comparison to skin colonising strains from the pre-admission patient (control) 
group. 
(b) To investigate the minimum inhibitory concentrations (MICs) of a panel of 18 
antimicrobial agents against CoNS isolates from both the in-patient and control patient 
groups. 
(c) To evaluate and compare the glycopeptide MICs of in-patient CoNS isolate MICs 
using two validated susceptibility test methodologies. The MICs for vancomycin and 
teicoplanin obtained with the automated VITEK®2 system were compared to the MICs 
obtained for the glycopeptides using the standard E-test gradient methodology. 
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(d) To evaluate the prevalence of reduced glycopeptide susceptibility 
(Intermediate/heteroresistance) amongst CoNS isolates recovered from bacteraemic 
patients using two different susceptibility testing techniques.  
(e) To determine the MICs of in-patient CoNS isolates to the newer antimicrobial 
agents, including daptomycin, tigecycline and ceftaroline using standard E-tests. 
 
4.3 Materials and Methods 
One hundred bacteraemic isolates of CoNS together with 100 skin colonising CoNS isolates 
from the pre-admission patient group were tested for susceptibility using current standard 
laboratory protocols.  All the CoNS isolates previously characterised by conventional 
biochemical tests using the VITEK®2 system (Chapter 2 section 2.4) saved on Microbank™ 
beads at -20°C were sub-cultured twice onto Columbia blood agar, incubated at 37°C hours 
in ambient atmosphere to recover viable colonies.   
4.3.1 Antimicrobial susceptibility testing using the automated VITEK® 2 system 
Automated antimicrobial susceptibility testing (AST) of the CoNS isolates, to a panel of 18 
antimicrobials, was undertaken using the Gram-Positive AST P575 and the updated P578 
(2012) susceptibility card (bioMérieux, Marcy l’Etoile, France).  In accordance with the 
manufacturer’s product literature, the updated AST-578 susceptibility card validated for 
routine use, includes an improvement in the formulation of two antibiotics, vancomycin and 
erythromycin.  The MIC ranges of these two antibiotics were extended to allow greater 
accuracy of resistance detection.  
A bacterial suspension of 0.5 McFarland standard, was prepared in 3ml sterile saline solution 
(aqueous 0.45 w/v NaCl, pH 7 bioMérieux, France) and used to load the test cards in 
accordance with the manufacturer’s instructions.  The bacterial suspension was further auto-
diluted to give a final density of 1.5 x 107 CFU/mL after the AST cards were placed into the 
VITEK® 2 system.  The cards were then automatically filled, sealed and inserted into the 
system incubator-reader module at an ambient temperature of 37°C in accordance with the 
manufacturers User-Manual instructions (VITEK®2 systems product information 410791).  
The VITEK®2 automated system susceptibility testing results were based on fluorescence 
measurements performed every 15 minutes for up to 18 hours and automatically analysed 
with the installed VITEK®2 software which is also interfaced with the laboratory informatic 
system.  The updated Global European-based phenotypic EUCAST interpretative guidelines 
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were automatically applied in compliance with the manufacturers installed VITEK®2 software 
version 25; 5.04 (2011). 
The panel of 18 antimicrobials contained in the VITEK®2 - AST P575 card included the β-
lactams, aminoglycosides, macrolides, fluroquinolones, glycopeptides, tetracyclines, 
trimethoprim, fuscidic acid (Fucidin), mupirocin, chloramphenicol, and rifampicin.  The 
concentrations of the tested antibiotics ranged from 0.125 to 32mg/L.  The quality control 
strain S. aureus ATCC 29213 was tested concurrently with each batch analysis as 
recommended by the manufacturer's product protocol. 
4.3.1.2 Data analysis of antibiogram patterns 
Following analysis of the MICs determined by the VITEK®2 automated system susceptibility 
results of tested CoNS isolates were categorised and reported as susceptible, intermediate, 
or resistant based on the installed software EUCAST (2010) interpretative criteria.  Primary 
antibiogram analysis was carried out based on resistance profiles. 
Computer assisted analysis of antibiograms was further carried out by converting the 
antibiotic resistance patterns of CoNS isolates into TIFF file format.  These files were 
imported into the BioNumeric software database as fingerprint types and processed by 
definition, of fingerprint lanes, optimisation of the densitometric curves and normalisation of 
resistance patterns (Gelcompar 2 version 5.1: Applied Maths, Belgium).  Further data 
analysis of the antibiotic resistant fingerprint patterns was carried out using dice coefficient 
and UPGMA.  Antimicrobial resistance patterns with a dice coefficient of ≥95% were 
assigned as similar types (StatSoft Inc, 2011). 
 
4.3.2 Antimicrobial susceptibility testing using standard E-test methodology 
For quantitative antimicrobial susceptibility testing the Epsilometer-test (E-test) antibiotic 
gradient strips (AB Bodisk, Solna, Sweden; AB bioMérieux, Marcy-I’Etoile, France) were 
used.  These E-test strips at a predefined concentration gradient of antibiotic across 15 two-
fold dilutions from 0.016 to 256mg/L, impregnated with vancomycin, teicoplanin daptomycin 
and tigecycline, were used to determine the MICs of the 100 CoNS isolates recovered from 
bacteraemic patients.  Likewise, for ceftaroline MIC evaluation, the M.I.C.E 
(M.I.C.EvaluatorTM  Oxoid, UK), test strips at an antibiotic concentration gradient of 0.015 to 
256mg/L were used. 
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An inoculum of 0.5 McFarland density-adjusted suspension, of colonies from pure culture 
was prepared for each CoNS test isolate in 0.45% w/v sterile saline solution equating to 
microbial concentration of 1.5x108cfu/mL.  In accordance with the recommended BSAC 
methodology (2012), a sterile swab was dipped into the prepared inoculum and rolled firmly 
against the side of the inoculum tube to remove excess inoculum.  For each test isolate, the 
entire surface of a 90mm Mueller-Hinton sensitivity test agar (bioMérieux, France) plate was 
streaked evenly in a three-way direction, each time rotating the plate 60 degrees to achieve 
even distribution of the inoculum.  The inoculum was then allowed to be absorbed into the 
agar for 10 minutes prior to applying the E-test strips.  Two antibiotic E-test strips were used 
per sensitivity plate following the manufacturers recommended protocol (ETEST® Application 
Sheet EAS 300 bioMérieux SA Marcy-I’Etoile France 2011/06).  The susceptibility plates 
were incubated at 37°C for 18 hours in ambient atmosphere.  Vancomycin, teicoplanin, 
daptomycin and tigecycline MIC values were read at the interaction point of growth inhibition 
with the E-test gradient strip.  
Ceftaroline sensitivity was tested using Mueller-Hinton plus 5% horse blood susceptibility 
agar (bioMérieux, France) as recommended by the manufacturer.  The MIC values, with the 
M.I.C.E test strip were determined nearest the concentration value at the point above the 
growth/inhibition interaction. 
Two control strains, S. aureus ATCC 29213 and S. epidermidis ATCC 12228 were 
concurrently tested with each test batch.  The sensitivity test plates were incubated at 37°C 
for 18 hours in ambient atmosphere. 
During the initial part of this study, BSAC susceptibility interpretive criteria were applied 
(Reference E-Test Application Sheets EAS 16029 D-2011/06: Staphylococci).  Further to 
this, the updated, recommended EUCAST susceptibility interpretive criteria guidelines were 
applied for determination of MIC values (www.eucast.org).  The VITEK®2 global automated 
susceptibility result interpretation rule base criteria for detecting and reporting vancomycin 
resistance for all staphylococcal species was determined at MIC >2mg/L in accordance with 
the implemented VITEK®2 software.  Conversely, for further data analysis the breakpoint MIC 
value of >4mg/L for vancomycin was applied in accordance with the EUCAST (2010 v. 2.1) 
clinical breakpoints for all CoNS isolates.   
4.3.2.1 Detection of heteroresistance using the modified E-test macro-method 
The presence of heterogeneously glycopeptide-intermediate staphylococci (hGIS) among the 
100 in-patient CoNS isolates was determined using the modified macro-method as 
previously described (Wootton et al., 2007). 
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The macro-method E-test was performed using a 2 McFarland standard turbidity suspension 
prepared in 0.5% w/v sterile saline solution equating to a bacterial concentration of 6 x108 
cfu/mL.  For each CoNS test isolate, a 200µL suspension was used to inoculate the surface 
of BHI agar (Brain Heart Infusion Agar; bioMérieux, France).  The inoculum was spread in a 
three-way direction across the whole surface of the agar plate using a sterile swab. The 
inoculum was allowed to absorb into the agar for 15 minutes prior to applying the 
vancomycin and teicoplanin E-test strips in accordance with the manufacturers 
recommended protocol (ETEST® Application Guide 16273B-EN 2012).  The inoculated BHI 
agar plates were incubated at 37°C for 24 hours in ambient atmosphere and MICs confirmed 
at 48 hours.   
The vancomycin MIC values were read at the interaction of growth with the E-test strip, 
looking for slower growing sub-populations presenting as hazes of growth including the 
presence of both micro-colonies and smaller, isolated variant colonies.  This procedure for 
observing presence of such colonies was carried out under oblique light aided by a 
magnifying glass.  Similarly, teicoplanin MIC values were read at the interaction of growth 
with the E-test strip.  EUCAST (2011) interpretative criteria for MIC breakpoints were applied 
for susceptibility categorisation. 
The following control strains were included in each susceptibility batch test; S. aureus ATCC 
29213 and the two glycopeptide resistant strains Mu50 ATCC 700699 (GISA) and Mu3 
ATCC 700698 (hGISA).   These control strains were obtained from the Bristol Centre for 
Antimicrobial Research and Evaluation, Southmead Hospital, Bristol, UK. 
 
4.3.2.2 Detection of glycopeptide resistance and heteroresistance using the GRD E-
test  
The double sided, Glycopeptide Resistance Detection (GRD) E-test prototype is unavailable 
for clinical use but is currently available for research purposes only.  These GRD E-tests are 
a potential screening method for the detection of the slow growing hGIS strains that also 
display a pronounced resistance to teicoplanin.  In accordance with the manufacturer’s 
recommendations, the GRD E-test strip with double sided vancomycin (VA) and teicoplanin 
(TP) with concentration gradients across seven two-fold dilutions of 0.5-32mg/L was tested 
with an inoculum of 0.5 McFarland standard.  For each CoNS test isolate, 20µL of prepared 
suspension was used to inoculate Mueller-Hinton plus 5% horse blood susceptibility agar 
plates (bioMérieux, France).  The inoculum was streaked evenly across each test plate and 
allowed to be absorbed for 15 minutes before applying the GRD E-test strip.  Plates were 
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incubated at 37°C for 24 hours in ambient atmosphere and the results were read at 24 hours 
and confirmed after 48 hours to detect delayed resistance.  The S. aureus ATCC 29213 
control strain was set up concurrently with each test batch GRD E-test VA:TP with specified 
quality control ranges of 0.5-2mg/L and 0.5-4mg/L respectively (www.eucast.org).  The two 
glycopeptide resistant control test strains Mu50 (GISA) and Mu3 (hGISA) were also included 
in each test batch. 
Agreed interpretive standards are currently unavailable for heterogenous-intermediate 
resistance CoNS.  Therefore, interpretation of the GRD results were used for CoNS in 
accordance with the manufacturers reading guidelines.  The criteria for which are based on 
the previously described definitions for S. aureus as stated in their Research Use Only 
(RUO), 2012, instruction leaflet (Supplement GRD RUO, bioMérieux, France).  The E-test 
MIC cut-off values were read at the point of complete inhibition of growth. The recommended 
protocol for the interpretative endpoints defined for the phenotypic detection of glycopeptide 
resistance with the E-test GRD strips for CoNS read at 24 and 48 hours were applied as 
follows: (a) E-test GRD plus VAN or TEI cut-off values of ≥16mg/L result would indicate 
GIS/hGIS; (b) Glycopeptide intermediate resistance result  would be indicated with E-test 
GRD TEI or VAN MIC value of ≥16mg/L and a standard E-test VAN MIC value of ≥8mg/L (c) 
hGIS resistance result would be indicated with E-test GRD TEI or VAN MIC value of ≥16mg/l 
and a standard E-test VAN MIC of <8mg/L. 
 
4.4 Statistical Analysis 
Descriptive statistical analysis was performed using the existing software packages 
(STATISTICA version 10 and IBM® SPSS® Statistic version 24).  Comparison of categorical 
variables was carried out using the Chi-square or Fisher exact test.  The difference in the 
prevalence of each CoNS species antimicrobial resistance rates and between patient groups 
were analysed using the two-tailed Fisher’s exact test and the non-parametric comparisons 
of antimicrobial susceptibilities were performed by Freemans Test.  The Friedman test was 
used to determine the differences between the antibiotics, patient groups and the techniques 
used for evaluation of MICs.  The difference in frequency of resistance distribution and 
glycopeptide MICs were analysed using the non-parametric two-tailed Mann-Witney U Test.  
Statistical significance were represented by p value of <0.05.   
R version 3.5.3 (2019-03-11) -- "Great Truth" Copyright (C) 2019.  The R Foundation for 
Statistical Computing Platform: i386-w64-mingw32/i386 (32-bit) was used to construct 
logistic regression models to compare the proportion of CoNS species inhibited as a function 
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of antibiotic concentration, the glycopeptide type, CoNS species type and the two test 
methodologies used. (Data analysis: courtesy of Biomedical Statistician - Dr Martyn 
Wilkinson) 
Data analysis of the phenotypic susceptibility antibiograms of CoNS species isolate 
comparisons were carried out by calculations of dice coefficient and clustering was 
performed by UPGMA to construct dendrograms.  Analysis was performed using the 
StatSoft, Inc. (2011) STATISTICA version 10 (USA) Software package. Gelcompar 2 version 
5.1 (Applied Maths, Belgium). 
 
4.5 Results 
4.5.1 VITEK®2 automated susceptibility testing of CoNS isolates to a panel of 18 anti-
staphylococcal agents 
The VITEK®2 is the AST methodology system currently in-use in routine clinical microbiology.  
In total, phenotypic antibiotic resistance profiles were evaluated for the 100 CoNS isolates 
from both the in-patient and the pre-admission control patient group.  These isolates were 
previously identified to the species level by VITEK®2 bio-analysis.  In accordance with the 
EUCAST guidelines for VITEK®2 automated AST system, susceptibility to oxacillin was used 
to determine methicillin resistance.  For the purposes of this study, the prescribed active 
isoxazole penicillin antimicrobial agent namely, flucloxacillin is the terminology also used to 
describe susceptibility to oxacillin (methicillin).  Assessments based on the quantitative MIC 
results of each antimicrobial tested were categorised as susceptible, intermediate or resistant 
in compliance with the computer software installed global EUCAST (2010) susceptibility 
interpretive criteria guidelines. 
Comparative analysis of the overall resistance profiles of the 100 CoNS isolates from both 
the in-patient and control patient groups to the panel of 18 anti-staphylococcal agents tested 




Figure 4-1: Comparison of antibiotic resistant profiles of CoNS isolates from both, the 
in-patient and control patient groups against a panel of 18 antibiotics using the 
VITEK® 2 automated micro-dilution methodology. Antibiotic code abbreviations: CHL 
(Chloramphenicol), CIP (Ciprofloxacin), ERY (Erythromycin), FLU (Flucloxacillin), FUS 
(Fusidic Acid), GEN (Gentamicin), PEN (Penicillin), RIF (Rifampicin), TEI (Teicoplanin), 
TET (Tetracycline), TOB (Tobramycin), TRI (Trimethoprim), VAN (Vancomycin), TIG 
(Tigecycline), CLI (Clindamycin), KAN (Kanamycin), LIZ (Linezolid), MUP (Mupirocin). 
Of the 18 antimicrobials tested by VITEK®2, in both patient groups, tigecycline was observed 
to be the most active compound followed also by linezolid as the most active in the in-patient 
group only.  Overall, resistance was more apparent to the 18 antibiotics tested in the in-
patient group in comparison to the resistance profiles displayed by the control patient group 
isolates.  Reviewing resistance rates of all the 100 CoNS isolates from both patient group 
CoNS isolates, the comparative lowest rates of resistance to specific antibiotic groups 
differed considerably.  In the in-patient group isolates, the lowest rates of resistance were 
observed to the three antibiotics, mupirocin (1%), vancomycin (1%) and chloramphenicol 
(3%), with no resistance observed to linezolid.  Conversely in the control patient group CoNS 
isolates, the lowest, 1% resistance was observed to four antibiotics, chloramphenicol, 
vancomycin, rifampicin and linezolid.  Resistance to the aminoglycosides, gentamicin, 
kanamycin and tobramycin was observed to be just over 55% in the in-patient group 
compared to 11% resistance in the control patient group.  Overall, penicillin resistance was 
observed to be consistently high (>80%) in both patient group CoNS isolates. 
The Friedman test was used to determine the significance of observed difference between 
the overall distribution of antimicrobial resistance to the panel of 18 antibiotics and CoNS 
isolates from the in-patient group in comparison to the control patient group.  Test analysis 
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frequency of antimicrobial resistance to the 18 agents displayed by CoNS isolates from both 
the in-patient and control patient groups. 
Flucloxacillin or methicillin resistance was noted to be higher in the in-patient CoNS isolates 
in comparison to the control patient group (78% and 28% respectively).  The Mann-Whitney 
U test was applied to determine the significance of observed difference between CoNS 
isolates from the in-patient group and the control patient groups and distribution frequency of 
methicillin resistance as the single variable factor.  The results reveal a significant difference 
in distribution frequency of methicillin resistance between the in-patient and control patient 
CoNS isolates (p = 0.0001). 
Following data analysis using similar microbiological criteria, results from the total 100 CoNS 
species-specific isolates tested for each of the patient groups and the proportional number of 
resistant isolates to the panel of 18 antimicrobials are summarised in Tables 4-1 and 4-2. 
  
 
VITEK®2: Gram-Positive Antibiotic Panel – Number of Resistant 

























































S. epidermidis (n=57) 1 45 45 50 39 35 57 7 18 40 34 45 0 0 42 35 0 1 
S. hominis (n=18) 0 7 14 12 10 6 17 1 2 10 7 13 0 0 13 7 0 0 
S. haemolyticus (n=16) 2 15 14 15 7 14 16 1 3 14 13 14 1 0 12 14 0 0 
Other CoNS (n=9) 0 0 2 1 3 0 5 1 0 1 0 1 0 0 2 0 0 0 
Table 4-1: Number of in-patient group CoNS species-specific isolates resistant to each 
antibiotic tested against a panel of 18 antibiotics using the automated micro-dilution 
VITEK®2 system.  
 
  
                         
VITEK®2: Gram-Positive Antibiotic Panel – Number of Resistant 

























































S. epidermidis (n=32) 1 5 18 11 24 2 30 1 19 15 3 9 1 0 10 3 1 5 
S. hominis (n=24) 0 1 13 5 17 1 21 0 1 15 1 4 0 0 8 1 0 2 
S. haemolyticus (n=17) 0 4 9 9 7 8 12 0 8 9 5 9 0 0 3 5 0 1 
Other CoNS (n=27) 0 0 7 3 7 0 17 0 2 6 0 7 0 0 6 0 0 2 
Table 4-2: Number of control patient group CoNS species-specific isolates resistant to 
each antibiotic tested against a panel of 18 antibiotics using the automated micro-
dilution VITEK®2 system. 
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Similar to the overall antimicrobial results obtained for in-patient and the control patient 
groups, the number of species-specific CoNS isolates resistant to the panel of 18 
antimicrobials were observed to be variable dependent on the antibiotic/CoNS species-
specific combination.  As such, penicillin resistance was more apparent in isolates of S. 
epidermidis in both patient groups in comparison to the other CoNS species.  Conversely, 
the least resistant were the CoNS species comprising the other minor group of CoNS 
isolates.   
The Friedman Test used to determine any significant association between CoNS species-
specific isolates and patient group revealed that there was a significant association between 
the antimicrobial resistant profiles of S. epidermidis, S. hominis and S. haemolyticus to the 
18 antibiotics and the patient group from which they were isolated from (p <0.0001 with 1df).  
Analysis carried out based on pairwise comparisons of species-specific CoNS isolates for the 
in-patient group revealed there was a significant difference between the frequency 
distribution of antimicrobial resistance observed in the other minor group of CoNS and 
isolates of S. epidermidis, S. hominis and S. haemolyticus (p ≤0.001).  Conversely, for the in-
patient species-specific isolates there was no significant difference observed between 
isolates of S. hominis and S. epidermidis and the frequency distribution of antimicrobial 
resistance (p = 0.369 and 0.35 respectively).  Likewise, no significant difference between 
isolates of S. epidermidis or S. haemolyticus and the overall frequency of antimicrobial 
resistance against the panel of 18 antibiotics tested (p >0.05).  For the control patient group 
isolates no statistically significant differences were observed between the frequency 
distribution of antimicrobial resistance and any of the species-specific CoNS isolates (p 
>0.05).  The notable exception was the resistance frequency observed between other minor 
group of CoNS isolates and S. haemolyticus similar to that also observed for methicillin 
resistance (p = 0.003).  There was an overall significant association between the distribution 
frequency of methicillin resistance and all species-specific CoNS isolates with the exception 
of the other minor CoNS species isolates from both in-patient and the control patient groups 
(p <0.0001).  The other minor group of CoNS isolates in both patient groups demonstrated 
least resistance to methicillin. 
Data analysis was further carried out to assess phenotypic relationship of the CoNS species 
isolates from each of the patient groups expressing comparable resistance profiles to 
determine clonal similarity. 
Results of the comparative assessment of the CoNS species antibiogram resistant profile 
analysis from each patient group using PCA with cluster analysis (UPGMA) carried out to 
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distinguish related CoNS species isolates based on antibiotic resistance profiles are 
represented in Figures 4-2 and 4-3. 
 
4.5.2 Data Analysis of the antibiotic profiles using Pearsons-Principle Component 
Analysis (PCA) with Unweighted Pair Group Method with Arithmetic Mean (UPGMA) 
Phenotypic antibiotic resistance profiles for the 100 CoNS isolates from each of the patient 
groups were further analysed using PCA with UPGMA using the Statisca v.10 Bionumeric 
Software package.  Analysis was performed based on levels of similarity or differences of 
antimicrobial resistance patterns between all the species-specific CoNS isolates.  A cut-off 
value of >95% indicating antibiotic resistance profiles to be identical therefore indicating 
antibiogram CoNS isolate similarity. 
Figures 4-2 and 4-3 represent dendrogram constructs of the antimicrobial resistance profiles 
of the previously characterised 100 CoNS isolates from the in-patient and control patient 
group respectively.  Computer assisted cluster analysis by UPGMA based on antimicrobial 
susceptibility similarity matrices did not identify any major phenotypic clusters.  For each 
patient group isolates the results demonstrated a greater number of unique antimicrobial 
resistance profiles with little similarity (cut-off value set at ≥ 95%). 
The UPGMA dendrogram analysis revealed a high degree of antibiotic resistance pattern 
variability within and between CoNS isolates and among isolates of the same species.  A 
higher degree of diversity was observed to be in and amongst the different species of the in-
patient CoNS isolates in comparison to the skin colonising control patient group isolates.  In 
both patient groups, a few isolates of the same CoNS species were indistinguishable.  
Furthermore, the isolates showing 100% antimicrobial resistance profile similarity, grouped 









Figure 4-2: Phenotypic relatedness of 100 in-patient group CoNS: Dendrogram based 
on Vitek®2 antibiotic analysis using Dice coefficient UPGMA method.  The scale bar at 
















Figure 4-3: Phenotypic relatedness of 100 control patient group CoNS: Dendrogram 
based on Vitek®2 antibiotic analysis using Dice coefficient UPGMA method.  The scale 
bar at the top represents the cut-off value set at >95%. 
 
 





























































































































































4.5.2.1 Interpretation of PCA antibiogram data analysis 
For each of the patient groups 100 CoNS isolates dendrograms constructed using UPGMA 
to investigate species-specific isolates in relation to their antibiotic resistance profiles 
revealed very few definitive clusters.  The levels of similarity of CoNS isolates calculated with 
Dice coefficient and grouped by UPGMA were predominantly less than the cut-off value set 
at 95% for similarity antibiogram profile determination.  In both patient groups, species-
specific CoNS isolates did not group together in large defined clusters in any particular part 
of the dendrogram axis. 
Overall CoNS phenotypic relatedness based on antibiogram resistance profiles, determined 
by means of UPGMA dendrogram analysis among the 100 in-patient CoNS isolates, 
revealed 66 different antibiogram profiles as illustrated in Figure 4-2.  Overall, 100% similarity 
correlation was observed in 50% of the isolates independent of the CoNS species type.  Of 
these 50%, identical antibiogram profiles were observed in seventeen small isolate groups.  
The largest two profile groups (a) and (b), Figure 4-2 consisted of five CoNS isolates 
whereas the smallest groups showing 100% antibiogram relatedness consisted of two 
isolates each.  In profile group (b) all the five isolates showing 100% similarity were isolates 
of S. epidermidis whereas profile group (a) comprised of four isolates of S. epidermidis and 
one of S. hominis with 100% identical resistance antibiograms.  Likewise, the other smaller 
profile groups also consisted of dissimilar CoNS species showing 100% antibiogram 
relatedness. As such, undistinguishable antibiograms were observed in four isolates in profile 
group (c) comprising of two strains of S. haemolyticus A39 and A86 and one isolate each of 
S. hominis and S. epidermidis.  Greatest species diversity with indistinguishable 
antibiograms was observed in profile group (d) consisting of Kocuria varians, S. capitis, S. 
epidermidis and S. hominis.  Except for one small group consisting of two different CoNS 
species with identical antibiograms, which included S. hominis (A2) and S. warneri (A41).  
The other small groups were represented predominantly by S. epidermidis isolates. 
The diversity observed within species-specific CoNS isolates based on antibiogram 
relatedness was even greater in the control patient group.  Results revealed 13 small groups 
consisting of 45 isolates independent of species-specific CoNS, demonstrating 100% 
identical antibiogram profiles.  Of the 100 CoNS isolates analysed, 68 different antibiogram 
profiles were observed in the control patient group isolates.  The largest of the groups 
showing 100% similarity was profile group (a) Figure 4-3 consisting of 11 isolates in total, 
comprising four different species-specific CoNS isolates.  This profile group included seven 
isolates of S. capitis, two of S. hominis and one each of S. epidermidis and S. simulans.  
Profile groups (b) and (c) consisted mainly of S. hominis isolates sharing indistinguishable 
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antibiogram resistant profiles with isolates of S. epidermidis and S. warneri.  However, in 
profile group (d) only one isolate of S. hominis displayed 100% similarity to one isolate each 
of S. epidermidis and S. lugdunensis.    
The rest of the ten smaller profile groups in the control patient CoNS isolates revealed a high 
degree of both species and strain diversity within each of the small groups showing 100% 
antibiogram based strain relatedness.  Overall, comparison of UPGMA dendrogram cluster 
analysis results based on the antibiograms using PCA factor analysis demonstrated a lack of 
antibiotic susceptibility pattern association or correlation between and among isolates of the 
same CoNS species in both patient groups. 
 
4.5.2.2 Antibiotic resistance rates among species-specific CoNS isolates 
Further to the total number of resistant CoNS species-specific isolates from both patient 
groups, (Table4-1 and 4-2), the percentage resistance rates exhibited by S. epidermidis, S. 
hominis, S. haemolyticus and the other minor group of CoNS species to the 18 antimicrobials 
are summarised in Figure 4-4 for the in-patient group and Figure 4-5 for the control patient 
group. 
 
Figure 4-4: Percentage number of S. epidermidis, S. hominis, S. haemolyticus and the 
other CoNS species in-patient group isolates resistant to each antibiotic tested 
against a panel of 18 antibiotics using the automated micro-dilution VITEK®2 system. 
The proportion of CoNS species-specific isolates resistant to all the classes of antibiotics 






















CHL CIP ERY FLU FUS GEN PEN RIF TEI TET TOB TRI VAN TIG CLI KAN LIZ MUP
S.epidermidis (n=57) 2% 79% 79% 88% 67% 61% 100% 12% 32% 70% 60% 79% 0% 0% 74% 61% 0% 2%
S. hominis (n=18) 0% 39% 78% 67% 56% 33% 94% 6% 11% 56% 39% 72% 0% 0% 72% 39% 0% 0%
S. haemolyticus (n=16) 13% 94% 88% 94% 44% 88% 100% 6% 13% 88% 81% 88% 6% 0% 75% 88% 0% 0%
Other CoNS (n=9) 0% 0% 22% 11% 33% 0% 56% 11% 0% 11% 0% 11% 0% 0% 22% 0% 0% 0%
I n - P a t i e n t  G r o u p :  P e r c e n t a g e  n u m b e r  o f  e a c h  C o N S  s p e c i e s  
i s o l a t e s  r e s i s t a n t  t o  a  p a n e l  o f  1 8  a n t i m i c r o b i a l s
177 
 
comparison, the lowest overall resistance rates were observed in the other minor group of 
CoNS in both patient groups comprising species including, S. capitis, S. warneri, S. 
lugdunesis, S. auricularis, S. simulans, Kocuria species and Dermococcus. 
Primary data analysis based on the reported susceptibilities of the in-patient CoNS isolates 
to the clinicians indicate high rates of penicillin resistance amongst all the three predominant 
CoNS species.  Nonetheless, relatively similar rates of penicillin resistance were also noted 
amongst the control group skin colonising isolates.  Although, proportionally similar rates of 
penicillin resistance were observed in both patient group isolates, 100% resistance was only  
exhibited by the in-patient S. epidermidis (n=57) and S. haemolyticus (n=16) isolates.  
Conversely, the percentage of isolates demonstrating proportionally higher penicillin 
resistance rate were the other minor group of CoNS species-specific isolates from the control 
patient group in comparison those of the in-patient group (27)63% and (9)56% respectively.   
Figure 4-5: Percentage number of control patient group isolates of S. epidermidis, S. 
hominis, S. haemolyticus and the other CoNS species resistant to each antibiotic 
tested against a panel of 18 antibiotics using the automated micro-dilution VITEK®2 
system. 
Overall, VITEK®2 system analysis of antimicrobial profiles for the species-specific strains of 
CoNS show that although the most frequently isolated species was S. epidermidis in both 
patient groups, proportionally, the most resistant were isolates of S. haemolyticus.  Likewise, 
variable and lower resistance rates were observed to each of the antibiotic classes amongst 
isolates of the three predominant CoNS species in the control patient group in comparison to 




























CHL CIP ERY FLU FUS GEN PEN RIF TEI TET TOB TRI VAN TIG CLI KAN LIZ MUP
S. epidermidis (n=32) 3% 16% 56% 34% 75% 6% 94% 3% 59% 47% 9% 28% 3% 0% 31% 9% 3% 16%
S. hominis (n=24) 0% 4% 54% 21% 71% 4% 88% 0% 4% 63% 4% 17% 0% 0% 33% 4% 0% 8%
S. haemolyticus (n=17) 0% 24% 53% 53% 41% 47% 71% 0% 47% 53% 29% 53% 0% 0% 18% 29% 0% 6%
Other CoNS (n=27) 0% 0% 26% 11% 26% 0% 63% 0% 7% 22% 0% 26% 0% 0% 22% 0% 0% 7%
C o n t r o l  P a t i e n t  G r o u p :  P e r c e n t a g e  n u m b e r  o f  e a c h  C o N S  
s p e c i e s  i s o l a t e s  r e s i s t a n t  t o  a  p a n e l  o f  1 8  a n t i m i c r o b i a l s
178 
 
the panel 18 antibiotics tested, displayed similar activity against all the CoNS isolates in both 
patient groups.  As such, of the aminoglycoside class of antibiotics, resistance to gentamicin, 
tobramycin and kanamycin was observed to be highest amongst isolates of S. haemolyticus 
followed by S. epidermidis and S. hominis in both patient groups.  Likewise, for both patient 
groups, the other minor group of CoNS species displayed complete susceptibility to all the 
aminoglycosides.  Similarly, higher resistance activity was observed with the macrolides, 
erythromycin and clindamycin among isolates of S. haemolyticus, S. epidermidis and S. 
hominis in the in-patient group.  In the control patient group isolates however, for the 
macrolide class of antibiotics all CoNS isolates demonstrated higher resistance rates to 
erythromycin n=50 (53%) in comparison to clindamycin n=18 (33%).   
Resistance rates of isolates compromising the other minor group of CoNS were much lower 
in comparison to the three predominant species in both patient groups.  The lowest 
resistance rates to the panel of 18 antimicrobials tested was observed in one isolate of S. 
lugdunensis (G41) out of the five isolates in the other minor CoNS species in the control 
patient group demonstrating full susceptibility.  The other four isolates of S. lugdunensis in 
this patient group, displayed proportionally, lower resistance rates, exhibiting non-
susceptibility to less than two antimicrobials.  Similarly, in-patient isolates of S. warneri and 
S. auricularis displayed resistance to ≤3 antimicrobials.  
Methicillin resistance interpreted in accordance with the 2012 BSAC/EUCAST breakpoints 
criteria of ≤0.25 to >0.5mg/L, was observed to be much higher amongst all in-patient CoNS 
species-specific isolates in comparison to those of the control patient group.  The highest 
overall resistance to methicillin was detected in 78 out of the 100 in-patient CoNS isolates in 
comparison to 28% methicillin resistance observed in the control patient group isolates.  
Performing CoNS species-specific analysis revealing a degree of methicillin resistance 
variability between and within isolates of the same species from both patient groups are 
detailed in Table 4-3.  The highest rates of methicillin resistance in both the in-patient and 
control patient group were observed in isolates of S. haemolyticus 15(94%) and 9(53%) 
respectively.  However, among the in-patient CoNS isolates there was a significant 
association between S. epidermidis and its propensity to be methicillin resistant (p <0.05).  Of 
the 57 in-patient group S. epidermidis isolates 50 (88%) were classified as methicillin 
resistant in comparison to 11(34%) resistance in the control patient group.  Likewise, 
although isolates of S. haemolyticus 9(53%) of the control patient group displayed higher 
rates of methicillin resistance no significant correlation (p >0.05) was however revealed 




it is also noteworthy, that resistance to mupirocin, a topical decolonising antimicrobial agent 
used for the eradication of colonising strains of healthcare associated MRSA, was observed 
to be more common among the control group CoNS species.  Mupirocin resistance in the 
control patient group was observed to be highest among isolates of S. epidermidis (5)16% 
with the lowest resistance observed in one isolate of the S. haemolyticus (6%).  Conversely, 
for the in-patient group, mupirocin resistance was observed in only one S. epidermidis isolate 
(2%). 
 
4.5.2.3 Glycopeptide susceptibility rates among species-specific CoNS isolates 
VITEK®2 susceptibility data analysis shows that each of the three predominant species of 
CoNS in the in-patient group differed in response to the glycopeptides in comparison to those 
in the control patient group.  Resistance to teicoplanin in the control patient group was 
observed to be greater in CoNS isolates of S. epidermidis and S. haemolyticus, 19(59%) and 
8(47%) respectively.  Comparatively, in the in-patient group teicoplanin resistance was 
observed in 18(32%) of S. epidermidis isolates and 2(13%) of the S. haemolyticus isolates.  
Teicoplanin resistance rates displayed by isolates of S. hominis were comparatively lower in 
both patient groups, with nil resistance detected in the in-patient and the other minor group of 
CoNS isolates.  In the control patient group however, 2(7%) isolates of the minor group of 
CoNS S. warneri (G20) and S. lugdunensis (G67) exhibited resistance to teicoplanin.  The 
majority of all species-specific CoNS isolates were however, observed to be susceptible to 
vancomycin in both patient groups with the exception of reported resistance in an isolate of 
S. epidermidis (3%) in the control patient group and in one isolate of S. haemolyticus (6%) in 
the in-patient group.   
Computed PCA applied to the in-patient data amongst the different CoNS species tested 
using the VITEK®2 system to reveal any significant association between species-specific 





Figure 4-6: Scatter graph of factor loadings calculated by 2D PCA whereby the 
components are the glycopeptides factor 1 by factor 2 versus the CoNS species-
specific identification differences tested using the VITEK®2 system. 
 
The 2D PCA factor plot from the grouping variables which were the speciation identity of 
CoNS isolates against the two antibiotics, vancomycin and teicoplanin revealed one 
noticeable in-patient isolate A53, S. haemolyticus (plot position 119) away from the main 
predominating cluster.  This suggests that this in-patient S. haemolyticus isolate exhibits a 
significantly distinct susceptibility response to the glycopeptides in comparison to the rest of 
the species-specific CoNS isolates.  The remainder of the CoNS species isolates do not 
appear to reveal any distinctive clusters with the exception of few outlier isolates of S. 
epidermidis and S. haemolyticus near the main cluster.  These isolates, although not forming 
distinct clusters appear individually spaced out on the factorial scale (Factor 2 axis: below 
zero) due to difference in susceptibility to the glycopeptide antibiotics in relation to species-
specific CoNS identification. 
Explanatory data analysis was further applied to summarise the vancomycin and teicoplanin 
inhibitory MIC values obtained with the VITEK®2 system in relation to each of the species- 





Figure 4-7: Box plot illustrates the overall comparative distribution of vancomycin and 
teicoplanin susceptibility (MIC mg/L) based on CoNS species-specific isolates from 
both patient groups tested using the VITEK®2 system. 
The box and whisker plot, showing a summary of the overall susceptibility distribution of 
inhibitory concentrations of the two glycopeptides based on CoNS species-specific isolates, 
reveals a relatively symmetrical distribution with the exception observed with a few outliers 
and extreme values observed with isolates of S. haemolyticus. 
Further application of descriptive statistics, result analysis reveal that there was a significant 
difference noted between the distribution of both vancomycin and teicoplanin MIC values 
between the in-patient and control patient group CoNS isolates (p = 0.0001 with 3df). 
 
4.5.2.4 Comparative CoNS species-specific methicillin and multidrug resistance rates 
The categorisation of multidrug resistance defined by Magiorakos and colleagues (2012) was 
applied for the characterisation of multiple antimicrobial resistance. Therefore, following this 
criteria, multidrug resistance-CoNS (MDR-CoNS) were defined as those isolates 
demonstrating non-susceptibility to ≥1 agent in ≥3 antimicrobial categories.  Hence data 
analysis of spectrum of overall resistance to multiple antimicrobial classes in the panel of 18 
antimicrobials tested, revealed higher rates of MDR in the in-patient CoNS isolates (75%) in 
comparison to 23% in the control patient group.   
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The results of data analysis carried out to further assess the correlation between CoNS 
species-species isolates and their propensity to demonstrate MDR in each of the two patient 
groups using a generalised linear regression model are displayed in Figure 4-8. 
Figure 4-8: Antimicrobial resistance data plot of CoNS species-specific isolates of the 
in-patient group in comparison to isolates of the control patient group.  The hollow 
circles are representative of each data point.  The mean resistance to antimicrobials 
for each species group is represented by white diamonds and the black dotted line 
shows the cut-off point for MDR. 
 
The output from the result analysis shows that there is strong evidence that the in-patient 
CoNS isolates are significantly associated with an increase in the number of antibiotics 
expressing resistance (p <0.0001).  Furthermore, the results show good evidence that 
isolates of S. hominis are associated with expressing resistance to fewer classes of 
antibiotics in comparison to isolates of S. epidermidis and S. haemolyticus (p = 0.0004 and p 
= 0.0001 respectively).  Additionally, the model provided weak evidence that S. haemolyticus 
isolates demonstrated resistance to a greater number of antimicrobials on average than 
those of S. epidermidis (p = 0.09). 
Based on the defined phenotypic resistance criteria, the in-vitro activity of methicillin in 
comparison to drug resistance to multiple antibiotic groups in the panel of 18 agents tested 




 Number of Resistant Isolates / Total Number of 
Isolates Tested (%)  
 Methicillin Resistant Multi-Drug Resistant 
In-patient Group         
S. epidermidis (n=57) 50/88% 47/83% 
S. hominis (n=18) 12/67% 13/72% 
S. haemolyticus (n=16) 15/94% 15/94% 
Other CoNS (n=9) 1/11% Nil 
      
Control Patient Group     
S. epidermidis (n=32) 11/34% 12/38% 
S. hominis (n=24) 5/21% 3/13% 
S. haemolyticus (n=17) 9/53% 6/35% 
Other CoNS (n=27) 3/11% 2/7% 
Table 4-3: Comparison of methicillin resistance and multi-drug antibiotic resistance 
patterns of species-specific isolates of CoNS from the in-patient and control patient 
groups. 
Both S. epidermidis and S. haemolyticus isolates from the in-patient group exhibited high 
MDR rates (83% and 94% respectively).  Additionally, methicillin resistance rates of 15(94%) 
were observed to correspond equally to MDR rates in, in-patient isolates of S. haemolyticus 
15(94%).  Conversely for the control patient group, almost similar correspondingly high rates 
of MDR with methicillin resistance were observed in isolates of S. epidermidis (38 and 34% 
respectively) but not in S. haemolyticus isolates.  The least resistance to all antimicrobial 
classes was observed mainly amongst isolates of the other minor group of CoNS species in 
both patient groups.  Nonetheless, in isolates of the control patient group two (7%) of the 
other CoNS, G20 and G25, S. warneri and S. capitis respectively, expressed resistance to 
greater than six antimicrobials.  
Statistical analysis of overall data reveals that multi-drug resistance is significantly 
associated with methicillin resistance in both patient groups (p = 0.0001 with 1df).  Analysis 
further revealed a significant association between MDR, methicillin resistance and in-patient 
isolates of S. epidermidis (p = 0.0001).  Conversely, there was no significant association 
observed between methicillin resistance, MDR and isolates of the minor group of CoNS 
species from both patient groups (p >0.05). 
 
4.5.3 Evaluation of phenotypic susceptibility using the standard E-test method 
The MICs of vancomycin and teicoplanin in comparison to tigecycline, daptomycin and 
ceftaroline were determined by the standard E-test method for 100 in-patient CoNS isolates.  
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As recommend by the manufacturer the MICs for these antibiotics were evaluated using 
Mueller-Hinton susceptibility agar (Figure 4-9). 
Figure 4-9: A representative in-patient CoNS isolate tested using standard E-test 
antibiotic gradient strips on Mueller-Hinton agar. (a) TP (teicoplanin) and (VA) 
vancomycin. (b) DPC (daptomycin) and TG (tigecycline).  MIC values read at the point 
of complete inhibition for each antibiotic are indicated by the arrows. 
The standard E-test MIC provided quantitative MIC antimicrobial data generated from the E-
test gradient scale ranged from MIC values of 0.016 to 256mg/L for vancomycin, teicoplanin, 
tigecycline and daptomycin.  In accordance with the manufacturers protocol, the MIC for 
each isolate was determined at the end-point of interaction of the lower part of ellipse shaped 
growth area with the E-test strip as illustrated in Figure 4-9a and b.  The end point of 
inhibition differed for teicoplanin in comparison to the clear cut endpoints noted for the other 
test antibiotics.  The presence of smaller resistant colonies around the ellipse were also 
taken into account when evaluating teicoplanin resistance.  EUCAST (v.2, 2010/11) 
susceptibility interpretative criteria was applied as follows: Vancomycin ≤4mg/L, teicoplanin 
≤4mg/L, daptomycin ≤1mg/L, tigecycline ≤0.5mg/L and ceftaroline ≤2mg/L.  Similar 
microbiological criteria for S. aureus were used to categorise susceptibility to ceftaroline as 
breakpoint determination by consensus organisations have yet to be established for CoNS 
and this antimicrobial agent. 
 
MICs for ceftaroline were determined using Mueller-Hinton plus 5% horse-blood with the 
M.I.C.E standard E-test strips in accordance with the manufacturers recommended protocol.  
The concentration gradient scale of the ceftaroline standard E-test strip ranged from MIC 
value of 0.002 to 32mg/L as shown in Figure 4-10.  The MIC value for each isolate was 
determined at the end point of growth inhibition to include small colony variants.  As 
illustrated, the end points of inhibition differed dependent on the CoNS species.  Following 
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recommendations, for those end-points of growth inhibition falling between the intersection of 
two MIC value points, the MIC was rounded up to the next two fold dilution value for MIC 
categorisation as illustrated in Figure 4-10(b). 
 
The MIC measurements obtained for the ATCC reference strains for all the five 
antimicrobials tested using the standard E-test method fell within the standard published 
quality control ranges.   
 
Figure 4-10: Two representative in-patient CoNS isolates tested using (CPT) 
ceftaroline standard E-test antibiotic gradient strip on Mueller-Hinton agar with 5% 
horse blood.  The MIC values were read at the end points as indicated by the arrows 
(a) S. epidermidis MIC value read at the point of inhibition at 0.25mg/L. (b) S. 
haemolyticus inhibition intersection point falling between two MIC values was read at 
4mg/L. 
Applying the susceptibility interpretative criteria adopted from EUCAST/BSAC (2012) 
published guidelines, the standard E-test MIC values for vancomycin were all within the 
susceptibility range of ≤4mg/L with the mean and median MIC value of 2mg/L.  On the other 
hand, the MIC values of teicoplanin were more widely distributed with 26 out of the one 
hundred in-patient CoNS isolates displaying MICs of >4mg/L.  Borderline susceptibility to 
teicoplanin at breakpoint MIC of 4mg/L was observed in 20(27%) out of the 74 susceptible 
isolates.  The highest MIC of 24mg/L was observed in one out of the 26 CoNS isolates 




Figure 4-11 illustrates the overall in-vitro activity of the newer antibiotics daptomycin, 
tigecycline and ceftaroline in comparison to the glycopeptides, vancomycin and teicoplanin 
against the 100 in-patient CoNS isolates.  
 
 
Figure 4-11: Antimicrobial susceptibility, MIC distribution range of the glycopeptides, 
vancomycin (VAN) and teicoplanin (TEI) in comparison to daptomycin (DAP), 
tigecycline (TIG) and ceftaroline (CEFT) for the 100 in-patient CoNS isolates as 
determined by the standard E-test method. 
 
Based on the standard established susceptibility breakpoints, Figure 4-11 also shows that 
the MIC susceptibility ranges of the CoNS isolates evaluated by the standard E-test method 
were variable dependent on the antibiotic tested.  Daptomycin (MIC ≤1mg/L) remained the 
most active compound against all the 100 in-patient CoNS isolates tested.  Susceptibility to 
daptomycin at the upper limit range at MIC 1mg/L was noted in only one S. capitis (A7) in the 
other minor group of CoNS isolates.  Of the newer antimicrobials tested similar in-vitro 
potency was not demonstrated by either tigecycline or ceftaroline against all the 100 in-
patient CoNS isolates.  In total 13 and 6% of the CoNS isolates demonstrated non-
susceptibility to tigecycline and ceftaroline respectively.  Standard E-test MIC values for 
teicoplanin were observed to spread across a much wider scale, ranging from 0.047 to 





























Antibiotic - MIC mg/L
Antimicrobial susceptibility MIC (mg/L) range of the 100 In-patient 






 Standard E-test : MIC ( mg/L) distribution range of the number of isolates out of the total 100 In-patient CoNS tested
0.032 0.047 0.064 0.094 0.125 0.19 0.25 0.38 0.5 0.75 1 1.5 2 3 4 6 8 12 16 24
VAN 1 3 4 7 23 52 9 1
TEI 1 3 3 5 1 4 3 1 3 7 18 5 20 8 8 6 3 1
DAP 3 6 3 5 19 23 21 9 8 2 1
TIG 1 3 5 11 7 27 19 14 5 5 2 1
CEFT 3 6 11 8 46 13 7 6
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daptomycin.  Similar, MIC values spread across a wider scale were also observed for 
ceftaroline, ranging from 0.032 to 4 mg/L with a median MIC value of 0.5mg/L.  
Higher resistance rates to the newer antibiotics, tigecycline and ceftaroline as determined by 
standard E-test methodology were noted amongst strains of the predominant CoNS species.   
In general, tigecycline resistance ranging from MIC 6-24mg/l was observed amongst the13 
in-patient CoNS isolates which included 9(16%) strains of S. epidermidis, 3(19%) S. 
haemolyticus and 1(6%) of S. hominis.  Borderline susceptibility to tigecycline was observed 
in a total of 14 of the hundred CoNS isolates tested at MIC 0.5 mg/L which included 6(11%) 
S. epidermidis and 3 (19%) S. haemolyticus.  Similarly, all 6(38%) of the ceftaroline resistant 
isolates were strains of S. haemolyticus isolates expressing MIC of 4mg/L.  Overall 
borderline ceftaroline susceptibility at MIC 2mg/L was observed in a total of 7(44%) of the 
CoNS isolates of these, 6(38%) and 1(2%) were isolates of S. haemolyticus and S. 
epidermidis respectively. 
The data was further subjected to descriptive statistical analysis to describe the association 
between the independent variable (antimicrobials) and concentration dependent proportional 





                                                                                                                                                                        
Figure 4-12: Comparative proportion of in-patient CoNS isolates inhibited at specified 
concentrations (mg/L) (logarithmic scale) by each of the four antibiotics ceftaroline, 




The logistic regression model fitted to the overall susceptibility data obtained for the in-
patient CoNS was used to observe the proportion of CoNS isolates inhibited as a function of 
the specified antibiotic concentration.  Figure 4-12 details the proportion of CoNS isolates 
inhibited at specified MIC concentrations by the newer antibiotics daptomycin, tigecycline 
and ceftaroline in comparison to the glycopeptides using the standard E-test methodology.  
The results reveal that there is a significant association between increasing concentration of 
antibiotic and increase in the proportion of CoNS isolates inhibited.  However, the model also 
demonstrates that in comparison to ceftaroline, the proportion of isolates inhibited by 
vancomycin at a given concentration is significantly lower (p <0.005).  Additionally, the model 
contains two-way interactions for concentration versus daptomycin, teicoplanin and 
tigecycline (p = 0.0014, p = 0.0004 and p = 0.00048 respectively), demonstrating that 
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daptomycin and tigecycline produce significantly greater inhibition at a given concentration 
and teicoplanin gives a proportionally lower inhibition at the same concentration in 
comparison to ceftaroline.   
 
Antibiotic MIC₅₀ (mg/L) MIC₉₀ (mg/L) 
Ceftaroline 0.44 1.7 
Daptomycin 0.17 0.4 
Tigecycline 0.24 0.65 
Vancomycin 1.62 2 
Teicoplanin 2.2 8 
Table 4-4: Comparative MIC50 and MIC90 (mg/L) values for the newer antibiotics 
evaluated against vancomycin and teicoplanin by standard E-test. 
 
In-vitro MICs of the newer antibiotics ceftaroline, daptomycin and tigecycline in comparison 
to the glycopeptides summarised as MIC₅₀ and MIC₉₀ values for the 100 in-patient CoNS 
isolates are presented in Table 4-4.  The medians MIC₅₀ and MIC₉₀ for daptomycin are the 
lowest followed by tigecycline and ceftaroline in comparison to the glycopeptides.  The 
results indicate the daptomycin is deemed to be significantly the most potent (p = 0.001) in 
comparison to the other antimicrobial agents.  Conversely, the highest MIC₅₀ and MIC₉₀ 
displayed by teicoplanin indicates that significantly higher concentrations (p = 0.0004) of this 
antimicrobial are required to achieve comparatively similar proportional inhibition rates 
relative to the other four antibiotics tested. 
 
4.5.3.1 Comparison of glycopeptide susceptibilities determined by the two validated 
AST methodologies 
Overall comparative distribution of vancomycin and teicoplanin MICs for the 100 in-patient 
CoNS species-specific isolates determined by the standard E-tests with those determined by 
the automated microdilution methodology are illustrated in Figure 4-13.  Comparative 
glycopeptide inhibitory concentrations (MIC mg/L) displayed by the two test methodologies 
used for detection of susceptibility revealed an overall MIC value similarity of 42% and 52% 




Figure 4-13: Comparison of antimicrobial inhibition concentration MIC (mg/L) 
distribution range of the glycopeptides, vancomycin (VAN) and teicoplanin (TEI) for 
the 100 in-patient CoNS isolates as determined by both the standard (Std.) E-test and 
VITEK®2 automated methodologies. 
 
Vancomycin and teicoplanin MIC distribution by automated VITEK®2 system were relatively 
different from those evaluated by standard E-test.  The VITEK®2 system demonstrated 
performance within a much narrower MIC susceptibility range in comparison to the standard 
E-tests.  Of these a total of 74 isolates in comparison to 77 CoNS isolates expressed 
susceptibility to teicoplanin as determined by E-test and VITEK®2 respectively.  Twenty 
(27%) of the isolates analysed by E-test were at the lower end of the teicoplanin 
susceptibility range, falling below 0.5mg/L, similar to those obtained by the automated 
method 21(27%), however the susceptibility distribution range at the upper end of the MIC 
value ranges differed considerably.  Nonetheless, the highest number of isolates exhibiting 
teicoplanin MICs of 2mg/L and 4mg/L were similar with both test methodologies. 
Likewise, CoNS isolates by standard E-test method were observed to express teicoplanin 
inhibitory MICs across a much wider MIC value range in comparison to the automated 
microdilution method.  Therefore, comparatively fewer isolates at each MIC inhibitory value 
across a much wider scale were observed with the standard E-test method.  Additionally, due 
to the greater sensitivity and specificity of E-test methodology, in total 26 CoNS isolates were 
classified as resistant to teicoplanin in comparison to resistance observed in 22 isolates with 
the VITEK®2 method.  Similarly, higher teicoplanin susceptibility rates were noted in isolates 
tested by VITEK®2 with 25(24%) and 27(35%) of the CoNS isolates in comparison to 




































































Antibiotic  Inhibition Concentration (mg/L)
Glycopeptide MIC distribution: Comparison of VITEK®2 and 
Standard E-test methodology
VAN : VITEK 2
VAN : Std. E-test
TEI : VITEK 2
TEI : Std. E-Test
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Conversely, the number of CoNS isolates exhibiting teicoplanin resistance at higher MICs, 
ranging from 6-24mg/L were observed in a total of 26 isolates investigated by E-test.  
Comparatively a lower resistance rate was observed with the VITEK®2 system, with a total of 
22 isolates expressing resistance at MICs between 8 and 16mg/L.  However, performing 
paired sample statistics comparing teicoplanin MIC result distribution revealed no significant 
difference (p = 0.624) between VITEK®2 and the standard E-test susceptibility test 
methodologies. 
 
Data analysis of the vancomycin susceptible in-patient CoNS isolates on the other hand 
revealed similar difference in MIC value ranges with the two test methodologies.  The 
majority of in-patient CoNS isolates (n=52) displayed an MIC of 2mg/L as determined by E-
test in comparison to the VITEK®2, where the majority of isolates (n=51) were noted to 
display MIC of 1mg/L with 33 isolates demonstrating MICs of 2mg/L.  CoNS isolate A53, on 
the other hand presented vancomycin MIC of 8mg/L categorised as resistant when 
determined by VITEK®2 in comparison to an MIC of 4mg/L by E-test method.  This one fold 
dilution difference lower than that obtained by VITEK®2 classifies this isolate as borderline 
susceptible when tested by E-test.  Comparative analysis of vancomycin susceptibilities 
however, revealed a significant difference (p = 0.0001) in MIC result distribution between the 
two AST methodologies. 
 
VITEK®2 CoNS species-specific MIC inhibitory value range results interpreted according to 
the 2011 Global European-based phenotypic EUCAST interpretative guidelines for 
comparative activity of vancomycin and teicoplanin are detailed in Table 4-5.  Of note, 
susceptibility testing analysis for isolate number A64 identified as Kocuria rosea in the other 
minor group of CoNS species could not be performed by VITEK®2 due to the organisms 
growth condition requirement.  Therefore, this isolate was excluded from MIC value range 
analysis for both the glycopeptides.  AST results for this isolate carried out manually on blood 
Mueller-Hinton agar incubated in 5% Co2 at 37°C for 18 hours were categorised as sensitive 









VITEK®2 automated microdilution method: Number of Isolates (Cumulative %) 











<0.5  2(4%) 6(33%) 2(13%) 5(56%) 
1 34(60%) 6(33%) 7(39%) 3(33%) 
2 21(37%) 6(33%) 6(38%)   
8     1(6%)   










<0.5 4(7%) 11(61%) 2 (13%) 4(44%) 
1 2(4%) 1(6%)   1(11%) 
2 16(28%)   6 (38%) 3(33%) 
4 17(30%) 5(28%) 5 (31%)   
8 14(25%) 1(6%) 2 (13%)   
16 4(7%)   1 (6%)   
Table 4-5: MIC value ranges (mg/L) of in-patient CoNS species to vancomycin and 
teicoplanin investigated with the VITEK®2 automated microdilution system, with 
application of breakpoint susceptibility criteria of ≤4mg/L for both antibiotics.  One 
isolate of the other CoNS group (n=9*) failed automated AST was excluded from MIC 
analysis.  
All investigated isolates with the exception of one (6%) S. haemolyticus isolate, A53 
demonstrated susceptibility to vancomycin when tested by VITEK®2.  As shown in Table 4-5 
species-specific strains of in-patient CoNS expressed differing levels of vancomycin 
susceptibilities with MIC values ranging from <0.5 to 8mg/L.  The lowest inhibitory 
vancomycin MIC values were found among isolates of the other minor CoNS species 56% 
and 44% (<0.5 and 1mg/L) respectively. 
On the other hand, with the application of the revised interpretative breakpoint criteria used 
for S. aureus to the susceptibility data obtained for the in-patient CoNS isolates, revealed just 
over 30% of the three predominant species-specific isolates expressed vancomycin MICs of 
2mg/L.  This current susceptibility breakpoint of 2mg/L, considered to be at the upper limit of 
the susceptibility range for clinically relevant isolates of S. aureus was established to include 
those isolates expressing low level vancomycin resistance known to be associated with 
clinical failures (Tenover et al., 2007).  Data re-analysis following application of the modified 
interpretive criteria, shows that the highest rates were prevalent in isolates of S. 
haemolyticus at breakpoint of MIC 2mg/L followed by S. epidermidis and S. hominis (38, 37 
and 33% respectively).  In comparison to vancomycin, the difference in teicoplanin MIC 
susceptibility range among in-patient CoNS isolates was more species-specific dependent.  
Of the 22 teicoplanin non-susceptible species-specific CoNS isolates, S. epidermidis, 3(19%) 
S. haemolyticus 18(32%) and one (6%) S. hominis demonstrated MIC value ranges between 
8 and 16mg/L above the breakpoint value of 4mg/L. 
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Comparative CoNS species-specific glycopeptide susceptibility data analysis carried out 
using the standard E-test methodology are detailed in Table 4-6. 
Standard E-test:  Number of Isolates (Cumulative %) Inhibition at MIC in mg/L 











<0.5   3 (17%)   1 (11%) 
0.75   2 (11%)   2 (13%) 
1 1 (2%) 6 (33%)     
1.5 8 (14%) 3 (17%) 5 (31%) 6 (67%) 
2 43 (75%) 3 (17%) 8 (50%)   
3 5 (9%) 1 (6%) 2 (13%)   
4     1 (6%)   










<0.5 1 (2%) 13 (72%)  2 (13%) 5 (56%) 
0.75       1 (11%) 
1 2 (4%)     1 (11%) 
1.5 3 (5%) 1 (6%)  1 (11%) 
2 13 (23%)   6 (38%) 1 (11%) 
3 5 (9%)       
4 14 (25%)  2 (11%) 5 (31%)   
6 4 (7%)  2 (11%)    
8 7 (12%)   2 (13%)   
12 6 (11%)       
16 1 (2%)   1 (6%)   
24 1 (2%)       
Table 4-6: Comparative distribution of vancomycin and teicoplanin MIC value ranges 
of species-specific in-patient CoNS isolates investigated using the Standard E-test 
method. 
In total, of the 100 CoNS species-specific isolates from the other minor group of CoNS 
demonstrated a high degree of susceptibility to both the glycopeptides with MICs ranging 
from <0.5-2mg/L.  With the application of EUCAST (2011/12) susceptibility breakpoint 
criteria, none of the CoNS species-specific isolates tested exhibited resistance to 
vancomycin.  Only one S. haemolyticus isolate A53, expressed an MIC of 4mg/L at the upper 
end of the susceptibility range.  Conversely, application of the revised vancomycin breakpoint 
of 2mg/L, associated with sub-optimal clinical outcomes in similar S. aureus BSIs, a total of 
54 CoNS isolates were noted to exhibit susceptibility at the upper end of the susceptibility 
range with the E-test method.  Hence, with application of the modified breakpoint criteria, 
borderline susceptibility at MIC of 2mg/L was noted to be expressed by S. epidermidis and S. 
haemolyticus, 43(75%) and 8(50%) respectively.  On the other hand, the lowest rates of 
teicoplanin susceptibility was observed among 19(33%) in-patient, S. epidermidis isolates 
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followed by 3(19%) and 2(11%) resistance observed in isolates of S. haemolyticus and S. 
hominis respectively.   
 
Figure 4-14: Box plot illustrates the overall comparative distribution of vancomycin 
and teicoplanin susceptibility (MIC mg/L) based on CoNS species-specific isolates 
tested using the standard E-tests. 
 
The box and whisker plot, Figure 4-14 presents a summary of the overall susceptibility 
distribution of inhibitory concentrations of the two glycopeptides based on CoNS species-
specific isolates using the E-test methodology.  With the exception of the other minor CoNS 
species group, a few extreme values for both vancomycin and teicoplanin were observed in 
the plot for isolates of S. epidermidis, S. haemolyticus, and S. hominis.  Conversely, a 
relatively symmetrical MIC distribution with few outliers and extreme values for inhibitory 
concentrations for teicoplanin alone were observed for all three of the predominant CoNS 
species isolates. 
2D PCA factor analysis (Figure 4-15) was also preformed to further assess the comparative 
significance of vancomycin and teicoplanin susceptibilities and their association with species-




Figure 4-15: Scatter graph of factor loadings calculated by 2D PCA whereby the 
components are the glycopeptide susceptibilities factor 1 by factor 2 versus the CoNS 
species-specific differences when tested using the VITEK®2 system or Standard E-test 
method. 
 
The 2D PCA plot of factor 1 versus factor 2 for the 100 CoNS species isolates shown in 
Figure 4-15, include the grouping variables which were the test methodology, against 
species-specific CoNS glycopeptide susceptibility.  The PCA of the dataset produced two 
factors, 1 (VITEK®2) and 2 (standard E-test) accounted for 69.81% and 30.19% respectively 
in line with the CoNS species related glycopeptide susceptibilities.  Based on discriminatory 
factors, one isolate of S. haemolyticus (plot position 119) was pulled out from the main 
cluster around the factor axis suggesting a significant difference in expressing susceptibility 
in comparison to the rest of the CoNS species-specific isolates.  The overall result analysis 
suggest that there is no significant difference between the two antimicrobial test 
methodologies for glycopeptide susceptibility expression in relation to species-specific CoNS 
isolates. 
Linear regression analysis of the three variables, the glycopeptides, VITEK®2 and E-test 
methodologies and in-patient species-specific CoNS isolates was performed to determine 
any significant differences with the use of the two validated AST methodologies.  The 
antimicrobial inhibitory concentration dataset was used to construct logistic regression 
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models, displaying the proportion of CoNS species-specific isolates inhibited by teicoplanin 
and vancomycin dependent on the AST method used to confirm findings (Figure 4-16). 
 
Figure 4-16: Comparative analysis of the proportion of species-specific in-patient 
CoNS isolates inhibited in relation to glycopeptide antibiotic concentrations 
(logarithmic-scale) as determined by the VITEK®2 system and the standard E-test 
method. 
 
The primary model shows the proportion of isolates inhibited as a function of the antibiotic 
concentrations, the antibiotics namely vancomycin or teicoplanin, the susceptibility test 
methods either VITEK®2 or standard E-test and the in-patient CoNS species-specific 
isolates.  The results from this analysis demonstrate that there is a significant increase in the 
proportion of species-specific CoNS isolates inhibited as the concentration of the 
glycopeptides increased (p = 0.003).  Conversely, vancomycin was in general, associated 
with a significantly decreased probability of inhibition (p = 0.009).  Additionally, there was a 
two-way interaction observed between vancomycin and VITEK®2 test method, such that, the 
proportion of isolates inhibited significantly increases when the effect of the antibiotic is 
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measured on this platform (p = 0.0005) when compared to the E-test method.  Significantly, 
similar two-way interactions were also observed between concentration of the antibiotics and 
proportional number of species-specific isolates, S. epidermidis, S. haemolyticus and S, 
hominis inhibited (p values of 0.026, 0.028 and 0.018 respectively).   
Moreover, the two-way interaction between vancomycin and S. epidermidis further 
demonstrates that there is a significant tendency for this combination to produce a lower 
proportion of inhibited isolates (p = 0.0003).  Result analysis further reveal that the two-way 
interactions tends to decrease somewhat the effect that increasing the antibiotic 
concentration has on the proportion of all CoNS species-specific isolates inhibited, in 
comparison to those of the other minor group of CoNS species.  Overall, the results also 
show a three-way interaction observed between concentration, vancomycin and only isolates 
of S. epidermidis with the use of E-test.  With this methodology an increase in concentration 
tends to produce a significantly greater increase in the proportion of isolates inhibited when 
dealing with vancomycin and S. epidermidis species (p = 0.0035).  Similarly, there was a 
significantly lower assignment probability (p = 0.008) between concentration, S. epidermidis, 
vancomycin and VITEK®2.  Conversely, no significant correlation was observed between 
concentration, vancomycin and either of the S. haemolyticus or S. hominis isolates (p = 0.44 
and 0.93 respectively) with the VITEK®2 method.  
Comparative data analysis was further performed to ascertain the significance of MIC50 and 
MIC90 of species-specific CoNS using the two AST test methodologies, the standard E-test 
and VITEK®2 (Table 4-7) by means of a similar partial liner regression coefficient model.  The 
MIC50 and MIC90 concentration values were calculated using the following formula: 
MIC = LBC +
TPoI −  LBPoI
UBPoI − LBPoI
(UBC − LBC) 
Whereby, MIC is the minimum inhibitory concentration; LBC is the lower bound concentration 
which is the highest concentration that gives a proportion of inhibition less than or equal to 
the target proportion of inhibition (TPoI).  LBPoI is the proportion of inhibition at the LBC ad 
UBPoI is the proportion of inhibition at the upper bound concentration which is the lowest 







   Vancomycin Teicoplanin 
  MIC₅₀ MIC₉₀ MIC₅₀ MIC₉₀ 
 Isolate        
VITEK®2 S. epidermidis 0.89 1.73 2.76 7.51 
  S. hominis 0.75 1.7 <0.5 3.68 
  S. haemolyticus 0.93 1.9 2 6.8 
  Other CoNS <0.5 0.87 0.5 1.73 
        
Std. E-test S. epidermidis 1.73 1.99 3.32 9.53 
  S. hominis 0.92 1.87 <0.5 4.2 
  S. haemolyticus 1.69 2.7 2 7.4 
  Other CoNS 1.13 1.43 <0.5 1.55 
Table 4-7: Comparative MIC₅₀ and MIC₉₀ value ranges (mg/L) of in-patient species-
specific CoNS isolates to vancomycin and teicoplanin investigated with the VITEK®2 
automated microdilution system and standard E-tests  
 
The computed MIC results that this model produces shown in Table 4-7 reflects apparent 
differences in MICs exist dependent on the AST technique used for species-specific MIC 
determination.  Among the 100 in-patient species-specific CoNS isolates the MIC50 and 
MIC90 for vancomycin were on average approximately one doubling dilution higher by 
standard E-test in comparison to those obtained using the VITEK®2 automated system.  
These differences were also observed with teicoplanin for all three predominant species of 
CoNS with the exception of the other minor group of CoNS isolates.  The single exception 
was results obtained for teicoplanin in the other minor group of CoNS species, where almost 
no significant difference was observed for MIC50 and MIC90 values (p = 0.9).  The overall 
assignment probability for vancomycin and teicoplanin susceptibility with both AST methods 
was determined to be high (p >0.05), demonstrating good correlation between standard E-
test and VITEK®2 AST methodologies for the MIC evaluation. 
 
4.5.4 Macro-method E-test for heteroresistance detection 
The prevalence of heteroresistance amongst the 100 in-patient CoNS isolates was evaluated 
using the previously described modified screening method using BHI agar (van Hal et al., 
2011; Satola et al., 2011).  
All batch test results that included the ATCC positive controls Mu3 (hGISA), Mu50 (GISA) 
and the negative control S. aureus (ATCC 29213) preformed within the expected quality 




Figure 4-17: Macro-method using BHI agar and E-test antibiotic gradient strips on 
Brain-Heart Infusion agar. (a) Representative in-patient CoNS isolate displaying 
vancomycin MIC of 2 mg/L, b) Mu3 shows lower VA value MIC of 4mg/L with 
discernible small-colony variants visible within the inhibition ellipses area. c) Mu50, 
the GISA strain shows a higher MIC value of 16mg/L. 
 
Due to the lack of defined breakpoints for the interpretation of glycopeptide susceptibility 
using the macro-method the interpretative criteria as previously proposed by other 
researchers was applied (Tenover et al., 2001; Walsh et al 2001; Wooton et al., 2007; Satola 
et al., 2011).  The following E-test MIC interpretative criteria for heteroresistance detection 
for CoNS strains exhibiting MIC of ≥8mg/L for both vancomycin and teicoplanin or MIC of 
>12mg/L for teicoplanin regardless of vancomycin MICs were applied for evaluation of 
resistance.  These are not true MIC values, but interpretative MICs based on the heavier 
inoculum of 2 McFarland standard on enriched BHI medium incubated over a longer period 
of time.  The higher inoculum and media combination supports the growth and hence 
detection of small subpopulations of resistant cells as shown in Figure 4-17. 
Based on these criteria the MIC values for the glycopeptide heteroresistant control strain 
Mu3 was observed to be typically between 4-6mg/L and for intermediate resistance control 
strain Mu50 was 12-16mg/L for each test batch.  The overall comparative MIC distribution 
ranges of vancomycin and teicoplanin read at 48 hours using the E-test macro-method 
performed on the 100 in-patient CoNS isolates are illustrated in Figure 4-18.  Applying the 
proposed evaluation criteria for determination of heteroresistance prevalence in CoNS in-
patient isolates, 3 and 28 out of the 100 isolates tested exhibited MICs ≥8mg/L for 





Figure 4-18: MIC (mg/L) distribution range of the glycopeptides, vancomycin (VAN) 
and teicoplanin (TEI) for the 100 in-patient CoNS isolates as determined by the macro-
method for detection of heteroresistance. 
 
Further evaluations carried out based on the criteria for isolates expressing teicoplanin MICs 
≥12mg/L regardless of the vancomycin susceptibilities 14 of the 100 CoNS isolates tested 
with MICs ranging from ≥12-24mg/L met the criteria for hVIS.  In total these 14 isolates would 
be considered for the presence of hVIS, as the number of isolates expressing teicoplanin 
MICs of 8 and >12mg/L, were within the defined criteria inclusive of the 3 isolates 
demonstrating vancomycin MICs of ≥8mg/L.  Therefore, the overall result evaluations reveal 
a probable total prevalence of 14% heteroresistance amongst the 100 in-patient CoNS 
isolates tested using the BHI macro-method for detection glycopeptide resistance. 
 
Further analysis of the in-vitro activity of vancomycin and teicoplanin against species-specific 















































Distribution MIC Range of 100 In-patient CoNS using Marco-





BHI Macro-method:  Number of Isolates (Cumulative %) Inhibition at MIC in mg/L 
against 100 in-patient CoNS Predominant Species Groups 
BHI  
Macro-method 









<0.5       2 (22%) 
1   1 (6%)   1 (11%) 
1.5 3 (5%) 2 (11%) 1 (6%) 6 (67%) 
2 18 (32%) 8 (44%) 7 (44%)   
3 24 (42%) 3 (17%) 6 (38%)   
4 9 (16%) 4 (22%) 1 (6%)   
6 1 (2%)       
8 1 (2%)   1 (6%)   
12 1 (2%)       
BHI  
Macro-method 









<0.5   6 (33%)   2 (22%) 
0.64    1 (11%) 
1 1 (2%) 3 (17%)   1 (11%) 
1.5 3 (5%) 3 (17%)   3 (33%) 
2 9 (16%)      
3 12 (21%) 1 (6%) 1 (6%) 1 (11%) 
4 11 (19%) 1 (6%) 5 (31%) 1 (11%) 
6 5 (9%) 1 (6%) 1 (6%)   
8 7 (12%) 3 (17%) 4 (25%)   
12 5 (9%)   1 (6%)   
16 4 (7%)   1 (6%)   
24    1 (6%)   
≥32     2 (13%)   
Table 4-8: MIC value ranges (mg/L) of in-patient species-specific CoNS to vancomycin 
and teicoplanin investigated using the E-test BHI Macro-method.   
 
The other minor group of CoNS isolates did not demonstrate vancomycin and teicoplanin 
MICs above 1.5 and 4mg/L respectively therefore demonstrating nil resistance to the 
glycopeptides.  Similarly, Isolates of S. hominis did not exhibit heteroresistance as 
vancomycin and teicoplanin MICs were <8 and 12 mg/L respectively which were below the 
criteria range for presence of heteroresistance determination.  Conversely, heteroresistance 
prevalence was apparent in a total of 9(16%) S. epidermidis isolates of which all nine 
exhibited teicoplanin MICs of ≥12mg/L including 2(4%) which exhibited vancomycin MICs 
≥8mg/L.  Similarly, hVIS resistance was apparent in a total of five isolates of S. haemolyticus 
with 5(31%) exhibiting teicoplanin MICs ≥12mg/L including the isolate A53 that also 
expressed vancomycin, MIC of 8mg/L.  Analysis carried out based on pairwise comparisons 
between standard E-test method and BHI macro-method for the glycopeptides, revealed no 
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significant differences between the frequency distribution of either vancomycin or teicoplanin 
MICs for the in-patient CoNS species-specific isolates tested (p >0.05). 
 
4.5.4.1 GRD E-test method for glycopeptide intermediate/heteroresistance detection 
The presence of GIS or hGIS strains was determined for all the 100 in-patient CoNS using 
the new prototype double sided gradient E-test strip in accordance with the manufacturer’s 
instructions.  Results were read after an incubation period of 48 hours to allow detection of 
the slower growing resistant colonies within the susceptible population.  Defined 
heteroresistance/glycopeptide intermediate resistance consensus for CoNS has however yet 
to be established.  As specified, the endpoints read from the GRD E-tests were used for 
determination of interpretative classification similar to those defined for isolates of S. aureus.   
Result analysis was primarily carried out following the manufacturers application of 
interpretative criteria for glycopeptide resistance indication.  For heterogenous resistance, 
interpretative criteria was defined as E-test GRD TEI or VAN cut-off MIC value of ≥16 mg/L 
and a standard E-test VAN MIC of <8 mg/L.  Accordingly, the results for the resistant control 
strains Mu3 and Mu50 VA:TP values were 4:16 mg/L and 16:>32 mg/L respectively.  GRD 
MIC values for the glycopeptide sensitive S. aureus ATCC 29213 VA:TP varied typically 
between 0.5-1.5 mg/L and 1-2 mg/L for each test batch which was within the specified quality 
control range. 
Figure 4-19 shows example of results obtained for two in-patient CoNS isolates using the 
GRD E-test strips in comparison to those obtained with the Mu3 control strain.  
Figure 4-19: Susceptibility results obtained with the prototype GRD (VA)/(TP) 
vancomycin/ teicoplanin, E-test strips for two in-patient representative CoNS isolates 
and the hGIS control isolate.  a) Susceptible S. epidermidis isolate displaying VA/TP 
MICs of 1.5/1.5 mg/L b) S. epidermidis isolate displaying VA/TP MICs of 2/32mg/L c) 
Mu3, isolate displaying VA/TP MICs of 4/32mg/L. 
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The overall comparative MIC distribution ranges of vancomycin and teicoplanin read at 48 
hours using the GRD E-test method performed on the 100 in-patient CoNS isolates are 
illustrated in Figure 4-20.   
Figure 4-20: MIC (mg/L) distribution range of the glycopeptides, vancomycin (VAN) 
and teicoplanin (TEI) for the 100 in-patient CoNS isolates as determined by the GRD E-
test method. 
 
Overall, the use of GRD E-test methodology indicates that although in total 70% of the CoNS 
in-patient isolates displayed high teicoplanin resistance ranging from 6 to >32mg/L, with the 
exception of one isolate, all others remained vancomycin susceptible.  Likewise, neither of 
the two CoNS isolates expressing vancomycin MICs of 4 mg/L were observed to display 
typical growth of small colony variants after 48h incubation similar to those observed with the 
Mu3 (hVISA) control strain.  Mu3 displays sub-populations (micro-colonies) of cell growing up 
to vancomycin concentration level of ≥4mg/L as shown in Figure 4-19c. 
Comparing results for vancomycin and teicoplanin MIC values, although a total of 55 in-
patient CoNS exhibited GRD E-test teicoplanin resistance at MIC values of ≥16mg/L, none of 
these isolates expressed vancomycin MIC value of ≥8mg/L tested by standard E-test 
methodology.  Therefore, based on the application of manufacturers interpretive guidelines, 
none of the in-patient CoNS isolates met the criteria for the presence of heteroresistance 
detection.  Likewise, none of the 100 in-patient CoNS isolates demonstrated the presence of 
GIS with the GRD E-test, based on the manufacturers interpretative criteria of TEI or VAN 
MIC value of ≥16 mg/L and a standard E-test VAN MIC value of ≥8 mg/L. 
Conversely, results based on the application of modified interpretive cut-offs for the GRD E-
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among the 100 in-patient CoNS strains tested (Yusof et al., 2008).  Data for the 100 CoNS 
in-patient isolates was re-evaluated based on interpretive cut-off criteria proposed by the 
researches of TP or VA MIC ≥8mg/L and vancomycin standard E-test MIC value of ≥6mg/L 
for GIS and TP or VA MIC ≥8mg/L and standard E-test VA MIC ≤4mg/L for hGIS detection.  
Data analysis based on these interpretive cut-offs values for GIS detection of TP:VA MIC of 
≥8mg/L and standard E-test vancomycin MIC ≥6mg/L, results reveal an absence of 
glycopeptide intermediate resistance among the 100 CoNS in-patient isolates.  However, re-
evaluated results based interpretive cut-offs values for hGIS detection reveal the possible 
presence of heteroresistance in a total of 66 CoNS isolates.  This includes all isolates 
exhibiting GRD E-test TP MICs of ≥8mg/L and the one isolate exhibiting breakpoint VA MIC 
of 4mg by standard E-test. 
GRD E-Test (Double-Sided) Method: Number of Isolates (Cumulative %) 











<0.5   3 (17%)   3 (33%) 
0.75   4 (22%)     
1 1 (2%) 4 (22%)   1 (11%) 
1.5 10 (18%) 2 (11%) 8 (50%) 2 (22%) 
2 34 (60%) 4 (22%) 4 (25%) 3 (33%) 
3 11(19%)   3 (19%)   
4 1 (2%) 1 (6%)     











<0.5   4 (22%)   3 (33%) 
0.75 1 (2%) 5 (28%)   1 (11%) 
1 2 (4%) 3 (17%)     
1.5 1 (2%)     1 (11%) 
2 1 (2%) 1 (6%)   1 (11%) 
3         
4 3 (5%)   2 (13%) 1 (11%) 
6 3 (5%)   1 (6%)   
8 2 (4%)   3 (19%) 1 (11%) 
12 3 (5%)   2 (13%)   
16 2 (4%)   2 (13%)   
≥32 39 (68%) 5 (28%) 6 (38%) 1 (11%) 
Table 4-9: MIC value ranges (mg/L) of in-patient species-specific CoNS to vancomycin 
and teicoplanin investigated with the Double-Sided GRD E-Test.   
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Data analysis carried out using of the GRD E-test to detect the prevalence of 
heteroresistance based on the distribution of MICs measured for vancomycin and teicoplanin 
for each of the species-specific in-patient CoNS isolates are presented in Table 4-9. 
With the exception of one, all CoNS species-specific isolates tested by double-sided GRD E-
Test, expressed vancomycin MIC values ranging from <0.5 to ≤4mg/L.  Accordingly, all 
species-specific CoNS were classified as vancomycin susceptible with the exception of 
1(6%) S. haemolyticus isolate displaying MIC of 6mg/L.  Conversely the highest GRD E-test 
teicoplanin resistance rates were observed in 14(88%) S. haemolyticus followed by S. 
epidermidis 49(86%).  Comparatively lower TP: GRD resistance rates were observed in 
isolates of S. hominis and the other minor group of CoNS 5(28%) and 2(22%) respectively 
ranging from MIC 6 to >32mg/L.  Based on the manufacturers interpretative guidelines for 
GRD E-test overall results therefore reveal an absence of CoNS species-specific 
glycopeptide intermediate/heterogenous resistance.  
In comparison, using the interpretive MIC cut-offs for hGIS evaluations with GRD E-test as 
proposed by Yusof and colleagues (2008), one (16%) isolate of S. haemolyticus in particular 
would be defined as expressing heterogenous glycopeptide intermediate resistance.  
Therefore, S. haemolyticus isolate, A53 expressing vancomycin standard E-test MIC of 
4mg/L and GRD E-test, VA:TP 6:>32mg/L would fit the hGIS classification criteria.  
Moreover, using these MIC cut-offs interpretive criteria, heterogenous resistance expression 
could also be demonstrated in a total of 66 species-specific in-patient CoNS isolates.  These 
include, 46(81%) S. epidermidis, 13(81%) S. haemolyticus, 5(28%) S. hominis and in 2(22%) 
of the other minor CoNS species displaying TP MICs ≥8mg/L, GRD E-test values therefore 
meeting the defined criteria for heteroresistance detection. 
GRD E-test glycopeptide MIC data further subjected to pairwise sample statistics revealed 
that there was a significant difference observed between CoNS species-specific, distribution 
of vancomycin and teicoplanin MICs and the two test methodologies BHI macro-method and 
GRD E-test method (p = 0.0001 with 99 df).  Similarly, a significant difference was observed 
between MIC frequency distribution of teicoplanin in comparison to use of the standard E-test 
method and GRD-E-test methodology for detection of glycopeptide resistance (p = 0.0001 
with 99 df).  Conversely, no significant difference was however demonstrated between 
vancomycin MIC susceptibility distribution with use of GRD-E-test and the standard E-test 






Colonisation with potentially pathogenic isolates of staphylococci which may become 
invasive are common amongst the haematology patient population, where immunity defects 
are related to underlying malignancy or therapy.  The clinical significance of CoNS disease in 
the healthcare setting continues to increase as strategies in advancing medical practice lead 
to more invasive procedures.  CoNS infections have been noted to compose a serious 
problem among immunocompromised patients, not only as a result of widespread use of 
vascular catheters but also the extensive use of antimicrobial prophylaxis (Feld, 2008).  
CoNS in-patient infections in this vulnerable patient group have become a major concern 
because of their extraordinary ability to rapidly adapt to antibiotic stress due to the extended 
usage of broad-spectrum antibiotics (Livermore, 2000).  Antibiotic resistance may therefore 
also contribute to the poor rates of bacteraemia-related patient outcomes following treatment 
through insufficient clearance of infection (Harbarth et al., 2003).  Hence, effective 
antimicrobial therapy is critical in controlling commonly encountered CoNS bacteraemia in 
the haematology and BMT patient group.  Clinically significant CoNS in this patient group are 
reported to have become increasingly resistant to commonly used antimicrobials and hence 
remain a significant challenge to the provision of successful therapeutic outcomes (Deikema 
et al., 2001; Yadegarynia et al., 2003; Falcone et al., 2015).   
Appropriate antimicrobial therapy is continually challenged not only by the emergence of 
antibiotic resistance but also the underlying disease state such as developing febrile 
neutropenia complicating the in-vivo response to implemented therapeutics (Collin et al., 
2001; Bal and Gould 2007).  Effective empirical antibiotic therapy is therefore dependent on 
the microbiology laboratory providing accurate information of existing spectrum of resistance 
among local strains of CoNS causing BSIs in these patients.  AST is therefore necessary, not 
only to confirm susceptibility to the chosen empirical antimicrobial agent but more essentially, 
for the detection of acquired resistance in species-specific isolates of CoNS.  This is because 
anti-staphylococcal agents from several different antibiotic classes demonstrate differing 
resistance mechanisms hence affecting drug efficacy.  
May and colleagues (2014) in their study demonstrated the significant increase in antibiotic 
resistance in CoNS pathogens over a 13 year period.  The importance of these results 
further indicates the value of monitoring resistance trends within specialist healthcare units 
as has it has become apparent that CoNS can serve as sentinels of resistance.  Additionally, 
study results revealed that CoNS colonisers played a role in potential pathogenesis, acting 
as reservoirs for resistance genes responsible for nosocomial transmission to other 
pathogens. The link between inappropriate broad-spectrum antibiotic prescribing and 
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resistance levels suggests the critical importance of curbing the reservoir of resistance in 
these potentially pathogenic CoNS colonisers (Piette and Verscharegen, 2009).  Hence 
awareness of the predominant BSI isolates and their antibiograms that depict in-vitro 
susceptibility patterns of the prevalent potential pathogens are of importance for clinical 
selection of effective initial empirical therapy.  In most healthcare institutions the provision of 
quantitative MIC antimicrobial data is a prerequisite for the management of in-patient 
infections among the critically ill.  Antimicrobial susceptibility testing is, therefore, important 
not only to confirm susceptibility to the chosen empirical antimicrobial agent but also 
detection of acquired resistance mechanisms especially important in species-specific 
Staphylococcus isolates.  Hence, provision of accurate MICs ensures correct dosage 
guidance for clinicians to ensure targeted patient therapies, which limits antimicrobial 
resistance development thus leading to optimal clinical outcomes (Raney et al., 2002; 
Nonhoff et al., 2005). 
In routine diagnostic laboratories, antibiotic susceptibility profiles are the “first-line” 
phenotypic typing scheme, often used towards identification of clinically significant strains of 
CoNS and their emerging spectrum of resistance.  Therefore, the main purpose of this part of 
the study was to determine the prevalence of resistance among the 100 in-patient CoNS 
isolates recovered from haematology patient group to the commonly used anti-
staphylococcal drugs.  Performance of comparative antibiotic profile analysis of CoNS 
isolates from the pre-admission control patient group in this study also aimed to provide an 
insight into the incidence of resistance amongst the skin colonisers to the same panel of 
antimicrobials.  This was based on the postulation that these skin colonising CoNS isolates 
could be the potential source of nosocomial acquisition and transmission in the 
haematology/BMT patient group.  
The study results using the VITEK®2 automated AST system for all one hundred CoNS 
isolates from both patient groups, demonstrated variable resistance to all classes of 
antibiotics to the panel of 18 agents tested with the exception of tigecycline.  The lowest 
resistance rates were observed to vancomycin, chloramphenicol, linezolid, rifampicin and 
mupirocin in both patient groups.  These results are consistent with other study reports, 
showing that there has been minimal to no resistance to linezolid noted among isolates of 
CoNS with the exception of a few recovered from blood cultures of patients who had 
undergone previous extensive treatment with linezolid (Kelly et al., 2006).  Although the use 
of linezolid is known to be limited in the haematology hospitalised patient group, nonetheless, 
1(3%) skin colonising S. epidermidis isolate (G70) was found to exhibit linezolid resistance.  
However, none of the in-patient CoNS isolates expressed resistance to linezolid.  These 
finding suggest that the absence of resistance to linezolid noted in the in-patient isolates may 
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be due to lack of antibiotic pressure.  Linezolid is exceptionally limited for use in the 
haematology patient group because of its low bioavailability associated with 
immunosuppression and haematopoietic toxicity (Kuter, 2001).   
With the exception of penicillin, the other minor group of CoNS isolates in both patient 
groups, presented the lowest percentage resistance to all the other classes of antibiotics in 
the panel of 18 antimicrobials tested.  The overall antibiogram resistant profiles obtained 
from both patient groups show that less than 10% of the CoNS isolates remained susceptible 
to a few of the commonly used anti-staphylococcal agents, including antimicrobials such as 
rifampicin.  Although infrequently used, rifampicin usually forms part of combination 
therapeutic regimen with either vancomycin or the aminoglycosides for treatment of 
infections that are difficult to eradicate (Rose and Poppens, 2009).  Similarly, of the 
aminoglycosides, gentamicin is a drug frequently used in combination with vancomycin or 
rifampicin particularly for the treatment for MRSA BSIs in healthcare facilities for optimal 
clinical outcomes in high-risk patient groups (LaPlante and Woodmansee, 2007; Rehm et al., 
2008).  While resistance to rifampicin was observed to be low in both patient groups 
comparatively high resistance to all three aminoglycosides, gentamicin tobramycin and 
kanamycin was observed in the in-patient isolates.  Overall, 50% of the in-patient CoNS 
isolates in comparison to around 10% of control group skin colonising isolates demonstrated 
resistance to the aminoglycosides.  It is possible that the higher rates of aminoglycoside 
resistance in the in-patient isolates may have disseminated from the reservoirs of resistance 
present in skin colonising CoNS isolates.  These findings are supported by evidence from 
other studies, reporting that the predominant aminoglycoside resistant phenotype is 
commonly found among CoNS isolates colonising the skin of hospitalised patients.  Hence, 
the prevalence of aminoglycoside resistance observed among nosocomial isolates causing 
serious infection in high-risk patient populations may be due to dissemination from skin 
colonising resistant isolates of CoNS (Klingenberg et al., 2004; Koksal et al., 2009).  The 
present study results therefore suggest that 10% of the control group skin colonising isolates 
may be representative of the resistant aminoglycoside phenotype involved in the spread of 
nosocomial infections. 
The overall percentage resistance rates to all the other classes of antibiotic including the β-
lactams in particular to methicillin was higher amongst the in-patient CoNS isolates in 
comparison to skin colonising isolates of the control patient group.  However, there was no 
significant difference noted between the overall distribution of resistance to all antimicrobial 
classes in both patient group CoNS isolates (p >0.05), with the exception of resistance to 
methicillin.  Through in-vitro studies authors have previously, demonstrated that the majority 
of staphylococcal species are resistant to the penicillins, due to production of beta-lactamase 
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with methicillin resistance among clinical isolates of CoNS having a worldwide prevalence of 
75% (Brown, 2001; Miragaia et al., 2002; Stefani and Varaldo, 2003).  Similar levels of 
methicillin resistance were observed in the in-patient CoNS BSI isolates in comparison to 
much lower rates displayed by the control group isolates. 
Results obtained with the VITEK®2 system analysis has been shown to have excellent 
accuracy for the detection of methicillin resistance in CoNS isolates with a 
sensitivity/specificity of 99/96% accuracy with the use of the anti-staphylococcal antibiotic 
AST-P507 test card (Raney et al., 2002; Ligozzi et al., 2002; Nonhoff et al., 2005).  Based on 
the BSAC/EUCAST breakpoint of 0.25mg/L for oxacillin (a proxy antibiotic drug used for the 
detection of resistance to methicillin) the highest resistance to methicillin was detected in 
78% of the in-patient CoNS isolates in comparison to 28% resistance in the control patient 
group.  The results of this study are also concordant with a previously published study of 
susceptibilities of blood stream isolates from BMT patients reviewed over a seven year 
period; showing a trend of increasing resistance among staphylococcal species to 
semisynthetic penicillins, ciprofloxacin and gentamicin.  The authors demonstrated that some 
staphylococcal species remained uniformly susceptible with the exception of others, 
including isolates of CoNS (80%) demonstrating increasing resistant to methicillin over this 
period (Collin et al., 2001).  Likewise, the present study results indicated high levels of 
resistance among isolates of the in-patient group, with less than five percent of CoNS strain 
remaining susceptible to agents such as linezolid, vancomycin, tigecycline and linezolid. 
Additionally, these in-patient CoNS isolates also demonstrate a significantly higher 
percentage resistance to methicillin in comparison to the skin colonising strains (p <0.05).  
The overall resistance rates observed in haematology patient group in-patient CoNS isolates 
concur with those of a UK based surveillance study of 25 hospitals, where 68.9% of the 
CoNS isolates from blood or line infections were reported to be resistant to methicillin 
(Henwood et al., 2001).  Furthermore, MR-CoNS rates in this study investigation were also 
consistent with data collated from worldwide surveillance programmes, showing that the rate 
of methicillin resistance in CoNS varied from between 70-80% (Fluit et al., 2001).  The 
variation in resistant rates are reported to be dependent on prevalence of MR-strains 
concomitant with the different geographical regions of Europe, USA, Canada and the Latin 
American countries (Falcone et al., 2004; Vincent et al., 2006). 
Observational studies indicate that hospitalisation and antimicrobial treatment tend to 
influence colonisation patterns which impacts on both the risk of cross-transmission between 
patients and probability of acquiring nosocomial infections.  The lower rates of MR (28%) 
observed among control patient group skin colonising isolates were also consistent with 
studies demonstrating that CoNS isolated from the skin of healthy persons were considerably 
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less resistant in comparison to clinical isolates and those belonging to indigenous 
nosocomial populations (Agvald-Öhman et al., 2003).  Furthermore, Cherif and colleagues, 
(2013) in their study comparing skin S. epidermidis isolates from healthy volunteers with 
those causing CR-BSIs in hospitalised patients also demonstrated that resistance to 
methicillin and other β-lactams was found to be much higher amongst CR-BSI isolates than 
those that were CoNS skin colonisers.  Similarly, the observed, overall distribution of MR in 
CoNS isolates recovered from blood cultures of patients in the haematology unit were 
comparatively higher than those of the pre-admission skin-colonisers, results which are  
corroborated by other studies (Yamada et al., 2017).  The authors demonstrated that 
infections attributed to MR-CoNS (60%) were more common in febrile neutropenic patients 
with haematological malignancy in comparison to other high-risk patient group isolates.  The 
observed inefficacy of methicillin therefore, limits treatment options for CoNS associated BSI 
in the haematology patient group related to unfavourable clinical outcomes. 
It was indeed interesting to find that most species-specific CoNS isolates of the control group 
were resistant to mupirocin a topical decolonisation antimicrobial agent frequently used for 
the eradication of healthcare associated methicillin resistant S.aureus colonisers.  Mupirocin 
resistance was observed to be present in up to 16% of all the CoNS skin colonising species 
isolates however, only one, in-patient S. epidermidis isolate (2%) displayed resistance to 
mupirocin.  Predisposition to mupirocin resistance is a factor known to be significantly 
associated with persistent carriage of MR-strains in particular MRSA with failure of 
decolonisation strategies increasing the risk of adverse clinical outcomes (Poovelikunnel et 
al., 2015).  Therefore, study results demonstrate that the therapeutic indication for mupirocin 
would perhaps be limited in up to 16% of the ward population if these patients were 
colonised with mupirocin resistant CoNS isolates.  This level of mupirocin resistance 
displayed by skin colonising strains raises cause for concern, because of the potential risk of 
selection and spread of methicillin resistance among susceptible CoNS associated with 
nosocomial BSIs in high-risk patient groups.  MR-CoNS responsible for healthcare 
associated BSIs and their associated multidrug resistance potential also adds to challenge of 
patient management for optimal clinical outcomes.  These factors, particularly among 
vulnerable patient groups are known to play as important drivers for the emergence and 
dissemination of highly resistant epidemic CoNS strains which may also essentially be 
related to species-specific traits (Rossolini et al., 2010).  Observations made in the present 
study revealed some further important points relating to the antimicrobial spectrum of 
species-specific in-patient CoNS in comparison the skin colonising isolates. 
Documented evidence suggests that resistance may be elicited via transfer of resistance 
elements from nosocomial CoNS strains, acting as reservoirs for resistant genes and are 
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postulated to be the main source of horizontal transfer between species-specific isolates 
(May et al., 2014).  Therefore, of the CoNS species-specific isolates phenotypically 
expressed resistance traits to the 18 principle anti-staphylococcal drugs explored further to 
determine clonal similarity highlighted some important differences.  Comparative analysis of 
species-specific CoNS antibiogram resistance profiles facilitated by use of multivariant 
statistical PCA methodology revealed a high degree of species-specific isolate unrelatedness 
in both patient groups.  Additionally, dendrograms of percent similarity calculated with Dice 
coefficients from the antimicrobial resistant data from both the in-patient and control patient 
groups, using a cut-off set at 95% revealed no major clusters among species-specific CoNS 
resistant isolates.  Sixty-six and 68 antibiograms were distinguished in both in-patient and 
control group respectively.  This phenotypic antibiotic typing scheme revealing a large 
number of unique resistance patterns indicates the presence of highly heterogenous 
populations among CoNS isolates from both patient groups.  PCA-UPMGA analysis further 
revealed a significant lack of correlation between antimicrobial resistance profiles among and 
between species-specific CoNS, particularly noticeable amongst isolates of the control 
patient group.  Such significant differences were more apparent among the other minor 
group of CoNS species-specific isolates of the control patient group in comparison to the in-
patient isolates.  Of these, delineation levels revealed 30% of the isolates exhibiting distinct 
antibiograms comprising predominantly isolates of S. capitis, S. lugdunensis and S. warneri.  
Although antibiogram typing is a relatively simple method with a low discriminatory power 
compared to genotypic methodologies for determination of species-specific isolate 
delineation; results of this study confirm a high degree of unrelatedness among and between 
species-specific CoNS isolates of both patient groups.  Quantitative antibiogram 
determination combined with cluster analysis can therefore be valuable as a simple 
screening method to determine species-specific isolate and clonal relatedness in order to 
elucidate the source of infection. 
The occurrence of highly diverse range of antimicrobial resistance profiles observed between 
and among species-specific in-patient CoNS isolates in comparison to those of the control 
group skin colonisers may also be due a number of different factors that influence resistance 
acquisition.  As such, it could be postulated that the hospital environment may be involved in 
evoking various adaptive responses in colonising strains for survival.  Conversely, 
prevalence of diverse phenotypes among the in-patient CoNS population may be because of 
evolving adaptive responses due to selective pressure and propagation of resistance as a 
consequence of antibiotic overuse.  Such adaptive and coincidental mutational events in the 
context of antimicrobial resistance are well documented, notably amongst clinical isolates of 
staphylococci demonstrating high frequency of resistance to various classes of antimicrobials 
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in particular to the β-lactams (Klingenberg et al., 2004; Arslan and Özkardes, 2007; Koksal et 
al., 2009).  Antibiogram analysis for the determination of phenotypic species-specific isolate 
delineation, although of a lower discriminatory power in comparison to genotypic 
characterisation, could therefore also be used for the clear purpose of confirming and 
elucidating the source and transmission of infection due to species-specific CoNS in the 
hospitalised patient group.  In this study a major diversity in antibiotic susceptibility profiles 
found between and among the different species-specific CoNS isolates in both patient 
groups suggests the in-patient CoNS may belong to hypervirulent clones as opposed to 
being drawn from the hospital environment of patient endogenous skin colonising isolates. 
All antibiotics are known to exert selective pressure favouring resistant variants, such that 
some have a stronger effect in comparison to others as a consequence of their 
pharmacodynamics and mode of action demonstrated by the development and spread of 
MR-staphylococci associated with MDR in the hospital environment.  Such effects of 
antimicrobial resistance development have been noted to be more frequent in isolates of S. 
epidermidis and S. haemolyticus in comparison to all other species of CoNS (Archer and 
Climo, 1994; Diekema et al., 2001).  A pattern of high variability of resistance profiles to more 
than one antibiotic in the panel of 18 antimicrobials tested was found for both in-patient and 
control patient CoNS isolates.  Evaluation of species-specific resistance patterns in this study 
showed that isolates of S. epidermidis S. haemolyticus as well as those of S. hominis in both 
patient groups remained uniformly resistant to penicillin but expressed differing rates of 
resistance to all the other antimicrobial classes.  MDR was significantly more apparent in the 
in-patient isolates of S. haemolyticus (p <0.05), in comparison to the lowest resistance 
observed in isolates of the other minor group of CoNS species.  Of note, one these isolates 
also expressed resistance to vancomycin.  Nonetheless, of the control patient group isolates 
of S. epidermidis demonstrated higher rates of MDR with one isolate also expressing 
vancomycin resistance.  By comparing antibiotic resistance patterns results show that of the 
control patient group isolates there was no significant correlation between S. epidermidis 
isolates and the predisposition for MDR expression (p >0.05).  These findings are supported 
by data from other studies of species-specific resistance patterns of clinical CoNS isolates 
(Biavasco et al., 2000; Tabe et al., 2001; Kristóf et al., 2011).  Conversely in both patient 
groups, the other minor group of CoNS species-specific isolates including those of S. capitis 
S. lugdunensis, S. auricularis and S. warneri generally demonstrated least resistance not 
only to the β-lactams but also exhibited higher levels of susceptibility to the other 
antimicrobial classes as well.  The CoNS resistance patterns noted in this study illustrate the 
role of some species-specific traits in response to particular anti-staphylococcal agents.  
These species-specific differences of non-susceptibility to the various antimicrobial agents, 
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particularly among in-patient isolates suggests that such resistance exhibited by these 
clinical isolates may have emerged under definitive antibiotic pressures.  
Becker and colleagues (2014) in their review publication of clinical and other relevant CoNS, 
report that over the past few decades CoNS isolated from clinical specimens have become 
significantly more resistant to the commonly used antimicrobials.  Previous reports 
comparing antibiotic resistance patterns demonstrate that methicillin resistant species-
specific isolates usually also display MDR, defined as resistance to three or more antibiotic 
classes (Diekema et al., 2001).  Moreover, with the continuously increasing percentage of 
MDR-CoNS noted in patients with haematological malignancies with Gram-positive BSIs, 
MDR raises particular concerns because of limited treatment options and the associated 
consequence of higher mortality rates (Marin et al., 2014).  MR-CoNS in-patient isolates in 
this study were generally observed to demonstrate a higher degree of multi-drug resistance 
in comparison to those that were susceptible.  The overall frequency of MDR and MR among 
the 100 CoNS in-patient isolates was high (75% and 78% respectively).  These results are 
concordant with results of a study which demonstrated that MR-CoNS blood culture isolates 
(67.5%) from septic patients also displayed resistance to more than three antibiotic classes 
in comparison to isolates expressing methicillin susceptibility (Koksal et al., 2009).  
Comparatively, lower rates of MDR and MR were observed to be exhibited by the skin 
colonising control group CoNS isolates (23% and 28% respectively).  Overall analysis of both 
patient group CoNS antimicrobial resistance data indicated that there was a significant 
correlation between prevalence of MDR and corresponding high rates of methicillin 
resistance (p = 0.0001).  Although S. haemolyticus exhibited higher resistance rates to all 
antimicrobial classes in comparison to all other species isolates; a significant association 
between MDR and the propensity to express methicillin resistance was observed only in the 
in-patient S. epidermidis isolate (p = 0.0001).  These findings are supported by data from 
other studies showing resistance to other classes of antimicrobials are much lower in 
methicillin sensitive CoNS in comparison to those that express methicillin resistance (Sader 
and Jones 2012). 
VITEK®2 analysis of species-specific antibiotic resistance profiles in this study revealed that 
of the three predominant CoNS species from the in-patient group the highest rates of 
methicillin and MDR was observed among 15 out of the 16(94%) isolates of S. haemolyticus.  
Of these one (6%) in-patient S. haemolyticus isolate notably also demonstrated resistance to 
vancomycin, results which are concordant with observations made by authors of previous 
studies.  Falcone and colleagues (2006) study of patients with haematological malignancies 
over a seven month period, reported that S. haemolyticus exhibiting high rates of methicillin 
and teicoplanin resistance were second only to S. epidermidis as causative agents of 
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bacteraemia in post-transplantation period, further concurring with the results of the present 
investigation.  Furthermore, clinical isolates of S. haemolyticus have been consistently 
documented as emerging nosocomial pathogens, particularly characterised by their tendency 
to develop MDR with a higher predisposition to glycopeptide resistance (Schwalbe et al., 
1987, 2007; Stefani and Varaldo, 2003).  Exploration of inter and intraspecies relationships 
isolate relatedness utilising PCA dataset analysis producing two factors variables, 
antimicrobial resistance and species-specific characteristic (Figure 4-6 and 4-14), 
demonstrated that one of the in-patient isolates of S. haemolyticus was significantly 
unrelated to the others in the sample group based on the Euclidean distance between the 
other species and this isolate.  In comparison to all the other species-specific CoNS, this 
particular in-patient S. haemolyticus isolate appears to demonstrate a significantly distinct 
response not only to vancomycin but also to all the other 18 antimicrobials in the test panel.  
Although the majority of S. haemolyticus isolates demonstrated higher levels of MDR and 
MR in comparison to the other species-specific CoNS, isolates of S. epidermidis from both 
the in-patient and the control patient group demonstrated a higher prevalence of MDR 
significantly associated with methicillin resistance 88/83% and 34/38% respectively (p <0.05).  
Interestingly, in the control patient group although not statistically significant, the prevalence 
of MR associated with MDR was observed to be higher in isolates of S. epidermidis in 
comparison to S. haemolyticus (34%/38% and 21%/13% respectively).  Additionally, the 
observed resistance to vancomycin in one (3%) S. epidermidis skin colonising isolate would 
be of concern as this could potentially be the causative agent of nosocomial BSI in the 
haematology patient group.  The prevalence of such MDR-CoNS isolates including 
resistance to vancomycin limit therapeutic options in high-risk patient groups.  In recent years 
however, concerns have also been raised regarding the efficacy of vancomycin in the 
treatment of serious BSIs caused by MR and MDR-staphylococci.  There is increasing 
evidence of high rate of vancomycin therapeutic failures of BSI caused by such organisms. 
This has been noted particularly amongst MRSA isolates displaying vancomycin MICs of 
1.5mg/L and at the breakpoint of 2mg/l, although considered susceptible in accordance with 
the BSAC, CLSI and EUCAST guidelines, such isolates have failed in-vivo eradication 
(Sakoulas et al., 2004; Steinkraus et al., 2007).  Although, acquired resistance to the 
glycopeptides has also been recognised among MR-CoNS, teicoplanin resistance has been 
reported to occur more commonly than vancomycin resistance particularly among isolates of 
S. haemolyticus followed by S. epidermidis in comparison to vancomycin resistance 
(Biavasco et al., 2000).  Unlike such previously published data, teicoplanin resistance in this 
study was noted to be much higher amongst in-patient S. epidermidis isolates in comparison 
to S. haemolyticus (34% and 19% respectively); with even higher rates of resistance noted in 
those of the control patient group (49 and 47% respectively).  Additionally, a significant 
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association between isolates expressing MR with those demonstrating resistance to 
teicoplanin was noted only amongst S. epidermidis in-patient isolates (p >0.05).  Of note, 
such resistance rates are also known to correlate with treatment failures in high risk patient 
groups.  As such, D’Antonio and colleagues (2004), in their study of teicoplanin or 
vancomycin for the treatment of Gram-positive cocci infections in neutropenic patients with 
haematological malignancies, documented there were there were more therapeutic failures 
associated with use of teicoplanin than with vancomycin treatment.  Furthermore, these 
therapeutic failures rates were noted to be greater in episodes caused by S. epidermidis and 
to a lesser extent by S. haemolyticus with use of teicoplanin than with vancomycin.  The 
authors demonstrated that the response rate to both teicoplanin and vancomycin was higher 
in S. hominis isolates, further corroborating the findings of the present study.  Conversely, a 
case controlled retrospective comparative analysis of MR-bacteraemia in patients with 
haematological malignancies, demonstrated an overall reduced susceptibility to teicoplanin 
noted to be higher among  MR-S. haemolyticus in comparison to bacteraemia caused by 
MR-S. epidermidis isolates (47.5% and10% respectively), (Falcone et al., 2004).  Multi-drug 
resistance and the increased use of vancomycin necessitates the availability of reliable 
methods for detection of resistance especially in cases of decreased susceptibility to the 
glycopeptides 
Clinical isolates are known to have the ability to accumulate antibiotic resistance determinant 
and therefore, with the substantial increase in the incidence of MR-CoNS noted over the last 
few decades has resulted in the frequent use of glycopeptides for the treatment of infections 
with such isolates(Tacconelli et al., 2001; Stefani and Varaldo, 2003).  The glycopeptide, 
vancomycin has long been established as the foundation of chemotherapy for the treatment 
of CoNS BSIs in the haematology patient group.  Progressive antibiotic resistance caused by 
unwarranted vancomycin therapy is however, thought to be a possible risk factor for limiting 
susceptibility and therefore continues to be an important determinant of clinical outcomes in 
the high-risk haematology patient group (Biavasco et al., 2000; Boisson et al., 2001; Natoli et 
al., 2009; Chen et al., 2010).  Currently few studies exist demonstrating the link between 
reduced vancomycin susceptibility and the potential clinical significance associated with 
MDR-CoNS BSIs, in comparison to the numerous published reports linking vancomycin 
treatment failure associated with MRSA infections (Tenover et al., 2001; Howden, 2005; 
Howden et al., 2004; 2010).  However, with the extensive use of vancomycin due to 
widespread MR for the treatment of Gram-positive cocci in neutropenic patients with 
haematological malignancies more therapeutic failures have been documented associated 
with infections particularly caused by S. epidermidis and S. haemolyticus isolates (D’Antonio 
et al., 2004; Nunes et al., 2007; Ahlstrand et al., 2011).  Such isolates have however been 
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noted to demonstrate a much lower response to teicoplanin in comparison to vancomycin.  It 
has therefore become imperative to reliably detect developing resistance to the 
glycopeptides which may be associated with species-specific CoNS isolates concomitant 
with adverse clinical outcomes.  With the potential of emerging resistance possibly due also 
to the presence of isolates exhibiting heterogenous resistance to vancomycin, it becomes 
increasingly important for clinical laboratories to distinguish such isolates using more 
sensitive phenotypic detection methodologies.  This study therefore further focused on 
investigating the prevalence of reduced glycopeptide susceptibilities among the in-patient 
CoNS isolates based on MIC evaluations using AST techniques which had greater specificity 
than those currently available in routine laboratories.  
Both the VITEK®2 and the standard E-test susceptibility testing methods provide quantitative 
results (MICs) and categorical qualitative assessments of susceptibilities which fulfil the 
requirements for earlier microbiological diagnosis and appropriate directed therapy based on 
evaluated in-vitro antimicrobial efficacy (Reller et al., 2009).  MIC testing of the antibiotics for 
the causative organisms remains the ‘gold-standard’ methodology.  The VITEK®2, AST 
system utilising micro-broth in-vitro diagnostics, calculates MIC values by extrapolating 
growth curves and application of dedicated algorithms.  However, the standard E-test 
method which incorporates both intermediate and traditional two-fold dilutions provides a 
more sensitive susceptibility marker for MIC evaluations in comparison to the VITEK®2 
system.  Therefore, comparative analysis to ascertain the true prevalence of glycopeptide 
resistance amongst the 100 in-patient isolates revealed differences in MIC values and hence 
susceptibility classification with the use of E-tests.  The generation of MICs across a gradient 
of 15 dilutions with the E-test technique providing a greater degree of sensitivity and 
specificity allows for easier detection of small changes that occur in MICs over time due to 
antimicrobial pressure (Balouiri et al., 2016).  Thus, this technique provides a useful means 
for tracking trends in resistance development over time due to the prevalent use of 
vancomycin in most healthcare institutions. 
In-patient CoNS isolates in this study exhibited overall susceptibility to vancomycin, however, 
a number of isolates expressed variable susceptibility to teicoplanin with the use of the two 
test methodologies.  There was an overall 22% and 26% disparity observed between 
teicoplanin susceptibility as determined by VITEK®2 and E-test method respectively.  
However, comparing overall teicoplanin MIC result distribution revealed no significant 
difference (p = 0.624) between VITEK®2 and the standard E-test susceptibility test 
methodologies.  Conversely, however the highest E-test MIC₅₀ and MIC₉₀ displayed by 
teicoplanin indicates that significantly higher concentrations (p <0.0004) of this antimicrobial 
are required to achieve comparatively similar proportional inhibition rates relative to 
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vancomycin.  Interestingly, although the majority of CoNS isolates displayed susceptibility to 
vancomycin, there were considerable difference in MIC distribution rates with this 
antimicrobial and the two test methodologies.  The majority (52%) of the in-patient CoNS 
exhibited vancomycin MICs at 2mg/L when tested by E-tests, whereas when tested by 
VITEK®2, the majority (51%) displayed MIC of 1 mg/L with one isolate classified as resistant, 
exhibiting an MIC of 8mg/L.  These observed significant difference with vancomycin MIC 
distribution was dependent on the AST methodology used (p = 0.0001).  These findings are 
evidenced in a similar study comparing vancomycin MICs obtained by E-test with broth 
microdilution methodology (Paiva et al., 2010).  The authors of the study demonstrated that 
the E-test method provided MICs of vancomycin 1-2 fold dilutions which were significantly 
higher (p <0.0001) than those determined by broth microdilution.  Additionally, the majority of 
S. epidermidis isolates in their study presented MIC of 1mg/L by broth microdilution and 
despite S. haemolyticus isolates being more resistant to the glycopeptides, the isolates 
presented MICs between 1-2 mg/L.  Similarly, comparisons of the species-specific CoNS 
glycopeptide MIC evaluations performed on the in-patient isolates in this study reflected 
similar differences in vancomycin MICs as determined by E-tests.  The S. epidermidis in-
patient isolates demonstrated comparable difference in MICs evaluation using the two test 
methodologies.  The majority of isolates (75%) demonstrated MICs of 2mg/L by E-test and 
60% at MIC of 1mg/L by VITEK®2.  Interestingly, comparative analysis of the performance of 
the E-test revealed that significantly higher proportions of S. epidermidis isolates (p = 0.0035) 
were inhibited with increasing antibiotic concentrations in comparison to VITEK®2.  On the 
other hand, no such correlation (p >0.05) was noted between isolates of S. haemolyticus, S. 
hominis and the other minor group of CoNS species-specific isolates with VITEK®2 (Figure 4-
15).  On the whole, among the 100 species-specific in-patient CoNS isolates the MIC50 and 
MIC90 for vancomycin were on average approximately one doubling dilution higher by 
standard E-test in comparison to those obtained using the VITEK®2 automated system. 
The disparity in MIC evaluations using the two AST methodologies was however, observed 
to be greater among isolates of S. haemolyticus.  The majority of in-patient S. haemolyticus 
(n=16) 50%, presented MICs of 2mg/L by E-test and 19% MICs >2mg/L with none of the 
isolates expressing MIC at 1mg/L.  On the other hand, with the VITEK®2, the majority (76%) 
of MDR-isolates of S. haemolyticus presented MICs between 1 and 2mg/L with one isolate 
expressing resistance at 8mg/L. However, this resistant S. haemolyticus isolate A53, 
demonstrated borderline susceptibility to vancomycin at MIC 4mg/L, one doubling dilution 
lower than that observed with VITEK®2 and therefore classified as susceptible when tested 
by E-test.  Similar differences were also observed with teicoplanin for all three predominant 
species-specific CoNS with the exception of the other minor group of CoNS isolates.  In total, 
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twenty two and 24 CoNS isolates demonstrated resistance to teicoplanin when tested by 
VITEK®2 and E-tests respectively.  Resistance to teicoplanin was observed predominantly in 
S. epidermidis in just over 30% of the isolates in comparison to (19%) of the S. haemolyticus 
with MICs ranging between 6-24mg/L.  The level of teicoplanin resistance expressed was 
however, significantly different with E-tests, demonstrating teicoplanin activity across a much 
wider MIC distribution range in comparison to VITEK®2 (p <0.05).  The higher E-test MIC₅₀ 
and MIC₉₀ displayed by teicoplanin and those obtained by VITEK®2, in comparison to 
vancomycin indicates that significantly higher concentrations of the antibiotic (p = 0.0004) are 
required to achieve relatively similar proportional inhibition rates.  The single exception was 
results obtained for teicoplanin with the other minor group of CoNS species, where almost no 
significant difference was observed for MIC50 and MIC90 values (p = 0.9). 
These significant difference in CoNS species-specific MIC results observed with the use of 
the two different AST methods are concordant with results of other studies reporting that the 
determination of vancomycin MIC, in particular is method specific (Sader et al., 2009; Paiva 
et al., 2010).  However, in the present study, with the exception of S. haemolyticus, overall 
comparative MIC dataset analysis by PCA, suggest that there is no significant difference 
between the two antimicrobial test methodologies for glycopeptide susceptibility expression 
in relation to species-specific CoNS isolates.  Nonetheless, variability in susceptibility 
categorisation based on evaluated MICs by different test methods, would clearly influence 
clinical decisions for targeted therapies and impact on resistances selection. 
Successful treatment of complicated staphylococcal infections is particularly challenging 
especially if the isolates are MDR.  Selective pressure increasingly leads to antibiotic 
resistance thus limiting therapeutic options and increased use of vancomycin (Kirst et al., 
1998).  The high use of vancomycin in the haematology unit may be an important factor that 
has influenced the higher levels of glycopeptide MICs noted particularly amongst in-patient 
isolates of S. epidermidis and S. haemolyticus.  This would be a genuine cause for concern 
in the haematology patient group as the higher observed MICs may be indicative of the 
possible rise in resistance development due to antibiotic pressure.  More importantly, 
nosocomial CoNS, known for their innate adaptive capability have the potential to acquire 
and spread such resistance among and between other susceptible species-specific isolates 
which would, therefore, significantly impact on patient clinical outcomes.  The, use of reliable 
susceptibility methods are therefore fundamental for the adequate prediction of clinical 
response.  The findings in study support the fact that E-tests in comparison to the current 
VITEK®2 laboratory technology provide more definitive MIC results.  This is evidenced by 
reports of data of similar analysis from other studies demonstrating that vancomycin MIC 
evaluations by E-tests were comparatively more reliable for detecting antimicrobial 
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resistance and are therefore also more reliable for the predication of treatment responses 
(Sakoulas et al., 2004; Sader et al., 2009).  Moore and colleagues (2011) in their study, 
comparing clinical outcomes of patients on vancomycin treatment for BSIs due to MRSA also 
used E-test methodology to demonstrate clinical failures; reporting that this was due to 
isolates exhibiting higher vancomycin MICs.  On the other hand, although E-tests are 
observed to overestimate MICs generally by 0.5-1.5 log2 dilution difference, authors of other 
studies have found an agreement between vancomycin MICs by E-test and other 
comparative test methods (Hope et al., 2013). The log2 dilution differences observed with E-
tests have been attributed to the different calibration standards of the test methodologies 
which are thought not to impact significantly on overall susceptibility results (Raney et al., 
2002).  Other studies however have shown the importance of evaluating vancomycin MICs 
using reliable test methodologies whereby the reported results impact significantly on clinical 
guidance particularly for the management of MRSA or MR-CoNS BSIs (Sakoulas et al., 
2004; Moore et al., 2011).  Therefore, antibiotic resistance detection using appropriate test 
techniques is an issue of importance for CoNS-associated BSIs in the haematology patient 
group.  Results of the overall assignment probability for vancomycin and teicoplanin 
susceptibility with both AST methods in the present study was however, determined to be 
high (p >0.05), thus demonstrating good correlation between standard E-test and VITEK®2 
AST methodologies for the MIC evaluation.  The retrospective result analysis of these 
comparisons suggest that the laboratory reported VITEK®2 based vancomycin MICs for 
CoNS-associated BSIs are potentially reliable for predicting treatment response to 
vancomycin in the haematology patient group.   
Although glycopeptides, in particular vancomycin as initial empirical therapy, until recently 
have been effectively used for the treatment of MR-staphylococci, the number of isolates 
demonstrating reduced susceptibility or complete resistance to the glycopeptides however, 
have been increasingly reported (Tabe et al., 1998; Baivasco et al., 2000).  However, low-
level glycopeptide resistance associated with therapeutic failure has been more commonly 
described in S. aureus infections (Howden, 2005; Howden et al., 2010; Chen et al., 2011; 
Satola et al., 2011).  On the other hand, glycopeptide heteroresistance among invasive 
CoNS infection has had limited characterisation to date (Van Der Zwet et al., 2002).  CoNS 
isolates with decreased susceptibility to the glycopeptides are difficult to detect, particularly, 
where heteroresistance sub-populations are present.  Standard methodologies are limited 
when attempting to detect resistance amongst a heterogenous population consisting of cells 
expressing susceptibility and a sub-population expressing low-level susceptibility to 
vancomycin.  These limitations have been noted with even the latest version of the VITEK®2 
software, which may not report vancomycin MICs above 4mg/L for most species-specific 
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CoNS except for isolates of S. haemolyticus.  The VITEK®2 displays low sensitivity for the 
detection of heteroresistant subpopulations as it tends to categorise VIS strains as 
susceptible.  VITEK®2 therefore remains unreliable for the detection of heteroresistant strains 
because the standard AST inoculum  used is below the requisite threshold for the detection 
of the resistant subpopulations (Wootton et al., 2007).  The clinical relevance of low-level 
glycopeptide resistance in potential pathogenic isolates of CoNS remains difficult to ascertain 
however, similar to infections with hVISA and VRSA these may be associated with treatment 
failures (Jones, 2006).  In the haematology patient group, BSI-associated CoNS expressing 
decreased susceptibility to the glycopeptides not only limits treatment options but more 
importantly requires the implementation of control of infection measures to restrict 
nosocomial spread of such resistant isolates.  The lack of standardised protocols for the 
phenotypic detection of slower growing cells expressing resistance to the glycopeptides 
within a predominantly susceptible population does not allow elucidation of such resistance 
in the routine laboratory (Del’Alamo et al., 1999; Howden et al., 2010). 
The standard method for optimal detection of hVIS strains is the PAP-AUC, an impractical 
method, currently confined to reference laboratories and does not provide results in a 
clinically relevant time frame (Howe et al 2000; Wooton et al 2001).  However, alternative 
methods purposed for evaluating staphylococci expressing heterogenous or intermediate 
resistance to the glycopeptides were employed in this study to describe the prevalence of 
heteroresistance amongst in-patient CoNS from the haematology patient group.  Although no 
standardised diagnostic methodology exists for these tests either, both the E-test macro-
method and GRD E-test methodology used in this study to assess susceptibility to both 
vancomycin and teicoplanin revealed differing levels of activity against the hundred CoNS in-
patient isolates.  In general, these variable difference in test results are thought to be mainly 
due the influence of various technical factors associated with these protocols (Wooten et al., 
2007; Howden et al., 2010; Satola et al., 2011).  Furthermore, as the criteria used to classify 
heterogenous of intermediate resistance has yet to be defined for CoNS; application of the 
CLSI/EUCAST MIC breakpoints categorisation for hVISA and VISA used for the evaluation of 
heterogenous resistance in the in-patient CoNS isolates may not be a definitive of the actual 
prevalence of heterogenous isolates in the haematology patient group. 
Significant differences defining the presence of reduced susceptibility to the glycopeptides 
were observed with the two test methodologies.  Using the manufacturers interpretative 
guidelines, the double sided GRD E-test evaluations revealed an absence of glycopeptide 
intermediate or heterogenous resistance in all 100 of the in-patient CoNS isolates. 
Conversely, based on the method specific interpretative criteria, heteroresistance was 
defined in a total of fourteen CoNS isolates using the E-test macro-method.  Of these, 
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heteroresistance was expressed predominantly by 5(31%) and S. haemolyticus and 9(16%) 
isolates of S. epidermidis.  This method optimises detection of hVIS isolates because the 
enriched BHI media used, supports the growth of slower growing subpopulations and the 
predefined stable E-test gradient is also largely inoculum tolerant (Walsh et al 2001).  On the 
other hand, reclassification, using defined interpretive MIC cut-off values purposed by Yusof 
and colleagues (2008) with the GRD E-tests, demonstrated heterogenous resistance in the 
majority (81%) of both S. epidermidis and S. haemolyticus isolates.  Five (28%) S. hominis 
isolates and 2(22%) of the minor group of CoNS species-specific isolates would also be 
defined as expressing heteroresistance.  The apparent variability in result evaluation 
observed with the two test methods is not only dependent on the technicality of these test 
protocols but also on the non-standardised criteria used to define hVIS. 
As stated by authors of previous studies, evaluation of heteroresistance is method 
dependent and technical factors have an inevitable variability inherent within the test protocol 
which affects differentiation of staphylococcal isolates with MICs around the susceptibility 
breakpoint (Walsh et al., 2001: Wootton et al., 2007; Vaudaux et al., 2010).  With the use of 
these defined characteristics, the main differences in the degree of glycopeptide 
antimicrobial resistance noted with use of E-test macro-method in comparison to GRD E-
tests was primarily the test media.  The main critical variable in the macro-method is the use 
of BHI agar media for AST together with the use of higher inoculum density.  This non-
susceptibility test media is basically an enriched culture medium which allows growth of 
slower growing resistant isolates requiring prolonged incubation period of up to 48 hours.  
Therefore, established interpretive guidelines are not applicable for definitive 
heteroresistance identification.  However, researchers have ascertained that these 
methodologies could be used as initial screening methods for evaluating presence of 
heteroresistant isolates, as these methods incorporate media supplements that improve their 
detection (Wootton et al., 2007; Howden et al., 2010; Satola et al., 2011).  On the other hand, 
the GRD E-test method utilises horse blood enriched Mueller-Hinton, an AST medium with a 
defined composition and a standard inoculum  which however also requires prolonged 
incubation for isolation of slow growing resistant sub-populations.  The use of a standard 
inoculum with this methodology, however, increases the risk of reduced sensitivity for the 
detection of slow-growing or low-frequency heteroresistance subpopulations thus increasing 
the risk of underestimating resistance.  Nonetheless despite the limitations of the two 
screening methodologies used in this study for heteroresistance detection, it is interesting to 
note, that definitive low level vancomycin resistance was potentially expressed by the one 
MDR-S. haemolyticus (A53) that expressed teicoplanin resistance but borderline vancomycin 
resistance when tested by standard E-test methods.  This isolate exhibited high level 
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vancomycin resistance at MIC 8mg/L by both BHI macro-method and VITEK®2, however 
confirmation of heteroresistance would be determined by PAP-AUC method.  Overall result 
analysis revealed not only significant differences between the two test methodologies, but 
also significant differences in MIC distribution of teicoplanin (p = 0.0001) but not with 
vancomycin.  
Previous studies have established that increasing resistance to teicoplanin is frequently 
accompanied by an increase in vancomycin resistance expressed at a relatively much lower 
level.  Furthermore, all identified VISA strains to date have also been shown to express 
reduced susceptibility to teicoplanin (Hiramatsu et al., 1997; Hiramatsu, 2001).  Other studies 
using quantitative MIC tests have also demonstrated that isolates with higher MICs within the 
susceptible category range for vancomycin are likely to be associated with treatment failure 
rather than success (Sakoulas et al., 2004).  In-vitro glycopeptide resistance in staphylococci 
evaluation studies have demonstrated that teicoplanin resistance is a previous stage for 
development of resistance to vancomycin, thus making this glycopeptide a useful maker for 
isolates demonstrating intermediate and potentially heterogenous resistance to vancomycin 
(Sieradzki et al., 1998; Sader et al., 2001, Liu and Chambers, 2003).  Indeed, investigation of 
the prevalence of intermediate or heterogenous resistance to the glycopeptides therefore 
provides crucial data for clinical relevance and therapeutic choices for better patient 
outcomes (Tevell et al., 2014). 
Prevalence of teicoplanin resistance among the in-patient CoNS isolates were observed to 
significantly higher in isolates of both S. epidermidis and S. haemolyticus particularly with 
evaluations using the GRD-E-tests (p = 0.0001).  Interestingly, no significant differences 
were observed with MIC susceptibility distributions with the BHI macro-method, GRD-E-tests 
and with the standard E-tests.  The high rates of observed teicoplanin resistance among 
CoNS isolates suggests that this may be due to extensive use of vancomycin for the 
treatment of CoNS-associated BSIs in the haematology patient group.  Similarly, although 
the clinical significance of decreased susceptibility to teicoplanin at MICs >4mg/L, still remain 
somewhat unclear, the disparity in teicoplanin susceptibility as noted in this study versus that 
of vancomycin has been well documented in other studies (Del’Alamo et al., 1999; Liu and 
Chambers 2003; Nunes et al., 2007).  Furthermore, Bertin and colleagues (2004) in their 
study evidenced that the high incidence of CoNS isolates with decreased susceptibility to 
teicoplanin correlated significantly with high vancomycin use in haematology patients in their 
institution.  The findings of this study are further corroborated by authors of other studies 
correlating the high incidence of teicoplanin resistance with an increase in vancomycin use, 
resulting in a lower clinical response in comparison to isolates that were susceptible (Falcone 
et al., 2004; 2006).  Additionally, increasing vancomycin pressure favours the selection of 
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rare clones that demonstrate resistance to teicoplanin but under continued antibiotic 
pressure favour development of heterogeneous resistance.  In such cases isolates 
expressing teicoplanin resistance is a strong indicator of developing resistance to 
vancomycin and hence suboptimal clinical responses (Liu and Chambers 2008).  The 
present study, because of its retrospective nature however limits correlation of evaluated 
teicoplanin MICs with therapeutic outcomes.  It would have been of interest to note if the 
differences in higher teicoplanin MICs observed predominately amongst both S. epidermidis 
and S. haemolyticus, in-patient isolates were associated with therapeutic failures in the 
haematology patient group, where empirical use of vancomycin is high for the treatment of 
staphylococcal BSIs. 
It is possible that CoNS bacteraemia caused by antibiotic-resistant species-specific isolates 
may be related to features that are intrinsic to resistant isolates under antibiotic pressure or 
are characteristics that are also unique to the immunocompromised patient infected with 
these CoNS.  Widespread antimicrobial resistance is therefore an important problem 
challenging the treatment of CoNS-associated infections in the immunocompromised host 
thus leading to the frequent use of vancomycin.  However, excessive long term vancomycin 
therapy with minimal changes detected by conventional MIC determination methods can be 
seen to severely compromise the therapeutic efficacy of severe infections with MR-CoNS 
with a tendency to also express MDR.  This is evidenced in a prospective surveillance study 
regarding the incidence and the risk factors of glycopeptide resistance among CoNS-
associated BSIs, demonstrating a significant correlation between high glycopeptide use in 
individual wards and the development of glycopeptide resistance (Tacconelli et al., 2001).  
Vancomycin inefficacy facilitated by the immunosuppressive state of haematological patient 
therefore adds to the risk of serious infections due to MDR-CoNS becoming notoriously 
difficult to treat with current drugs of choice. 
Overcoming the limitations of currently in use anti-staphylococcal drugs, the implementation 
of newer antimicrobial agents may have a potential role particularly for the treatment of 
recalcitrant BSIs.  These new antimicrobials may be less susceptible to mechanisms of 
resistances that render them ineffective and therefore their use has the potential to improve 
patient outcomes.  In view of the resistance observed in majority of CoNS isolates and the 
lack of effective of antibiotics available for the treatment of infections caused by MDR-CoNS 
isolates; it was therefore of interest to investigate the in-vitro efficacy of newer antibiotics 
against the in-patient isolates in this study, utilising the standard E-test AST methodology.  
Of these, daptomycin, tigecycline and ceftaroline were the agents investigated as these 
agents have been recently introduced into clinical practice for the treatment of serious 
infection due to MR-staphylococci and MDR-CoNS.  Daptomycin, a cyclic lipopeptide, 
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tigecycline a glycylcycline and ceftaroline a fifth generation cephalosporin have all been 
shown to have good in-vitro activity against most Gram-positive isolates (Kratzer et al., 2007; 
Guay, 2011).  Daptomycin has been described to have superior activity to vancomycin in 
patients with bacteraemia caused by MR-CoNS.  Additionally, greater resolution of clinical 
infection has been associated with patients receiving daptomycin in comparison to 
vancomycin therapy (Falcone et al., 2012).  
In the present study, in comparison to tigecycline and ceftaroline the highest in-vitro activity 
against all 100 species-specific CoNS in-patient isolates was demonstrated by daptomycin. 
Additionally, in comparison to both the glycopeptides, tigecycline and ceftaroline MIC50 and 
MIC90 for daptomycin observed in this study was significantly lower (p = 0.001) 
demonstrating the greater potency of the drug at comparatively lower concentrations.  Both 
daptomycin and tigecycline in comparison to ceftaroline produced significantly greater 
inhibition for a given antibiotic concentration (p = 0.001).  These results are concomitant with 
results of a previous study demonstrating the superior efficacy of daptomycin used for the 
treatment of primary bacteraemia associated with CoNS isolates expressing low level 
vancomycin in severely ill patients (Kelesidis, 2011).  Similarly, Moore and colleagues, 
(2011) also demonstrated that daptomycin was more effective and associated with better 
clinical outcomes compared to vancomycin use for treatment of MRSA bacteraemia 
expressing high vancomycin MICs (≥1 mg/L) or in patients that were unresponsive to 
vancomycin therapy.  Daptomycin use, as an alternative to vancomycin could therefore be 
deemed to be more efficacious with negligible toxicity for the treatment of MDR-CoNS 
associated bacteraemia in the haematology patient group. 
Tigecycline a broad spectrum antimicrobial, known to be efficacious against both Gram-
negative isolates and MR-staphylococci on the other hand, demonstrated comprehensive 
susceptibility against all in-patient CoNS isolates when tested by VITEK®2.  However, 
tigecycline resistance was noted in 13% of the isolates when tested by the more sensitive 
standard E-test methodology.  Tigecycline working within a narrow susceptibility spectrum 
when compared to the other antimicrobials was noted to demonstrate resistance 
predominantly in isolates of S. haemolyticus followed by S. epidermidis and S. hominis (19%, 
16% and 6% respectively).  Similar results were reported by Natoli and colleagues (2009) in 
their study, of MDR-CoNS in haematology patients with reduced susceptibility to the 
glycopeptides.  The authors reported results concordant with those of this study where 
isolates of S. epidermidis and S. haemolyticus responsible for BSIs demonstrated 
susceptibility to daptomycin, linezolid and tigecycline with a few however, also expressing 
resistance to tigecycline. 
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The development of broad spectrum bactericidal fourth and fifth generation cephalosporins 
such as ceftaroline that demonstrate efficacy have been shown to have time-dependent 
killing activity against Gram-positive organisms that are clinically resistant to the β-lactams 
(Guay, 2011; Laudano, 2011).  Primarily, ceftaroline as an alternative therapeutic agent has 
been documented to have good activity against MRSA bacteraemia and in cases of reported 
failures in patients on vancomycin therapy demonstrating elevated vancomycin MICs 
(Polenakovik and Pleiman, 2013).  Other studies have also documented similar activity 
against both methicillin susceptible and MR-CoNS isolates of S. epidermidis, S. 
haemolyticus, S. hominis and S. lugdunensis (Mushtaq et al., 2007; Saravolatz et al., 2011; 
Sader et al., 2013).  In the absence of defined EUCAST/CLSI for CoNS and using the 
susceptibility criteria for S. aureus for ceftaroline susceptibility evaluation, the present study 
results showed that ceftaroline exhibited high in-vitro activity against the majority of all 
methicillin sensitive and resistant in-patient CoNS isolates.  The results obtained in this study 
are similar to those obtained in a study by Ge and colleagues (2008).  The authors 
demonstrated that ceftaroline exhibited potent activity against both methicillin sensitive and 
methicillin resistant isolates with MIC90 of 0.12mg/L and 0.5mg/L respectively.  Likewise, in 
the present study with the exception of resistance noted in 6(38%) MDR-S. haemolyticus 
expressing MIC of 4mg/L the majority displayed MIC50 and MIC90 of 0.09 and 1.7mg/L 
respectively demonstrating good activity against both methicillin sensitive and resistant in-
patient CoNS isolates.  Thus, the greater activity of ceftaroline suggests it could be a better 
alternative for the treatment of CoNS associated BSIs particularly against those that also 
express reduced activity to teicoplanin with limited susceptibilities to other commonly used 
antimicrobials.  Moreover, the in-vitro profile of daptomycin in comparison to both ceftaroline 
and tigecycline in particular, suggests that this drug could potentially be an important addition 
to the diminishing arsenal of currently available antimicrobial therapies for the treatment of 
nosocomial-acquired CoNS BSIs. 
 
4.7 Conclusion 
Overall data analysis of this study provides affirmation that there are high levels of resistance 
to antimicrobials, in particular to methicillin amongst haematology patient group CoNS 
isolates.  These infective isolates exhibited resistance to the majority of antimicrobial classes 
widely used in this setting, including resistance to β-lactams, aminoglycosides, macrolides 
quinolones and the glycopeptides in particular to teicoplanin.  Although in-patient S. 
haemolyticus isolates demonstrated high levels of MDR, the prevalence of both MR and 
MDR was significantly associated with S. epidermidis, the predominantly isolated CoNS 
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species.  It was, however, alarming to note that similar but relatively lower levels of 
antimicrobial resistance were also expressed by the pre-admission patient group skin-
colonising isolates.  Monitoring of antimicrobial resistance in these isolates which act as 
reservoirs of resistance determinants, is of importance as these isolates are known to be 
commonly associated with both cross-transmission and acquisition of nosocomial infection in 
high-risk patient groups. 
With respect to the criteria studied, phenotypic antimicrobial resistance profile typing 
assessing the correlation with species-specific CoNS isolates from both the in-patient and 
control patient group revealed great diversity between and among the same CoNS species-
specific isolates.  PCA cluster analysis further highlighted species-specific isolate and clonal 
unrelatedness, which therefore suggests that such skin colonising isolates are highly unlikely 
to be the common source of CoNS-associated bacteraemia in the haematology patient 
group. 
Although vancomycin continues to be the mainstay of therapy for CoNS-associated BSIs in 
the haematology patient group, virtually all isolates expressed in-vitro susceptibility to 
vancomycin (MIC50 and MIC90 of between 1-2mg/L), with the exception of one in-patient S. 
haemolyticus isolate.  This isolate however, expressed borderline susceptibility (MIC=4mg/L) 
when tested by the more sensitive standard E-test methodology, signifying that the observed 
MIC distribution ranges for the glycopeptides are test-method dependent.  However, the 
excessive levels of teicoplanin resistance identified predominantly, amongst in-patient 
isolates of both S. epidermidis and S. haemolyticus may potentially be predictive of 
unfavourable response to vancomycin therapy.  As such in-vivo vancomycin efficacy may be 
compromised because resistance expressed to teicoplanin is thought to be a precursor stage 
to developing vancomycin resistance, based on their comparable mode of resistance.  In the 
haematology patient group isolation of BSI CoNS expressing high levels of teicoplanin 
resistance and a low clinical response to vancomycin therapy could therefore be linked to 
potential therapeutic failures particularly in bacteraemic episodes caused by S. epidermidis 
and S. haemolyticus. 
Comparative testing of both vancomycin and teicoplanin by conventional routinely used AST 
automated system with standard E-tests and screening protocols for heteroresistance 
prevalence, revealed some major assay-dependent differences in MIC distribution of each 
glycopeptide.  Distinguishing heteroresistance phenotypes from isolates demonstrating 
overall vancomycin susceptibility was problematic because of the protocol lacking sensitivity 
for accurate evaluation of low-level resistance to the glycopeptides, a critical factor for the 
detection of hGIS.  Despite these indications, following the criteria allowing discrimination of 
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hGIS isolates from  those that were vancomycin susceptible, there is a possibility that a small 
percentage of in-patient isolates may potentially express heteroresistance.  The data results 
further correlate with findings of other studies showing that although some isolates primarily 
characterised as vancomycin susceptible, express significantly elevated teicoplanin MICs.  
As teicoplanin serves a good marker for developing resistance, indication are that both in-
patient isolates of S. epidermidis and S. haemolyticus observed to express significantly high 
levels of teicoplanin resistance are also likely to also express heteroresistance.  Further 
studies using established protocols for hGIS/GIS are however required to confirm the 
prevalence of low-level resistance in the in-patient CoNS isolates and correlation with clinical 
outcomes. 
Current evidence demonstrating the possible inefficacy of vancomycin commonly used to 
provide coverage against CoNS-associated BSIs in the haematology patient group has 
necessitated the use of alternative therapeutics.  The findings in this study demonstrated that 
daptomycin’s excellent spectrum of activity distinguishes it not only from the glycopeptides 
but also from the other new competitors, tigecycline and ceftaroline.  The significantly high in-
vitro susceptibility demonstrated by daptomycin against all species-specific CoNS isolates 
therefore indicates its greater potential as a suitable alternative therapeutic agent to 
vancomycin for the treatment of CoNS BSIs.  Therefore, for optimal clinical outcomes, in the 
high-risk haematology patient group the use of daptomycin would be particularly suitable, 
especially in situations where MDR-CoNS expressing reduced susceptibility to teicoplanin 
are suspected.  Hence, improved therapeutic options using reliable diagnostic AST 
methodologies will optimise treatment for better clinical outcomes whilst also reducing 












Chapter 5 Assessment of the potential virulence factors present in the in-patient CoNS 
isolates in comparison to the pre-admission patient group skin colonisers and their 
association with antibiotic resistance. 
5.1 Introduction  
CoNS demonstrate a narrow spectrum of virulence factors in comparison to S. aureus, 
nonetheless their pathogenic potential is greatly enhanced due to their increasing antibiotic 
resistance.  Of the virulence factors produced by various species-specific CoNS isolates, 
apart from biofilm formation or slime production as the major known factor, others include the 
exoenzymes, lipases and proteases which are involved in host tissue damage (Otto, 2004).  
As a result, post-chemotherapy and post-transplant patients with malignant diseases are at a 
greater risk of such CoNS incited infections. 
S. epidermidis is the most frequently isolated aetiological agent associated with a spectrum 
of infections linked to biofilm formation particularly in connection with intravascular devices 
(O'gara and Humphreys, 2001).  The ability to form biofilm, in S. epidermidis has been 
postulated to be representative of a virulence factor that promotes phenotypic resistance to 
antimicrobial therapy (Holby et al., 2009).  Antibiotic efficacy is primarily dependent on the 
antimicrobial agents ability to reach the target site and accumulation within planktonic 
bacterial cells at a sufficient concentration to achieve eradication.  In patients with 
haematological malignancies with an already compromised immune response, the biofilm 
mode of growth particularly on surfaces of intravascular catheters renders bacteria 
embedded in biofilms more resistant to antibiotics.  The polymeric matrix (slime) causes 
reduction of antimicrobial efficacy by decreasing infiltration, neutralisation and binding, 
essentially reducing the antimicrobial to sub-lethal concentration levels prior to contact with 
the infective agent (Hogan and Kolter 2002).  Clinical and in-vitro research both support the 
theory that antimicrobial inefficacy associated with biofilm producing bacterial strains also 
negatively affects treatment outcomes (Stewart, 2002; Stewart and Franklin 2008).   
Clinical efficacy in-vivo is predicted by evaluating the MIC and MBCs of antimicrobials in-vitro 
essentially against planktonic organisms in the exponential growth phase.  These evaluations 
are therefore an assessment of antibiotics effectiveness against the aetiological agent in 
acute infections.  However, in chronic and device-related bacteraemic infections, clinical 
failures have been noted despite antibiograms of the causative organisms displaying 
susceptibility to standard antimicrobials at appropriate attainable concentrations.  In such 
cases, clinical failures are usually attributed to refractory infections related to surface-
adherent biofilms, where standard susceptibility tests fail to predict in-vivo susceptibility.  
Furthermore, of deep concern is the limited effectiveness of vancomycin therapy used for 
treatment of nosocomial acquired CoNS BSIs due to antibiotic tolerance demonstrated by 
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biofilm producing CoNS isolates (Claessens et al., 2015).  In such cases, eradication of 
biofilm-associated CoNS infections has been shown to be highly effective with the use of 
combination therapeutics instead of vancomycin monotherapy associated with persistent 
bacteraemia (El-Azizi et al., 2005).  Recommended synergistic combination therapies usually 
include the use of gentamicin or rifampicin in addition to vancomycin.  These combinations 
may however prove problematic in the immunocompromised host, as gentamicin increases 
the risk of nephrotoxicity and rifampicin increases the potential of adverse drug interactions 
and resistance development (Stewart, 2000; Fey, 2010).  Greater achievement of 
bactericidal activity has nonetheless been documented against more than 90% of biofilm 
producing isolates of S. epidermidis, by the addition of rifampicin to gentamicin or 
vancomycin for treatment of chronic staphylococcal infections (John and Harvin, 2007). 
On the other hand, there is little information at present to support the use of newer 
therapeutics such as daptomycin in combination with commonly used synergetic agents for 
the treatment of BSIs caused by biofilm producing Gram-positive organisms. (LaPlante and 
Mermel 2007, LaPlante et al., 2007;2009; Kaplan 2009; Kaplan et al., 2011).  The use of 
combination antimicrobial regimens have nevertheless been associated with higher survival 
rates of patients with MDR Gram-positive infections (Dall et al., 2018).  Further investigations 
are therefore merited to assess the in-vitro activities of daptomycin and vancomycin alone 
and in combination with other commonly used anti-staphylococcal agents against clinically 
important isolates of CoNS.  Additionally, in-vitro activities of these antimicrobials against 
biofilm producing CoNS associated with BSI also necessitates evaluation due to increasing 
concerns over the decreasing efficacy of vancomycin associated with sub-optimal patient 
outcomes. 
 
5.2 Aim of the current study  
a) To investigate the association of antimicrobial resistance with the virulence factors 
amongst blood culture isolates of well-characterised CoNS recovered from in-patients in the 
haematology unit.  These characteristics were compared with skin colonising isolates from 
the pre-admission control patient group. 
b) To evaluate four well established virulence traits expressed by CoNS including 
exopolysaccharide (slime), haemolysin, protease and lipase.  These were further assessed 
and correlated with the resistant phenotypes. 
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c) To investigate the in-vitro activity of vancomycin, daptomycin, gentamicin and rifampicin 
combination for synergy or antagonisms against three S. epidermidis BSI isolates from the 
in-patient group, representing a range of susceptibility patterns using the E-test methodology. 
d) To evaluate the antimicrobial efficacy of the four antimicrobials (vancomycin, daptomycin, 
gentamicin and rifampicin) individually and in binary combinations against the panel of three 
BSI isolates of S. epidermidis to determine antibiotic synergy or antagonistic effect using 
time-kill assays. 
e) To evaluate the activity of vancomycin, daptomycin and rifampicin individually and in 
combination using an in-vitro model of the well characterised biofilm producing S. 
epidermidis reference strain RP62A/ATCC 35894.  The minimum antibiotic concentration 
required to inhibit biofilm growth (biofilm MIC) and the minimum bactericidal concentration 
(biofilm MBC) required to inhibit biofilm load was also determined. 
 
5.3 Materials and Methods 
5.3.1 Isolates 
The four most common virulence factors produced by CoNS isolates were studied in all the 
one hundred of the in-patient CoNS isolates as well as in the 100 skin colonising CoNS 
isolates from the pre-admission patient group. 
Three well characterised BSI isolates of S. epidermidis, representative of three differing 
susceptibility categories were used for assessment of antimicrobial synergy.  The isolates 
from the haematology patient group used in the assay included, S. epidermidis isolates, A37 
exhibiting susceptibility to all antimicrobial classes with the exception of penicillin; A57 
exhibiting intermediate resistance (resistant to ≥4 but <6 antimicrobials) and the MDR isolate 
A91 (resistance to 12 antimicrobials).  Isolates A37 and A91 were also positive for slime 
production, whilst A57 was slime negative.  Fresh 24 hour stock cultures were prepared of 
each isolate maintained at minus 20°C on Microbank beads by defrosting and sub-culturing 
twice on nutrient agar at 37°C for 18 hours in ambient atmosphere.  S. aureus quality control 
strain NCTC 6571/ATCC 9144 expressing high level susceptibility to all antimicrobial classes 
was used as the control for both E-test synergy studies. 
For biofilm formation in 96-well microtitre plates and subsequent susceptibility assays; 
several single colonies of a fresh 24 hour culture of S. epidermidis RP62A biofilm producing 
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strain grown initially on nutrient agar and then in tryptic soya broth media was used for 
further investigations.  
 
5.3.1.2 Antimicrobial agents  
Vancomycin, rifampicin and gentamicin (250mg) in powder form were sourced from Sigma-
Aldrich, UK.  Stocks of each antibiotic were freshly prepared for use in accordance with 
manufacturers recommendations.  The antibiotics were dissolved in sterile distilled water to 
give a working stock concentration of 50mg/L and filter-sterilised using 0.2µm syringe filter 
(Sartorius™ Minisart®, SigmaAldrich, UK).  The prepared antibiotic stock solutions were 
stored at 4°C and brought to room temperature prior to use.   
Similarly, for daptomycin lyophilised powder (Cubicin®) was reconstituted as recommend with 
the addition of 10% (v/v) dimethyl sulfoxide (co-solvent) to an equal volume of sterile distilled 
water supplemented with 50mg/L calcium and 12.5mg/L magnesium chloride (Sigma-Aldrich, 
UK).  Addition of Ca2+ was added as recommended to effectively improve the bactericidal 
activity of daptomycin in-vitro and the filter sterilised stock concentration of 50mg/L stored at 
-20°C was defrosted and brought to room temperature prior to use.  However, daptomycin 
solution in a ready to use formulation (Cubicin®; Cubist Pharmaceuticals, UK) kindly supplied 
by the Queen Elizabeth Hospital pharmacy through the microbiology pharmacist, was used 
for all subsequent biofilm assays. 
Interpretation criteria for susceptibility testing was based on BSAC and EUCAST (2013) 
published guidelines. 
 
5.3.2 Virulence factors 
All media and reagents used were sourced from Oxoid (Basingstoke, UK) unless where 
stated otherwise. 
 
5.3.2.1 Lipase   
For the detection of lipase production, previously described method (Lang, PhD Thesis: 
2000) was used to produce olive oil agar using, 1% (w/v) Tryptone, 1.3% (w/v) agar No.1, 
0.5% (w/v) yeast extract and 0.5% (w/v) NaCl, mixed with distilled water and sterilized 
following the standard parameters of 121˚C for 15 minutes.  The media was then allowed to 
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cool to 60˚C, mixing constantly prior to the addition of the olive oil 2.5% (w/v) (Thornton & 
Ross Ltd, Huddersfield) and 0.001% (w/v) aqueous rhodamine B, which were filter sterilised 
using a 0.5 µm pore size cellulose nitrate filter (Sartorius Stedium, GMBH).  The agar poured 
to a depth of 4mm in 90mm petri dishes was then left to set at ambient room temperature for 
18 hours before use. 
CoNS colonies from a 24 hour sub-cultured blood agar plate were used to prepare a 
bacterial suspension in 0.5% saline equivalent to McFarland standard 0.5.  A sterile swab 
dipped into the prepared bacterial suspension was pressed lightly against the side of the 
tube to remove excess fluid prior to inoculating the olive oil agar plates.  Pseudomonas 
aeruginosa ATCC15442 as the positive control and Staphylococcus epidermidis 
RP62A/ATCC 35894 as the negative control strain were included in each test batch.  Plates 
were incubated at 35˚C for 18 hours in ambient atmosphere.  Positive lipase activity was 
detected by production of fluorescence by isolates when subjected to ultraviolet light (UV 
Light Box DaRO UV Systems II). 
 
5.3.2.2 Proteases 
For the detection of protease production by CoNS, a previously described method was used 
to produce skimmed milk agar (Lang, PhD Thesis: 2000).  Agar No.1, 1% (w/v) and 1% (w/v) 
skimmed milk powder were dissolved in 1000ml distilled water and autoclave sterilized at 
120˚C for 15 minutes.  The prepared media was dispensed to a depth of 4mm in sterile petri 
dishes and left to set at room temperature prior to inoculation.  Four, equally spaced 5mm 
diameter wells were cut into each plate using a sterile glass pipette end.  Aliquots of 50µL 
bacterial suspension prepared equivalent to McFarland standard 0.5, was then added to 
each well.  The suspensions were allowed to absorb into the agar before incubating the 
plates at 37°C for 18 hours in ambient atmosphere.  An equivalent volume per well of 
protease positive control strain, Pseudomonas aeruginosa ATCC15442 and sterile distilled 
water as the negative control were included in each test batch.  Hydrolysis signified a 
positive result indicated by zone of clearance around the well area of protease producing 
isolates. 
 
5.3.2.3 Slime  
The modified, Congo red agar test was utilised to Investigate bacterial isolate slime 
production using previously described phenotypic methods (Freeman et al., 1989; Kaiser et 
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al., 2013).  Brain heart infusion broth (37g/L) was prepared with 1L of distilled water.  A 
volume of 50mL of the well mixed BHI broth was removed into a glass universal, to which an 
aqueous solution of Congo red dye (0.8g/L) was added and autoclaved separately.  To the 
rest of the 950mL BHI broth, 1% (w/v) agar No.1 and 5% (w/v) sucrose was then added, and 
autoclave sterilised.  The sterilised solutions were allowed to cool to 55˚C.  The Congo red in 
BHI broth solution was then aseptically added to the rest of the BHI sucrose broth and mixed 
thoroughly.  The agar plates were then poured and allowed to set at ambient temperature 
prior to inoculation. 
A sterile swab dipped into McFarland standard 0.5 of each test bacterial suspension, pressed 
lightly against the side of the tube to remove excess fluid was used to evenly streak half the 
Congo red agar plate.  The inoculated plates were initially incubated for 24 hours at 37˚C 
followed by incubation at ambient temperature for a further 24 hours prior to reading results 
for slime production.  A positive slime producing control strain of S. epidermidis RP62A/ 
ATCC 35894 and the negative control, S. hominis ATCC 35982 a non-biofilm producing 
strain were included in each batch test. 
Positive slime production was determined by the appearance of black crystalline colonies 
with areas of transparency surrounding the colonies, where diffusion of slime production into 
the agar causes clearance of the Congo red pigment.  Slime negative colonies were 




The expression of haemolysin was determined on pre-poured plates containing Columbia 
blood agar base and 5% sheep blood (COS agar bioMérieux, France).  A sterile 10µL loop of 
CoNS bacterial suspension prepared in 0.5% (w/v) saline equivalent to McFarland standard 
0.5 was used to inoculate each half of a COS agar plate. 
A haemolysin negative control strain, S. epidermidis ATCC 12228 and a haemolysin positive, 
S. haemolyticus (clinical isolate) was included in each test batch.  The inoculated plates were 
incubated at 35˚C for 18 hours in ambient atmosphere.  A positive result was indicated by the 





5.3.3 In-vitro antimicrobial combination activity  
All test assays were performed independently in duplicate using the E-test technique to 
determine combination antimicrobial interactions against three S. epidermidis BSI isolates. 
The three S. epidermidis isolates were randomly selected based on their susceptibility 
category, including susceptibility to all but one of the antimicrobials in the panel of 18 test 
antibiotic, moderate susceptibility and a MDR isolate.  
 
5.3.3.1 Combination antimicrobial susceptibility testing using E-tests 
Determination of vancomycin, daptomycin, rifampicin and gentamicin MICs against each of 
the three in-patient BSI S. epidermidis isolates were performed individually, in duplicate, 
using the E-test methodology.  Combinations of each of the four antibiotics, were 
subsequently tested against each of the three S. epidermidis isolates A37, A57 and A91.  
Cultures of each isolate including the control strain were grown in nutrient broth, incubated at 
37°C for 18 hours in ambient atmosphere to ensure isolates were in the stationary growth 
phase prior to each batch test assay. 
The E-test method as previously described (Chapter 4) was used to determine MICs of the 
antibiotic individually.  Using a sterile swab, a 0.5 McFarland standard inoculum of each 
bacterial strain was used to inoculate Iso-Sensitest Agar (ISA) plates in a three way direction 
to create a lawn of semi-confluent growth.  For synergy testing combinations of each the four 
antimicrobials, the E-test strips were placed on the inoculated ISA plates in a cross formation 
at a 90° angle.  The E-test strips were placed such that the MIC value of the first antibiotic 
was positioned at the base intersection of the respective MIC value of the second antibiotic 
for the test isolate (Figure 5-5).  After incubation at 37°C for 18 hours in ambient atmosphere, 
the MIC of each antimicrobial was evaluated.  The combined effect of the two agents against 
each test isolate was calculated using the following previously defined algorithms: MIC of 
antibiotic A (MICA), MIC of antibiotic B (MICB), MIC of antibiotic A in the presence of antibiotic 
B(MICAB) and MIC of antibiotic B in the presence of antibiotic A (MICBA).  Fractional Inhibitory 
Concentration (FIC) index calculations were performed using the formula FIC index = 
MICAB/MICA + MICBA/MICB.  Results of antimicrobial combinations were accordingly classified 
as, synergy if FIC ≤ 0.5, additive FIC > 0.5 and ≤ 1, indifference if FIC > 1 and ≤ 4 and 





5.3.4 Antimicrobial efficacy determination against S. epidermidis RP62A biofilm 
Qualitative and quantitative evaluation of vancomycin, daptomycin and rifampicin singly and 
in combination was ascertained against the S. epidermidis RP62A biofilm producing 
reference strain, using previously described in-vitro chequerboard techniques for 
determination of antibiotic susceptibilities of bacterial biofilms (Christensen et al., 1983,1985; 
Steenbergen et al., 2009). For antimicrobial efficacy evaluation against S. epidermidis 
RP62A biofilm the test assays were performed in triplicate and repeated twice on 
independent occasions.  
Figure 5-1 illustrates the checkerboard method used for testing the in-vitro efficacy of the 
three antibiotics either individually or in combinations against either S. epidermidis RP62A 
planktonic cells or developed biofilm.  The three antibiotics tested, included vancomycin, 
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Figure 5-1: Schematic of checkboard method layout for the testing of two-
antimicrobial combinations, concentration range 0.5-64mg/L.  Antibiotic A 
(vancomycin) interaction activity in combination with Antibiotic B (daptomycin or 
rifampicin against S. epidermidis RP62A test strain.  Control wells c-1 and c-2 contain 
S. epidermidis planktonic culture in MHB, c-3 and c-4 MHB only.  For tests against 
biofilm: control wells, c-1 consists of biofilm, c-2 biofilm and MHB, c-3 empty and c-4 
MHB only. 
 
5.3.4.1 Planktonic MIC and MBC determination 
Cultures of S. epidermidis RP62A in nutrient broth incubated at 37°C for 18 hours in ambient 
atmosphere were obtained at stationary phase growth for test assay.  S. epidermidis RP62A 
culture inoculum were standardised to give a one McFarland turbidity equating to 
approximately 1x109 CFU/mL and further adjusted by diluting with sterile nutrient broth 
solution to obtain a final concentration of 1x105 CFU/mL.  Using aseptic techniques under the 





round bottomed 96 well polystyrene microtitre plate (Sterlin™ Clear Microtiter™ plates, 
Thermo-Fisher Scientific, UK) with the exception of the first two wells and last well of each 
row serving as controls. The first two control wells contained a 300µL aliquot bacterial 
culture, Figure 5-1 wells c-1 and c-2 (absence and presence of MHB respectively).  The last 
control well of each row contained 300µL aliquot of sterile MHB only (Figure 5-1, well c-4). 
With the exception of the control wells, to each well a 150µL aliquot of previously prepared 
series of log2 antibiotic dilutions prepared in MHB was added to give final serial antibiotic 
concentrations of 0.5 to 64mg/L in a total volume of 300µL per well.   
To allow the antibiotics to mix well with the bacterial culture, the prepared microtitre plates 
were then transferred onto an incubator shaking platform and agitated at the lowest speed 
(25 rpm) for 30 seconds.  The microtitre plates were sealed with clear adhesive plate seals 
(VWR™, UK) prior to incubation statically at 37°C for 18 hours in ambient atmosphere.  Each 
test assay was performed in triplicate.  
Visual observations were made after incubation for MIC determination, defined at the point of 
lowest concentration of antibiotic in which there was no visible growth.  For quantitative MBC 
evaluations,100µL from the contents of three wells at the point of MIC were removed and 
serially diluted and sub-cultured in duplicate on freshly poured MH-agar.  The plates were 
incubated overnight at 37°C for colony counts and MBC was determined as the lowest 
antibiotic concentration showing ≥99.9% kill after incubation. 
 
5.3.4.2 Biofilm formation for susceptibility testing 
Tryptone soya broth (TSB) supplemented with 1% glucose was prepared in accordance with 
manufacturers instruction, autoclave sterilised at 121°C for 15 minutes and stock solution 
stored at 4°C for use as the growth suspension medium for biofilm production.  Cultures of 
biofilm forming reference strain S. epidermidis RP62A in nutrient broth incubated at 37°C for 
18 hours in ambient atmosphere were obtained at stationary phase growth for biofilm test 
assays using a modified version of previously described techniques for testing of antibiotics 
against biofilm producing strains (Christensen et al., 1985; Stepanović et al., 2000; Oliveira 
et al., 2010).  S. epidermidis RP62A growth culture suspension inoculum standardised to 
give a one McFarland turbidity equating to approximately 1x109 CFU/mL was then prepared 
in TSB growth media and diluted further to obtain a final concentration of 1 x105 CFU/mL.  
With the exception of last two rows of wells per assay plate, 200µL aliquots of the prepared 
bacterial suspension equating to 1 x105 CFU/mL was then added to each well of a 96 well 
round bottomed polystyrene microtiter plate (Sterlin™ Clear Microtiter™ plates, Thermo-
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Fisher Scientific, UK).  A 200µL aliquot of sterile TSB was then added to each but one well of 
the last row of the microtiter plate serving as negative controls (Figure 5-1 wells c-3 empty 
and c-4 TSB only).  The plates were incubated for 18 hours at 37°C in ambient atmosphere 
to allow the S. epidermidis RP62A bacterial cells to form biofilm.  After incubation, using 
aseptic techniques, the contents of each well were gently aspirated using a sterile pipette 
and discarded and replaced with 200µL aliquots of fresh growth medium.  This process was 
carried out over a three day period to allow development of an adequate biofilm layer in each 
well. 
Prior to susceptibility assays, using aseptic techniques the biofilm formed in each well was 
washed three times with phosphate-buffered saline (PBS) (Sigma Aldrich, UK), to eliminate 
the presence of free-floating planktonic cells.  To ascertain biofilm formation, 200µL volumes 
of crystal violet stain were added to each well initially and left for 10 minutes before washing 
off with distilled water.  The plates were left to air dry prior to undertaking absorbance 
readings.  Using the automated plate reader (Pharmacia Biotech, Ultrospec 2000) the extent 
of the fixed air dried adherent bacterial cells in biofilm layer were quantified 
spectrophotometrically by determining the optical density at 570nm (OD570nm).  Experimental 
test readings were taken in triplicate with negative blank control well readings obtained 
subtracted from the calculated average test values (Figure 5-1 empty well c-3, background 
reading).  OD570nm readings for S. epidermidis RP62A formed biofilms were furthermore 
considered positive when the average reading for these were significantly higher than those 
obtained for the negative wells.  The resulting optical density data from the plate reader 
software system were imported into Microsoft Excel application for further analysis.  
 
5.3.4.3 Evaluation of S. epidermidis RP62A biofilm MIC and MBCs 
The biofilm forming reference strain S. epidermidis RP62A was challenged with vancomycin, 
rifampicin, and daptomycin alone and in combinations to evaluate biofilm MIC and MBC to 
assess antimicrobial efficacy. Biofilm MIC and MBC determination was performed following 
an adaption of previously described 96-well microtitre plate biofilm susceptibility testing 
method (Oliveira et al., 2010; Leite et al., 2011). 
MIC determination of the tested antimicrobials was performed, starting with a stock 
concentration of 128mg/L, two-fold serial dilutions in MHB of each filter-sterilised test 
antibiotic prepared in a separate microtitre plate for subsequent testing.  For daptomycin test 
assays the serial two-fold antimicrobial dilutions were prepared using MHB supplemented 
with 50mg/L of calcium and magnesium chloride.  Subsequently 200µL aliquots of each of 
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the antibiotic concentrations at two-fold dilution ranging from 0.5-64mg/L in MHB were then 
added to each well of the microtitre plates comprising formed biofilms.  The first and last two 
control wells per row of the 96-well microtitre plate included in the assays consisted of control 
wells as detailed in Figure 5-1.  The first two control wells, c-1 consisted of S. epidermidis 
RP62A biofilm with the absence of MHB and well c-2 consisted of addition of MHB 200µL 
aliquot.  The last but one well was left empty with one each of the last negative control wells 
per row contained only MHB without the presence of bacterial biofilm.  Wells containing 
uninoculated MHB were used as sterility controls and also served as spectrophotometric 
blanks.  The antibiotic challenged biofilm microtitre plates were incubated for 24 hours at 
37°C in ambient atmosphere.  After antibiotic exposure, using the plate reader, the extent of 
adherent bacterial cells in the biofilm layer were quantified spectrophotometrically by 
determining the OD570nm.  The results obtained were derived from the two separate 
experiments run in triplicate and average biofilm cell density OD570nm values were expressed 
as ± standard deviations.  Additionally, calibration curves quantifying biofilm S. epidermidis 
isolates previously produced by other researchers were subsequently used to convert 
spectrophotometric values to conventional CFU/mL to assess overall antimicrobial biofilm 
efficacy.  Biofilm MICs were determined as the lowest concentration of antibiotic required to 
inhibit biofilm embedded bacterial growth (Adams et al., 2005; Leite et al., 2011). 
After exposure, the antibiotic solution was discarded, and the wells washed again three times 
with PBS ensuring neutralisation of residual antibiotic.  200µL aliquots of fresh MHB were 
then added to each well of the washed biofilms and microtitre plates re-incubated for 24 
hours at 37C in ambient atmosphere.  The degree of cell regrowth within antibiotic 
neutralised biofilms after re-incubation was further assessed by spectrophotometric 
determination of biofilm cell density at OD570nm. 
Similar to the previously described methodology, combinations of daptomycin and rifampicin 
with vancomycin were studied against S. epidermidis RP62A produced biofilm in order to 
determine synergy.  According to the previously described checkerboard method, with the 
exception of the control wells c-1 and c-2, the first test antibiotic was added across each row 
giving a final serial concentration ranging from of 0.5 to 64mg/L (Figure 5-1).  Serial 
concentrations of the second antibiotic was then added, such that the bottom row containing 
the highest concentration (64mg/L) with the lowest final serial dilution across the top row.  
Experiments were again performed in triplicate and analysis of results were based on taking 
spectrophotometric absorbance reading at 570nm.  The overall results of combination 




Calculated FIC index values were further used to interpret the biofilm checkerboard test as 
previously described.  The FIC index calculation of the two combinative antibiotics against 
biofilm embedded cells was based on both direct visual observation and the 
spectrophotometric absorbance values obtained at the interaction point of wells showing 
turbidity and non-turbidity/decreased turbidity.  Average values of the experiments preformed 
in triplicate were taken to determine the mean or cumulative FIC index value and results of 
antibiotic interactions were categorised in accordance with previously described classification 
of synergy, antagonism, additive or indifference (Bonapace et al., 2000). 
To determine biofilm MBC, after the 24 hour incubation period with antibiotics, the biofilm 
cells were dislodged from each of the test wells around the interaction points following a 
simple scrape method previously described by Adams and colleagues, 2005.  Suspension of 
cells from each of the specified wells were then serially diluted in sterile saline.  An aliquot of 
100µL of each dilution was then inoculated and spread on MH-agar plates and incubated for 
24 hours at 37°C in ambient atmosphere.  Viable colony counts were performed after 
incubation and cell density accordingly calculated as log10 CFU/mL.  MBCs were determined 
as the lowest concentration to show a highly significant or 99.9% reduction in biofilm 
CFU/mL, in comparison to the control wells containing no antimicrobials.  
 
5.4 Statistical analysis 
Data were analysed using the SPSS statistical software for Windows.  Descriptive statistics 
were computed for all variables in this study.  Difference testing between the CoNS isolates 
obtained from the two patient groups, was performed using the Chi-squared test, and the 
Students t-test was utilised to compare antimicrobial combination pair variables with 
statistical significance accepted at a confidence level of >95%. 
Data evaluations of virulence factors produced by both in-patient and control patient skin 
colonising isolates in relation to their previously characterised phenotypic antibiotic 
resistance profiles, were analysed using Pearsons-Principle component analysis (PCA) 
StatSoft, Inc. (2011) STATISTICA version 10 (USA) Software package.  Gelcompar 2 version 
(Applied Maths, Belgium). The linear-regression model constructed using the Holm-
Bonferroni method was used to explore the association of CoNS species-specific isolates 
from each of the patient groups with the slime production, the predominant virulence factor.    
Reduction in biofilm density after 24 hour antimicrobial challenge were compared for single 
and antimicrobial combinations with assays performed in triplicate, run twice independently 
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and data presented as means of optical densities ± standard deviation.  The R Foundation 
Statistical Computing Platform R version 3.6.2 (2019) was used to perform the Kruskal-Wallis 
H test to assess the efficacy of vancomycin, daptomycin and rifampicin individually and in 
binary combinations against biofilm producing S. epidermidis reference strain RP62A.  The 
Conover-Iman test, the non-parametric multiple-comparison method was further applied to 
the analysed data to determine significant differences between individual and combination 
antibiotic efficacy against biofilm embedded cells.  For all data analysis comparisons, a p-
value of ≤0.05 were considered to donate statistical significance. 
 
5.5 Results 
5.5.1 Virulence  
Of the one hundred previously well characterised CoNS isolates tested, slime and 
haemolysin were the most commonly expressed virulence factors amongst both the in-
patient and control patient groups (58% and 46% respectively).  Haemolysin positivity was 
70% in the in-patient group in comparison to 52% in the control patient CoNS colonising 
isolates.  Lipase expression on the other hand was absent in the control patient group 
isolates and poorly expressed among CoNS isolates of the in-patient group.  Similarly, 
protease production was also low, expressed by only six and 1% of the in-patient and control 
group isolates respectively.  Figure 5-2 shows examples of the positive and negative results 
obtained using the selective test agars for the detection of the four commonly expressed 




Figure 5-2: Detection of four commonly expressed virulence factors by CoNS isolates. 
a) Slime positive is demonstrated by zones of transparency around black crystalline 
colonies b) Lipase positive isolates produce fluorescence under UV light c) Protease 
positive isolates demonstrate zones of clearance d) Haemolysin production is 
observed as zones of complete haemolysis around colonies.  
 
Comparative results detailing the detection of virulence factors produced by both the in-
patient and control group CoNS species-specific isolates are presented in Table 5-1.  The 
results reveal clear differences in positivity rates for the production of the four different 










Number of isolates expressing virulence factors/ 
Total number (%) of isolates tested for virulence 
factors 
 Slime Protease Lipase Haemolysin 
In-patient Group         
S. epidermidis (n=57) 41/72% 5/9% 1/2% 36/63% 
S. hominis (n=18) 8/44% Nil Nil 13/72% 
S. haemolyticus (n=16) 5/31% Nil Nil 15/94% 
Other CoNS (n=9) 4/44% 1/11% 1/11% 6/67% 
          
Control Group         
S. epidermidis (n=32) 16/50% Nil Nil 14/44% 
S. hominis (n=24) 10/43% Nil Nil 13/54% 
S. haemolyticus (n=17) 6/36% 1/6% Nil 15/88% 
Other CoNS (n=27) 14/52% Nil Nil 15/56% 
Table 5-1:  The distribution of species-specific isolates of CoNS from the in-patient 
and control patient groups according to the production of the four virulence factors. 
 
Slime production was noted predominantly amongst isolates of S. epidermidis in both the in-
patient and control patient group (72% and 50% respectively), followed by isolates of S. 
hominis and S. haemolyticus.  However, the other minor group of CoNS species of the 
control patient group also expressed slime at a similar frequency (52%); predominantly 
expressed by S. warneri and S. captis.  On the other hand, such predominance of slime 
production was not noted amongst the in-patient minor group of CoNS isolates.  
Similar to the haemolysin produced by S. aureus the δ-type haemolysins produced by CoNS 
species demonstrating haemolysis on blood agar containing sheep erythrocytes was 
observed predominantly amongst S. haemolyticus isolates in both the in-patient and control 
patient groups (94% and 88% respectively).  However, the frequency of haemolysin 
production was notably greater among in-patient and control patient group S. hominis 
isolates and equally in the other minor CoNS species of the control group (72, 54 and 56% 
respectively).  Conversely, with the exception of one protease positive isolate of S. 
haemolyticus (6%), none of the control group isolates were noted to produce either lipase or 
protease.  Similarly, all of the in-patient group S. haemolyticus and S. hominis isolates were 
also negative for protease and lipase production.  Conversely, low frequency production of 
both protease and lipase was noted amongst in-patient isolates of both S. epidermidis and 
one, S. capitis isolate of the minor group of other CoNS species. 
Data analysis subjected to the Holm-Bonferroni method was used to construct a generalised 
linear regression model to assess whether the proportion of CoNS isolates that produce the 
predominant virulence factor, slime was associated with CoNS species-specific isolates.  
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Application was based on the assumption that slime production (response variable) follows a 
binomial distribution and the in-patient and control groups respectively as explanatory 
variables.  The constructed linear regression model demonstrates there was no evidence of 
a difference in the proportion of slime production in isolates of S. epidermidis and S. 
haemolyticus when compared to the other minor group of CoNS species (p = 0.293, p = 
0.121 and p = 0.441 respectively).  Similarly, there was no significant difference observed 
between the in-patient and control group of species-specific CoNS isolates and the 
proportion of isolates associated with slime production (p = 0.230).  However, application of 
partial regression coefficients for the different species-specific CoNS isolates using the Holm-
Bonferroni method to control the family-wise error rate, resulted in analysis showing strong 
evidence that isolates of S. epidermidis contain a significantly higher proportion of slime 
producers in comparison to S. haemolyticus isolates in both patient groups (p = 0.0284).   
 
Additionally, the relationship between the production of the four virulence factors and 
antimicrobial resistance expressed to the panel of 18 anti-staphylococcal agents previously 
evaluated for the 100 CoNS isolates of both patient groups was explored using PCA factor 
analysis.  The results of three dimensional PCA analysis performed on the data evaluated for 
each of the patient group CoNS isolates to determine the relationship between the two 
principle variable components, antibiotic resistance and the production of the four main 
virulence factors are show Figures 5-3 and 5-4.   Computed analysis of both data sets for 
each of the patient group CoNS isolates and the antimicrobial resistance to the panel of 18 
antibiotics, with respect to the production of the four virulence factors to create the 3D PCA 
scatter plot A; demonstrated no correlation between any of virulence factors and resistance 
to the antimicrobials.  This was further represented in the linear regression plot B, 
demonstrating the relationship between the two principle component variables, resistance to 






Figure 5-3: Plot A shows 3D Extraction Principle Components Analysis scatter plot of 
resistance to a panel of 18 antimicrobials and their association with the four virulence 
factors produced by CoNS isolates from the haematology patient group. Plot B 
represents PC1(x-axis) vs. PC2(y-axis) plot of data variables to identify correlation of 












Figure 5-4: Plot A shows 3D Extraction Principle Components Analysis scatter plot of 
resistance to a panel of 18 antimicrobials and their association with the four virulence 
factors produced by CoNS isolates of the control patient group.  Plot B represents 
PC1(x-axis) vs. PC2(y-axis) plot of data variables to identify correlation of antibiotic 
resistance profiles with the four virulence factors. 
PCA result analysis for both patient group CoNS isolates represented by the variance in data 
plots demonstrate a lack of correlation between the two principle variables.  The distribution 
of data plots do not demonstrate any significant clustering, therefore indicating there is no 
association between antimicrobials resistance to the 18 agents and the expressed virulence 
factors.  Similarly, comparative scatter plot data analysis showed no association between the 
two principle variants, antimicrobial resistance and virulence factors with respect to the 100 






Figure 5-5: Overall comparison of PCA scatter plots obtained for the in-patient 
haematology patient group (red squares) with the control patient group (blue 
diamonds) to investigate association of the two variables, virulence factor production 
with the antibiotic resistance profiles of CoNS isolates from the two patient groups.   
 
The resultant data points for each of the patient groups associated with the two variable 
vectors were observed to be projected on different sides of the plot axis with little overlap or 
clustering.  Therefore, the overall PCA result analysis of the multivariant data indicates a 
significant lack of correlation between antimicrobial resistance and the four virulence traits 
expressed by both patient group CoNS isolates. 
 
Comparisons specifying the percentage distribution of isolates expressing MDR in relation to 
the major virulence trait, slime production or absence by species-specific CoNS isolates in 
both patient groups are detailed in Table 5-2.  The results reveal a difference in the rate of 
distribution of species-specific isolates that demonstrate MDR not associated with slime 
production.  Isolates of S. epidermidis, S. hominis and S. haemolyticus in comparison to the 
other minor group of species-specific CoNS isolates had the greatest number of slime-
producers but did not expressing MDR (44% and 41% in the in-patient and control group 
respectively).  Conversely, the greater proportion of non-slime producing isolates exhibiting 
MDR were predominantly S. haemolyticus in both the in-patient and control patient group 








 Number of Isolates Number of isolates 
 
Slime Positive/ MDR 
Negative 
Slime Negative/ MDR 
Positive 
In-patient Group     
S. epidermidis (n=57) 5/ 9% 12/ 21% 
S. hominis (n=18) 6/ 33% 2/ 11% 
S. haemolyticus (n= 16) 1/ 6% 11/ 69% 
Other CoNS (n=9) 4/ 44% Nil 
      
Control Group     
S. epidermidis (n=32) 10/ 31% 4/ 13% 
S. hominis (n=24) 8/ 33% 1/ 4% 
S. haemolyticus (n=17) 3/ 18% 3/ 18% 
Other CoNS (n=27) 11/ 41% 1/ 4% 
Table 5-2:  The distribution of none-MDR species-specific CoNS isolates but slime-
positive in comparison to slime-negative isolates expressing MDR from both the in-
patient and control patient groups. 
 
A generalised linear regression model was further constructed to statistically assess the 
differences between the proportion of isolates that express MDR and variation dependent on 
CoNS species.  Result analysis based on the proportion of isolates that expressed MDR as 
the response variable and the CoNS species-specific isolates, slime production and the two 

















In-patient Group         
S. epidermidis (n=57) 8.7 0.4 0.825 0.719 
S. hominis (n=18) 6.61 0.825 0.667 0.444 
S. haemolyticus (n= 16) 9.62 0.625 0.938 0.312 
Other CoNS (n=9) 1.78 0.434 0 0.444 
         
Control Group         
S. epidermidis (n=32) 4.94 0.5 0.375 0.5 
S. hominis (n=24) 3.75 0.494 0.125 0.417 
S. haemolyticus (n=17) 5.24 0.897 0.353 0.353 
Other CoNS (n=27) 2.11 0.428 0.111 0.519 
Table 5-3:  Summary data of each of the patient groups dependent on the proportion 
of species-specific CoNS isolates expressing MDR in comparison to the proportional 




From the model used to assess the significance of association between MDR, species-
specific CoNS isolates, slime production and patient groups, it was observed that S. 
epidermidis and S. haemolyticus were both associated with an increase in the proportion of 
isolates expressing MDR in comparison those isolates comprising the minor group of CoNS 
(p <0.0001).  Overall result analysis presented strong evidence that CoNS isolates belonging 
to the in-patient group were significantly associated with an increase in the proportion 
expressing MDR (p <0.0001).  Furthermore, there was good evidence showing that isolates 
expressing increasing resistance to the tested antimicrobials were significantly associated 
with the production of slime (p <0.0098).  No such correlation between slime production and 
expression of MDR was observed among species-specific CoNS isolates of the control 
patient group (p = 0.222).   
 
5.5.2 Antimicrobial synergy testing using E-tests  
The in-patient S. epidermidis isolates A37, A57 and A91 tested against combinations of 
vancomycin, daptomycin, rifampicin and gentamicin were evaluated for demonstration of 
synergy using the quantitative E-test synergy method.  The E-test strips were placed on the 
susceptibility agar in a cross formation at the interaction point corresponding to the 
previously determined individual MICs of the respective test antibiotics.  Figure 5-6 shows an 




Figure 5-6: E-test synergy test method showing the placement of daptomycin and 
rifampicin E-test strips in cross formation with a 90° angle at the interaction points of 
their respective MIC values tested against S. epidermidis isolate A91. 
The combination antimicrobial MIC was interpreted as the value at zone of inhibition at the 
point of interaction of the scale on each respective antimicrobial E-test strip.  The MIC for the 
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combined effect of the two antibiotics calculated using the previously defined algorithms were 
used to calculate the FIC index to evaluate the efficacy of the combination.  The in-vitro 
activities of the test antimicrobials in combination and the interpretive classification criteria 
based on the FIC index calculation are summarised in Table 5-4 for the control strain, S. 
aureus NCTC 6571 and in Table 5-5 for the representative in-patient S. epidermidis isolates 
A37, A57 and A91.  
 
Table 5-4: E-test synergy test method results for combinations of rifampicin (RIF), 
gentamicin (GEN), daptomycin (DAP) and vancomycin (VAN) measured against the 
control strain S. aureus NCTC 6571. 
 
The S. aureus control strain classified as susceptible to all classes of anti-staphylococcal 
drugs including the β-lactams, showed high level susceptibility to all the four antimicrobials 
tested individually.  Although no synergy was defined, an additive effect was however noted 
between combination of rifampicin with gentamicin and daptomycin and between 
daptomycin-gentamicin.  Indifference was however, observed between vancomycin 
combination with daptomycin, rifampicin or gentamicin against the control S. aureus strain. 
Similar differences were also observed between the different antimicrobial interactions and 
the representative in-patient S. epidermidis isolates.  Nonetheless, no antagonistic effects 
were observed with any of the binary drug interactions.  The results displayed in Table 5-5 
show that the majority of the interactions were predominantly additive, defined as the total 




Combination MIC Value mg/L FIC Index value Classification
S. aureus RIF and GEN 0.002
NCTC 6571 GEN and RIF 0.047
0.68 Additive
S. aureus RIF and DAP 0.001
NCTC 6571 DAP and RIF 0.047
0.71 Additive
S. aureus DAP and GEN 0.064
NCTC 6571 GEN and DAP 0.047
0.56 Additive
S. aureus DAP and VAN 0.125
NCTC 6571 VAN and DAP 1
2 Indifference
S. aureus RIF and VAN 0.002
NCTC 6571 VAN and RIF 0.5
1.17 Indifference
S. aureus VAN and GEN 0.5





Table 5-5: E-test synergy test method results for combinations of rifampicin (RIF), 
gentamicin (GEN), daptomycin (DAP) and vancomycin (VAN) measured against the 





Combination MIC Value mg/L FIC Index value Classification
A37 RIF and GEN 0.003
GEN and RIF 0.032
1.09 Indifference
A37 RIF and DAP 0.002
DAP and RIF 0.25
1.17 Indifference
A37 DAP and GEN 0.064
GEN and DAP 0.032
0.63 Additive
A37 DAP and VAN 0.19
VAN and DAP 0.5
0.71 Additive
A37 RIF and VAN 0.002
VAN and RIF 0.5
1 Additive
A37 VAN and GEN 0.75
GEN and VAN 0.015
0.73 Additive
A57 RIF and GEN 0.004
GEN and RIF 0.047
0.87 Additive
A57 RIF and DAP 0.002
DAP and RIF 0.095
0.58 Additive
A57 DAP and GEN 0.38
GEN and DAP 0.125
1.8 Indifference
A57 DAP and VAN 0.172
VAN and DAP 0.5
0.78 Additive
A57 RIF and VAN 0.002
VAN and RIF 0.5
0.83 Additive
A57 VAN and GEN 0.75
GEN and VAN 0.095
1.1 Indifference
A91 RIF and GEN 0.004
GEN and RIF 8
0.75 Additive
A91 RIF and DAP 0.004
DAP and RIF 0.32
1.31 Indifference
A91 DAP and GEN 0.5
GEN and DAP 32
2 Indifference
A91 DAP and VAN 0.188
VAN and DAP 0.75
0.88 Additive
A91 RIF and VAN 0.002
VAN and RIF 0.5
0.83 Additive
A91 VAN and GEN 0.38




The highly susceptible isolate A37 (penicillin resistance only), moderately resistant isolate, 
A57 and the MDR isolate A91, all demonstrated additive interaction between daptomycin-
vancomycin and rifampicin-vancomycin (FIC index ≤1).  In comparison to the fully 
susceptible S. aureus control strain, all three in-patient S. epidermidis isolates with one 
exception, demonstrated either indifference or additive interaction effect between 
combinations of rifampicin with vancomycin, daptomycin or gentamicin.  Although the control 
strain showed indifference between combinations of daptomycin-vancomycin and rifampicin-
vancomycin, A37, the susceptible isolate and the resistant isolates A57 and A91 all 
demonstrated an additive effect with these combinations.  Moreover, combination of 
vancomycin-gentamicin was observed to be most effective, as synergy was exceptionally 
noted against MDR isolate A91.  In contrast however, isolate A91 demonstrated vancomycin 
susceptibility at MIC 1.5mg/L but high-level resistance at MIC >32mg/L to gentamicin 
individually.  Nonetheless, the calculated FIC index result of 0.44 relating to synergy was 
further evidenced by the defined observation of a greater than fourfold decrease in the MIC 
produced by combination of gentamicin-vancomycin against isolate A91.  More importantly 
however, none of the binary drug combination evaluations, demonstrated in-vitro inefficacy. 
Combination antimicrobial efficacy assessment using the E-test assay in accordance with the 
standard definitions for the methodology against the three S. epidermidis BSI isolates and 
the S. aureus control strain are summarised in Table 5-6. 
 
Table 5-6: Comparison of the E-test assay results for classification of combination 
antimicrobial interactions of rifampicin (RIF), gentamicin (GEN), daptomycin (DAP) and 
vancomycin (VAN) against the three S. epidermidis isolates A37, A57, A91 and the 
control strain S. aureus. 
Of all the six antimicrobial combinations assessed an overall additive effect was observed for 
combination of vancomycin-daptomycin and vancomycin-rifampicin against all of the three in-
patient S. epidermidis isolates tested for synergy.  Likewise, all three test isolates 
demonstrated an indifference effect with rifampicin-gentamicin combination whereas the 
other antibiotic combination exhibited differing interaction effects. 
S. epidermidis  A37 S. epidermidis  A57 S. epidermidis  A91 S.aureus  Control
Antibiotic 
Combination    
VAN and DAP Additive Additive Additive Indifference
VAN and GEN Additive Indifference Synergy Indifference
VAN and RIF Additive Additive Additive Indifference
RIF and DAP Indifference Additive Indifference Additive
RIF and GEN Indifference Indifference Indifference Additive
DAP and GEN Additive Indifference Indifference Additive
Classification of Combination Antibiotic Interaction based on E-test Assay 
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5.5.4 Antimicrobial activity assessed against S. epidermidis RP62A adherent biofilm 
5.5.4.1 Effect of vancomycin, rifampicin and daptomycin challenge on biofilm 
Vancomycin, daptomycin and rifampicin showed good activity against the biofilm forming 
reference strain S. epidermidis RP62A in the planktonic mode of growth.  For all the tests run 
in triplicate the average MICs evaluated by the microtitre broth microdilution method for 
vancomycin and rifampicin were within the susceptibility range of 1 and 0.5mg/L respectively.  
Conversely, the MIC of 2mg/L for daptomycin was one doubling dilution above the 
susceptibility MIC breakpoint in accordance with the EUCAST susceptibility breakpoint of 
1mg/L.  MBC values obtained for rifampicin, vancomycin, and daptomycin were 0.5, 2 and 
8mg/L respectively.  Overall results indicated the superior activity of rifampicin against 
planktonic state S. epidermidis RP62A isolate in comparison to the other test antimicrobials. 
The effect of daptomycin, vancomycin and rifampicin was further assessed for biofilm killing 
across a range of concentrations from 0.5 to 64mg/L after 24 hour incubation.  The biofilms 
developed in the 96-well microtitre plates were characterised in terms of the total killing of 
adherent cells and the calculated logarithmic cell density reduction with the selected 
antimicrobial agents (Figure 5-7).  The overall comparative in-vitro activity of vancomycin, 
rifampicin and daptomycin assessed against the S. epidermidis RP62A adherent biofilm, are 
presented in Figure 5-7A.  These were quantified spectrophotometrically by determining the 
OD at 570nm and the spectrophotometric values obtained converted to conventional CFU/mL 
to evaluate and assess average biofilm cell density reduction for all tests run in triplicate. 
This isolate demonstrated sufficient biofilm formation after three days incubation with an 
OD570nm of 0.875 ± 0.01 equating to biofilm cell density of 1.457 x 108 CFU/mL on average.  
This first negative control wells after 24 hour incubation demonstrated OD570nm of 0.99 ± 0.21 
equating to an average biofilm cell density of 1.92 x 108 CFU/mL.  In comparison, the 
negative control well with no bacterial cell growth remained constant, resulting in an average 
background reading at OD570nm of O.085.  The second sterility check, negative control well 
containing MHB only, presented an OD570nm value of 0.096 ± 0.005.  The sterility check 
performed on the contents of the control wells subsequently plated out after incubation on 







Figure 5-7: Activity of rifampicin, daptomycin and vancomycin individually against 
biofilm encased S. epidermidis RP62A cells. A) Antimicrobial activity after 24 hour 
incubation with antibiotics B) Biofilm cell density after washing antibiotic affected 
biofilm cells with the addition of MHB C) Antibiotic neutralised, washed biofilm cell 
density after further 24 hour re-incubation. 
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The MIC of vancomycin was determined at 8mg/L for S. epidermidis RP62A adherent biofilm, 
which was four fold higher than the MIC observed for the isolate in planktonic state. For all 
the tests run in triplicate the total average calculated biofilm cell density reduction was 
equivalent to 0.54 x 108 CFU/mL after 24 hour exposure to vancomycin.  Furthermore, an 
exponential decrease in biofilm cell density was not observed with exposure to increasing 
concentrations of vancomycin from 16-64mg/L.  Similarly, the biofilm MIC value for rifampicin 
and daptomycin visually observed at concentration of 1 and 2mg/L resulted in an average 
calculated biofilm cell density reduction of 0.22 and 0.04 x 108 CFU/mL respectively at these 
concentrations.  Similar to the activity of vancomycin, both daptomycin and rifampicin 
showed no further decrease in cell density with increasing antimicrobial concentrations.  The 
overall calculated average logarithmic reduction value for all three antimicrobials tested was 
<1 log10 CFU/mL. 
 
Base-line assessment of biofilm cell density was carried out prior to re-incubation of the 
antibiotic neutralised biofilm to assess the presentation of residual antimicrobial activity within 
the biofilm layers.  Figure 5-7B details the antibiotic neutralised washed biofilm cell densities 
with the addition of MHB.  The average calculated biofilm cell density of the control wells and 
those that had been antibiotic challenged previously were, 1.773 ± 0.15 x 108 CFU/mL and 
1.716 ± 0.26 x 108 CFU/mL respectively.  After 24 hour re-incubation the control well biofilm 
cell density increased on average by 0.196 ± 0.02 x 108 CFU/mL.  Similarly, vancomycin, 
daptomycin and rifampicin neutralised biofilm cell densities on average increased by 0.267 ± 
0.06x 108 CFU/mL as detailed in Figure 5-7C.  This indicates a comparative difference of 
0.071x108 CFU/mL, equivalent to <1 log10 CFU/mL increase in calculated cell densities of re-
incubated biofilm. 
 
Furthermore, the average calculated cell densities for biofilm MBC determination for 
vancomycin at concentration of 8, 16 and 32mg/L ranged from 2.44, 4.95 and 6.96 x108 
CFU/mL and for daptomycin 3.65, 1.33 and 1.11 x108 CFU/mL respectively.  Similarly, for 
rifampicin the average calculated MBC was 5.12 x108 CFU/mL at the upper concentration 
level of 32mg/L.  The overall data result analysis indicates, that defined MBCs determined as 
the lowest concentration to show a highly significant or 99.9% reduction in biofilm CFU/mL 





Spectrophotometrically quantified results for similar comparisons of antimicrobial efficacies of 
vancomycin, rifampicin and daptomycin against S. epidermidis RP62A biofilm embedded 
cells individually and in combination obtained at OD 570nm are detailed in Figures 5-8 and 5-
9 respectively.  The error bars reflect ± standard error of the mean.  Figure 5-8 1a, 2a and 3a 
represent individual activity of vancomycin, rifampicin and daptomycin respectively against 
biofilm embedded cells.   
There were no significant difference observed in base-line OD readings taken of all test 
assay plates with the addition of MHB plus the antibiotics prior to incubation (p = 1.000).  
Similar results were obtained for average OD readings taken after the addition of fresh MHB 
to the washed and antibiotic neutralised biofilms prior to re-incubation for a further 24 hours 











Figure 5-8: Effect of vancomycin (1a), rifampicin (2a) and daptomycin (3a) challenge 
on S. epidermidis RP62A biofilm cell density.  Spectrophotometric measurements at 
OD570nm of cell-density across antimicrobial concentration range of 0.5-64mg/L were 
determined and compared to effect on biofilm cell density after vancomycin (1b), 
rifampicin (2b) and daptomycin (3b) neutralisation and re-incubation.  Controls c-1 and 
c-2 (biofilm and biofilm with MHB respectively).  
 
The overall measured OD570nm result values of the experimental assays for all the three 
single antibiotic challenged biofilm after 24 hour incubation, indicate that none of these tested 
antibiotics were capable of appreciably reducing biofilm cell densities across antibiotic 






The presence of viable S. epidermidis cells was further assessed within the antimicrobial 
neutralised biofilm by removing unbound sessile cells and residual antibiotics by washing the 
biofilm with PBS.  Spectrophotometric measurements at OD570nm applied to quantify viable 
bacteria within each antibiotic neutralised biofilm microtitre assay after 24 hour incubation at 
37°C are detailed in Figure 5-8 1b, 2b and 3b for vancomycin, rifampicin and daptomycin 
respectively.  In comparison to the antibiotic treated biofilm test assay the mean OD570nm 
values of untreated biofilm samples (controls c-1 and c-2) remained constant at 1.16 ± 0.98 
on average.  This indicates that substantive increase in biofilm cell density in the control well 
biofilm samples was not observed on further incubation with the addition of fresh MHB.  
 
The mean OD570nm values of vancomycin and rifampicin neutralised biofilm similarly 
demonstrate a small rate of increase in OD570nm values across the entire concentration test 
range.  The small difference in biofilm cell density measured by OD570nm values was however, 
observed to be comparatively higher in the daptomycin neutralised biofilm assay.  Likewise, 
the mean difference in the increase of OD570nm values for daptomycin were higher in 
comparison to those obtained for vancomycin and rifampicin after re-incubation.  An average 
overall increase of biofilm cell density (OD570nm value 0.25 ± 0.2) for daptomycin indicates the 
possible presence of potentially viable persister cells embedded within the biofilm.  This may 
however also be associated with the lower biofilm killing effect of daptomycin in comparison 
to the activity of vancomycin and rifampicin against the isolate embedded in biofilm.  
 
Significant differences in activity among the three antibiotics, vancomycin, rifampicin and 
daptomycin against S. epidermidis RP6A biofilms after both 24 hour challenge and post 
neutralisation and re-incubation were evaluated with the application of the Kruskal-Wallis 
sum test.  Overall data analysis results comparing ranks of median distribution of OD values 
indicate that there was significant differences observed among the three antibiotics tested 
after 24 hours antibiotic challenge, post neutralisation and re-incubation (Kruskal-Wallis chi 
squared = 896.8833, df =13, p <0.00005). 
 
Comparisons between vancomycin, rifampicin and daptomycin were further made using 
similar application of the Kruskal-Wallis sum test to determine significant reduction in biofilm 
cell density through quantitative OD measurements.  Therefore, statistical analysis of the 
data shows that the mean OD values for vancomycin and rifampicin ranked significantly 
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higher post-neutralisation and re-incubation in comparison to the 24 hour challenged biofilm 
OD values (Kruskal-Wallis chi-squared = 70.7995 df =15, p <0.00005 and Kruskal-Wallis chi-
squared = 115.1363, df =15 p = 0.0214 respectively).  This suggests that there were a 
discernible number of viable bacteria present within the vancomycin and rifampicin post-
neutralised biofilms to allow for the significant increase in biofilm cell density observed after 
re-incubation (p <0.05).  Conversely, no statistically significant difference was observed when 
comparing the median OD values for daptomycin after 24 hour antibiotic challenge with the 
OD values obtained after post-neutralisation and re-incubation (p = 1.0000).   
Similarly, the biofilm control well with addition of MHB showed mean OD values ranking 
significantly higher after further incubation of washed biofilm and with addition of fresh MHB 
(p <0.00005).  Conversely, there was strong evidence of no statistical difference observed 
when comparing the median OD values for the biofilm control well incubated without the 
addition of fresh MHB after 24 hour incubation and post-incubation after washing of biofilms 
(p = 0.3198). 
Statistically significant differences in OD values were noted when comparing data results of 
individual antibiotic activity of vancomycin with rifampicin and also with daptomycin against 
S. epidermidis RP62A biofilms pre and post re-incubation (p <0.00005).  Similar significant 
differences were observed when comparing 24 hour challenge of biofilm, individually with 
rifampicin and daptomycin on biofilm cell density after antimicrobial neutralisation and re-
incubation (p <0.00005 and p = 0.0081 respectively).  The overall results reveal a significant 
difference in the overall effect each antibiotic has on OD, as a measure of biofilm cell density 
after incubation with antimicrobial challenge across the entire antibiotic concentration range 
of 0.5-64mg/L.  Furthermore, there was good evidence showing that the overall effect on 
biofilm viability after antibiotic neutralisation was similar for each antibiotic neutralised biofilm 
test assay on re-incubation (p <0.00005).  This suggests that the biofilm washing process 
reduced the concentration of each of the test antibiotic sufficiently to below active levels to 








5.5.4.2 Effect of vancomycin combinations with rifampicin and daptomycin challenge 
on biofilm 
The results of mean killing difference of vancomycin-rifampicin, vancomycin-daptomycin and 
rifampicin-daptomycin combinations against S. epidermidis RP62A biofilm assessed 
spectrophotometrically across concentration range 0.5-64mg/L are presented graphically in 






Figure 5-9: Effect of combination challenge of vancomycin with rifampicin (1a) and 
with daptomycin (2a) and daptomycin with rifampicin (3a) on biofilm cell density. 
Biofilms formed by reference strain S. epidermidis RP62A were determined 
spectrophotometrically at OD570nm across antimicrobial concentration range of 0.5-
64mg/L.  Comparison of antimicrobial neutralisation and re-incubation effect on 
biofilm cell density (1b), (2b) and (3b) respectively.  Negative controls c-1 and c-2 






In comparison to the untreated biofilm controls, the killing effect of combinations of 
vancomycin-rifampicin, vancomycin-daptomycin and daptomycin-rifampicin on S. epidermidis 
RP62A biofilms determined by reduction in OD values of the biofilm cell densities was 
discernibly low.  Additionally, the overall low killing effect for all three antimicrobial 
combination interactions did not appear to vary considerably with increasing antimicrobial 
concentrations. 
S. epidermidis RP62A biofilms challenged with a combination of vancomycin-rifampicin 
showed no difference in OD values equating to any noticeable reduction of biofilm cell 
density up to interaction concentrations of 32mg/L.  Conversely the biofilm cell densities after 
showing a small increase, remained in a steady state with a comparatively small reduction in 
biofilm cell density, noticeable at the maximum concentration level of 64mg/L.  However, the 
observed OD value at this maximum concentration point did not exceed the value noteworthy 
of logarithmic reduction in comparison to the values obtained for the untreated biofilm 
controls.  Additionally, combinations of vancomycin-daptomycin and daptomycin-rifampicin 
demonstrated no visible killing effect on S. epidermidis RP62A challenged biofilms across all 
antimicrobial concentration interactions.  Furthermore, the OD values of biofilm cell densities 
with these two antimicrobial combinations challenged biofilms also appeared to remain in a 
steady state (Figure 5-9 2a and 3a). The inefficacy of combinations of vancomycin-
daptomycin and rifampicin-daptomycin interactions against S. epidermidis RP62A biofilms 
was further noted with no apparent changes in the OD values of antibiotic neutralised 
biofilms (Figure 5-9 2b and 3b respectively).  Similarly, no variation in OD values for 
vancomycin-rifampicin combination challenged biofilms were observed in comparison to the 
antimicrobial combination neutralised biofilms (Figure 5-9 1a and 1b respectively). 
To further assess the generalised low or indifferent killing effect of three binary antimicrobial 
combinations against the S. epidermidis RP62A biofilm, the mean FIC Index was calculated, 
based on previously described method for the interpretation of biofilm checkerboard synergy 
testing (Bonapace et al., 2002).  This method of assessment was utilised for result 
interpretation as the requirement for entire rows or columns to show complete growth 
inhibition is not essential.  This standardised biofilm checkerboard assay utilising inhibition of 
growth as the endpoint, with comparisons made to the positive growth control well without 
antibiotic addition was used to evaluate the degree of reduced turbidity both visually and by 
measure of OD.  Hence, overall results of the antimicrobial interaction were based on 
evaluating the point of interface for each of the test antimicrobial combination interactions 
and assessed visually and by spectrophotometric difference in OD values of selected wells in 
specified rows with comparison to results obtained for untreated biofilm control wells. 
261 
 
The biofilm FIC index calculations were therefore based on using the concentration value of 
the first well showing the lowest amount of turbidity compared to the positive control well in 
each row and column along the interface of high-turbidity/lowest or non-turbidity.  Analysis of 
the data obtained for all the experiments run in triplicate, resulted in the calculated 
cumulative mean ƩFIC index values of 4.03, 4.72, and 4.345 obtained for combinations of 
vancomycin-rifampicin, vancomycin-daptomycin and daptomycin-rifampicin respectively 
against S. epidermidis RP62A biofilm.  These results interpreted in accordance with the 
previously defined categorical interpretation for synergy, such that ƩFIC ≤0.5 categorised as 
indifference, additive as ƩFIC >0.5-4 and ƩFIC >4 as antagonism (Bonapace et al., 2002).  
Accordingly, for the resultant ƩFIC index values of >4 obtained for all three antimicrobial 
combinations the interactions were all categorised as demonstrating an antagonism effect 
against S. epidermidis RP62A biofilm. 
Data results evaluating the activity of individual antibiotics in comparison to the binary 
combinations both indicate poor activity against biofilm-embedded isolates.  Overall, no 
discernible logarithmic decrease in biofilm cell density, measured through OD570 across the 
test concentration range of 0.5-64mg/L was demonstrated.  Furthermore, biofilm bactericidal 
activity was not observed with any of the three binary antimicrobial combinations at the upper 
limit of the test concentration range.  Single and combination antimicrobial activity therefore 
appears to be significantly ineffective at reducing biofilm cell density, additionally 
demonstrating a poor response with increasing antimicrobial concentrations (p >0.5). 
The Kruskal-Wallis sum test was further applied to test the significant association of the 
effect of each binary combination antimicrobial challenge on S. epidermidis RP62A biofilm 
cell density after 24 hour incubation.  Overall data analysis comparing ranks of median 
distribution of OD values for combination of vancomycin-rifampicin did not reveal any 
evidence of statistically significant difference when tested against 24 hour challenged biofilm 
across the interaction concentration range of 0.5-64mg/L (Kruskal-Wallis chi-squared = 
116.98 df =127, p = 0.7271).  Similarly, there was no evidence of statistically significant 
reduction of biofilm cell densities observed with 24 hour challenge of S. epidermidis RP62A 
biofilm with rifampicin-daptomycin combination across the antimicrobial interaction 
concentration range of 0.5-64mg/L (Kruskal-Wallis chi-squared = 118.68 df =127, p = 
0.6886).  Conversely, data analysis of median OD value distribution for combination 
antimicrobial effect of vancomycin-daptomycin, demonstrates good evidence of a statistically 
significant difference to S. epidermidis RP62A biofilm cell density after 24 hour challenge 
with combination (Kruskal-Wallis chi-squared = 299.33 df =127, p <0.00001).  The statistical 
analyses results further indicate the greater effect of vancomycin-daptomycin combination 
against biofilm encased S. epidermidis RP62A cells across all the test concentration range in 
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comparison to the efficacy of combinations of vancomycin-rifampicin and rifampicin-
daptomycin. 
Evaluating the association between binary combinations on the other hand revealed there no 
significant differences noted between the activity of vancomycin-rifampicin in comparison to 
vancomycin-daptomycin and rifampicin-daptomycin efficacy against 24 hour S. epidermidis 
RP62A biofilms (p = 0.934 and p = 0.8967 respectively).  However, comparison of the binary 
combination activity of vancomycin-daptomycin with that of rifampicin-daptomycin revealed a 
significant difference in effectiveness against 24 hour challenged biofilm (p = 0.0092).   
Comparing the OD value distribution of the control wells for combination test assays there 
was no significant difference observed in biofilm cell densities for the biofilm without addition 
of MHB pre and post re-incubation (p = 0.0945).  However, there was a significant difference 
in observed OD values for the control wells consisting of biofilm with the addition of MHB (p = 
<0.00001).  The increase in cell density post-washing with the addition of fresh MHB is likely 
due to the provision of  fresh nutrients required to stimulate growth of viable cells within the 
biofilm thus showing a significant difference in OD values post re-incubation.  Comparatively, 
similar statistically significant differences in biofilm cell densities were observed with 
combinations of vancomycin-daptomycin as well as with rifampicin-daptomycin post-
neutralised biofilms (p = <0.00001 and p = 0.0005 respectively).  Conversely no significant 
difference in OD values were observed after 24 hour vancomycin-rifampicin combination 
challenged biofilms, compared to the OD values obtained post-neutralisation and re-
incubation (p = 0.7271 and p = 0.1940 respectively).  Combination of vancomycin- rifampicin 
interaction in this case suggests growth suppression activity rather than reduction in biofilm 
density due to eradication of biofilm encased cells. 
Further data analysis to determine whether single antibiotics were more effective than in 
binary combination against S. epidermidis RP62A biofilms was carried out by comparing 
ranks of median distribution of OD values.  These values demonstrated that single antibiotics 
were overall significantly more effective than in binary combination against S. epidermidis 
RP62A biofilms (p <0.00001).  As such, biofilm antimicrobial challenge individually with 
vancomycin or rifampicin was significantly more effective than in combination after 24 hour 
incubation (p = 0.0422 and p <0.00001 respectively).  Likewise, there was a significant 
difference noted with vancomycin-daptomycin in compassion to the combination of 
vancomycin-rifampicin interactions against 24 hour challenged biofilms (p = 0.0002 and p 
<0.00001 respectively).  Rifampicin and daptomycin were also significantly more effective 
individually, in comparison to rifampicin-daptomycin combination against S. epidermidis 
RP62A biofilms after 24 hour challenge (p <0.00001).  The overall data analysis suggests 
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that the kill effect of the three antibiotics individually on biofilm encased cells is significantly 
greater in comparison to the effectiveness of the antibiotics in binary combination (p 
<0.00001).  Thus, vancomycin, daptomycin and rifampicin individually demonstrate 
significantly greater efficacy in comparison to their activity in combination against biofilm 
embedded S. epidermidis RP62A cells. 
 
5.6 Discussion 
Virulent isolates of CoNS most frequently involved in nosocomial infections particularly 
among immunocompromised patients are due to their inherent ability to form biofilms on any 
abiotic surfaces (de Allori et al., 2006; Ninin et al., 2006; Fey, 2010).  Such infections, in 
particular BSIs are frequently associated with the extensive use of CVCs and other medical 
devices becoming colonised with biofilm-producing CoNS strains.  S. epidermidis strains in 
particular, contribute to the significant pathogenesis of medical device related infection 
particularly among immunocompromised patients.  This is due to their inherent ability to form 
biofilms on abiotic surfaces hence affording the isolates protection against the antibiotics 
administered for treatment of infection (O'gara and Humphreys, 2001; Otto, 2004).  
 
There is increasing evidence that virulence factors produced by CoNS significantly contribute 
to the pathogenesis of serious infection in the immune-incompetent host.  These virulence 
factors are surface expressed or secreted components that include enzymes or toxins that 
allows the bacterium to invade and cause disease when host defences are compromised 
(Otto, 2004; de Lourdes et al., 2006).  Among the CoNS, S. epidermidis represents the 
species most commonly associated with the production of virulence factors, in particular, the 
formation of multi-layered biofilms surrounded by slime an extracellular polymeric matrix 
conferring increased tolerance to antimicrobial therapeutics (Holby et al., 2009).  The present 
study therefore aimed to explore the prevalence of some of the few common virulence 
factors produced by both the skin-colonising and associated potential pathogenic isolates of 
CoNS causing BSIs concomitant with phenotypic antimicrobial resistance.  Based on these 
considerations, in this study, both the in-patient BSI CoNS and the skin colonising isolates 
from the pre-admission control patient group were screened for their ability to produce four 
clinically relevant virulence factors common to CoNS.  In addition to the production of 
protease, lipase and haemolysin, the CoNS species-specific isolates from both patient 
groups were evaluated for their ability to produce slime, the main virulence factor often 
associated with resistance to systemic antimicrobial therapy.   
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Of the in-patient CoNS species-specific isolates, S. epidermidis the most frequently isolated 
species was found to be associated with the production of all four virulence factors 
evaluated.  Slime production, the major virulence factor associated with CoNS pathogenicity 
in this study was found to be prevalent among both the in-patient and control patient group S. 
epidermidis isolates (72% and 50% respectively).  Similar results of higher rates of slime 
production in pathogenic strains of CoNS compared to normal skin-colonising isolates have 
been previously reported (Koksal et al., 2009).  Slime production was also expressed at a 
similar frequency (52%) among the other minor group of CoNS isolates of the control patient 
group, predominantly isolates of S. warneri and S. capitis.  Although results show no 
significant difference in the proportion of slime producing isolates of S. epidermidis and S. 
haemolyticus when compared to the other minor group of CoNS species (p >0.05); there was 
however, strong evidence that S. epidermidis isolates, comprise of a significantly higher 
proportion of slime producers in comparison to S. haemolyticus isolates in both patient 
groups (p = 0.0284).  These findings are consistent with those presented in other studies 
showing that the more virulent strains of S. epidermidis and S. haemolyticus, the 
predominant species isolated in clinical infections are concomitant with slime production 
(Voung and Otto, 2002; Arciola et al., 2004; Arslan and Özkardes, 2007).  Likewise, the 
comparatively higher frequency of slime producing isolates of S. epidermidis associated with 
bacteraemia in the in-patient group could be due to seeding from colonised intravascular 
devices that are extensively used in this in-patient group for treatment access.  Similar 
device-related infections with virulent CoNS species-specific isolates have been reported by 
several other investigators (Ahlstrand et al., 2012; Martiínez-Morel et al., 2014; Yamada et 
al., 2017).  Additionally, the greater capacity for virulence resulting from triggering of 
exoenzyme expression during the course of infection is likely to be associated with adaptive 
survival responses of these clinical isolates.  
 
Furthermore, in addition to haemolysin, the expression of hydrolytic exoenzymes, protease 
and lipase were mainly observed among the BSI CoNS in comparison to the skin-colonising 
isolates.  Lipase and protease were predominantly expressed in six (11%) S. epidermidis 
and by one (11%) S. capitis BSI isolates.  Conversely, only one (6%) control patient group 
isolate of the S. haemolyticus expressed protease.  The role for lipase in virulence although 
predominantly reported in S. epidermidis has also been described in some clinical isolates of 
S. haemolyticus and S. warneri.  In such cases the associated exoenzymatic activities of 
these isolates is concomitant with their role as potential pathogens because of their collagen 
binding ability and survival in fatty sections of infected hosts (Otto, 2004).  Similarly, the 
hydrolytic activity of protease expressed by some S. epidermidis strains, trigging degradation 
of fibrinogen and other proteins associated with the immune defence system causing tissue 
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damage correlates with potential for virulence.  Similar homologues of protease identified in 
some minor group of CoNS species-specific isolates interacting with other enzymes confer 
these isolates with the capacity to adhere to host cells.  These enzymatic activities 
expressed by some virulent strains of CoNS enhance their role in biofilm formation, hence 
significantly contributing to their pathogenic potential (Otto, 2004).  Haemolysin, on the other 
hand, one of the major virulence factors expressed was prevalent among both the in-patient 
and control patient group CoNS isolates (94% and 88% respectively).  Although the positive 
expression of haemolysin was also observed among all other CoNS, it was notably higher 
among in-patient species-specific CoNS isolates.  These findings were not surprising as 
haemolysin expressed by pathogenic strains of S. haemolyticus is associated with host 
erythrocytes lysis releasing free iron, the uptake of which promotes growth and subsequent 
spread of the organism during course of infection when host immunity is compromised 
(Hellbacher et al., 2006).  Hence, the potential pathogenicity of CoNS associated with 
expression of disease-conferring determinants in immunocompromised patients described by 
other researchers, further corroborate the findings of this study (Cunha et al., 2006; de 
Lourdes et al., 2006). 
 
Further evidence indicates, that of the few virulence factors expressed by CoNS contributing 
to pathogenicity of infection, slime production, is the indicator that tends to be predominantly 
associated with antimicrobial resistance (Baker et al.,2018).  The data obtained in this study 
subjected to PCA analysis to facilitate determination of association between virulence 
expression and resistance pattern characteristics of both patient group isolates revealed a 
distinct lack of association between these two variants which are concomitant with potential 
pathogenesis.  The scatter plots generated by PCA indicate that CoNS species-specific 
isolates from both patient groups exhibiting resistance to the 18 antimicrobials indicate that 
this variable factor did not influence the expression of either lipase, protease, haemolysin or 
slime.  Additionally, the three-way PCA plot analysis and the generated scatter plots, 
revealed no evidence of sample grouping and separation based on patterns in the highest 
significant detected features despite the observed predominance of methicillin-resistant, 
slime-positive S. epidermidis and S. haemolyticus isolates, in both patient groups.  Other 
researchers have however demonstrated that slime-positive S. epidermidis were significantly 
associated with MR and other widely used antimicrobials (Koksal et al., 2007).  This may be 
to do with the tiggering of adaptive responses of slime-producing infective strains for both 
survival and spread, dependent on the physiological condition of the immunocompromised 
host.  Similar assessment of association between slime-positive expression and MDR 
resulted in both a significant portion of in-patient S. epidermidis and S. haemolyticus isolates 
demonstrating MDR correlation with slime production (p <0.0001), a response likely to be 
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determined in the presence of antimicrobial pressure.  Conversely, no such correlation was 
observed between slime production and expression of MDR among the skin-colonising 
isolates of the control patient group (p = 0.222).  However, studies have provided strong 
evidence that slime-positive MDR-CoNS skin flora isolates, serving as reservoirs of 
antimicrobial resistance, colonise hospital environments and are therefore the major 
determinants of nosocomial acquired infections (Koksal et al.,2009). 
Resistance to multiple therapeutic agents commonly used for the treatment of CoNS-
associated bacteraemia limits clinical efficacy, therefore the use of antimicrobial combination 
are recommended for eradication of infection and optimal outcomes particularly among the 
immunocompromised patient group (Islas-Muñoz et al., 2018).  Effective combination therapy 
is, however, dependent on evaluation and provision of accurate assessment of synergy 
between antibiotic interactions as a guide to targeted patient therapy (Raad et al., 2007).  
Consequently, evaluating the efficacy of drug combinations is another clinically relevant 
aspect associated with predicting in-vivo resistance of recalcitrant infections.  
 
Although numerous in-vitro methods have been described for gauging synergy between 
antimicrobial combinations, there are currently no standardised simple to perform methods 
available routinely in clinical laboratories for synergy detection.  For the purposes of this 
study, the E-test agar diffusion method for synergy testing was used to assess in-vitro 
antimicrobial interaction and activity of. four antimicrobial combinations commonly for the 
treatment of CoNS-associated bacteraemia.  The E-test agar diffusion method for synergy 
testing (White et al., 1996; Doern, 2014).  Investigations therefore carried out in order to 
ascertain the efficiency of vancomycin, daptomycin, gentamicin and rifampicin individually 
and in binary combinations against three representative in-patient S. epidermidis isolates 
expressed a range of antimicrobial susceptibilities  All the three in-patient S. epidermidis 
isolates A37, A57 and the MDR isolate A91 exhibited susceptibility to vancomycin 
daptomycin and rifampicin.  Susceptibility to gentamicin was also expressed by isolates A37 
and A57, well within the susceptibility range of ≤1mg/L whereas isolate A91 expressed high 
level resistance at MIC >32mg/L.  Although gentamicin demonstrates a concentration-
dependent killing effect in-vivo, it is likely to induce nephrotoxicity in patients exposed to drug 
concentrations above a certain MIC threshold (BMJ-Best Practice, 2017).  However, 
gentamicin is often used in combination with other agents such as vancomycin for broad-
spectrum cover for GP- and GN-associated bacteraemia results in better clinical outcomes 
with few adverse effects (Cohen and Drage, 2011).  The efficacy of gentamicin-vancomycin 
combination was evident in this study with antibiotic synergy demonstrated against the MDR 
isolate A91 expressing a fourfold decrease in MIC.  Although there is no defined relationship 
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between gentamicin and vancomycin expressed individual  and combination susceptibilities, 
it is likely that synergism occurrence is due to the differing modes of actions against 
staphylococcal isolates.  Hence combined action of the two antibiotics involving different 
cellular targets, results in synergistic activity as vancomycin inhibiting cell wall synthesis, and 
gentamicin targeting bacterial ribosomes inhibits growth thus leading to cell death (Rehm et 
al., 2008). 
 
Comparatively, all three S .epidermidis isolates A37, A57 and A91 vancomycin combination 
with both rifampicin and daptomycin demonstrated an additive effect.  These results are 
concomitant with previous reports of enhanced activity of rifampicin in combination with 
vancomycin due to its potent bactericidal activity and ability to penetrate cells more 
effectively is associated with improved clinical outcomes (Rose et al., 2009).  Concomitant 
overall additive effects of such combination interactions noted in this study vancomycin-
daptomycin and rifampicin would prove to be advantageous in clinical practice as rifampicin 
is rarely used as an effective mono-therapeutic agent due to resistance development in early 
stages of infection (Zheng and Stewart, 2002).  Synergy testing for all six drug combinations 
assessed either resulted in an indifference or additive effect with no defined antagonism 
noted.  The ease of use for the in-vitro E-test method for testing of combination antimicrobial 
susceptibilities offers the possibility of synergy testing in routine laboratories for 
determination of drug combination efficacy.  However, further in-vivo studies are potentially 
required to validate the in-vitro findings of this study to include patients physiological factors 
such as immune status and drug-drug interactions encountered during the course of infection 
which are critical for accurate predication of combination therapeutic outcomes (Doern, 
2014). 
 
There are, however, several other limiting factors that influence antimicrobial efficacy which 
include the interaction between different antimicrobial class combinations, concentration 
levels, species-specificity and essentially the presence of biofilms.  Biofilm-embedded 
isolates in comparison to planktonic cells consist of phenotypes that exhibit reduced 
susceptibility to most antimicrobials resulting in persistent infections despite adequate 
therapy (Kaplan et al., 2011; He et al., 2017).  Several published studies however, report that 
the antimicrobials limited efficacy is attributable to several exogenous factors produced by 
infective agents, characterising traits such as tolerance, poor tissue penetration and 
resistance (Mah and O'toole 2001; Otto, 2004, 2008, 2009; Sakoulas et al., 2004; Casey et 
al., 2007).  It therefore becomes imperative to determine the response of  biofilm producing 
species-specific CoNS to commonly used therapeutics.  One of the objectives of the current 
study was to investigate and compare the effect of three common anti-staphylococcal 
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agents, individually and combinations utilised for the treatment of potentially biofilm-
producing CoNS-associated bacteraemia in the haematology patient group.  
Biofilm assays were therefore used to determine the concentration dependent killing effect of 
the commonly used agents vancomycin, and rifampicin including the newer agent, 
daptomycin individually and in combinations against S. epidermidis RP62A, a well 
characterised reference strain with a high capacity to form biofilm.  Differences between the 
planktonic MIC and MBC values obtained using the standard microdilution assay, did not 
however relate to the values obtained with the biofilm plate assay on primary evaluation. 
Nonetheless, comparative MBC values demonstrate rapid kill of planktonic state S. 
epidermidis RP62A at the lowest concentration of 0.5mg/L for rifampicin in comparison to 
vancomycin and daptomycin (2 and 8mg/L respectively).  Conversely, biofilm culture of S. 
epidermidis RP62A were found to be much more resistant to the inhibitory effects of 
vancomycin, daptomycin and rifampicin determined both spectrophotometrically at OD570nm 
and enumeration of viable cells reported as log reduction.  Study results revealed no 
significant bactericidal effect on the S. epidermidis biofilm-embedded cells after 24 hour 
exposure to a range of antimicrobial concentrations.  Data analysis indicates that defined 
MBCs determined for the concentration to show a discernible viable cell reduction in biofilm 
was not achieved at the upper limit of 64mg/L determined both by calculated log reduction of 
viable biofilm-embedded cell counts and spectrophotometrically for all for all three test 
antibiotics (Figures 5-8 and 5-9 respectively).  These results are concordant with findings of 
other studies which describe no killing effect on biofilm embedded bacterial cells at 
antimicrobial concentrations of >10⁴ times the MIC (de Allori et al., 2006, Høiby et al., 2010, 
2014; Dall et al., 2018). 
Furthermore, relative to the effect on cell density, increasing concentrations of rifampicin and 
daptomycin also appeared to have little effect with regrowth levels noted equivalent to 
untreated biofilm cell densities, post-neutralisation and incubation (Figure 5-9, 2b and 3c 
respectively). Overall data obtained for antibiotic challenged S. epidermidis biofilms, 
subjected to statistical analysis using Kruskal-Wallis sum test revealed no significant 
differences in concentration-dependent cell density reduction for all three antibiotics 
individually (p = 0.7).  These finding are concomitant with other reports indicating that biofilm-
embedded isolates are inherently resistant to antimicrobial agent concentrations of more 
than 1000 times higher than their planktonic state MICs (Mah and O'toole, 2001).  Although 
study results confirm the increased resistance of antimicrobials against S. epidermidis 
embedded in biofilm, rifampicin, individually was the most active agent against the planktonic 
form of S. epidermidis RP62, but as a constituent of antimicrobial combinations was distinctly 
less active against the biofilm embedded cells.  However, these finding do not correlate with 
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studies showing the superior bactericidal activity of rifampicin singly and in combination with 
vancomycin against S. epidermidis associated biofilms (Saginur et al., 2006).  Other, studies 
also demonstrate the superior biofilm-associated activity of rifampicin, particularly in 
combination with other antimicrobials, as it is shown to retain its potency in the presence of 
slime (John and Harvin, 2007).   
Vancomycin due to its potent bactericidal activity is commonly used for the eradication of 
staphylococci associated with recalcitrant infection.  Surprising, in this study vancomycin 
demonstrated a significant lack of bactericidal activity against biofilm-embedded S. 
epidermidis cells, as biofilm production appeared to be elevated in the presence of higher 
antimicrobial concentrations of 32-64mg/L (p = 0.7271).  Additionally, increase in biofilm cell 
density post-antibiotic neutralisation and re-incubation suggests that there is a likelihood of 
either reduced penetration of vancomycin through the biofilm, tolerance or most sub-
populations within the deeper layers of the biofilm may have persisted in a dormant state 
refractory to antimicrobial inhibition (Figure 5-9,1b).  The lack of penetration through the 
biofilm layer may also relate to the large molecular weight of vancomycin molecules 
(molecular weight of 1450) which could become entrapped in the extracellular 
mucopolysaccharide slime layer thus reducing effective penetration (Souli and Giamarellou, 
1998).  Similar to these findings the lack of response or tolerance to vancomycin in S. 
epidermidis biofilm associated infection have been previously reported.  Investigators have 
reported diminished antimicrobial response against biofilm-embedded S. epidermidis strains 
despite high concentration achieved in the biofilm environment are linked to microbial growth 
suppression and inadequate kill-activity (Claessens et al., 2015; Dall et al., 2018).  
Additionally, physio-chemical interactions with slime composites may also decreases 
permeability of some antibiotics through the biofilm (Jefferson et al., 2005.).  Diminished 
responses to vancomycin, due to factors other than penetration, associated with slime 
production, include alteration of charge and free energy on bacterial surface and 
antimicrobial-tolerant sessile sub-populations found deeply embedded in the biofilm (Raad et 
al., 2007; Otto, 2009; Cerca et al., 2014).   
The addition of rifampicin is however reported to enhance the activity of vancomycin against 
staphylococcal biofilms because of its ability to penetrate cells and activity against stationary-
phase cells (Rose and Poppens, 2009; Saginur et al., 2006).  However, vancomycin-
rifampicin combinations recommendations are limited related to adverse effects due to drug 
interaction and possibility of rapid developing resistance in patient groups with underlying 
comorbidities.  Despite limited data availability, daptomycin-vancomycin/rifampicin 
combinations have been shown to exhibit better in-vitro anti-biofilm activity in comparison to 
other regimens (LaPlante and Mermel, 2007).  Unlike the finding of this study, comparing 
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combinations of vancomycin-daptomycin rifampicin and rifampicin-daptomycin did not show 
any significant difference in anti-biofilm efficacy (p = 0.9).  Conversely, vancomycin-
daptomycin revealed a significant difference in activity compared to  the other evaluated 
combinations (p = 0.0092).  Additionally, with no significant reduction in biofilm cell density 
after antimicrobial exposure the overall response of the combinations demonstrated 
antagonism based on the calculated cumulative mean ƩFIC index values of ≥0.4, for synergy 
assessment.  Further result analysis however, revealed vancomycin, rifampicin and 
daptomycin demonstrated significantly greater efficacy individually in comparison to the 
effectiveness in combinations against biofilm-embedded S. epidermidis cells (p <0.00001).  
Likewise, other investigations have demonstrated that daptomycin individually and in 
combination against biofilm isolates had better activity compared to vancomycin and 
rifampicin but did not significantly improve activity when combined with rifampicin and 
vancomycin (LaPlante and Woodmansee, 2009).  Conversely, other studies also report the 
superior in-vitro susceptibility response of daptomycin-rifampicin against S. epidermidis 
biofilm cells whereby approximately 3-4 log10 CFU/mL reduction post-antimicrobial 
combination exposure was observed (Leite et al., 2011).  These difference in reported anti-
biofilm activities may have been due to the methods used to evaluate antimicrobial efficacies 
against reference or clinical biofilm-producing isolates. 
In accordance with previous investigative techniques, the quantitative microtitre plate assay 
eliminates subjectivity in reading of results and provides a greater predictive clinical 
relevance.  Hence, the model experiment of OD-measurements applied in this study include 
taking into account test adherent bacteria both, on the sides of the walls and the bottom of 
the microtitre plate wells thus increasing the accuracy of evaluated reduction in biofilm cell 
density due to antimicrobial activity (Stepanović et al., 2000).  Therefore, overall results 
analysis demonstrating significantly reduced in-vitro activity of vancomycin, rifampicin and 
daptomycin individually and in combination against the reference biofilm-producing S. 
epidermidis strain, suggests that these antibiotics are not likely to demonstrate reduced 
antibactericidal activity against biofilm-associated infections in-vivo.  Moreover, study findings 
also demonstrated that a significant 99.9% reduction in biofilm cell densities at the highest 
antimicrobial test concentrations of 64mg/L was unachievable, which suggests that higher 
concentration would be required to acquire complete eradication of biofilm-embedded cells.  
Therefore, further test assays would be required to include a series of much higher doubling 
concentrations of 128, 256 and 512mg/L using similar viable count methodology pre and post 
antibiotic exposure to assess significant reduction in biofilm cell densities and hence 
antimicrobial efficacy.  Clinically, the requirement for much higher antimicrobial 
concentrations for eradication of biofilm-embedded cells implies serious limitation for 
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therapeutic application.  This is because such high serum dose-levels of >64mg/L are not 
achievable in-vivo as increasing clinical toxicity linked to higher dosing would adversely affect 
patient management. 
The present study provides good evidence that the presence of biofilm appears to have a 
negative effect on vancomycin, daptomycin and rifampicin activity.  These antibiotics may 
have some activity against the biofilm-embedded staphylococcal cells but none on overall 
biofilm cell density reduction as significant eradication at antimicrobial concentrations well 
above the expected MICs.  As both biofilm formation and density are known to influence the 
efficacy of antimicrobials used against biofilm-mediated infections, it would be of interest to 
study the in-vitro response of the biofilm-producing strains of both patient group species-
specific CoNS isolates.  The bioassay model employed in this study represents a valuable 
method for assessing antimicrobial efficacy on staphylococcal biofilms, given the frequency 
of biofilm-associated infection related to bacteraemia in haematology patients.  The 
evaluation carried out with the reference staphylococcal strain and representative antibiotics 
however requires further studies involving the previously characterised slime-positive in-
patient CoNS isolates.  Investigative studies including evaluation of species-specific CoNS 
isolates associated with the production of high density biofilms using previously described 
methods for quantification of biofilm mass and correlation with rate of antibiotic resistance 
would contribute significantly towards understanding the mechanisms governing biofilm-
associated resistance (Smith et al., 2008).  Furthermore, evaluation of anti-biofilm synergy 
interaction would be useful in supporting clinical therapeutic decision involving chronic 




Virulent skin colonising isolates of CoNS have become the one of the most important 
pathogens in clinical infections among patients with haematological malignancies, a group 
compromising highly immunocompromised patients with colonised medical devices as the 
common source of BSIs.  Among the species-specific CoNS isolates slime, the main virulent 
factor involved in pathogenesis was prevalent among isolates of S. epidermidis in both 
patient groups.  The findings in this study therefore support the potential role of skin-




The E-test method employed in this study to assess the in-vitro efficacies of vancomycin, 
gentamicin, daptomycin and rifampicin combinations against three representative BSI 
isolates of S. epidermidis demonstrated additive or indifferent effects overall.  Synergy was 
however, only confirmed with combination of vancomycin-gentamicin against the MDR-S. 
epidermidis test isolate  Most importantly no in-vitro antagonism of vancomycin and the other 
binary agent combination was confirmed in this study.  Conversely vancomycin, daptomycin 
and rifampicin, individually and in combinations demonstrated antagonistic interactions 
against the biofilm-embedded cells of S. epidermidis RP62A.  Hence, these antimicrobials 
individually and in combination, although demonstrating susceptibility against isolates in the 
planktonic mode could not be considered of clinical relevance; for the treatment of CoNS-
associated bacteraemia in haematology patients who are likely to have CVC-lines colonised 



















Chapter 6  Final Discussion 
 
This retrospective study aimed to evaluate the incidence of antimicrobial resistance among 
CoNS-associated BSI isolates from patients in the haematology and BMT unit of the Queen 
Elizabeth Hospital, Birmingham UK between April 2010 and March 2012.  The recovered 
CoNS (in-patient) isolates were characterised by both microbiological and molecular 
methods, evaluating both CoNS species-specific isolate prevalence and their antimicrobial 
resistance profiles.  These were compared to the pre-admission patient (control group) CoNS 
skin-colonising isolate characteristics, proposed to be the potential source of BSIs, for 
determination of both phenotypic and genotypic clonal similarity.  The primary purpose of this 
study was to ascertain whether the incidence of bacteraemia was attributable to the species-
specific isolates of CoNS comprising normal skin flora.  
 
BSIs due to CoNS are the most common cause of nosocomial infection associated with high 
rates of morbidity in patients with haematological disorders (Worth and Salvin, 2009).  These 
opportunistic infections are usually associated with MDR-CoNS isolates possessing 
determinants facilitating their survival on skin and medical devices.  Therefore, establishing 
the source of these potentially pathogenic strains is critical in prevention and management 
strategies (Coello et al., 2003).  For treatment purposes, the use of bactericidal antimicrobial 
agents are essential clinically, for the rapid eradication of severe life-threatening BSIs for 
optimal outcomes in haematology patients (LaPlante et al., 2007; Kratzer et al., 2007).  As 
such, all febrile patients on the unit, displaying clinical signs and symptoms of infection 
receive broad-spectrum empirical antimicrobial therapy prior to receiving results of positive 
blood cultures from the microbiology laboratory.  Vancomycin remains the most widely used 
first line therapeutic agent in combination with other antibiotics for the treatment of serious 
infections in the haematology patient group (Garcia-Vidal et al., 2018).  However, 
vancomycin has several limitations, including its slower bactericidal activity and associated 
toxicity requiring close monitoring of serum levels and renal function (Kitzis and Goldstein 
2004).  Moreover, most worrying are reports of emerging resistance due its extensive use 
and association with suboptimal treatment outcomes in patients with haematological 
malignancies undergoing BMT (D’Antonio et al., 2004; Safdar and Rolston, 2006).  
Therefore, in addition to the evaluation of resistance to commonly used anti-staphylococcal 
agents, this study also aimed to investigate the prevalence of reduced susceptibility to the 
glycopeptides, in particular to vancomycin, related to CoNS-associated bacteraemia, which 
remains a frequent complication in patients with haematological malignancies.  Furthermore, 
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the efficacy of newer alternative antimicrobials including daptomycin, tigecycline and 
ceftaroline were also evaluated against these BSI CoNS isolates. 
 
Despite medical and therapeutic advances, nosocomial infections with potentially pathogenic 
CoNS pose a major threat to patients admitted to hospital with haematological malignancies 
(Diekema et al., 2001; Wisplinghoff et al., 2003).  Because of the presumed assumption that 
this group of isolates are of low virulence, clinical debates continue regarding the clinical or 
therapeutic value of speciating BSI-associated CoNS isolates.  Nevertheless, evidence from 
studies have emerged suggesting that the source and the proceeding consequence of 
infection may differ considerably dependent on species-specific strains of infective CoNS 
(Piette and Verschraegen, 2009; Chen et al., 2010).  Hence, with the increasing incidence of 
CoNS-associated bacteraemia, speciation may become a necessity because of the link 
between species-specific strains and serious infection syndromes (von Eiff et al., 2002; 
Ahlstrand et al., 2012).  In such cases, isolates of S. epidermidis have been described to be 
most frequent aetiological agent associated with nosocomial BSIs (Feld, 2008).  
Furthermore, CoNS species-specific differentiation provides valuable information relating to 
antimicrobial resistance pattern associated with expression of virulence factors for clinical 
correlation targeting therapeutic interventions for optimal outcomes (Heikens et al., 2005; 
Otto, 2010).  Hence, a strong case exists for the identification of potential pathogenic strains 
of CoNS to the species level that are isolated from normally clinically sterile sites such as the 
bloodstream, thus supporting their role as aetiological agents of infection.  
 
In the clinical setting, several different simple phenotyping systems such as biotyping and 
antimicrobial susceptibility profiling are used to identify identical strains of CoNS continuously 
isolated from the same patient in an attempt to distinguish potentially pathogenic strains.  
Bio-analysis and antibiogram profiling of these isolates to the sub-species level has therefore 
become increasingly important in order to ascertain their role not only in colonisation and 
dissemination but also determine the source of infection in order to prevent nosocomial 
cross-transmission and infection relapse.  Furthermore, isolate identification to the 
genus/sub-species level is essential for interpretation of antimicrobial resistance patterns 
which are predictive of therapeutic outcomes (Stuart et al., 2011).  Consequently, the study 
findings using the commercial automated VITEK®2 system utilising computer software 
analysis of unique biochemical test profiles for species differentiation identified S. 
epidermidis as the predominant species among both the in-patient and control patient group 
isolates (57 and 32% respectively).  These results were further corroborated with use of  the 
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advanced proteomic based MS-MALDI TOF application.  Proteomic profiling by MS, because 
of its greater sensitivity and specificity in detecting the spectrum of proteins expressed by 
organisms, facilitates highly accurate species-level identification (Clark et al., 2013).  
Comparative speciation result analysis evidenced a statistically significant difference in the 
performance VITEK®2 and the MSMS MALDI-TOF system for isolate identification, 
predominantly among species-species CoNS isolates from the control patient group (p = 
0.0058).  Nonetheless, although accuracy level of species-specific identification was greater 
with MSMS MALDI-TOF, the overall species distribution frequency among both patient groups 
was not affected. 
 
As a prevalent member of the skin flora S. epidermidis is also the most frequently 
encountered aetiological agent associated with device-related BSIs in critically ill patients 
(Huebener and Goldmann 1999; Marin et al., 2014).  The distribution frequency of S. 
epidermidis, recovered from both bacteraemic patient and the control group skin-colonising 
isolates in this study was in concordance with results of other studies describing CoNS 
species-specific frequency and distribution.  The rising incidence of device-related CoNS-
associated bacteraemia has been attributed to S. epidermidis the predominant skin flora 
isolate as well as the principal isolate colonising long-term indwelling medical devices 
(Diekema et al., 2001; Longauerova, 2006; Koksal et al., 2009).  Similarly, S. hominis and S. 
haemolyticus were the second and third most abundant species isolated from both patient 
groups.  These findings are concomitant with the make-up of the human skin microbiome, as 
both S. epidermidis and S. hominis are the most abundant species found on the skin and 
mucosa membranes accounting for 46% and 22% of the total CoNS species recovered from 
individuals (Kloos et al., 1994; Costa et al., 2006; Cogen et al., 2008).  Furthermore, other 
research studies cite the predominance of S. haemolyticus as the second most common 
isolate of BSIs (D’Mello et al., 1999; Kristóf et al., 2011).  In clinical settings, this unique 
specificity is associated with critically ill patients having a greater number of invasive 
therapeutic interventions thus putting them at a higher risk of colonisation with S. 
haemolyticus strains (Fluit et al., 2001; Longauerova, 2006).  This study’s results however, 
revealed S. haemolyticus as the third most prevalent of the CoNS species, accounting for 16 
and 17% of the in-patient and control group isolates respectively.  These results, 
nonetheless, harmonise with those of another study, where S. haemolyticus accounted for 5-
38% of all CoNS clinical isolates investigated (Kristóf et al., 2011).  The overall existence of 
S. epidermidis, S. hominis and S. haemolyticus, representative of the three predominant 
CoNS species in both patient groups, is also consistent with findings of similar studies 
reported elsewhere (Raslinksi et al., 2018). 
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The presence of predominant CoNS species-specific isolates in the healthcare facility and 
hospitalised patients colonised with acquired microflora may be representative of clonal 
cross-transmission and hence the source of nosocomial infections (Ziebuhr et al., 2006).  
Colonisation with potentially pathogenic CoNS species is common amongst high-risk patient 
groups with underlying comorbidities, where these isolates survive on medical devices and in 
areas of skin surrounding insertion sites. Therefore, the source of infection may be 
endogenous or exogenous, derived either from the hospital environment of from healthcare 
staff.  Interestingly, environmental sample analysis of highly accessed points by all 
healthcare personnel around the haematology and BMT wards revealed a difference in 
bacterial loads and prevalence of species-specific CoNS isolates dependent on contact 
areas.  The frequency and distribution of dominant normal skin-colonising strains comprising 
of CoNS and other bacterial species such as Micrococcus, Corynebacterium, Bacillus and 
streptococci species also differed dependent on sampling period.  As such, overall 
distribution frequency of the eight predominant CoNS species recovered from sampling the 
high-access contact points in the ward, undertaken during March 2011 revealed S. 
epidermidis as the most frequently isolated species whereas in May 2011, S. haemolyticus 
predominated at a greater frequency across both ward areas.  Although all the CoNS 
species-specific isolates were confirmed as those comprising normal human skin microbiota 
their predominance and frequency appeared to be transient in the ward environment.  
Analysis and comparison of biotypic profiles of environmental species-specific CoNS with 
those of both the in-patient and control group isolates revealed distinctly diverse phenotypes.  
These findings therefore suggest that the transient presence of different predominant 
species-specific CoNS isolates in the ward areas are highly unlikely to be associated with 
dissemination and cause of bacteraemia in the haematology patient group. 
 
From the perspective of phenotypic identification with limited attention given to speciation in 
general, may have served as a barrier in understanding the epidemiology of CoNS-related 
bacteraemia in the haematology patient group.  Distinguishing potential pathogenic strains of 
CoNS as aetiological agents from contaminating skin flora however remains challenging, not 
only due to their extensive presence on the human body but also the spectrum of disease 
associated with species-specific strains (Otto, 2010).  On the other hand, phenotypically, 
expressed traits can be exploited for the purpose of elucidating the source and transmission 
of nosocomial infections due to CoNS species-specific isolates.  Moreover, CoNS species-
specificity has the potential for clinical correlation and together with appropriate therapeutic 
intervention, a necessity for patient survival (Ahlstrand et al., 2012).  Hence, both 
conventional methodologies and molecular techniques with increased sensitivity and 
277 
 
specificity were utilised in this study to determine the phenotypic and genotypic differences or 
similarities within and between in-patient blood culture isolates of CoNS and those skin 
colonisers which could be regarded as inducers of bacteraemia. 
 
For the purpose of species identification and demonstration of species-specific differences, 
biotyping based on biochemical profile analysis using the VITEK®2 system for CoNS isolate 
delineation was found have a relatively low discriminatory capacity.  Nonetheless, biotyping 
when combined with PCA and cluster analysis increased the discriminatory power confirming 
overall study findings, that CoNS isolates of both patient groups exhibited high levels of 
dissimilarity and hence diverse phenotypes.  Data analysis performed based on similarity or 
differences of CoNS biotype profiles (n=100) and dendrograms created, representative of 
percentage similarity revealed five main clusters comprising of very few isolates that 
demonstrated clonal relatedness in each of the patient groups.  S. haemolyticus isolates of 
the in-patient group demonstrated the greatest degree of biotype similarity followed by those 
of S. epidermidis.  Conversely in the control patient group, the same level of similarity was 
only apparent in isolates of S. epidermidis.  In both patient groups, however, the number of 
isolates within each cluster demonstrated a discernibly high level of un-relatedness within 
and between isolates of the same CoNS species.  Conversely, for comparative purposes, 
antibiogram profiles based on evaluating the prevalence of resistance to the 18 commonly 
used anti-staphylococcal agents using the VITEK®2 system were further subjected to PCA 
and cluster analysis for species-specific isolate delineation.  Among both patient groups the 
phenotypic antibiogram profiles of CoNS isolates revealed a distinct of lack of correlation 
between the antibiograms and isolates of the similar CoNS species  
 
As independent factors that are predictive of true bacteraemia rather than contaminants, 
antimicrobial resistance patterns in association with biotype although lacking in 
discriminatory power can be useful for differentiating clinically significant CoNS isolates 
(Raad et al., 1998; 2007).  Based on this predictive value, comparative data analysis of 
biotype in association with antimicrobial resistance profiles, revealed limited biotype 
similarity.  Conversely, amongst each of patient group CoNS isolates a distinct lack of 
correlation was noted between antimicrobial resistance profiles and isolates of similar 
species-specific CoNS.  These study findings therefore confirm that both patient group CoNS 
isolates exhibiting high levels of phenotypic dissimilarity are highly unlikely to have been 




Strain-specific characteristics can, however, only be distinguished effectively by genotypic 
methods rather than by phenotypic appearance or by antibiogram (Miragaia et al., 2002; 
Costa et al., 2006).  Molecular relatedness techniques allow evaluation determination of skin-
colonisers playing a significant role as the source of CoNS bacteraemia in patients with 
haematological malignancies.  Strain relatedness using molecular typing tools such as PFGE 
and rep-PCR utilised in this study to evaluate skin isolates as the potential source of CoNS 
BSIs showed highly diverse species-specific CoNS isolates present amongst both patient 
groups.  The results of this retrospective single centre study are concomitant with results 
obtained by Costa and colleagues (2006) where skin site colonisers were considered to be 
the unlikely source of bacteraemia.  The researchers study results were based on 
prospective evaluation of the colonising skin microflora from CVC exit skin-site samples post-
immunosuppressive therapy with patients receiving vancomycin therapy at time of sampling.  
These factors could be important in influencing not only colonisation sites but also the 
sequence of colonisation in relation to CoNS BSI pathogenesis.  Hence, investigations 
revealed translocation of genetically similar mucosal CoNS-colonising strains (nasal and 
rectal) and not skin-colonisers as the cause of bacteraemia.  Nonetheless, other authors in 
their investigations have evidenced skin-colonisers as the potential primary source of CoNS-
BSIs primarily in association with foreign-body or catheter-related infections (Livesley et al., 
1998; Becker et al., 2014). 
 
Advances in molecular-related epidemiological studies provide another interesting insight 
into the flexibility of CoNS skin-colonising strains generating both phenotypic and genotypic 
variants associated with life-threatening infections in the immunocompromised patient group 
(Cuna et al., 2004).  Although phenotypically expressed traits can differentiate some 
similarities between potentially pathogenic CoNS isolates, genotyping on the other hand, 
distinguishes clonally related similar species-specific isolates expressing the same 
characteristics during the course of infection.  These definitive genotypic traits are not only 
predictive of therapeutic outcomes, but potentially ascertain the source of clinical infections 
(Sloos et al., 2000).  
 
Accordingly, comparative analysis of biochemical and antibiogram profiling using standard 
phenotypic fingerprint typing protocols revealed a high degree of diversity observed within 
and between all CoNS species-specific isolates recovered from both patient groups.  
Conversely, techniques used to assess genomic relatedness among CoNS isolates (n=100) 
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employing rep-PCR technology based on the amplification of non-coding, repetitive 
sequences, interspersed throughout the bacterial genome revealed diverse PCR patterns 
among both patient group isolates.  rep-PCR analysis of both patient group CoNS species-
specific isolates identified a few distinct clones of similar species-specific isolates clustering 
in nine closely related rep-PCR genotypes differing by single DNA fragments.  Likewise, fifty 
of the 200(25%) predominant CoNS species-specific isolates randomly selected equally from 
both patient groups subjected to PFGE analysis, revealed two distinct clones of S. 
epidermidis in the in-patient group. The other isolates discriminated into diverse 
macrorestriction patterns, characteristics which reveal high level genotypic diversity between 
and among both patient group isolates.  Conversely, rep-PCR data analysis identified 
indistinguishable species-specific CoNS in 24% and 10% in-patient and control patient group 
isolates respectively, of which S. epidermidis predominated followed by S. haemolyticus.  
Direct comparisons of genotypes was not possible as species-specific isolate relatedness 
through rep-PCR was defined by assessing amplification of non-coding DNA repetitive 
sequences, whereas with PFGE this occurs thorough the digestion of the entire genome and 
resolution of macrorestriction fragments for strain delineation.  Nonetheless these two highly 
discriminatory molecular techniques utilised in this study demonstrated the presence of 
diverse species-specific genotypes in both patient groups.  These findings reflect 
observations made in previous studies demonstrating the heterogenic nature of CoNS 
species concomitant with infections of immunocompromised patient groups (Cuna et al., 
2004; Casey et al., 2005). 
 
Furthermore, comparative data analysis of the 50 predominant CoNS species-specific 
isolates randomly selected equally from both patient groups, investigated for phenotypic and 
genotypic characteristic comparisons subjected to PCA analysis, revealed no major groups 
or clusters.  The predominant species-specific CoNS isolates analysed demonstrated a 
significant lack of both genotypic and phenotypic relatedness between and among isolates of 
the in-patient and control patient group.  However, result analysis identified 2(4%) 
indistinguishable S. epidermidis in-patient genotypes and 2(4%) S. hominis isolates from 
each of the patient groups demonstrating a high degree of genetic similarity (Chapter 3 
Figures 3-12 and 3-14).  Likewise, although some phenotypic clusters were identified by 
biotypes (Chapter 2 Figures 2-2 and 2-3), no major clusters were distinguished among and 
between the two patient group CoNS isolates based on antibiogram typing (Chapter 4 
Figures 4-2 and 4-3).  This indicates high levels of heterogenicity among both the 
bacteraemic patient and control group skin-colonising CoNS, comprising of few isolates that 
were indistinguishable or closely related.  Due to the retrospective nature of this study, it was 
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not possible to ascertain whether the two clonally indistinguishable S. epidermidis isolates 
identified by PFGE analysis were recovered from the same patient, presenting multiple 
episodes of bacteraemia or were isolated from different patients, acquired through 
nosocomial transmission.  Nonetheless, overall results for phenotypic isolate differentiation 
and genotypic characterisation based on single restriction fragment differences revealed no 
dominating pulsotypes but diverse heterogenicity between and among isolates of the same 
CoNS species.   
 
The lack of genotypic similarities or relatedness suggest that as the skin-colonising isolates 
were no more homogenous than the in-patient BSI-associated CoNS species-specific 
isolates and are therefore unlikely to be the possible source of bacteraemia as postulated.  
Similarly, other epidemiological studies using molecular techniques have provided an 
interesting insight into the flexibility of skin-colonising CoNS isolates generating novel 
phenotypic and genotypic variant associated with opportunistic nosocomial infection (Cuna et 
al., 2004; Costa et al., 2004). The phenotypic and genotypic diversity noted among and 
between both the in-patient and control patient group CoNS species-specific isolates 
therefore underscores the fact that the hospital environment, antimicrobial pressure and the 
nature of the patients disease state may be factors that play a crucial role in promoting the 
adaptive nature of CoNS isolates and hence their importance as potential pathogens. 
 
Interestingly, the phenotypic antibiogram profiles of both patient group CoNS isolates 
revealed distinct clonal dissimilarity, with the majority of isolates demonstrating a wide 
spectrum of antimicrobial resistance to commonly used anti-staphylococcal agents.  
Administrating antibiotics disrupts the normal skin microbiota which is made up of a complex 
community of colonising microorganisms with the capability of acquiring resistance, hence 
acting as reservoirs of resistance genes and therefore the potential for pathogenicity.  
Hospitalised patients often acquire healthcare-associated colonising strains which partially 
and progressively replace normal microbiota, dependent on factors such as type of infection 
underlying co-morbidities, antibiotic pressure and prevailing epidemiology (Agvald-Öhman et 
al., 2003 (Cogen et al., 2008).  Similarly, of the 18 antimicrobial agents assayed, varied 
resistance responses were produced among both patient group CoNS isolates in a species-
specific dependent manner, with the majority demonstrating resistance to penicillin and 
others to more than three antimicrobial classes.  Understanding the spectrum of commonly 
used agents against CoNS species-specific isolates is essential for appropriate diagnosis 
and provision of targeted therapeutics guidance for optimal clinical outcomes.  Clinically 
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significant bacteraemia associated with MDR-CoNS isolates possess determinants that 
facilitate their survival on skin and device surfaces particularly in patients with underlying 
immunocompromised states (Coello et al., 2003).  In the clinical setting prevention and 
management strategies are critically dependent on ascertaining the source of recalcitrant 
infections associated with such potentially pathogenic isolates (Costa et al., 2004; 2006).  
 
An important characteristic of CoNS isolates is their multi-drug resistance to the 
antimicrobials commonly used for the treatment of staphylococcal infections.  The presence 
of MDR-CoNS isolates have been shown to present the most critical of compromises to 
favourable clinical outcomes in immunocompromised patients (Marin et al., 2014).  In 
agreement with previously published studies, the primary finding of this study indicated that 
of the species-specific CoNS isolated from bacteraemic patients, S. epidermidis and S. 
haemolyticus (88% and 94% respectively) indeed demonstrated significantly higher levels of 
MDR associated with high levels of methicillin resistance in comparison to other species-
specific isolates.  Conversely, species-specific MDR was most restricted among the minor 
CoNS species-specific isolates in both patient groups.  In total 78% of the in-patient isolates 
demonstrated significant levels of methicillin resistance (p = 0.0001), results  which are 
concomitant with several other studies undertaken across Europe and American countries, 
citing MR rates of 70-80% (Collin et al., 2001; Collin et al., 2001; Vincent et al., 2006).  Other 
study results also concurred with observed rates of MR expressed by skin-colonising isolates 
(28%) which although lower than those exhibited by blood culture isolates are thought to 
contribute significantly to nosocomial acquisition (Yamada et al., 2017).  Therefore, the 
emergence of MR and MDR-CoNS isolates are an important healthcare problem and a 
particular concern among patients with malignancies, in whom, BSIs are the most common 
manifestation because of severe immunosuppression.  The risks are further compounded by 
a number of complex factors which include length of hospitalisation and selective 
antimicrobial pressure promoting emergence of resistance, predisposing the patient to 
colonisation with resistant strains (Montassier et al., 2013).  Reports relating to the incidence 
of antimicrobial resistance in nosocomial-acquired CoNS are rising however, their 
association with clinical outcomes especially among immunocompromised patients remain 
limited (Natoli et al., 2009).  
 
Vancomycin however remains the standard of care for these problematic potential 
pathogenic strains in haematology patients with increasing reported case of suboptimal 
treatments resulting in clinical failures (D’Antonio et al., 2004).  The most worrisome issue 
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with prolonged vancomycin treatment has been the emergence of associated reduced 
susceptibility to the glycopeptides in CoNS isolates. whereby the precursors of glycopeptide 
intermediate and/or sub-populations of resistant strains display MICs in excess of 2mg/L.  In-
vivo this would relate to achieving serum drug concentrations of >30mg/L for efficacy.  
However, maintaining such high serum levels would compound toxicity leading to worse 
clinical outcomes (Cremniter et al., 2010).  Furthermore, there is increasing evidence of a 
significant relationship between elevated vancomycin MICs and treatment failures associated 
with the emergence and spread of nosocomial MR-staphylococci (Falcone et al., 2015). 
 
Associated therapeutic failures are thought to be multifactorial in the immunocompromised 
patient group including, insufficient drug serum levels achievement, attributable either to poor 
pharmacokinetic properties of the antimicrobial or heteroresistance expression.  Moreover, 
high protein binding properties of the glycopeptides in particular, teicoplanin leads to 
reduction of drug optimisation associated with the concentration-related inhibitory properties 
of the drug in-vivo (Howden et al., 2004; 2010).  The application of techniques to investigate 
the presence of reduced susceptibility due to the presence of  heteroresistant strains remains 
confined to the research field at present.  However, the proposed simple screening 
techniques although not currently in-use as a diagnostic tool in clinical microbiology despite 
their limitation can be utilised to determine the potential presence of low-level resistant 
strains in patients on long-term vancomycin therapy exhibiting signs of clinical failure  The 
results of this study demonstrate that the prevalent MDR-CoNS BSI phenotypes although 
exhibiting in-vitro susceptibility to vancomycin may not show clinical success as a fair 
proportion demonstrated resistance to the glycopeptide, teicoplanin.  In-vitro studies to 
monitor emerging resistance requires observing the presence of high levels of teicoplanin 
resistance proposed to be a precursor stage to developing resistance to vancomycin.  Due to 
the similarity of the mode of resistance demonstrated by both glycopeptides, the frequency of 
teicoplanin resistance can therefore act as a marker for emerging vancomycin resistance 
i(Hiramatsu, 2001). 
 
Staphylococci responding to sub-therapeutic glycopeptide drug levels are known to 
subsequently select for both heterogenous and variable resistance which are difficult to 
detect by conventional AST techniques.  The VITEK®2 automated AST system is deemed to 
be an unreliable platform for the detection of heteroresistance because the incubation period 
together with the standard inoculum used, is below the required threshold for detection of the 
slower growing heterogenous subpopulations (Wootton et al., 2007; Howden et al., 2010). 
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The accurate assessment of vancomycin susceptibility is therefore crucial with increasing 
numbers of CoNS isolates exhibiting MDR to commonly used anti-staphylococcal agents and  
reduced susceptibility to the glycopeptides.  Distinguishing heteroresistance phenotypes from 
isolates demonstrating overall vancomycin susceptibility was problematic because of the lack 
of both simple screening techniques and criteria for defining heteroresistance in CoNS.  
However, determination of low-level resistance, a critical factor for the detection of 
heteroresistance was carried out using by application of the macromethod E-tests and GRD 
E-tests.  Using these simple screening techniques, study results reveal that some in-patient 
isolates of S. epidermidis and S. haemolyticus may have the potential to express low-level 
glycopeptide resistance.  Due to the limitations of the techniques although heteroresistance 
in these isolates was not definitively confirmed; the significantly high levels of teicoplanin 
resistance expressed by both S. epidermidis and S. haemolyticus in-patient isolates indicates 
that these isolates are also highly likely to express heteroresistance.   
 
The increasing prevalence of glycopeptide inefficacy against CoNS-associated bacteraemia 
correlating with potential therapeutic failures therefore merited the evaluation of newer 
antimicrobials.  Of these, daptomycin demonstrated significantly higher levels of in-vitro 
activity in comparison to tigecycline and ceftaroline, against all the in-patient CoNS species-
specific isolates (p = 0.001).  Similar to the findings of other studies daptomycin 
demonstrated greater potency against all CoNS isolates expressing vancomycin MICs at the 
upper breakpoint level of 2mg/L; indicating its greater potential as a suitable alternative 
therapeutic agent to vancomycin for the treatment of CoNS-associated bacteraemia 
(Kelesidis, 2011; Moore et al., 2011).  More importantly, this study highlights the difficulties 
encountered with provision of accurately evaluated results to the clinician using standard 
AST protocols for therapeutic guidance.  Moreover, these in-vitro AST results do not take into 
account the complex relationship interaction between environmental factors, previous 
antimicrobial therapies and interaction of potential pathogenic strains of CoNS associated 
with the immune-depressed status of the host.  Optimal patient outcomes are therefore 
reliant on the use of reliable AST in-vitro diagnostic techniques for determination of accurate 
antimicrobial MICs thus ensuring correct dosage guidance and resistance development 
limitation.  Nonetheless, antimicrobial resistance due to aggressive use of broad-spectrum 
therapeutics for treatment of bacteraemic infections in the high-risk haematology patient 




Resistance to multiple classes of antimicrobials is estimated to be expressed by about 60-
80% of potentially pathogenic CoNS hence limiting therapeutic options for the treatment of 
severe infections due to such virulent strains in high-risk patient groups (Ma et al., 2011).  
Despite the use of appropriate antimicrobial therapies, MDR CoNS-associated bacteraemia 
often results in poor clinical outcomes.  Serious difficulties encountered with the excessive 
use of vancomycin and its reduced efficacy against drug tolerant CoNS species-specific 
isolates and the lack of effectiveness of other commonly used antimicrobials as mono-
therapeutic agents for the treatment of CoNS-associated bacteraemia; the use of two 
antimicrobials in combination are usually recommended for attaining optimal clinical efficacy.  
Additionally, combination treatment regimens prevent both relapse and difficulties related to 
antimicrobial-associated adverse effects (Climo et al., 1999; LaPlante and Woodmansee 
2009).  The selection of combination therapeutics are however deemed to be dependent on 
the process of effective pharmacokinetic antibiotic delivery at serum concentrations that are 
pharmacodynamically efficient without causing toxicity for improved clinical outcomes 
(Ahlstrand et al., 2012; Martins et al., 2013; Islas-Muñoz et al., 2018).  Therefore, the aim of 
employing antibiotic combination therapeutics are not only to produce synergistic bacterial 
killings in-vivo; but also, to decrease the risk of resistance development, by providing a 
predictable extended antimicrobial spectrum in comparison to that achievable by 
nanotherapeutics.  In clinical practice, vancomycin is frequently used in combination with 
other antibiotics including the aminoglycosides or cephalosporins for the treatment of serious 
MR-staphylococcal associated infections.  However, no clinical data is yet available to 
support the definitive use of some combination therapies, in particular to those related to 
specific factors which include potential association with drug toxicities in the 
immunocompromised patients (Deresinski, 2009).  
 
This study therefore served to characterise the in-vitro effectiveness of combinations of 
vancomycin, rifampicin, daptomycin and gentamicin against three in-patient S. epidermidis 
isolates representative of susceptible, intermediate and MDR susceptibility profiles.  The E-
test method employing specified conditions evaluated inhibitory data at a single time end-
point of antimicrobial combination interactions for synergy assessment.  Evidence of 
antimicrobial interactions between binary combinations of vancomycin rifampicin, gentamicin 
and daptomycin against the three representative in-patient S. epidermidis strains, 
predominantly demonstrated either an additive or indifference effect, with the exception of 
synergy demonstrated by the combination of vancomycin-gentamicin against the MDR-S. 
epidermidis isolate A91.  More importantly however, antagonism was not observed between 
any of the four antibiotic combination interactions against all three S. epidermidis test 
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isolates.  In clinical practice, optimal antimicrobial therapy is achieved by administration of 
vancomycin-gentamicin combinations for infections caused by MR-staphylococci (Dompeling 
et al., 1996; Rehm et al., 2008).  Although combining vancomycin with gentamicin may 
increase risk of nephrotoxicity however it has been shown that with additional serum level 
monitoring and appropriate dosing regimens the risk probability is lowered hence enhancing 
bactericidal activity (Rybak et al., 2009).  
 
The increased bactericidal activity of vancomycin when combined with other antimicrobial 
agents has been noted to provide an extended spectrum of activity against difficult to treat 
infections and prevent emergence of drug-resistant subpopulations (LaPlante and 
Woodmansee, 2009). Although vancomycin-daptomycin and vancomycin-rifampicin 
combinations did not demonstrate the same high level drug potency as combinations of 
vancomycin-gentamicin an overall additive effect was noted against all the three BSI S. 
epidermidis was in this study.  Similar to vancomycin-gentamicin combination, rifampicin, 
characterised by its potent bactericidal activity and ability to penetrate tissue cells has been 
reported to enhance vancomycin activity in-vivo (Rose et al., 2009).  Hence, the increased 
observed activity of vancomycin-rifampicin combination is in concordance with its use in 
clinical practice.  Overall results obtained in this study demonstrate that combinations of 
vancomycin-gentamicin or rifampicin and the newer antimicrobial, daptomycin in particular 
can be considered as effective alternatives for improved clinical outcomes in haematology 
patients, particularly in cases of clinical failures with commonly used monotherapies. 
 
Biofilm producing staphylococcal isolates also referred to as “slime producers” are known to 
be responsible for many recalcitrant infections associated with antimicrobial resistance (de 
Allori et al., 2006). The pathogenesis of these isolates in particular, S. epidermidis biofilm 
producers are dependent on their ability to produce adherent exopolymers or slime.  These 
exopolymers are an integral component of biofilm, the most important virulence trait of CoNS 
species, an adaptive survival response particularly associated with CR-BSIs (Otto, 2009; 
Claessens et al., 2015).  Of major concern among patients with haematological malignancies 
is the extensive colonisation of intravascular devices with such slime producing CoNS which 
also form part of the normal microbiome associated with the patients’ skin and mucosa. 
Difference in the immunological status of haematology patients and variation in expressed 
virulence factors among species-specific isolates determine the outcome of colonisation and 
disease development (Cervera et al., 2009 Ahlstrand et al., 2012).  Various phenotypic 
methods have been proposed for the investigation of biofilm producers in relation to skin-
colonising strains particularly for diagnosis of line-associated bacteraemia.   
286 
 
In this study, criteria based on visual analysis of colour changes due to the production of 
slime using the Congo red agar method identified in-patient isolates of S. epidermidis (72%) 
as the predominant CoNS species associated with slime production.  Conversely, in the 
control patient group the other minor group of CoNS isolates, predominantly S. warneri and 
S. capitis demonstrated slime production marginally higher than those S. epidermidis isolates 
(52% and 50% respectively).  The findings of this study corroborate those of other studies 
showing that dominant isolates exhibiting MDR, recovered from hospital patients 
demonstrate increased virulence in comparison to skin-colonising strains (Arslan and 
Özkardes, 2007; Baker et al.,2018).  However, data obtained for the virulence study 
subjected to statistical analysis revealed that there was no significant difference with respect 
to the proportion of CoNS species-specific isolates association with slime production and 
patient groups (p = 0.230).  Nonetheless, a significant proportion of in-patient S. epidermidis 
isolates were associated with slime production in comparison to those of S. haemolyticus (p 
= 0.0284). 
 
Furthermore, overall PCA multivariant data analysis used to explore the relationship between 
species-specific CoNS, production of four main virulence traits and association with 
antimicrobial resistance; revealed a distinct lack of correlation between all variant factors, 
including patient groups and isolates.  Study findings also showed that despite the 
predominance of slime producing S. epidermidis isolates in both patient groups, there was 
little evidence of clonal clustering of MDR-isolates related to the production of the four 
virulence factors (Chapter 5, Figure 5-5).  However, further analysis revealed a difference in 
the rate of distribution of isolates that demonstrating MDR not associated with slime 
production, which is a trait normally postulated to be associated with a higher degree of 
antimicrobial resistance (Arslan and Özkardes, 2007).  Hence, data subjected to further 
statistical analysis using the linear regression model to assess the expression of MDR in 
relation to species-specific isolates producing slime, revealed a significantly high proportion 
of in-patient MDR-S. epidermidis isolates associated with slime production (p < 0.0098).  
These findings are concomitant with numerous published studies which evidence the 
predominance of highly resistant, virulent, slime-producing S. epidermidis and S. 
haemolyticus isolates associated with causing recalcitrant infections in immunocompromised 
patients (Arciola et al., 2004; Martiínez-Morel et al., 2014; Yamada et al., 2017).  In 
comparison, the colonising CoNS isolates may have an inherent ability to produce slime as 




Accumulated data analysis in this study suggests that slime is one of the important factors 
related to virulence in association with either methicillin or MDR predominantly amongst in-
patient group S. epidermidis isolates.  Both clinical and in-vitro research findings support the 
theory that slime, an integral component of biofilm-producing staphylococci negatively affects 
treatment outcomes due to expression of increased resistance (Klingenberg et al., 2007).  
Studies have also shown that such isolates involved in biofilm formation are frequently 
associated with medical implants and devices serving as a common source of bacteraemia 
associated with suboptimal clinical outcomes (Casey et al., 2006, 2007; Longauerova, 2006; 
Martiínez-Morel et al., 2014).  The direct relationship between the virulence factors assessed 
and the source (patient group) did not however emerge in the present investigations.  
Furthermore, the phenotypic variation in slime production observed within and between 
CoNS species of the hospitalised patient group may also introduce a degree of complexity 
associated with pathogenicity.  Hence, the potential variations linked with the degree of slime 
production by different species-specific CoNS isolates associated with virulence related to 
antimicrobial resistance would require addressing in future studies.  Investigations would 
involve quantification of biofilm mass of slime-positive species-specific isolates of CoNS and 
correlation with rate of antibiotic resistance which contribute significantly towards biofilm-
associated resistance. 
 
Furthermore, colonisation of surfaces through the development of biofilms is known to 
increase the likelihood of resistance and reduces anti-bactericidal activity of commonly used 
antimicrobial agents leading to increased rates of treatment failures (LaPlante and 
Woodmansee 2009).  Therapeutics for biofilm-associated infections are usually selected 
according to conventional susceptibility testing.  However, this type of susceptibility data is 
largely inadequate for therapeutic decisions, as biofilm-embedded isolates display diverse 
mechanisms of antimicrobial resistance.  The interaction with antimicrobial agents and the 
mechanism of biofilm-mediated resistance is dependent on a number of specific factors that 
influence detection of susceptibility.  These include factors such as hydrophobicity and 
diffusion rates, dependent on the composite nature of the biofilm that influences antimicrobial 
efficacy in-vivo (Patel, 2005).  Therefore, in-vitro methods that address biofilm-associated 
susceptibility, need to take such factors into account to ascertain biofilm-mediated response 
to commonly used therapeutics.  Standardised in-vitro biofilm susceptibility test methods 
reflecting in-vivo antimicrobial efficacy against adherent staphylococcal isolates are yet to be 
elucidated.  Some well-established in-vitro study models although lacking in several 
components of in-vivo biofilm-associated infections, have been utilised to effectively predict 
the activity of various antimicrobials against adherent cells (Saginur et al., 2006).  With the 
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aim of determining antimicrobial efficacy of three commonly used anti-staphylococcal drugs 
against biofilm encased S. epidermidis, this study further explored the concentration-
dependent activity of vancomycin, rifampicin and daptomycin individually and in combination 
utilising the commonly employed bioassay model of S. epidermidis biofilm developed in-vitro.   
 
Investigation revealed an unexpected outcome in this study with respect to the bactericidal 
activity of all three antimicrobials assessed individually and in combinations for anti-biofilm 
activity.  Vancomycin, rifampicin and daptomycin appeared to have a negative effect on the 
reference strain, S. epidermidis RP62A biofilm embedded cells.  Biofilm-mediated non-
susceptibility was demonstrated by insufficient reduction in biofilm cell density measured 
spectrophotometrically and quantitatively by all three antibiotics individually.  Minimum biofilm 
inhibitory and eradication concentration combinations were well above the normally exhibited 
MICs.  The elevated values obtained were also significantly higher than those expected of 
peak serum values in patients during therapy.  This suggests that the significantly reduced 
anti-biofilm activity of these commonly used antimicrobials limits therapeutic options for 
biofilm-associated infections particularly for patients with malignancies and a blunted immune 
response.  These findings are concomitant with clinically relevant features of biofilm-
embedded isolates, demonstrating significantly higher antibiotic resistance expression which 
may be up to 1000-fold higher, relative to planktonic-state isolates (Mah and O'toole, 2001).  
 
The observed biofilm-mediated resistance to individual and combination antimicrobial in 
clinical practice for the treatment CoNS-associated bacteraemia, indicates the presence of 
multiple biofilm-specific mechanisms which may have contributed to the high levels of 
observed in-vitro antibiotics resistance.  These biofilm-specific resistance characteristics may 
include the age of biofilm, specificity of antimicrobials such as penetration ability linked with 
molecule size and concentration-dependent time of antimicrobial exposure.  Furthermore, 
researchers have shown that high antibiotic concentrations failing to achieve eradication and 
biofilm-mediated infection are due to the presence of persister cells, a dormant viable sub-
population found within biofilms.  These persister cells have be linked to induction of biofilm-
associated re-infections related to unresolving bacteraemia as persister cells disseminating 
from within the biofilm in the planktonic mode retain their phenotypic resistant characteristics 




Therefore, reduced susceptibilities observed against biofilms commonly produced by clinical 
S. epidermidis isolates, would generate serious consequences for therapy of biofilm-
associated infections.  This would subsequently result in serious clinical implications for 
haematology patients with inserted lines essential for continuous intravascular access that 
are colonised with CoNS biofilm-producers resistant to standard therapeutics.  Additionally, 
in-vitro antagonistic antimicrobial interactions against S. epidermidis biofilm embedded cells 
suggests that vancomycin-rifampicin, -daptomycin, combinations would also be restricted for 
treatment of device-related bacteraemia caused by CoNS-associated biofilm producers.   
 
Previous investigators have shown that in-vitro MIC assays for antimicrobial susceptibility 
investigations are poor predicators of treatment outcomes due to the extrinsic factors in the 
host environment that also influence antibiotic efficacy (Raad et al., 2007).  As such, factors 
that influence accurate prediction of efficacy include the pathogen’s metabolic state during 
the course of infection.  These include, stationary-growth phase biofilm-associated sessile 
cells or when circulating as ‘persister’ cells demonstrate increased antibiotic tolerance, hence 
exacerbating infection progression leading to suboptimal clinical outcomes (Radlinski and 
Conlon, 2018).  As this was a retrospective study, analysis of factors associated with 
antimicrobial resistance prevalence particularly for culture-confirmed CoNS bacteraemia in 
the haematology patient group could not be corroborated with therapeutic sequels.  The lack 
of both clinical and follow-up microbiological data availability prevented the definitive 
assessment of treatment outcomes in relation to prescribed antimicrobials and therapy 
duration. 
 
In conclusion, S. epidermidis was the predominant species isolated from blood cultures of 
patients with haematological malignancies presenting with CoNS-associated bacteraemia 
and those comprising skin-colonising isolates of the pre-admission patient group.  This study 
presented strong evidence that in-patient CoNS isolates compared to the control patient 
group were significantly associated with an increased proportion expressing multi-drug and 
methicillin-resistance, concomitant with the production of the major virulence factor, slime (p 
< 0.0001).  There was little evidence of vancomycin resistance, however the significant levels 
of teicoplanin resistance detected particularly among the in-patient isolates serves as a good 
marker for emerging resistance due to antibiotic pressure related to high vancomycin use in 
the haematology unit.  The spectrum of in-vitro activity exhibited by daptomycin against all 
species-specific CoNS isolates in this study suggest that it has the potential to be a viable 
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alternative treatment option for CoNS-associated bacteraemia in the high-risk haematology 
patient group. 
 
Significant overall differences in phenotypic and genotypic patterns were observed amongst 
and between CoNS species-specific isolates representing bacteraemia and those skin- 
colonising isolates considered as potential pathogens.  Hence the definitive findings of this 
study do not support the hypothesis that CoNS skin-colonising isolates may be the primary 
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The dendrogram created using the DiversiLab analytic tools based Pearson’s Correlation 
calculation reveals similarities between the fingerprint profiles of all the CoNS species 
isolates obtained through rep-PCR genotyping methodology. The similarity scale bar located 




























The dendrogram illustrates the rep-PCR profiles of the 233 CoNS isolates tested from both 
patient groups.  This includes all samples that were retested for unresolved rep-PCR 
fingerprints and for reproducibility checks.  The rep-PCR reference molecular ladder is 
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